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Bicyclic peptide ligands are promising molecules for the development of new thera-
peutics. They combine advantages from large protein therapeutics (high affinity and 
specificity) and small molecule drugs (accessibility to chemical synthesis and better dif-
fusion into tissues). Large combinatorial libraries of bicyclic peptides can be generated 
and screened by phage display using a recently developed strategy. In brief, ran-
dom peptides containing three cysteine residues are displayed on phage and reacted 
with a cyclization scaffold containing three thiol-reactive groups. The resulting bicyclic 
peptide library can be subjected to affinity selections following standard methods. Potent 
and selective bicyclic peptide inhibitors against several therapeutic targets have already 
been developed and their therapeutic potential is currently being evaluated in animal 
models. 
One aim of my thesis was the exploration of ring size diversity in bicyclic peptides. Most 
selections had been performed with a library of uniformly sized peptides consisting of 
two loops of 6 residues each. I generated a set of libraries of the format Cys-(Xaa)m-Cys-
(Xaa)n-Cys, where 'm' and 'n' = 3, 4, 5 or 6, and performed affinity selections against the 
tumor-associated serine protease urokinase-type plasminogen activator. Interestingly, 
bicyclic peptide inhibitors from virtually all ring size combinations were isolated, sug-
gesting that many peptide formats can be accommodated in the active site of this en-
zyme. Moreover, they showed a large variety of consensus sequences and several of the 
identified consensus sequences were exclusively found in bicyclic peptides having specif-
ic ring size combinations. Some of these peptides may bind in orientations that allow 
affinity maturation of non-conserved regions, while others do not. Having available mul-
tiple leads isolated from such bicyclic peptide libraries with variable ring sizes could 
therefore be a great asset for the generation of high affinity binders. Additionally, other 
targets may have preferences for specific peptide constraints and the availability of these 
libraries increases the chances to isolate high affinity binders to any desired target. 
A second goal of my thesis was to apply high throughput sequencing technologies to 
phage display selections of bicyclic peptides, in order to identify a larger number of spe-
cific target-binding sequences and motifs. I developed a procedure to efficiently compare 
the sequences of large numbers of phage-selected peptides to identify target-binding 
peptide motifs based on abundance and sequence similarity. Applying this approach to 
phage isolated in selections against five different protein targets, I was able to identify 
rare target-binding peptide motifs and could more precisely define groups and sub-
groups of consensus sequences. This information is valuable to choose peptide leads for 
drug development and facilitates the identification of epitopes. Moreover, binding motifs 
could be identified after a single round of phage panning. Such a selection regime reduces 
propagation-related bias and facilitates the application of phage display in non-
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specialized laboratories, as procedures such as bacterial infection, phage propagation 
and purification are not required. 
The final objective of my thesis was to discover bicyclic peptides that could be used as 
new antibiotics. Towards this end, I combined the newly generated variable ring size 
libraries and high-throughput sequencing procedures. I focused on the development of 
inhibitors of Staphylococcus aureus sortase A, an antivirulence target for which no potent 
and specific inhibitors have been reported. For the isolation of bicyclic peptide inhibitors 
to this target, the ring size diversity of the libraries turned out to be key. Inhibitors all 
shared the same motif (Leu-Pro-Pro) in a loop of 5 residues. Further characterization of 
their effects on S. aureus showed that they were not degraded by secreted proteases, and 
that they could inhibit sortase-mediated incorporation of external substrates on the 
staphylococcal cell wall. However, they were not sufficiently potent to compete with the 
native substrates of the enzyme, and therefore did not prevent their incorporation into 
the cell wall. More potent inhibitors are needed to effectively inhibit sortase A on S. 
aureus cells, and the bicyclic peptide inhibitors isolated constitute promising leads for 
the development of future antisortase therapeutics. 
 Keywords  
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Les peptides bicycliques sont de prometteuses molécules pour le développement de 
nouveaux agents thérapeutiques. Elles combinent les avantages des protéines thérapeu-
tiques de grande taille (caractérisées par leur grande affinité et spécificité pour leurs 
cibles) et des composés chimiques de taille plus réduite (ayant la faculté d’être synthéti-
sés chimiquement et de mieux diffuser dans les tissus).  De grandes librairies de peptides 
bicycliques peuvent être générées et criblées par "phage display" (expression phagique) 
en utilisant une stratégie récemment développée. En résumé, des peptides avec des sé-
quences aléatoires contenant trois cystéines sont présentés à la surface de phages. Les 
groupements thiols agissent comme des nucléophiles qui vont réagir avec une molécule 
jouant le rôle d’armature du peptide bicyclique. Les phages contenus dans la librairie 
ainsi créée peuvent être soumis à une sélection par rapport à leur affinité moléculaire ce 
qui permet de mettre en évidence les séquences qui se lient aux cibles d'intérêt.  Cette 
méthode a permis l’isolation d’inhibiteurs avec une grande efficacité et sélectivité contre 
plusieurs cibles thérapeutiques, et leur potentiel thérapeutique est à présent en train 
d'être évalué sur des modèles animaux. 
Un des buts du travail présenté dans cette thèse a été d'explorer la diversité obtenue 
grâce à différentes longueurs des boucles dans les peptides bicycliques. La plupart des 
sélections avaient jusqu’alors été effectuées avec une librairie de peptides de taille cons-
tante (deux boucles de 6 résidus chacune). Ainsi, j'ai généré une collection de librairies 
au format Cys-(Xaa)m-Cys-(Xaa)n-Cys, où 'm' et 'n' = 3, 4, 5 ou 6, et j'ai effectué des sélec-
tions contre l'activateur du plasminogène de type urokinase, une protéase à serine im-
pliquée dans le développement de certains cancers. J'ai pu isoler des peptides bicycliques 
inhibant la cible avec presque tous les formats. Cela suggère que des boucles de différen-
te longueur peuvent adopter des conformations afin d'interagir avec le site actif de cette 
enzyme. Qui plus est, ces différents formats ont permis l’isolation d’une grande variété de 
séquences consensus et plusieurs d’entre elles étaient spécifiques d’un seul type de li-
brairie particulière. Pour certains peptides, l’affinité peut être améliorée à cause de la 
présence de zones d’interactions plus faibles mais cela ne peut être généralisé. Par 
conséquent, la mise en évidence de multiples motifs peptidiques, provenant de librairies 
comportant différentes longueurs de boucles, représente un atout majeur pour la généra-
tion de ligands à forte affinité. En plus, certaines cibles peuvent présenter des préféren-
ces pour un format en particulier, et la disponibilité de plusieurs librairies augmente les 
chances d'isoler un ligand pour n'importe quelle cible désirée. 
Le deuxième but de ce travail a été d'appliquer la technologie de séquençage à haut débit 
pour analyser les sélections de phages. Cela devrait permettre l'identification d’un nom-
bre maximal de séquences et de motifs de liaison. J'ai développé une procédure pour 
comparer efficacement les séquences d'un grand nombre de peptides et pour identifier 
des motifs sur la base de leur abondance et de leur similarité. En utilisant cette approche 
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pour analyser les résultats obtenus avec des sélections contre cinq protéines cibles diffé-
rentes, j'ai été capable d'identifier des motifs de liaison rares (qui auraient été omis avec 
la méthode classique) et de définir plus précisément les groupes et sous-groupes de cha-
que consensus. Cette information est d’une grande utilité pour choisir les candidats au 
développement des médicaments et elle facilite l'identification d'épitopes. En outre, cela 
a permis d'identifier des motifs de liaison après la première série de sélection phagique. 
Une telle procédure réduit les chances d’avoir des résultats faussés par les biais de pro-
pagation des phages, et facilite l'application du "phage display" en laboratoire non spé-
cialisé, étant donné que les étapes telles que l'infection bactérienne, l’amplification et la 
purification des phages ne seront plus nécessaires. 
Le but final a été de trouver peptides bicycliques qui pourraient être utilisés comme de 
nouveaux antibiotiques, en combinant les avantages des librairies avec différentes lon-
gueurs de boucles et ceux des procédures de séquençage à haut débit. Plus spécifique-
ment, je me suis concentré sur le développement d’inhibiteurs de la sortase A de Staphy-
lococcus aureus, une cible impliquée dans la virulence des infections pour laquelle aucun 
inhibiteur puissant et spécifique n'a été rapporté. Pour l'isolation de peptides bicycliques 
inhibant cette cible, la diversité donnée par la longueur de boucle s'est révélée clé. Tous 
les inhibiteurs partageaient le même motif (Leu-Pro-Pro) dans une boucle à 5 résidus. 
Par la suite, la caractérisation de leurs effets sur S. aureus a montré qu'ils n'étaient pas 
dégradés par des protéases sécrétées, et qu'ils pouvaient inhiber l'incorporation de subs-
trats externes sur la paroi cellulaire par la voie de la sortase. Cependant, ils n'étaient pas 
suffisamment puissants pour entrer en compétition avec les substrats naturels de cette 
enzyme, et par conséquent ils n'empêchaient pas l'ancrage de facteurs de virulence. Des 
inhibiteurs plus puissants sont requis pour inhiber efficacement la sortase A sur les cellu-
les de S. aureus, et les peptides bicycliques isolés restent en bonne position pour le futur 
développement de médicaments antisortase.      
Mots-clés 
peptide, peptide bicyclique, diversité, évolution in vitro, expression phagique, séquen-
çage à haut débit, séquençage de la prochaine génération, antibiotiques peptidiques, thé-






ACN  acetonitrile 
AMP  antimicrobial peptide 
ATP  adenosine-5'-triphosphate 
BBMB  1,3-bis(bromomethyl)benzene 
BSA  bovine serum albumin 
CDR  complementarity determining region 
DARPin  designed ankyrin repeat protein 
DIPEA  N,N-diisopropylethylamine 
DMMA  (Z)-3-(2,5-dimethoxyphenyl)-2-(4-methoxyphenyl) acrylonitrile 
DMSO  dimethyl sulfoxide 
DNA  deoxyribonucleic acid 
DTT  dithiothreitol 
EDT  1,2-ethanedithiol 
EDTA  ethylenediaminetetraacetic acid 
ELISA  enzyme-linked immunosorbent assay 
ESI  electrospray ionization 
Fc region  fragment crystallizable region 
FDA  Food and Drug Administration (US) 
Fmoc  fluorenylmethyloxycarbonyl 
Fn3  fibronectin type III domain 
FXIIa  activated coagulation factor XII 
HBTU  O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium  
   hexafluorophosphate 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HOBt  1-hydroxybenzotriazole 
HPLC  high-performance liquid chromatography 
HTS  high-throughput sequencing 
IPTG  isopropyl β-D-thiogalactopyranoside 
LPS  lipopolysaccharide 
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Kd  dissociation constant 
Ki  inhibition constant 
mRNA  messenger ribonucleic acid 
NMR  nuclear magnetic resonance 
MALDI  matrix-assisted laser desorption ionization 
MRSA  methicillin-resistant Staphylococcus aureus 
MSCRAMM microbial surface component recognizing adhesive matrix molecules 
MS  mass spectrometry 
NGS  next generation sequencing 
NHS  N-hydroxysuccinimide 
PBS  phosphate buffered saline 
PCR  polymerase chain reaction 
PEG  poly-ethylene glycol 
PK  plasma kallikrein 
PVS  phenyl vinyl sulfone 
SA  streptavidin 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SrtA  sortase A 
SrtB  sortase B 
TATA  1,3,5-triacryloyl-1,3,5-triazinane 
TBAB  N,N′,N′′-(benzene-1,3,5-triyl)-tris(2-bromoacetamide) 
TBMB  1,3,5-tris(bromomethyl)benzene 
TCEP  tris(2-carboxyethyl)phosphine 
TFA  trifluoroacetic acid 
uPA  urokinase-type plasminogen activator 
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The discovery of ligands with tailored binding properties to targets of interest is es-
sential for the development of therapeutics and diagnostic tools, as well as for the study 
and manipulation of biological systems. In our laboratory, bicyclic peptide ligands 
against targets of interest are routinely developed using an affinity selection strategy 
based on phage display. A first objective of this work was to improve the performance of 
the selection process in two ways: (i) increasing the diversity of the bicyclic peptide li-
braries available by generating new libraries with different ring size combinations, and 
studying the influence of the ring size on the ligands identified; and (ii) maximize the 
amount of specific target-binding sequences and motifs obtained from phage display 
selections using high-throughput sequencing. The final aim was the application of the 
improved selection process to discover bicyclic peptides that could be used as new anti-
biotics. Specifically, I focused on inhibitors of Staphylococcus aureus sortase A, a potential 
antivirulence target. 
1.2 Peptide therapeutics 
Peptides are an attractive class of molecules for the development of novel therapeu-
tics. Natural peptides are able to perform very specific and complex functions, and exhib-
it high specificity for their targets with minimal off-target effects1,2. One of the main 
strengths of peptides as drugs lies in powerful new approaches for the generation and 
screening of combinatorial peptide libraries3, allowing peptide-based ligands to targets 
of choice to be evolved in vitro.  These approaches include phage display and other selec-
tion technologies that will be described in the following section. Peptides can then be 
chemically synthesized and easily conjugated to desired functional groups, such as labels 
or tags. In therapy, their small size allows better tissue penetration than large protein 
therapeutics and reduces the risk of immune reactions1. 
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However, peptides have been generally considered as poor drug candidates due to their 
low oral bioavailability, poor pharmacokinetics, limited systemic stability and poor 
membrane permeability1,4. In spite of the large diversities that can be generated and 
screened by in vitro selection technologies, very few of the identified candidates have 
reached the clinic. An example is peginesatide (Hematide®), a dimeric PEGylated eryth-
ropoietin-mimicking peptide, which was approved in 2012 by the FDA for the treatment 
of anemia associated with chronic kidney disease5,6. It was however withdrawn from the 
market soon after due to adverse side effects7. 
Almost all peptide drugs and drug candidates are naturally occurring peptides or deriva-
tives thereof. In contrast to in vitro evolved peptides, most naturally occurring peptides 
have non-canonical structures which include macrocyclization and unnatural residues 
and linkages8,9. In particular, structural rigidity conferred by macrocyclization can offer 
several advantages in peptide ligands. First, the smaller entropic loss upon binding al-
lows reaching higher target-binding affinities. Second, the lower number of possible con-
formers confers higher specificities. And third, structural constraints render peptides 
less accessible to protease cleavage, showing increased metabolic stability10,11. In certain 
cases, cyclization can additionally enhance membrane permeability12. 
There is therefore considerable interest in translating these non-canonical features into 
in vitro selection systems. Some of the approaches will be discussed in the following sec-
tion, with special emphasis on the generation of phage display libraries of bicyclic pep-
tides. 
1.3 Phage display for the selection of peptide ligands 
1.3.1 Phage display: technology overview 
Phage display is a powerful technology for the isolation of protein or peptide ligands 
to targets of choice13-15. It is an in vitro selection system, pioneered by G. P. Smith in 
1985, in which a library of polypeptide variants is expressed on the surface of phage 
particles as coat protein fusions13. Each particle displays a single polypeptide variant on 
the outside and contains the corresponding coding DNA inside. The linkage between 
phenotype (peptide displayed) and genotype (DNA coding for it) allows the isolation of 
ligands with specific binding properties through a process of affinity selection, and the 
identification of their primary sequence by DNA sequencing (Figure 1). Generally, several 
rounds of affinity selection, infection of bacteria and re-amplification of the phage are 
needed in order to enrich the population in target-specific binders16,17.  
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Figure 1. Scheme of a standard cycle of phage display selection. Combinatorial libraries of 
peptides are displayed on the surface of phage particles as coat protein fusions. In the 
picture, several copies of the peptide variant (blue) are displayed fused to the minor coat 
protein pIII (red). The phage library is incubated with an immobilized target. After exten-
sive washings, target-bound phage are eluted and amplified in new host cells for a subse-
quent round of selection. After several cycles, peptide sequences are identified by DNA 
sequencing. 
Filamentous phage strains M13 and fd are by far the most frequently used17. Phage parti-
cles of these strains consist of a rod-shaped protein coat enclosing the single stranded 
DNA viral genome (with 99% sequence identity between both strains). The coat proteins 
most frequently used for display are pVIII and pIII, although alternative systems on other 
coat proteins have also been described15,17-20. pVIII is present in more than 2000 copies 
and constitutes the body of the phage particle. pIII is present in five copies at one end of 
the phage particle and it is involved in bacterial infection. Different levels of valency (i.e. 
number of copies of the displayed peptide variant per phage particle) can be achieved by 
co-expressing wildtype coat proteins together with the peptide-displaying counterparts 
in order to produce a hybrid virion. Polyvalency (having multiple copies of the same var-
iant on the phage) can be of advantage to isolate binders from naïve libraries, as it en-
hances capture of the phage even when the peptides have weak affinities. However, for 
affinity maturation purposes, monovalent systems might provide a better discrimination 
between high-affinity and low-affinity binders. 
1.3.2 Protein and peptide ligands selected by phage display 
The first molecules to be displayed on phage were linear polypeptides13,21. During the 
1990s, Winter and co-workers applied the technology to the display of variable regions 
of antibodies14. The screening of phage antibody libraries has led to the development of 
several approved therapeutic drugs such as the blockbuster adalimumab, belimumab 
and raxibacumab22-24, all three human monoclonal antibodies. In contrast, linear pep-
Chapter 1. Introduction 
4 
tides isolated by phage display had typically weaker affinities and have been mainly used 
for epitope mapping and research applications25. 
The generation of constrained peptide libraries by cyclization of linear peptides via a 
disulfide bridge between two cysteines allowed the isolation of peptides with higher 
affinities26,27. However, in most cases their affinity was still not sufficient for therapeutic 
applications (in the micromolar to high nanomolar range, in contrast to sub-nanomolar 
affinities of antibodies)28. Only one cyclic peptide isolated by phage display has reached 
the market: the previously mentioned peginesatide, a disulfide-cyclized erythropoietin 
mimetic, approved in 2012 and withdrawn soon after due to undesired side effects. 
In addition to peptides and antibodies, phage display has recently been applied to a 
number of structurally diverse protein scaffolds based on the Z domain of protein A 
(affibodies), fibronectin domains (monobodies), lipocalins, DARPins, and many others29-
33. Several candidates derived from these alternative scaffolds are currently under clini-
cal development, such as the VEGFR2-targeting pegdinetanib34 and the VEGF-targeting 
abicipar35. Both are currently in phase II clinical trials. 
1.3.3 Chemical and enzymatic modifications of polypeptide phage dis-
play libraries 
In order to explore structures or functionalities beyond the ones present in the 20 
natural amino acids, peptides can be modified post-translationally on the surface of the 
phage36,37. In these cases, selectivity of the reaction is essential, as modifications in other 
coat proteins might reduce phage viability and infectivity. 
Thiols from cysteine residues on the peptide constitute ideal reaction handles. Cysteine 
is one of the least abundant amino acids on phage proteins36, and stable cysteine-free 
mutants of the pIII coat protein are available38. Thiol groups have been used to incorpo-
rate additional functionalities into linear polypeptides on phage, such as fluorophores or 
glycan moieties39,40 (Figure 2A). In addition to disulfide bridge formation between two 
cysteine residues on the peptide, thiol groups have also been used for chemical cycliza-
tion of peptides on phage. A very recent example is the modification of phage libraries 
with photo-reactive scaffolds to generate light-responsive cyclic peptide ligands41,42. 
Phage libraries of peptides containing two cysteine residues were cyclized with a thiol-
reactive azobenzene linker. Azobenzene undergoes a pronounced change in geometry 
upon UV irradiation from trans to cis conformation, which in turn changes the confor-
mation of the peptide backbone (Figure 2B). Phage selection of azobenzene-cyclized pep-
tide libraries led to the isolation of photoswitchable ligands with up to 4-fold difference 
in binding affinity between the cis and the trans isomers. Cysteine residues are also used 
for the generation of bicyclic peptides by chemical cyclization of phage-displayed linear 
peptides43,44 (Figure 2C). This cyclization strategy was used in the present work and will 
be discussed in further detail in the following section. 
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Besides thiol groups, recently Derda and coworkers proposed aldehydes, obtained by 
periodate oxidation of N-terminal Ser/Thr residues, as unique reactive handles45. For 
example, using an aminooxy mannose derivative, they were able to generate glycopep-
tide libraries via oxime ligation (Figure 2D). More recently, sortase-mediated 
transpeptidation was also applied to incorporate proteins or small molecules on phage46 
(Figure 2E). Although cysteine residues still represent the most convenient reactive han-
dle on phage, these new alternatives can be used to combine different modifications on 
the same peptide, further increasing the versatility and application of phage libraries. 
 
Figure 2. Modification of peptides on phage. Thiol groups represent convenient reactive 
groups for the incorporation of chemical groups (A) or for cyclization (B, C). Alternative 
strategies include the generation of N-terminal aldehydes (D) or the use of N-terminal 
polyglycine for SrtA-mediated transpeptidation (E). 
1.3.4 Alternative in vitro selection technologies 
Besides phage display, other in vitro selection technologies have been developed and 
applied for the isolation of peptidic ligands. They include mRNA display, ribosome dis-
play, yeast display, bacterial display, among many others. In contrast to phage display, 
mRNA display and ribosome display work entirely in vitro: in mRNA display the peptide 
variant is linked to the mRNA via puromycin47, and in ribosome display via the 
ribosome48. These entirely in vitro systems have the advantage that a transformation 
step is not needed for the generation of the libraries, allowing larger libraries to be ob-
tained with less effort. While the typical library size for phage display is 108 – 109 differ-
ent variants, mRNA display and ribosome display libraries can reach 1014 different vari-
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ants. Additionally, they are more flexible systems regarding the incorporation of unnatu-
ral amino acids. Although phage systems allowing the incorporation of non-natural resi-
dues have been described49, they were limited to one additional amino acid. Additionally, 
the efficiency of incorporation of non-natural residues is lower than their natural coun-
terparts, requiring the optimization of precise growth conditions to minimize this bias. 
mRNA display-based systems, such as the RaPID system developed by Suga and co-
workers8, can overcome some of these limitations. By using a custom-made cell-free 
translation system50, arbitrary aminoacyl-tRNA synthetases can be omitted to leave the 
corresponding codons vacant. These are then assigned to an unnatural residue by adding 
the adequate aminoacyl-tRNAs prepared externally. Such tailor-made aminoacyl-tRNAs 
can be prepared using the flexizyme technology developed by the same group51,52. This 
versatile and flexible system has been used for the selection of nanomolar or even 
picomolar binders of Sirtuin2 (IC50 = 3.7 nM), VEGFR2 (Kd = 33 nM) and E6AP (Kd  = 600 
pM)8. However, the application of this system is technically complex and limits its wide-
spread use by unspecialized laboratories. 
Despite its limitations, phage display remains the most commonly used selection tech-
nology, probably due to its robustness, its versatility and, in the case of peptides, the 
availability of commercial libraries.  
1.4 Previous work on bicyclic peptides 
1.4.1 Natural bicyclic and multicyclic peptides 
Bicyclic and multicyclic peptides are produced by organisms of all kingdoms, both by 
ribosomal and non-ribosomal synthesis, and have very diverse biological activities. Cy-
clization linkages in ribosomally synthesized peptides are typically disulfide, amide, 
thioether or ester bonds. For example, sunflower trypsin inhibitor 1 (SFTI-1) is  a bicyclic 
peptide cyclized head-to-tail and containing an internal disulfide bridge (Figure 3)53. 
Similarly, plant cyclotides are multicyclic peptides cyclized head-to-tail and bridged by 
two or more disulfide bonds54. Vertebrate defensins are antimicrobial peptides cyclized 
by three intramolecular disulfide bridges, where the subfamily of theta-defensins are 
also cyclized head-to-tail55. Multicyclic peptides produced by nonribosomal synthesis 
typically contain unnatural amino acids and show a greater variety of cyclization chemis-
tries. Two examples are the marketed bicyclic peptide drugs actinomycin-D, an antibiotic 
and chemotherapy agent that interferes with mRNA synthesis, and romidepsin, an anti-
cancer agent inhibiting histone deacetylases (Figure 3). 
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Figure 3. Examples of different cyclization chemistries in natural bicyclic peptides. The 
ribosomally synthesized SFTI-1 is cyclized head-to-tail and contains an internal disulfide 
bridge. Actimonycin D and Romidepsin are non-ribosomally synthesized. Actinomycin D 
contains two identical lactone rings connected through an aminophenoxazin group. 
Romidepsin is a cyclic depsipeptide with an internal disulfide bridge. This disulfide 
bridge undergoes reduction within the cells and binds to the Zn atom in the active site of 
histone deacetylases. 
1.4.2 Phage selection of bicyclic peptides 
Combinatorial libraries of bicyclic peptides can be generated by chemical cyclization 
of phage-displayed linear peptides via cysteine residues. In a proof-of-concept work in 
2009, bicyclic peptide libraries were generated by reacting linear peptides containing 
three cysteine residues with the thiol-reactive cyclization scaffold 1,3,5-tris-
(bromomethyl)benzene (TBMB) (Figure 4A). TBMB and other bromomethylbenzene 
derivatives had previously been proposed as suitable reagents for quantitative cycliza-
tion of peptides in aqueous solutions (CLIPSTM technology56,57), and such reactions 
proved compatible with phage. Selections of TBMB-modified phage libraries against two 
human serine proteases, plasma kallikrein and cathepsin G, allowed the isolation of po-
tent bicyclic peptide inhibitors43 (Figure 5). Since then, this system has been applied to a 
variety of targets, resulting in the isolation of inhibitors and ligands with high binding 
affinities (typically in the nanomolar range) and specificities44,58,59. 
In this system, two elements can be varied to increase the diversity of the libraries: the 
cyclization scaffold and the peptide loop lengths. Our laboratory recently developed 
three new cyclization linkers for the generation of phage libraries of bicyclic peptides 
(Figure 4B), namely 1,3,5-triacryloyl-1,3,5-triazinane (TATA),  N,N′,N′′(benzene-1,3,5-
triyl)-tris(2-bromoacetamide) (TBAB), and N,N′,N′′-benzene-1,3,5-triyltrisprop-2-
enamide (TAAB)60. They were designed to provide different environments to the pep-
tides, presenting different geometries and having additional hydrogen bond donors and 
acceptors that could establish further interactions with the backbone or side chains of 
the peptide loops. Two of the linkers, TATA and TBAB, have been successfully applied to 
phage selections. Moreover, the crystal structure of one of the TBAB-selected bicyclic 
peptides showed that this scaffold was able to establish hydrogen bonds with the back-
bone and side chains of the selected peptide61. These new scaffolds can be combined with 
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existing libraries and therefore triplicate their diversity. However, since they are not 
genetically encoded, selections with different scaffolds must be performed separately 
and competition among them is not possible. 
 
Figure 4. Generation of phage display libraries of bicyclic peptides. (A) Phage display li-
braries of peptides containing three cysteine residues are chemically modified with a thi-
ol-reactive scaffold, resulting in combinatorial libraries of bicyclic peptides. TBMB was 
the first scaffold to be used and provides a hydrophobic core. (B) New scaffolds devel-
oped to cyclize peptides on phage. They contain hydrogen-bond donor and acceptor 
groups that can further establish interactions with the peptide. 
Concerning loop lengths, most selections performed so far used the so-called 6×6 library, 
containing two loops of six amino acids each. Libraries of shorter bicyclic peptides (3×3 
and 5×5, containing two loops of three or five amino acids each, respectively) were used 
in selections against human plasma kallikrein (PK)62. In those selections, the specificity 
profiles of the inhibitors could be tuned by modulating the size of the macrocyclic rings. 
For example, the 6×6 inhibitor PK15 inhibited human and monkey PK in the low 
nanomolar range, rat PK in the micromolar range, and did not inhibit any of the 
paralogous proteases tested (such as human factor XIa, thrombin, plasmin or factor XIIa). 
5×5 inhibitors inhibited human, monkey and rat PK in the nanomolar range, but not 
paralogous proteases. Shorter bicyclic peptides of the 3×3 format inhibited human, mon-
key and rat PK as well as human factor XIa in the nanomolar range. For this target, the 
5×5 inhibitors were therefore best suited for drug development as they inhibited orthol-
ogous proteases (allowing their use in animal models) but not paralogous proteases 
(which would lead to undesired side effects). 
Recently, our group also demonstrated that, when libraries with three cysteine residues 
are subjected to panning without chemical modification, peptides with a fourth cysteine 
are strongly enriched63. Most probably, unpaired cysteines form disulfide bridges with 
cysteines of neighboring peptides, thus impairing infection and causing a less efficient 
propagation of such clones. This limitation of phage systems turned out to be of ad-
vantage for the screening of many different peptide topologies. Starting from libraries of 
peptides containing three cysteine residues, the fourth cysteine can appear in any of the 
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randomized amino acid positions, allowing the generation of a large number of topologi-
cally diverse bicyclic structures. In selections against two different model targets, a varie-
ty of binders with different topologies could be identified (Figure 5). 
 
Figure 5. Examples of bicyclic peptides selected from phage combinatorial libraries. PK15 
was identified from a phage library of TBMB-cyclized bicyclic peptides43, and it is a po-
tent inhibitor of human plasma kallikrein (Ki = 2 nM). UK504 was identified from a phage 
library of bicyclic peptides cyclized via two disulfide bridges, and inhibits human 
urokinase-type plasminogen activator (Ki = 7.7 μM). 
1.4.3 Phage selected bicyclic peptides 
Phage selection of bicyclic peptides has been applied to a variety of targets, including 
plasma kallikrein43, cathepsin G43, urokinase-type plasminogen activator (uPA)44, coagu-
lation factor XII58, proteases of other classes (unpublished data) and Her2 receptor59. 
One of the best characterized bicyclic peptide ligands is the uPA-inhibitor UK18 (Ac-
ACSRYEVDCRGRGSACG-NH2, cyclized via reaction of TBMB with the underlined cysteine 
residues, Figure 6). Its target, uPA, is a trypsin-like serine protease involved in tumor 
growth and migration64. It is a key component of the proteolytic cascade leading to active 
proteases responsible for the degradation of the extracellular matrix and other biological 
barriers. UK18 was originally identified from a 6×6 bicyclic peptide library modified with 
TBMB44. It is a potent and selective inhibitor, with a Ki of 53 nM for human uPA and much 
weaker inhibitory activities (Kis of 111-316 μM) for related proteases. Based on the X-ray 
structure of the UK18-uPA complex, a more potent UK18 derivative (UK202, Ki = 28 nM) 
was recently developed by replacement of the glycine at position 13 with D-serine65. 
Another promising bicyclic peptide is the FXII-inhibitor FXII402 (Ac-GCGGRPCPPAYCG- 
NH2, cyclized via reaction of TBMB with the underlined cysteine residues), with a 
Ki of 1.2 μM and more than 100-fold selectivity towards related proteases58. It was iden-
tified by selection of a 4×4 bicyclic peptide library cyclized with TBMB, followed by affin-
ity maturation by rational design. Potent and selective inhibitors of FXII constitute valu-
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able tools in hematology research and are attractive clinical candidates for antithrombot-
ic therapy. 
 
Figure 6. Crystal structure of bicyclic peptide UK18 bound to its target uPA. Both loops 
are involved in the binding, establishing a large interaction surface of 701 Å2. Reprinted 
with permission from Angelini et al. ACS Chem. Biol44. Copyright 2012 American Chemi-
cal Society. 
1.4.4 In vivo studies with phage-selected bicyclic peptides 
Despite successful examples of peptide drugs available on the market, there are sev-
eral limitations for the application of peptides as therapeutics, such as susceptibility to 
protease cleavage in plasma, short half-life due to renal clearance, low oral bioavailability 
and poor membrane permeability.  
Further work on the bicyclic peptide UK18 described above showed that UK18 was more 
resistant to proteolysis in plasma ex vivo than its monocyclic and linear counterparts, or 
the two separate rings alone66. The rigidity of the rings, the smaller size and reciprocal 
protection to a certain extent seemed to cause this increased stability. Moreover, substi-
tution of certain amino acids with unnatural residues could confer additional improve-
ments. For example, the UK18 derivative UK202, in which a glycine was substituted by D-
serine, showed 4-fold higher proteolytic stability65. 
Concerning renal clearance, pharmacokinetic studies with UK18 showed an elimination 
half-life of 30 minutes. In order to reduce renal clearance, two strategies have been ex-
plored: conjugation with an antibody Fc fragment67 and conjugation with an albumin-
binding peptide66 (SA21, developed by Denner and coworkers68). In both cases half lives 
could be substantially increased (36 h for the Fc-conjugate and 24 h for the SA21-
conjugate). More recent work has demonstrated that SA21-conjugated bicyclic peptides 
efficiently diffuse into organ tissues and solid tumor69. 
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Low oral bioavailability and poor membrane permeability still constitute limitations for 
the application of bicyclic peptides as therapeutics. Bicyclic peptides would need to be 
administered intravenously, like most peptide drugs, and their application might be lim-
ited to extracellular targets. These represent however minor limitations and leave a wide 
range of pathological processes or targets accessible to bicyclic peptide drugs. 
In summary, bicyclic peptides represent a promising molecule format for the develop-
ment of new therapeutics. The strategy to generate and screen large combinatorial li-
braries of bicyclic peptides was developed only recently and it has already shown very 
promising results. Ongoing work is focused both on improvements for in vivo therapeutic 
application of several bicyclic peptides leads, as well as on the discovery of new leads 
against different targets. 
1.5 High throughput sequencing (HTS) of DNA-encoded li-
braries 
One of the strengths of in vitro selection methods is the easy identification of the se-
lected peptides by DNA sequencing. Over the last 30 years, DNA sequencing technology 
has been dominated by Sanger sequencing and fluorescence-based electrophoresis70,71. 
Capillary-based, semi-automated implementations of Sanger biochemistry have been 
routinely used by virtually every biological and biomedical laboratory in basic and ap-
plied research, in academia, industry and clinic. It has led to a number of accomplish-
ments, by providing a tool for decoding complete genes and later genomes72. In the last 
decade, several high throughput sequencing (HTS) technologies – also called next gener-
ation sequencing (NGS) technologies – have emerged. They are able to provide unprece-
dented volumes of sequence data in a rapid and economic manner73, and have revolu-
tionized the field of DNA sequencing and genomics. 
1.5.1 HTS technologies 
At present, multiple platforms coexist in the market, with each having advantages for 
specific applications over others. Rather than individual clones, HTS platforms sequence 
whole libraries of DNA fragments, where the total number of fragments that can be se-
quenced and their maximum length depend on the platform. A summary of the character-
istic of the major HTS platform families is given in Table 1. Three technologies have been 
mainly applied for the sequencing of DNA-encoded libraries, and will be described in this 
section: Roche 454 pyrosequencing, Illumina dye sequencing and Ion semiconductor 
sequencing (also known as Ion Torrent). The sequencing process can be divided in three 
steps for all three technologies: (i) library preparation, (ii) clonal amplification of library 
fragments, and (iii) the sequencing reaction itself. 
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The library preparation consists on the generation of a library of DNA fragments of the 
adequate length flanked by platform-specific adaptors. For genome sequencing, it is nec-
essary to shear the DNA in shorter fragments and to ligate them to the adaptor sequenc-
es. In the case of DNA-encoded libraries, DNA fragments can be amplified by PCR using 
suitable primers containing the adaptor sequences. 
Next, library fragments are clonally amplified in localized foci. This step is necessary to 
increase the signal that will be detected during the sequencing reaction. 454 
pyrosequencing and Ion Torrent use emulsion PCR to amplify library fragments on the 
surface of beads, each bead bearing a single template. In the Illumina system, library 
fragments are amplified by "bridge amplification" to form clusters of identical clones in 





amplification Sequencing reaction 
Max. read 
length 
Max. # of 
reads 
454 Emulsion PCR Pyrosequencing  (seq-by-synthesis) 700 bp 1 Million 






Ion Proton Emulsion PCR 






SOLiD Emulsion PCR Oligonucleotide ligation (seq-by-ligation) 75 bp 3 Billion 
PacBio N/A (single molecule) Fluorescent nucleotides (seq-by-synthesis) 8500 bp 0.8 Million 
Table 1. Summary of the major NGS platforms available. 
Finally, the sequencing reaction relies in the three cases on the so-called "sequencing by 
synthesis": a polymerase is used to synthesize the complementary strand of a single-
stranded template, and the sequential incorporation of nucleotides is monitored. In the 
case of 454 pyrosequencing, each bead is placed on a different microwell on a chip, to-
gether with other smaller beads bearing the necessary enzymes (ATP-sulfurilase and 
luciferase). In each cycle, a single species of unlabeled nucleotide is introduced and in-
corporation events are detected thanks to pyrophosphate (PPi) release. ATP sulfurylase 
converts PPi to ATP, which allows the luciferase-mediated conversion of luciferin to 
oxyluciferin, generating visible light. The amount of light is proportional to the ATP and 
therefore to the number of nucleotides incorporated, and can be detected by a camera. 
Ion Torrent works similarly, but detects the release of protons upon nucleotide incorpo-
ration through the change of pH, which is also proportional to the number of nucleotides 
incorporated. In this case no additional enzymes or substrates are needed. Illumina se-
quencers rely on reversible dye terminators. All four nucleotides are provided in each 
cycle (carrying different fluorescent labels and with a 3'-OH blocking group) and the 
corresponding one is incorporated by the polymerase. After washing, the flow cell is im-
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aged and then the fluorescent group is cleaved leaving the 3'-OH deprotected for the next 
cycle. 
1.5.2 Application of HTS to in vitro selections 
High throughput sequencing for the analysis of in vitro selection processes is becom-
ing increasingly popular. The first technology to be developed was 454 pyrosequencing, 
and was also the first one to be applied to selections of DNA-encoded libraries74. Illumina 
sequencing has been the most extensively used technology, and was employed for the 
characterization of phage libraries of peptides and antibodies75,76, mRNA libraries of 
fibronectin domains77 and ribosome display libraries78. There are also some examples of 
the application of Ion Torrent for phage peptide libraries and mRNA peptide librar-
ies79,80. 
For the sequencing of antibody repertoires, the long sequences provided by 454 
pyrosequencing (Table 1) are well suited for V region analysis81. Illumina has also proven 
especially useful for phage antibody screenings. It provides a significantly higher 
throughput (> 100-fold), although the shorter read length has restricted its application 
for the analysis of CDR3 regions. The CDR3 regions of both light and heavy chains have 
proven to be the most relevant contributors to antibody specificity, and in some designed 
libraries are the only regions to be randomized76. For sequencing of peptide libraries, 
where short reads do not represent a limitation, Illumina sequencers have been the most 
commonly used75,82.  
HTS technologies have been mainly used for genome sequencing and for large-scale 
comparative and evolutionary studies. For such applications, the existence of genome 
assemblies of most model organisms has boosted the use of these short-gun technolo-
gies, which provide a large number of short reads. Most software therefore focuses on 
genome mapping of sequenced fragments to existing assemblies. In the case of in vitro 
selection technologies, HTS allows to get an unprecedented coverage of the selection 
outputs, which before was limited to a maximum of a few hundred clones. However, the 
bioinformatic challenges are very different and there are not yet broadly applicable tools 
to analyze HTS results from in vitro selections. As a consequence, although phage display 
is a wide spread technique used in many laboratories (especially due to the availability of 
commercial libraries), very few laboratories have the capabilities to apply HTS to charac-
terize their selection results. 
1.5.3 Ion Torrent sequencing 
In this work, the Ion Torrent PGM platform was chosen for the analysis of phage se-
lections, since it provides a suitable read length and a good trade-off between throughput 
and cost. Using the Ion 316TM Chip, more than 3 million sequences can be obtained. This 
is enough to cover the diversity of standard outputs from phage selections (typically 
between 103 and 105), and even allows multiplexing several samples in the same chip, 
Chapter 1. Introduction 
14 
further reducing the costs. The workflow for sample preparation and sequencing is de-
picted in Figure 7. In brief, the region coding for the bicyclic peptide is amplified from the 
phage vector using suitable primers, containing adaptor sequences (needed for the sub-
sequent steps) and a barcode. The barcode is a short sequence tag, typically 4-6 nucleo-
tides, that allows the parallel sequencing of several samples in the same chip (multiplex-
ing). The resulting PCR products are then clonally amplified on the surface of beads by 
emulsion PCR. Individual DNA molecules and primer-coated beads are isolated in aque-
ous droplets within an oil phase, where each droplet constitutes a PCR microreactor that 
amplifies a single DNA template. To guarantee only one template molecule per droplet 
(or none, but not more than one), most of the emulsion will be by definition empty of 
template molecules. After breaking the emulsion, the PCR-positive beads are separated 
from the non-templated beads, and loaded on the sequencing chip. The chip consists of 
millions of independent wells that essentially act as pH-meters, monitoring nucleotide 
incorporation by measuring the direct release of protons. The signal is converted to a 
sequence of nucleotides, generating two files: a "standard flowgram format" (SFF)- for-
matted file, which contains information about nucleotide flows that both did and did not 
result in base incorporation; and a FASTQ-formatted file, which contains the resulting 
sequence with quality scores. The Ion Torrent system also includes a pre-processing 
step, consisting of: (i) quality checks, to remove reads resulting from mixed DNA tem-
plates and/or having low signal quality, and (ii) trimming of 3' adaptor sequences. 
 
Figure 7. Ion Torrent sample preparation and sequencing workflow. First, the region of 
interest is amplified by PCR using primers containing adaptor sequences and barcodes. 
Then, library fragments are clonally amplified on beads by emulsion PCR. DNA-bearing 
beads are loaded on the sequencing chip, containing millions of independent wells. For 
the sequencing reaction, nucleotides are added sequentially and incorporation events are 
monitored by pH changes due to proton release. 
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1.6 Peptides as antibacterial agents  
The World Health Organization’s 2014 report on antimicrobial resistance highlights 
that antibiotic resistance is putting at risk the ability to treat common infections in the 
community and hospitals83. The report draws special attention to untreatable gonococcal 
infections resistant to third generation cephalosporins, multidrug resistant 
E. coli and K. pneumoniae infections, and methicillin-resistant S. aureus (MRSA). Despite 
significant efforts by pharmaceutical companies, very few antibiotics have reached the 
clinic in the last decades, and most are derivatives of previously approved drugs84,85. 
There is therefore a need of both new antibiotics and antibiotic-discovery platforms able 
to tackle this inevitable emergence of resistance. Phage libraries of bicyclic peptides 
could constitute a source of diversity to screen for new antibacterial compounds. 
1.6.1 Natural peptide antibiotics 
Many natural antibiotics and antimicrobial compounds are based on peptides. There 
are examples of both non-ribosomally synthesized (e.g. gramicidins, polymyxins, glyco-
peptides) and ribosomally synthesized (e.g.  human defensins and bacteriocins) peptide 
antibiotics. Their mechanisms of action are also very diverse. The term "antimicrobial 
peptides" (AMP) is typically used to refer to short cationic peptides present throughout 
all kingdoms of life as part of the innate immune defenses86. They disrupt bacterial mem-
branes causing cell death, although the precise mechanism is still a subject of debate87. 
Other peptide antibiotics exert their action through binding to specific targets. For ex-
ample, vancomycin binds to the D-Ala-D-Ala moiety of lipid II cell wall precursors, thus 
preventing their use for cell wall biosynthesis. Nisin has a dual mechanism of action: the 
N-terminal region binds to the phosphate groups in lipid II, preventing cell wall biosyn-
thesis, and the C-terminal region form pores on the membrane88. Some peptide antibiot-
ics are even able to target intracellular processes, like the thiopeptide thiostrepton, 
which blocks translation by interfering with the elongation factor G in the ribosome89. 
1.6.2 In vitro evolution of peptide-based antibiotics 
In vitro selection technologies have also been applied to find ligands to antibacterial 
targets with the aim of developing new drugs, although with limited success. One of the 
few successful examples is raxibacumab, a human monoclonal antibody for the treatment 
of inhaled anthrax24, originally isolated from a phage display library. It specifically binds 
the protective antigen (PA) protein, a component of anthrax toxin, and prevents its bind-
ing to the anthrax toxin receptor with an IC50 of 0.5 nM. It does not directly harm the 
pathogen but acts by preventing toxin-mediated damage to the host. 
Peptide libraries have been screened for inhibitors of several antibacterial targets such 
as Mur enzymes, involved in cell wall synthesis, β-lactamases, responsible for β-lactam 
antibiotic resistance, and other proteins85,90,91. However, only weakly active peptides 
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have been identified. An exception is the beta-hairpin peptide POL7080, a drug candidate 
against Pseudomonas infections92. It was discovered through iterative optimizations from 
a synthetic library of cyclic peptidomimetics that were designed based on the cationic 
antibacterial peptide protegrin-1, and cyclized through the beta-hairpin promoting di-
peptide D-Pro-L-Pro. It showed potent activity against Pseudomonas spp. (including 
drug-resistant strains), while being inactive against other species of gram-negative and 
gram-positive bacteria. The target LptD, an outer membrane protein that transports LPS, 
was identified in a subsequent genetic screen and was a previously unexploited antibac-
terial target. POL7080 recently completed Phase I clinical trials. 
 
Figure 8. Examples of peptide antibiotics. 
1.6.3 Targeting S. aureus pathogenesis 
S. aureus is one of the main causes of fatal infections. It causes both superficial and in-
vasive infections, including toxic shock syndrome, pneumonia, sepsis and infective endo-
carditis. Antibiotic treatment is often ineffective due to the development of resistant 
strains. Most isolates are penicillin resistant (between 65% and 90% in an European 
study on commensal S. aureus in 2013)93. Moreover, the prevalence of methicillin-
resistant S. aureus (MRSA) strains in hospitals is alarming, and community-acquired 
MRSA cases are increasingly common94. The last-resort antibiotic for the treatment of 
MRSA strains is vancomycin, but vancomycin-resistant strains (VRSA) have also been 
reported95. Although VRSA strains are fortunately still rare, there is an urging need to 
discover new effective S. aureus drugs. 
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S. aureus pathogenesis can be divided in 5 stages: (i) colonization, (ii) local infection, (iii) 
systemic dissemination and sepsis, (iv) metastatic infection, and (v) toxinosis. Between 
20% and 75% of the population is permanently or transiently colonized by S. aureus, 
which is carried asymptomatically. It behaves as an opportunistic pathogen, initiating 
infections when damage in skin or a mucosal barrier allows access to tissues or the 
bloodstream. Once in the vascular system, staphylococci can adhere to endothelial cells 
and be phagocytized. This intracellular environment can further protect the pathogen 
from the immune system and antibiotics, causing recurrent infections. It can also spread 
and colonize distant organs. Septic shock can ensue due to systemic infections or from 
locally secreted toxins, even when the bacteria have not reached the blood. 
There are several factors contributing to the success of S. aureus as a human pathogen: 
the abundance of cell-surface and secreted virulence factors96, and the great genetic rep-
ertoire for adapting to hostile environments97. In the search for new antibacterial ap-
proaches, antivirulence therapies have been proposed as potential alternatives. They aim 
at reducing virulence (pathogen-induced host damage) without killing the pathogen, 
offering a reduced selection pressure for drug-resistant mutations and preserving the 
host endogenous microbiome. Phosphosulphonates, for example, are drugs that inhibit 
S. aureus enzyme CrtM, responsible for the synthesis of a pigment that protects the bac-
teria from reactive oxygen species (ROS) produced by phagocytic defense of the host. 
S. aureus are not directly harmed by the drug, but are more susceptible to be killed by 
ROS at the site of infection. Proposed antivirulence strategies also include preventing 
toxin-mediated damage (as in the case of the previously mentioned raxibacumab, pg. 15), 
inhibiting "quorum sensing" (chemical signaling among bacteria that trigger responses to 
cell density and environment changes), and impeding microbial attachment and invasion 
of host tissues98,99. Regarding this last strategy, sortases, the enzymes responsible for the 
anchoring of adhesins and other virulence factors to the cell wall, have emerged as prom-
ising targets and will be described in the next section. 
1.6.4 Sortase A as an antivirulence target 
Sortases are transpeptidase enzymes from gram positive bacteria that anchor secret-
ed proteins to bacterial cell surfaces (Figure 9). They specifically cleave within a sorting 
motif, present at the C-terminus of surface proteins, and covalently anchor the resulting 
carboxyl end to the cell wall. They are classified into different groups based on sequence 
homology, the substrate motif they recognize, and the acceptor nucleophile of the 
transpeptidation reaction. In S. aureus two sortase enzymes have been described: 
sortase A (SrtA, recognizing the motif LPXTG), responsible for the anchoring of proteins 
involved in adhesion to host cells and tissues and in immune evasion100; and sortase B 
(SrtB, recognizing the motif NPQ/KTN), which anchors proteins involved in iron up-
take101. Interest in sortase as an antivirulence target comes from findings that loss of 
SrtA in S. aureus led to reduced pathogenicity. In a kidney abscess model, SrtA knockout 
mutants showed a 2-log decrease in cell titers in kidney lesions, and a 1.5-log increase in 
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LD50 (dose causing death in 50% of the mice)102. Similar results were observed in mouse 
models for infective endocarditis, septic arthritis and lung infection103-106. In contrast, 
SrtB contributed only marginally to the pathogenesis of staphylococcal infections, alt-
hough it seemed to be involved in the persistence of the infection103.  
 
Figure 9. SrtA recognizes membrane-bound precursors of surface proteins by the con-
served LPXTG motif and covalently anchors them to the pentaglycine moiety of lipid II.  
SrtA from S. aureus is a 206-residue cysteine protease with an N-terminal membrane 
anchor. Analysis of the NMR structure revealed a previously unseen β -barrel structure 
with eight β-strands (Figure 10B and C), with the active site within an elongated hydro-
phobic groove. A histidine residue at position 120 is located in close proximity to the 
catalytic cysteine residue (position 184). Both residues are essential for SrtA activity107, 
and most evidence suggest a reverse protonation catalytic mechanism, where only a mi-
nor fraction of the enzyme is catalytically active108 (Figure 10A). It cleaves surface pro-
tein precursors between the threonine and the glycine of the LPXTG motif, forming a 
thioester bond with its active site sulfhydryl. Nucleophilic attack of the amino terminus 
of the pentaglycine in lipid II peptidogylcan precursor completes the sorting reaction. 
The repertoire of cell wall-anchored proteins varies among strains. SrtA-anchored pro-
teins include MSCRAMMs (microbial surface components recognizing adhesive matrix 
molecules), which drive adhesion to fibrinogen, fibronectin, collagen and other matrix 
molecules in the host; and protein A, which binds the Fc portion of immunoglobulins and 
is therefore involved in immune system evasion. Surface proteins show functional re-
dundancy (e.g. at least five cell wall anchored proteins bind the plasma glycoprotein fi-
brinogen). Knockout mutants of single proteins are only partially defective in the studied 
function, thus the interest in targeting the common SrtA-mediated anchoring step. 
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Figure 10. (A) Proposed reversed protonation catalytic mechanism for SrtA. The 
nucleophilic Cys184 thiolate attacks the carbonyl of the scissile T-G bond, resulting in the 
formation of a tetrahedral intermediate. His120 facilitates the collapse of the tetrahedral 
intermediate and formation of the acyl-enzyme by protonating the substrate leaving 
group. Figure adapted from Ref. 109. (B) and (C) NMR structure of the acyl-enzyme in-
termediate with a LPAT* substrate (green) (PDB ID 2KID). Ca2+ stabilizes the β6/β7 loop 
by orienting Glu171, inducing a short helix (magenta) providing contacts with the sub-
strate. 
Importantly, the expression of sortases, MSCRAMMs and other virulence factors is regu-
lated in a growth-phase dependent manner by agr and sar loci110. Both surface proteins 
and sortases are predominantly expressed during exponential growth, while secreted 
proteins are upregulated during the stationary phase. This sequential expression may 
have clinical importance, as different stages of staphylococcal infection seem to require 
different panels of virulence determinants. 
1.6.5 Sortase A inhibitors 
SrtA has been targeted in several antibacterial drug discovery programs111, and a 
number of inhibitors have been reported, although none has reached the clinic yet. 
Several natural products have shown inhibitory activities against SrtA, the best in the 
micromolar range (Table 2, Figure 11A). Examples include aaptamines, topseptins and 
pigments such as curcumin and morin112-114. These natural products have shown effects 
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on adhesion and/or biofilm formation in S. aureus and other species when applied in the 
in vitro IC50 range. However, it is unclear whether these effects were due to the specific 
inhibition of SrtA or caused by off-target effects, since these compounds have also been 
shown to inhibit unrelated proteases or to induce cytotoxicity at the used concentra-
tions115-117. 
The screening of chemical libraries has also led to the identification of small molecule 
inhibitors of SrtA. An example is DMMA (Figure 11B) with an IC50 = 9.1 μM118. This com-
pound is the only SrtA inhibitor that has been evaluated in mice119. Mice treated with 
DMMA showed an increased survival rate and lower S. aureus titers in kidneys and joints. 
However, a similar effect was also observed in mice infected by S. aureus lacking SrtA, 
and therefore the reduced virulence could not be specifically attributed to SrtA inhibi-
tion. Inhibition of SrtB (for which DMMA has an IC50 = 34 μM) and other processes may 
have played a role. The most potent competitive inhibitor reported is a pyrazolethione 
compound111 (Figure 11B). It showed sub-micromolar in vitro activities against SrtA but 
was reported to be unstable and its effects on S. aureus have not yet been assessed. 
 
  IC50 in vitroa 
Assay on 
S. aureusb 






mercuribenzoic 120 μM 
Seb  
anchoring Covalent 74 μM 120 
Methanethiosulfonate N.D. Seb  anchoring Covalent N.D.** 120 
Natural  
products 
Isoaaptamine 16.2 μM Newman  adhesion to Fn N.D. 220 μM 112 
Bromodeoxytopsentin 
[bis(indole)alkaloid] 48 μM 
Newman  
adhesion to Fn N.D. 250 μM 113 
Curcumin 37.5 μM Newman  adhesion to Fn N.D. > 500 μM 114 
Morin  
(flavonoid) 37.4 μM Fg clumping N.D. > 300 μM 121 
β-sitosterol-3-O-
glucopyranoside 30 μM 
Newman  
adhesion to Fn N.D. > 300 μM 122 
Berberine chloride 23 μM N.D. N.D. 270 μM 123 
Chemical 
libraries 
DMMA 9.2 μM Newman  adhesion to Fn Competitive > 650 μM 118,124 
Pyrazolethione  
compound 0.3 μM N.D. Competitive > 500 μM 111 
Phenyl vinyl sulfone 740 μM Newman  adhesion to Fn Covalent 6 mM 125 
AAEK2 15 μM N.D. Covalent N.D.** 126 
Peptidic 
Peptidyl diazo/chloro-
methanes N.D. N.D. Covalent N.D. 127 
Phosphinic-
peptidomimetic 10 mM N.D. N.D. N.D. 128 
Table 2. Summary of SrtA inhibitors. (a) IC50 values reported in vitro with recombinant SrtA expressed 
in E. coli. (b) Assays performed to evaluate SrtA inhibition in S. aureus. (c) Minimum inhibitory concentration. 
N.D: not determined. **: antimicrobial activity was observed but MIC was not reported. 
In order to develop more specific inhibitors, various groups tried to design inhibitors 
based on the substrate. For example, substrate-derived affinity labels based on the 
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recognition motif coupled to a chemical warhead (LPAT-CHN2 and LPAT-CH2Cl) showed 
selective labeling of SrtA in crude cell lysates prepared from transfected E. coli and 
wildtype S. aureus. These inhibitors had low Ki values of 0.2 μM but inactivation rates 
were relatively poor (in the order of 10-2 min-1). In a different approach, phosphinic 
peptidomimetics (Figure 11C) were designed to mimic the transition state of the acyl-
enzyme intermediate. The resulting compounds proved useful for the characterization of 
the catalytic mechanism128, but they had weak affinities in the millimolar range, limiting 
their application as therapeutics. In conclusion, there is still a need for specific and po-
tent inhibitors of SrtA to evaluate it as an antibacterial target. 
 
Figure 11. SrtA inhibitors. (A) Natural products. (B) Small molecule inhibitors from li-




Chapter 2  
 
Phage display libraries of differently sized bicy-
clic peptides 
This chapter is based on a publication by Rentero Rebollo I, Angelini A, Heinis C. Phage display libraries 
of differently sized bicyclic peptides. Med. Chem. Commun. 2012, 4: 145-150 - Reproduced by permis-
sion of The Royal Society of Chemistry. 
2.1 Introduction 
Cyclic peptides are an enticing class of molecules for the development of therapeutics. 
They can act as protein domain mimics, reaching in some cases antibody-like affinity and 
specificity, while having favorable properties of small molecules such as high stability, 
access to chemical synthesis and good tissue penetration4,129. Phage display has emerged 
as a powerful tool for the high-throughput screening of polypeptides including cyclic 
peptides130. Since it relies on ribosomal synthesis, peptides are expressed as linear poly-
mers and cyclization can be achieved by flanking the randomized segment with a pair of 
cysteine residues, which form a disulfide bridge upon oxidation. Recently, a new strategy 
has been developed to generate phage-encoded libraries of bicyclic peptides43. In brief, 
random peptides containing three cysteine residues are displayed on phage and reacted 
with the trivalent thiol-reactive compound tris(bromomethyl)benzene (TBMB) (Figure 
12A). TBMB reacts efficiently and selectively with the cysteine side chains under mild 
conditions and yields bicyclic peptide structures56. Affinity selections against plasma 
kallikrein, cathepsin G and, more recently, urokinase-type plasminogen activator (uPA) 
yielded highly selective inhibitors in the nanomolar to sub-nanomolar range43,44,62. These 
bicyclic inhibitors had higher binding affinities than monocyclic ones previously generat-
ed to the same targets. 
Loop length diversity is already an acknowledged component for the engineering of mo-
lecular recognition surfaces in protein scaffolds or cyclic peptides. Length plays an im-
portant role in the diversity of complementarity-determining regions of natural antibod-
ies, and it is the primary determining factor for their conformations. Insertion of length 
diversity in synthetic antibody libraries allowed higher binding affinities to be 
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reached131. Similar results were obtained when the length of the binding loops was var-
ied in other protein scaffolds such as the 10th type III domain of human fibronectin 
(Fn3)132. Furthermore, conformational diversity, given by loop length variability, was 
sufficient to compensate for restricted chemical diversity when screening Fn3 libraries 
having loops consisting of only Tyr and Ser residues133. Studies on cyclic peptide libraries 
suggested that the tightest binders are more likely to be identified by screening multiple 
libraries with variable loop length since targets often have preferences for specific pep-
tide constraints134,135.  
So far, only macrocycle libraries having two rings of equal size have been screened by 
phage display43,44,62. Most affinity selections have been performed with a library having 
two equal rings, each containing six random amino acids (abbreviated as 6×6 bicy-
clic peptides)43,44. Phage panning against the serine protease plasma kallikrein yielded 
potent inhibitors43. Comparison of the peptide sequences revealed three consensus re-
gions present in the first or second peptide loop. To affinity mature these inhibitors, 
three semi-randomized libraries were created, each having one of the three consensus 
sequences in one loop and six random amino acids in the other loop. Several improved 
inhibitors with Kis as low as 2 nM were obtained, wherein all improved clones were de-
rived from only one of the three libraries. In selections against uPA, two classes of bicy-
clic peptides were isolated, the major one with a consensus sequence in the first peptide 
ring, and the minor one with a consensus sequence around the middle cysteine44. The 
best inhibitor (UK18) showed a Ki of 53 nM. In this case, affinity maturation attempts 
with libraries based on either of the consensus sequences could not improve the potency 
beyond the one of the best inhibitor. These results suggested that some peptide leads are 
more suited for the affinity maturation than others and that it is of advantage to have 
several consensus sequences as starting points. 
In this work, we aimed at generating libraries of bicyclic peptides with different combi-
nations of ring sizes in order to find more potent inhibitors and/or a larger diversity of 
binding motifs that could be used as constant regions in affinity maturation libraries. In a 
recent study, the size of bicyclic peptides was reduced to modulate their specificity. The-
se bicyclic peptides having slightly smaller rings (5 instead of 6 randomized amino ac-
ids per ring, termed 5×5 peptides) bound tightly to the serine protease plasma kallikrein, 
inhibiting the human and murine orthologs but not any human paralogous proteases62. 
Herein, we generated bicyclic peptide phage libraries with combinations of differently 
sized macrocyclic rings. Specifically, we cloned 14 phage peptide libraries of the format 
Cys-(Xaa)m-Cys-(Xaa)n-Cys, wherein the number ‘m’ and ‘n’ of random amino acids be-
tween the cysteine residues was 3, 4, 5 or 6 (Figure 12). The libraries were subjected to 
affinity selections either in groups or all together against the cancer-associated protease 
uPA. 
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Figure 12. Bicyclic peptide phage libraries with different ring sizes. (A) Chemical struc-
ture of a representative bicyclic peptide (UK368) with green rings of 3 and 4 amino acids. 
For size comparison, the peptide rings with 3, 4, 5 and 6 variable amino acids are shown 
as grey circles. (B) Overview of the libraries. Indicated on the axes is the number of vari-
able amino acids in the two rings of the bicyclic peptides. Libraries that were cloned in 
this work are indicated with light green (library A), green (library B) and black dots (li-
brary C). The 6×6 library indicated with a red dot was cloned previously. 
2.2 Results and discussion 
2.2.1 Phage-encoded bicyclic peptide libraries with variable ring sizes 
The 14 bicyclic peptide phage libraries were cloned using degenerate primers that al-
low all 20 amino acids in the randomized positions. The libraries are termed according to 
the number of random amino acids per peptide ring. For example, the library 3×4 con-
tains bicyclic peptides with 3 and 4 random amino acids in the first and second ring, re-
spectively (Figure 12A). The library 6×6 already existed and was not newly cloned 
(Figure 12B, indicated as a red dot). Libraries with similar numbers of random-
ized amino acid positions were pooled as follows: bicyclic peptides of the format 3×4, 
4×3, 4×4, 3×5 and 5×3 formed the library A (7 and 8 random amino acids; Figure 12B, 
light green dots), those of the format 3×6, 6×3, 4×5 and 5×4 formed the library B (9 ran-
dom amino acids; Figure 12B, green dots) and those of the format 4×6, 6×4, 5×5, 5×6, 
6×5 formed the library C (10 and 11 random amino acids; Figure 12B, black dots). The 
diversities of the libraries were quantified by counting the number of bacterial colonies 
formed after transformation and were relatively small (between 107 and 5×108 cfu). Se-
quencing clones from libraries A, B and C showed that peptides with all possible combi-
nations of ring sizes were represented (Table 3). 
2.2.2 Phage selections of bicyclic peptides against a serine protease 
Phage selections were performed against the human serine protease uPA. The three 
libraries A, B and C modified with TBMB56 were individually subjected to affinity selec-
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tions. In parallel, a fourth selection was performed mixing the three libraries with the 
previously generated 6×6 library (size: 4×109 clones)43, in order to allow competition 
among all the bicyclic peptide formats. Biotinylated uPA was immobilized on magnetic 
streptavidin beads in the first round and on magnetic neutravidin beads in the second 
round to prevent the enrichment of streptavidin or neutravidin binders. Negative con-
trols in which the libraries were panned against streptavidin- (first round) or 
neutravidin- (second round) coated beads allowed the quantification of phage that 
bound specifically to uPA. Already in the first round of selection, the number of phage 
isolated against uPA was 10-fold higher compared to the negative control selection 
(Figure 13A). The enrichment over the negative control rose to 104-fold in the second 
round. Similar enrichments were observed for all libraries, suggesting that all contained 
a large portion of uPA-specific bicyclic peptide binders.  
 
Library Loop length Before selection 2nd round 3rd round 
A 
3×4 7 3 12 
4×3 2 1 0 
4×4 8 4 7 
3×5 10 1 1 
5×3 6 3 1 
B 
3×6 4 1 0 
6×3 1 2 0 
4×5 15 12 8 
5×4 8 1 0 
C 
4×6 10 1 5 
6×4 4 4 6 
5×5 13 2 0 
5×6 3 1 0 
6×5 7 3 1 
Table 3. Representation of bicyclic peptide formats. Indicated are the numbers of differ-
ent clones with the respective format found in the library before and after two or three 
rounds of phage selection 
2.2.3 Consensus sequences of bicyclic peptides isolated after two 
rounds of selection 
Sequencing of 48 peptides isolated from the three libraries revealed a total of six dif-
ferent consensus sequences (Figure 14). One of the consensus sequences (S/TAR) was 
found in all the three libraries and in a total of 22 different peptides. This sequence ap-
peared in either the first or second peptide ring, and was found in peptide rings with 4, 5 
and 6 but not 3 amino acids length (Figure 14). The conformational constraint imposed 
in a loop with 3 amino acids might prevent the tri-peptide from binding to uPA. For the 
other five consensus sequences, bicyclic peptides within each group had in most cases 
the same or similar ring sizes. In peptides isolated from library A, two consensus se-
quences were identified, the first one being present in the second 4-amino acid ring of 
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3×4 and 4×4 peptides (K/RFSX; 'X' represents any amino acid). The second consensus 
sequence was found exclusively in bicyclic peptides having the 5×3 format 
(S/TI/LRCPSFC). In peptides isolated from library B, a consensus sequence was found in 
the second ring of 4×5 bicyclic peptides (TKY/FTL/M). In selections with library C, a con-
sensus sequence was found in bicyclic peptides of the 6×4 format (CNXYYSXCS/T). In the 
fourth experiment in which all libraries as well as the library 6×6 were mixed and sub-
jected to selections, none of the bicyclic peptide formats was enriched over the others. 
However, the more ubiquitous S/TAR motif, which can be accommodated in different ring 
sizes, predominated in this selection. 
 
Figure 13. Number of phage clones isolated from the various libraries in the 3 rounds of 
selection. (A) Enrichment factors found for the different selections (number of phage 
captured in the presence of uPA divided by the number of phage isolated in the absence 
of uPA). The enrichment factors of 103 to 104 obtained for all libraries indicate that uPA-
specific peptides were isolated. In the third round, phage isolated in all the four individu-
al second round selections were pooled, amplified and together subjected to a third 
round of panning towards uPA. (B) Phage selections performed with different concentra-
tions of uPA (third round of panning). The numbers of isolated infective phage particles 
are indicated. (C) Phage selections with competitive ligand (UK18) (third round of pan-
ning). After binding of phage to immobilized uPA, the competitive inhibitor UK18 
(Ki = 53 nM)44 was added for different incubation time periods (indicated on the abscissa 
in the graph) to prevent re-binding of weak ligands. The numbers of isolated infective 
phage particles are indicated. 
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Figure 14. Bicyclic peptides isolated after two rounds of affinity selection. Libraries with 
similar numbers of randomized amino acids were pooled and subjected to selections 
with uPA. (A) Library A (7 or 8 randomized amino acids). (B) Library B (9 random-
ized amino acids). (C) Library C (10 or 11 randomized amino acids). (D) Library A, B and 
C as well as library 6×6. Sequence similarities are highlighted with colors. 
2.2.4 Third round of panning applying more stringent selection condi-
tions 
Phage clones isolated after two rounds of panning in the four independent selections 
were mixed together and subjected to a third round (Figure 13A). To isolate only the 
tightest-binding peptides, we applied more stringent panning conditions. In one set of 
experiments, phage was incubated with lower concentrations of biotinylated uPA (rang-
ing from 2 nM to 31 pM) before capturing them on streptavidin-coated beads. At lower 
concentrations, the number of captured phage was gradually reduced (Figure 13B). In 
the second set of experiments, the bicyclic peptide UK18, which binds to the active site of 
uPA with nanomolar affinity, was used to compete off weak binders. As anticipated, few-
er phage remained on the beads at longer incubation times (Figure 13C). This latter ex-
periment indicated that a large portion of the bicyclic peptides isolated in the second 
round of selection was binding to the active site of uPA. 
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Figure 15. Bicyclic peptides isolated after three rounds of affinity selection. Sequence 
similarities are highlighted in color. The inhibitory activities (Kis) of several TBMB-
cyclized peptides are indicated (average values of at least three measurements). 
2.2.5 Consensus sequences of bicyclic peptides isolated after three 
rounds of selection 
Sequencing of 149 clones isolated in the third selection round showed a smaller but 
still high sequence diversity (50 different peptides) and significantly stronger consensus 
sequences (Figure 15). Two of the consensus sequences derived from the 6×6 library 
were exactly the same as found in previous selections against uPA (Figure 15, top two 
consensus sequences). Several peptides contained again the tri-peptide motif (S/TAR) 
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that was already found in different bicyclic peptide formats after the second round of 
panning. This consensus sequence was flanked by specific amino acids that likely in-
crease the binding affinity. A strong consensus covering 9 amino acid positions 
(CTA/VRTCPAT/SXVL/MC) and containing the TAR motif was preferentially found in the 
4×6 bicyclic peptide format with one exception, a 4×4 bicyclic peptide (UK364). Another 
consensus sequence also containing the TAR motif covered 6 amino acid positions 
(TARCPQS) and was found in bicyclic peptides of the 4×4 and 6×4 formats. A strong con-
sensus sequence not containing the TAR motif was found in 10 different peptides all hav-
ing the 3×4 format (CXGGCK/RF/YT/SL/MC). 
Synthetic bicyclic peptides of several clones were chemically synthesized. All of them 
inhibited uPA but none was more potent than the previously isolated UK18 (Figure 15). 
The most potent inhibitors isolated here, UK343 and UK344, were derived from the 6×6 
library and showed Kis of 0.90 and 0.71 μM, respectively. It is likely that the 6×6 library 
had yielded the best binders because of the larger number of randomized amino ac-
id positions and/or the larger number of different clones in the library 
(4×109 clones versus 107 to 5×108 clones in the libraries A, B and C). Although more po-
tent inhibitors could not be isolated from the naïve libraries, the numerous binding mo-
tifs identified provide more starting points for future affinity maturation attempts. Of 
particular interest are the bicyclic peptide formats with large rings that appear, based on 
the consensus sequences, not to be optimized in all of the amino acid positions. 
2.3 Conclusion 
Phage panning experiments with bicyclic peptides having different ring sizes yielded 
more diverse consensus sequences than previously found in selections with a 6×6 bicy-
clic peptide phage library. The bicyclic peptide inhibitors with unrelated consensus se-
quences are presumably interacting differently with the active site of uPA. Some of the-
se peptides may bind in orientations that allow affinity maturation of non-conserved 
regions while others do not. Having available multiple leads isolated from such bicy-
clic peptide libraries with variable ring sizes could therefore be a great asset for the gen-
eration of high affinity binders. It is likely that other multicyclic peptide structures 
evolved by phage display such as cysteine knots136 or other disulfide-constrained mini-
proteins137-139 would similarly benefit from variation of the peptide ring size. 
2.4 Experimental procedures 
2.4.1 Library generation 
All primers used for library cloning, as well as the vector 21tet(5), are described in 
the Supplementary Information found in APPENDIX I. Phage libraries were created by 
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inserting DNA sequences encoding the semi-random peptide sequences (Ala-Cys-(Xaa)m-
Cys-(Xaa)n-Cys, m and n ranged from 3 to 6 amino acids), the linker Gly-Gly-Ser-Gly, and 
the disulfide-free domains D1 and D2 into the phage vector 21tet(5). The insert was step-
wise created in two consecutive PCR reactions. First, the genes of D1 and D2 were PCR 
amplified with the two primers prepcr and sfi2notfo using the vector fdg3p0ss238 as a 
template. Second, the DNA encoding the random peptides was appended in a PCR reac-
tion using primers of the type 5′-TATGCGGCCCAGCCGGCCATGGCAGCATGC 
(NNK)mTGC(NNK)nTGTGGCGGTTCTGGCGCTG-3′ (m, n = 3, 4, 5 or 6) and the primer 
sfi2notfo. The PCR products were digested with SfiI (underlined in primers) and ligated 
into SfiI-digested vector 21tet(5). For each set of libraries (A, B and C), 23 μg and 7 μg 
of SfiI-digested vector and PCR products respectively were ligated and electroporated 
into E. coli TG1 cells. An equal amount of each insert was added into the ligation reaction 
to a total of 7 μg. After electroporation, cells were incubated for 1 hour in 2YT at 37 °C 
and plated on large (20 cm diameter) chloramphenicol (30 μg ml−1) 2YT plates. Colonies 
were scraped off the plates with 2YT media, supplemented with 10% v/v glycerol and 
stored at −80 °C. 
2.4.2 Phage selections 
Phage were produced and the peptides modified with TBMB as described previously4. 
Chemically modified phage were dissolved in 3 ml washing buffer (10 mM Tris–Cl, 
pH 7.4, 150 mM NaCl, 10 mM MgCl2, 1 mM CaCl2), and blocked by addition of 1.5 ml 
washing buffer containing 3% w/v BSA and 0.3% v/v Tween 20, for 30 min. In parallel, 
5 μg of biotinylated uPA was immobilized by incubation with 40 μl magnetic streptavidin 
beads (Dynabeads M-280 Streptavidin, Invitrogen, Switzerland). The beads with uPA as 
well as 40 μl magnetic streptavidin beads without uPA were blocked for 30 minutes in 
separate tubes with blocking buffer (washing buffer containing 1% w/v BSA and 
0.1% v/v Tween 20). The 4.5 ml blocked phage were distributed equally to the two tubes 
and incubated for 30 minutes on a rotating wheel. The beads were washed eight times 
with washing buffer containing 0.1% v/v Tween 20 and twice with washing buffer. The 
bound phage were eluted by incubation with 100 μl of 50 mM glycine pH 2.2 for 5 min. 
Eluted phage were transferred to 50 μl of 1 M Tris–Cl, pH 8.0 for neutralization, and in-
cubated with 30 ml of exponentially growing TG1 cells (OD600 = 0.4) for 90 min at 37 °C. 
The cells were pelleted by centrifugation, dissolved in 1 ml 2YT, spread on 2YT plates 
containing chloramphenicol (30 μg ml−1) and incubated at 37 °C overnight. The colonies 
were scraped off the plates with 2YT media, supplemented with 10% v/v glycerol and 
stored at −80 °C. In the second round of panning, uPA was immobilized on magnetic 
NeutrAvidin beads. The beads were prepared by coating tosyl-activated beads 
(Dynabeads M-280 Tosyl-activated, Invitrogen) with NeutrAvidin (Pierce, Rockford, IL, 
USA) following the manual of the manufacturer. In the third selection round, phage iso-
lated in the second round of the four independent selections were produced separately, 
mixed at equal numbers, blocked as described above and panned together against uPA. 
In the in-solution capture procedure, biotinylated uPA (10 nM) was blocked, and incu-
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bated at final concentrations ranging from 31 pM to 2 nM with 2 ml of blocked phage. 
After incubation for 45 min at room temperature with rotation, the phage/uPA–biotin 
complexes were captured by incubation for 7 min with 40 μl blocked streptavidin beads. 
The washes and the elution were performed as described above. In the competitive cap-
ture procedure, 120 ng biotinylated uPA was immobilized on 30 μl streptavidin beads, 
washed twice and incubated in 300 μl blocking buffer for 30 min. They were subsequent-
ly added to 2 ml blocked phage and incubated at room temperature with rotation. Bicy-
clic peptide UK18 was added at different time points to a concentration of 9 μM. The 
phage were washed, eluted and propagated as described above. 
2.4.3 Chemical synthesis of bicyclic peptides 
Peptides were synthesized by standard solid-phase peptide synthesis using Fmoc-
protected amino acids and Rink amide AM resin (see Experimental procedures in AP-
PENDIX I). Peptides were eluted under reducing conditions and partially purified 
by precipitation. Crude peptide (0.5 mM) was reacted with TBMB (1 mM) in 80% aque-
ous buffer (20 mM NH4HCO3, 5 mM EDTA, pH 8.0) and 20% CH3CN for 1 h at 30 °C. The 
product was purified by reversed-phase chromatography on a C18 column (XBridge 
BEH300 Prep 5 μm, Waters, Milford, MA, USA) using a linear gradient with a mobile 
phase composed of eluant A (99.9% v/v H2O, 0.1% v/v TFA) and eluant B (94.9% v/v 
CH3CN, 5% v/v H2O and 0.1% v/v TFA) and a flow rate of 20 ml min−1. Pure bicy-
clic peptides were lyophilized and dissolved in H2O. The molecular mass was confirmed 
by matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spec-
trometry. 
2.4.4 Determination of inhibitory activity 
Human uPA at a final concentration of 4 nM was incubated with different concentra-
tions of bicyclic peptides and 100 μM fluorogenic substrate (Z-Gly-Gly-Arg-AMC, Bachem, 
Bubendorf, Switzerland) and residual activity measured at 25 °C for 30 minutes. The 
reactions were performed in volumes of 150 μl and a buffer containing 10 mM Tris–Cl, 
pH 7.4, 150 mM NaCl, 10 mM MgCl2, 1 mM CaCl2, 0.1% w/v BSA, 0.01% v/v Triton-X100 
and 5% v/v DMSO at 25 °C. Fluorescence intensity was measured with a Spectramax 
Gemini fluorescence plate reader (excitation 355 nm, emission 480 nm, Molecular Devic-
es). The reactions were performed in triplicate. The final Ki was calculated using the 
Cheng–Prusoff equation140, wherein the kinetic constant Km for the hydrolysis of Z-Gly-
Gly-Arg-AMC by human uPA was determined by the standard Michaelis–Menten equa-
tion as previously described44.  
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Identification of target-binding peptide motifs 
by high-throughput sequencing of phage-
selected peptides 
This chapter is based on a publication by Rentero Rebollo I, Sabisz M, Baeriswyl V, Heinis C. Identifica-
tion of target-binding peptide motifs by high-throughput sequencing of phage-selected peptides. Nucle-
ic Acids Res. 2014. Reproduced with permission of Oxford University Press. 
3.1 Introduction 
Phage display of peptides is widely used for the development of peptide ligands and 
for epitope mapping141,142. The procedure involves 2-4 iterative rounds of affinity selec-
tion and phage amplification followed by an optional ELISA-based screen and sequencing 
of several dozens of positive clones. A panel of peptides is synthesized and their binding 
to the protein target or biological activity tested. An important step in the phage selec-
tion of peptides is the comparison of sequences and the identification of consensus mo-
tifs. Consensus sequences can provide valuable information about the binding site of 
peptides. Peptides sharing the same consensus motif likely bind to the same surface re-
gion of the target protein and form similar molecular interactions. Multiple different con-
sensus sequences indicate that peptides bind with different interaction modes to the 
same or different surface regions. Selections with peptide libraries often yield only one 
consensus sequence or at maximum a few different ones. In many phage selections with 
peptide libraries, no consensus sequences are reported at all. If isolated ligands are to be 
used as leads in drug development, multiple consensus sequences are desired as parallel 
development of several peptide leads increases the success rate of the development pro-
gram. For example, peptides of one consensus sequence might share unfavorable proper-
ties such as poor solubility or low proteolytic stability, hindering their further develop-
ment. 
The sequences of phage-selected peptides are typically obtained by Sanger sequencing. 
Our laboratory, for example, is routinely sequencing a half or a whole 96-well plate of 
clones isolated after 2-3 rounds of phage panning. Sequence similarities among peptides 
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are identified by manual comparison of the sequences, and highlighted by coloring amino 
acids of aligned peptides or by representation as so-called logos. In recent years, high-
throughput sequencing (HTS) methods have been applied for the analysis of ligands iso-
lated from DNA-encoded chemical libraries74,143, or antibodies76,144, protein 
domains77,145,146 and peptides75,79,82,147-150 isolated from phage display or mRNA display 
libraries. Most of the sequencing work was done using Roche’s 454 sequencing technolo-
gy (earlier work)74,144,145,147, the Illumina platform75-77,79,82,143,146,148-150, or an Ion Torrent 
sequencer79. The vast sequence data gave valuable information about diversity and 
abundance of isolated clones, as well as allowed monitoring of these parameters during 
the different iterative rounds of selection and amplification. In selections of peptide lig-
ands, the sequencing data was analyzed primarily by ranking the peptides according to 
their abundance, and the most frequent peptides were characterized. ‘t Hoen et al.82 and 
Olson et al.77 showed that peptide ligands can be identified in a single round of selection. 
In order to distinguish functional clones over background, Olsen et al. subjected each 
clone in > 1000 copies to the selection (input) and identified potential binding sequences 
from the 10 most abundant peptides. Herein, we proposed to analyze high-throughput 
sequencing data of phage-selected peptides not only based on abundance, but also based 
on sequence homology. We expected that sequencing and comparison of ten-thousands 
of peptides could allow a finer discrimination of consensus sequence sub-groups. Exten-
sive sequence homology information could provide information about binding interac-
tions and the importance of specific residues for the binding.  
Powerful tools to compare extensive sequence data and to identify multiple different 
consensus sequences within large datasets of sequences have been developed. The algo-
rithms of MEME (Multiple Em for Motif Elicitation)150, MUSI (MUltiple Specificity Identi-
fier)151 and Gibbs Cluster152 can process large numbers of sequences and group them in 
clusters of similar peptides. The three tools unfortunately do not provide information 
about frequencies and nucleotide sequences in the analysis result. Derda and co-workers 
developed MatLab-based software for the analysis of phage-selected peptides sequenced 
by the Illumina platform75. The tool tailored for the commercial Ph.D.TM -12 Phage Dis-
play Library (New England Biolabs) provides information about sequence abundance 
and DNA sequences but it does not include a function for automated identification of 
sequence homologies. 
In this work, we conceived a strategy to identify target-binding peptide motifs by high-
throughput sequencing and sequence comparison. We developed a procedure and soft-
ware for vast data processing, sequence quality filtering and homology finding. We ap-
plied it to bicyclic peptides that were isolated against five different protein targets. The 
tools allowed identification of numerous sub-families of consensus sequences. We show 
that target-binding peptide motifs can be identified even after only one round of affinity 
selection. 
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3.2 Results 
3.2.1 Phage selection and high-throughput sequencing 
Bicyclic peptide phage libraries were generated by displaying linear peptides of the 
format  XlCXmCXnCXo (C = cysteine; X = any amino acid; l, m, n, o = number of random 
amino acids) on filamentous phage and subsequent chemical cyclization of the peptides 
with tris-(bromomethyl)benzene (TBMB)153. The libraries were panned against the five 
targets sortase A from S. aureus (SrtA), human urokinase-type plasminogen activator 
(uPA), activated human coagulation factor XII (FXIIa), human plasma kallikrein (PK) and 
streptavidin (SA). Bicyclic peptide libraries were previously screened against four of 
these targets (uPA, FXIIa, PK, SA) and had yielded binders with micromolar to picomolar 
dissociation constants58,62,63,154. In these previous selections, consensus sequences were 
identified by sequencing around 100-300 clones per target after 2-3 iterative selection 
rounds. Against the bacterial target SrtA of S. aureus, bicyclic peptides were not devel-
oped so far. Isolated peptides were analyzed after a single round of phage selection in-
stead of after 2-3 iterative rounds, as usually done. A single round of selection minimizes 
out-competition of weaker binders by stronger ones. In this way, a maximal number of 
target-binding peptide motifs was expected to be identified. Conversely, a single round of 
selection bore the risk that binders were not sufficiently enriched over non-binders, 
making the identification of consensus sequences more difficult. Bicyclic peptide libraries 
with different format (ring sizes of 3 to 6 amino acids), different complexity (107 to 
4×109 different clones) and different representation of individual phage clones (ranging 
from 2 to 1000 copies per clone) were applied as shown in Table 4. In some selections, 
phage clones were represented in high copy numbers to facilitate enrichment of individ-
ual clones over non-specifically selected ‘background’ peptides. This was expected to 
facilitate analysis of data and identification of consensus sequences. After one round of 
phage selection, phage DNA was sequenced on an Ion PGMTM Sequencer instrument us-
ing an Ion 316TM Chip, yielding a maximum of 5×106 reads per chip. This number was 
exceeding by far the number of phage isolated in the phage selections, ranging from 
4×102 to 3×104 (Table 4). It even allowed sequencing phage from multiple selections on a 
single chip. DNA of selected phage was isolated from bacterial cells and amplified by PCR 
using suitable primers as shown in Figure 16A and APPENDIX II-Table S2. A 6-letter bar-
code was included in the forward primers right after the adaptor sequence to allow mul-
tiplexing of up to ten different phage selections on a single chip. Samples run on an Ion 
316TM Chip yielded more than a million reads and thus more than 100,000 sequences per 
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SrtA Library A  5 × 108 3 × 1010 8 × 103 1.8 × 105 5.1 × 104 2.8 × 103 26% 
SrtA Library B 1 × 107 2 × 1010 1 × 104 2.4 × 105 6.8 × 104 1.4 × 103 75% 
uPA Library B 1 × 107 9 × 109 3 × 104 3.4 × 105 1.1 × 105 3.1 × 103 56% 
FXIIa 4×4 7 × 108 5 × 1010 1 × 104 4.1 × 105 1.7 × 105 7.9 × 103 15% 
PK 3×3, 4×4 1 × 109 2 × 109 2 × 103 1.8 × 105 7.5 × 104 1.4 × 103 40% 
SA 3×3, 4×4 1 × 109 2 × 109 4 × 102 1.1 × 105 6.1 × 104 3.4 × 102 84% 
Table 4. Summary of the protein targets and peptide phage display libraries. aLibraries are 
named according to Ref. 153. Library A contains 3×4, 4×3, 4×4, 3×5, 5×3 peptides, library B contains 3×6, 6×3, 4×5, 
5×4 peptides. bNumber of transformants. cTransducing units (t.u.). dTotal number of sequences after quality filter. 
eEstimated number of different sequences. fPercentage of the population corresponding to the top 200 clones. 
3.2.2 Data processing and analysis 
We developed MatLab software for the processing and analysis of sequence data as 
outlined in the flow diagram shown in Figure 16B. Several of the applied procedures such 
as sorting of sequences, quality filtering, abundance ranking and translation were based 
on scripts developed by Derda and co-workers75. In a first step, sequences provided by 
the Ion Torrent sequencer in fastq format155 were distributed into different files accord-
ing to their barcode to separate peptides from different phage selections. For barcodes 
having a single base mutation, deletion or insertion, a correction function was developed 
but it proved to rescue only a small fraction of peptides and was not further used (de-
scribed in APPENDIX II-Supplementary Data and Figure S4). In a second step, low-quality 
sequences were removed from the dataset, and identical sequences sorted by their 
abundance. In the same step, the DNA sequences were translated into amino acid se-
quences. The software allows specifying the start and end of the region to be evaluated, 
so that it can be applied to any peptide library, regardless of the length of the random 
sequence and the flanking residues. In a third step, peptides were optionally sorted ac-
cording to their format (i.e. number of cysteines and number of residues between them) 
or based on inter-dataset comparisons (e.g. peptides isolated in two independent phage 
selections). In a fourth step, peptides were pairwise compared to find consensus se-
quences and to identify target-binding motifs. In a fifth and last step, identified peptide 
motifs were used to search the entire dataset for more related sequences. In all process-
es, information about peptide abundance and nucleotide sequence is displayed. All de-
scriptions of the scripts are available in the APPENDIX II. The scripts can be used for the 
analysis of any files in fastq format and thus also for data sequenced with other technol-
ogy platforms such as Illumina. 
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Figure 16. High-throughput sequencing and sequence analysis strategy. (A) Primer de-
sign for Ion Torrent sequencing of bicyclic peptide libraries (Library A and Library B). 
(B) Procedure for the analysis of sequencing data applying MatLab scripts. First, reads 
are separated into several files according to their barcode. Second, low-quality sequences 
are removed from the dataset, and remaining sequences are translated and sorted by 
abundance. At this point, two optional steps are performed: distribution of the isolated 
peptide sequences based on the format (e.g. peptide ring size in the case of bicyclic pep-
tides) and comparison of two different datasets. Then, the sequences of the most abun-
dant peptides (e.g. top 200) are compared and clustered in consensus groups or sub-
families of consensus groups, allowing the identification of specific motifs. Finally, the en-
tire pool of sequences is searched for other less abundant sequences sharing such motifs 
in order to identify promising candidates. 
3.2.3 Reducing bias by optimizing quality parameters 
A critical step in the data processing is the filtering of sequencing data based on quali-
ty criteria. Ion Torrent is prone to over-calling or under-calling the length of 
homopolymeric regions, leading to insertion/deletion (indel) errors156. The confidence of 
each sequenced nucleotide (Q-value) is provided in the fastq file with a single-character 
Phred-based quality score155, assigned by the PGM base-caller. This information can be 
used to remove sequences containing low confidence basecalls prior to sequence analy-
sis. Application of too strict quality filters, however, can lead to a bias against 
homopolymer-containing sequences. Different quality filter stringencies were tested and 
an optimal one chosen. A filter allowing a maximum of three nucleotides having a quality 
score below 'Q18' was found to be optimal for all datasets. The importance of optimal 
quality filtering is illustrated in Figure 17 in which different quality filters were applied 
to peptides isolated from the 4×4 library against PK (Figure 17A): a "permissive" filter, in 
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which reads containing 3 nucleotides below quality score 'Q18' were discarded, and a 
"restrictive" filter, where only 1 nucleotide below quality score 'Q20' was allowed. Alt-
hough the difference in the total number of reads passing each filter was minimal (Figure 
17C), certain peptide sequences were completely lost when using the restrictive filter 
(Figure 17A). DNA of such peptides contained a tetra-thymine homopolymer (TGT-TTT; 
encoding Cys-Phe) as well as a penta-thymine homopolymer (TGT-TTT-TCT; encoding 
Cys-Phe-Ser) (Figure 17B). We observed similar biases in all datasets. In order to reduce 
the bias against sequences containing long homopolymers, the less strict quality filter 
with a maximum of three nucleotides under the quality score 'Q18' was applied. 
 
Figure 17. Application of an optimal sequencing quality filter. Comparison between per-
missive (a maximum of 3 bases with quality value lower than Q18 are allowed) and re-
strictive (a maximum 1 base with quality value lower than Q20 is allowed) filtering pa-
rameters. (A) Example of peptides rescued by applying a less restrictive quality filter to 
the selection against PK. The rescued peptides with the highest abundance are indicated 
(top 10). (B) DNA sequence of rescued peptides. The homopolymers in the DNA sequenc-
es are underlined. (C) Effect on the number of reads passing the different filtering pa-
rameters. 
3.2.4 Diversity of phage-selected peptides 
The copy number of the most abundant peptides varied strongly among different se-
lections. In some selections, the 200 most frequently found peptides represented more 
than 80% of the sequenced clones, while in other selections they formed a fraction of less 
than 20% (Figure 18A). We plotted the number of different peptide sequences against 
the number of analyzed reads to extrapolate the absolute number of different peptide 
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sequences found in each selection. We expected that the number of different sequences 
converges to a maximal value at larger numbers of analyzed peptides and fits to equa-
tion 1 where a is the total number of different peptide sequences in the dataset and k is a 
constant that depends on the abundance distribution of the sample. Equation 1 was 
found to be suitable for fitting simulated datasets containing (i) different numbers of 
peptides, and (ii) different peptide abundance distributions (APPENDIX II-
Supplementary Data, Figure S5 and Figure S6).  
Equation (1) ݕ = ܽ ቀ1 − ݁ିೣೖቁ 
The number of different sequences increased linearly at larger numbers of sequences 
analyzed and did not converge to a maximal value, as well as did not fit to equation 1. The 
linear increase was due to sequencing errors, which were directly proportional to the 
number of sequences. Taking this phenomenon into account, we fitted the data to equa-
tion 2 where a and k are again the total number of different peptide sequences in the 
dataset and a constant that depends on the abundance distribution of the sample, respec-
tively, and b is the average error rate of the population. Equation 2 was also verified with 
simulated datasets containing (i) different number of peptides, (ii) different abundance 
distributions, and (iii) different error rates (APPENDIX II-Supplementary data and Figure 
S7). 
Equation (2) ݕ = ܽ ቀ1 − ݁ିೣೖቁ + ܾݔ 
Data of all selections was fitting well to equation 2 (Figure 18B). The linear coefficient b 
was similar in datasets of all selections. Experimental datasets of this study contained a 
significant percentage of sequencing errors estimated to be between 2.8% and 5.1%. The 
number of different sequences calculated for the various selections ranged between 340 
and 8,000 and was hence consistent with the number of isolated phage (Table 4). The 
different peptides isolated in selections could thus essentially all be identified by se-
quencing around 100,000 clones. 
After one round of phage selection, we expected that propagation advantages of specific 
clones would not have a large impact on the selection results. To evaluate the extent of 
the propagation-related bias after one round of selection, phage of library A and B were 
produced and bacterial cells infected without affinity selection. The copy number of indi-
vidual clones increased only marginally and the most abundant clones represented in 
both cases less than 0.02% of the population (APPENDIX II-Figure S8) and were not 
found after selection. 
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Figure 18. Diversity of peptides isolated after one round of phage selection. (A) The 
abundance of the 200 peptides that were most frequently found is indicated in percent of 
the whole population of sequenced clones (indicated in blocks colored in different 
grayscales). (B) Number of different sequences found when increasing numbers of reads 
were analyzed. Saturation plots were used for the calculation of the total number of dif-
ferent sequences. 
3.2.5 Identification of target-binding peptide motifs 
Based on MatLab built-in functions, we developed a script that groups peptides ac-
cording to similarities. First, it calculates pair-wise distances among the peptides. It then 
constructs a phylogenetic tree using the distances calculated. Last, it clusters the pep-
tides in suitable groups, with two optional parameters to fine-tune this grouping (see 
script description in APPENDIX II). This script allowed to efficiently identify target-
specific binding motifs. The MatLab script generated well-arranged groups of around 3-
20 peptides with high sequence similarity that can be analyzed and validated by eye.  
Inspection of consensus groups revealed that some of them were not true consensuses 
but artifacts that resulted from sequencing errors as explained in the following. For high-
ly abundant peptides, peptide variants with nearly the same sequence were found. These 
peptides occurred in small copy numbers and typically differed in only one base from the 
abundant clone (e.g. insertion, deletion or mutation). An example from a selection 
against SrtA using library A is shown in Figure 19A: the most abundant clone was pre-
sent 4592 times and several clones with similar DNA sequences appeared in only a few 
copies (ranging from 8-26). It is likely that the low-copy sequences resulted from se-
quencing errors because peptides with such small sequence differences are unlikely rep-
resented in the library. For example, library A contains only a small fraction (around 108 
different peptides) of the theoretically possible sequences (around 1012 sequence calcu-
lated from 8 positions encoded by NNK codons). To eliminate sequencing errors and 
prevent false identification of consensus sequences, we developed a MatLab script that 
finds sequences that differ at only one or two positions and corrects them to the se-
quence of the more abundant clone. Indeed, application of this script led to elimination of 
a significant fraction of the errors. Consensus sequence artifacts were no longer found. 
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Additionally, after this correction, the parameter b in equation 2 decreased below 1% 
(Figure 19B and APPENDIX II-Table S3).  
 
Figure 19. (A) Example for the identification of false consensus sequences due to se-
quencing errors. In a selection of Library A against SrtA, the most abundant sequence 
(present 4592 times) was clustered with sequences differing in only one nucleotide and 
being present at much lower frequency. These sequences likely resulted from sequencing 
errors. A MatLab script (fixingerrors.m script) was developed to eliminate these errone-
ous sequences. For the high-abundance sequence shown in the figure, 467 erroneous se-
quences were found (9%). For other high-abundance sequences, wrong sequences 
ranged between 0 and 48%. (B) Examples of saturation plots for different datasets before 
and after correcting sequencing errors (all datasets were obtained after one round of 
phage selection). 
Consensus groups found after elimination of false sequences in the selections against all 
five protein targets are shown in Figure 20. As the required computational power in-
creases quadratically with an increasing number of peptides, we compared only the top 
200 abundant sequences from the different datasets. This was sufficient to identify con-
sensus motifs in all selections. The analysis of larger numbers of sequences (up to 1000 
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sequences), did not lead to the identification of more target-binding motifs in this work 
(data not shown), but it may do if applied to other selections. In all phage selections per-
formed, groups of peptides with high sequence similarities were found. Many of the 
groups formed by the MatLab script represented subfamilies of a few entirely different 
consensus sequences. We manually highlighted the sequence similarities in all consensus 
groups with color (Figure 20).  
Consensus sequences shared by only a small number of peptides were identified too. For 
example, the SA-binding motif HPQ was shared by as little as 3 different peptides in the 
SrtA selection and was still identified by the software. These peptides were isolated be-
cause biotinylated SrtA was immobilized on SA in the phage selection. In the uPA selec-
tion, the minor motif ‘K/RF/YS/TL’ was shared by 9 different peptides. The peptides could 
be assigned even to two different consensus sequence subfamilies (Figure 20). 
In all the selections, at least one or two target-binding peptide motifs could be found, 
namely ‘LPP’ for SrtA, ‘T/SAR’ and ‘K/RF/YS/TL ’ for uPA, ‘VxxKCL’ for FXIIa, ‘F/Y\W xxCRV’ 
for PK and ‘HPQ’ for SA (Table 5). The number of different consensus sub-families was 
much larger; it was 15 for SrtA, 16 for uPA, 2 for FXIIa, 11 for PK, and 2 for SA. The motifs 
identified in selections with uPA, FXIIa, PK and SA were previously found by us or others 
after iterative rounds of phage selection and peptides with these motifs proved to be 
binders58,62,63,154. In contrast, most of the consensus sub-families had not been previously 
identified. The peptide motif ‘LPP’ found in selections against SrtA was not reported be-
fore; synthetic peptides with this motif bound to SrtA (results are described in Chap-
ter 4). Searching the whole pool of sequenced peptides for the identified target-binding 
peptide motifs revealed many additional sequences that are potential ligands of interest 
for characterization. Some consensus sequences contained up to around 2000 different 
peptides (e.g. in the uPA selection). Other contained as little as 93 different peptide se-
quences (FXIIa selection). In some selections, peptides with binding motifs represented 
more than 50% of the total number of sequenced peptides (uPA selection) or as little as 
1% (FXIIa selection). 
 




 with motifs  
in top 200 
Different peptides 
with motifs 




SrtA Library A LPP 15 143 (72%) 1531 (41%) 47% 
SrtA Library B LPP 14 164 (82%) 1253 (54%) 81% 
uPA Library B 
T/SAR 14 165 (82%) 1943 (42%) 70% 
K/RF/YS/TL 2 8 (4%) 44 (1%) 2.7% 
FXIIa 4×4 RPCP 1 2 (1%) 23 (0.2%) 0.4% VXXKCL 1 5 (2%) 93 (1%) 1.2% 
PK 3×3, 4×4 F/Y\W XXCRV 11 90 (45%) 758 (43%) 43% 
SA 3×3, 4×4 HPQ 2 17 (8.5%) 37 (9%) 7.4% 
Table 5. Target-binding peptide motifs (patterns of conserved residues) found after one 
round of selection. 
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Figure 20. Identification of target-binding peptide motifs. The 200 most abundant pep-
tides of each selection were computationally compared and clustered into groups of pep-
tides that share a maximal sequence similarity. The raw data of the automated sequence 
comparison is included in the APPENDIX II. The sub-groups generated computationally 
were arranged manually to group those together that belong to the same consensus 
group. The cysteines are colored in black and regions in the peptides with sequence simi-
larities were manually highlighted in color. Top: Consensus groups of peptides isolated in 
the selection with uPA. Peptide sequences of two of the sub-groups are enlarged and 
shown together with the abundance on the right side. Bottom: Consensus groups of pep-
tides isolated against SrtA, FXIIa, PK and SA. 
Chapter 3. Identification of target-binding peptide motifs by high-throughput sequencing 
44 
3.2.6 Peptide motif identification from inter-dataset comparisons 
In phage panning experiments, many phage particles are isolated unspecifically 
(named background phage) along with the peptides that are selectively isolated through 
binding to a target. If the number of specifically isolated peptides is small compared to 
the unspecific ones, it is more difficult to identify specific target-binding sequences after 
just one round of selection. Additional rounds of phage selection may be needed. We 
hypothesized that, in such cases, a possible way to identify specific target-binding se-
quences in the presence of high background would be to perform two parallel selections 
and compare the sequences obtained. Identical peptides would be considered as target-
specific peptides. We repeated a first round of selection against FXIIa and found that only 
six peptide sequences were common in both pools. Four of them corresponded to con-







Peptide sequence Peptides identified in previous phage selections* 
307 12  ACDARPCPQTYCL yes 
40 110 QCVPLKCLWDRCE yes 
27 22 VCERQVCYLMSCW no 
12 36 TCLCKRCIKELCC yes 
11 16 YCVWDKCLWLMCE no (but similar to consensus) 
5 9 ACGMSICVLYGCN no 
Table 6. Peptides identified by inter-dataset comparison. (*) In previous phage selections, three it-
erative rounds of panning were performed and around 100 clones sequenced. 
3.2.7 Formats of isolated peptides 
The number of cysteines found in phage-selected peptides can indicate if they are 
forming linear, monocyclic or bicyclic peptide structures. We anticipated the isolation of 
peptides with three cysteines that are cyclized with TBMB and form bicyclic peptide 
structures. Occasionally, peptides with less or more than three cysteines are isolated 
from the applied phage peptide libraries. Previous work showed that peptides having a 
fourth cysteine residue in the randomized region are isolated as bicyclic peptides formed 
by two disulfide bridges63. Due to errors in the library generation, some peptides have 
two cysteines and are isolated as disulfide-linked monocyclic peptides. Availability of the 
vast sequence data allowed detection of small differences in the number of cysteines and 
preferences for one or the other format in the different selections. In selections per-
formed with libraries containing peptides of different ring sizes (number of amino acids 
spacing the cysteines), we analyzed if one or the other format was preferentially isolated. 
Peptides with certain ring sizes were preferentially enriched in selections with some 
protein targets. In the selection of SrtA binders from library A, bicyclic peptides of the 
formats 3×5 and 5×3 were enriched over other formats (Figure 21A). Panning of li-
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brary B against SrtA enriched bicyclic peptides of the format 5×4, while panning against 
uPA yielded more bicyclic peptides of the format 4×5 (Figure 21B). When the libraries 
3×3 and 4×4 were mixed and panned against PK, 3×3 clones had a selective advantage, 
which was not the case when the same mix was panned against SA (Figure 21C). 
  
Figure 21. Statistical analysis of peptide formats using large sequence data. The percent-
ages of peptides containing 0, 1, 2, 3, 4 or > 4 cysteine residues are indicated. For pep-
tides containing 3 cysteines, the percentage of peptides with different formats are indi-
cated. For example ‘3×4’ means that the peptides contain 3 amino acids between Cys1 
and 2, and 4 amino acids between Cys2 and 3. (A-C) Results of selection with different 
targets and libraries. ‘Naive’ means the peptides in the library before selection. 
3.2.8 Iterative rounds of phage selection 
We performed a second round of phage selection to study the population diversity 
(number of different sequences) and homogeneity (abundance distribution) over two 
rounds of selection. In particular, we were interested to learn (i) how many sequences 
with consensus motifs are lost in a second round of selection, and (ii) if new sequences 
with binding motifs appear. Phage isolated from library A and library B against SrtA in 
the first round were subjected to a second round of affinity selection against SrtA and 
isolated clones sequenced. The population underwent a progressive loss of diversity over 
iterative rounds of selection (Figure 22). The number of different sequences decreased 
from 2800 (round 1) to 800 (round 2) in the case of library A, and from 1400 to 170 in 
the case of library B. In the selection with library A, around half (47%) of the peptides 
isolated in round 1 contained the ‘LPP’ motif and thus were binders. In round 2, nearly all 
the peptides (98.4%) were binders. Around one third of the sequences with the binding 
motif ‘LPP’ found in round 1 were lost in round 2. Interestingly, 22% of the population of 
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the second round corresponded to sequences that were not found in the first round, indi-
cating that the sampling of the first round was not complete and not all the diversity of 
the first round was sequenced. In the selection with library B, in the first round already 
81% of the population of reads corresponded to binding sequences. After the second 
round, virtually all the population consisted in target-binding sequences (99.4%). A large 
fraction of the population after round 1 was also found in round 2 (71%), and new bind-
ing sequences found in the second round corresponded to less than 1% of the population. 
 
Figure 22. Dynamic change of the population over two rounds of selection. Results are 
shown for the selection of SrtA binders from libraries A and B. (A) Copy number of se-
quenced peptides. Indicated is the percentage of peptides that were identified at the indi-
cated range. (B) Abundance distribution of the output of the second round. The most 
abundant 200 peptide sequences are separated in blocks. 
3.3 Discussion 
Sequencing of phage-selected peptides by high-throughput methods can offer a deep 
insight into the nature of selected peptides and the process of affinity panning and prop-
agation. Pioneering studies in which phage-selected peptides were sequenced with high-
throughput methods primarily used the data to study the peptide diversity and to identi-
fy highly abundant clones that are expected to bind with the highest affinities75,79,82,147-
150. Herein, we proposed to use high-throughput sequencing data to identify target-
binding motifs as well as to obtain a more detailed picture of consensus sequences. A 
limitation we encountered was the lack of broadly applicable and flexible open-access 
computational tools to compare and analyze the sequences of a large number of peptides. 
We therefore devised a procedure and developed software that processes high-
throughput sequencing data and that can identify consensus sequences. 
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In our strategy, phage-selected peptides are first ranked by their abundance and then 
compared pairwise to align peptides with sequence similarities. The software reads se-
quence raw data from fastq files that are provided by most high-throughput sequencing 
platforms. The output of the tool consists on groups of 3-20 peptides sharing sequence 
similarities. Importantly, the software is keeping the information about the abundance 
and nucleotide sequence of each peptide sequence and displays this information in the 
analysis result. The software can deal with commercially available as well as self-tailored 
libraries. It includes functionalities for analysis of specific library formats such as disul-
fide-cyclized peptides or bicyclic peptides. Additional functions allow inter-dataset com-
parisons as well as searching for peptides containing specific sequence motifs. 
While developing the analysis procedure and software, we learned that it is important to 
understand biases introduced by next-generation sequencing technologies. It is para-
mount to optimize quality filters to prevent introduction of biases. The main error source 
in Ion Torrent PGM sequencing is inaccurate flow-calls, which result in inser-
tion/deletion (indel) errors, most frequently in homopolymeric regions157,158. Even cor-
rectly called homopolymeric regions are typically assigned less confidence156. Filters 
applied inappropriately could remove too many sequences and in this way introduce 
strong biases. We empirically identified an optimal quality filter which tolerates three 
bases with qualities below Q18. This filter gave the best result for all selections present-
ed in this work and most likely is suitable for analysis of peptides isolated from any other 
type of combinatorial peptide library. 
Sequencing errors were found to mislead standard algorithms that are used to identify 
sequence similarities and consensus sequences. We show that sequencing errors on 
highly abundant clones produce a series of erroneous variants, whose abundance is gen-
erally lower. The abundant clone together with a group of similar erroneous sequences 
were recognized by the software as a consensus group. We developed a procedure that 
eliminates sequencing errors from the dataset. False sequences are identified as such if 
they have identical nucleotide sequences except for one or two positions. Application of 
this filtering procedure eliminated the identification of false consensus sequences. 
Our software was able to identify consensus sequences and sub-families of consensus 
sequences in datasets of all phage selections. Even consensus motifs that were shared by 
only a few peptides in the population could be identified. As we compared only the most 
abundant 200 peptides in each selection, some consensus motifs were most likely 
missed. More target-binding motifs may be identified if significantly more peptides are 
compared. The scripts were run on a standard personal computer within minutes. Thou-
sands of sequences may be compared by using high performance computers. In the ana-
lyzed 200 sequences per selection, 1-3 consensus sequences were found that were fur-
ther divided into many sub-families with slight consensus variations. This finding indi-
cated that most proteins have only one or at most few regions where peptides can bind 
with sufficiently high affinity allowing their isolation. This is in contrast to antibodies 
that typically bind to more different epitopes. 
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An important parameter in the phage selection is the copy number of the peptides that 
are subjected to affinity selections. Only if a peptide is available in the library in a suffi-
ciently large copy number, it can be isolated and sequenced in multiple copies and ap-
pears as an ‘enriched’ peptide. In some of the selections performed in this work, the av-
erage copy number of the peptides was rather low and the isolated peptides diverse. The 
identification of target-binding peptide motifs was thus difficult. For example in the se-
lections against PK and SA, the average copy number was 2. Consensus sequences could 
in these cases only be identified because many peptides were sharing the same motif.  
In selections with more challenging targets such as FXIIa, it was difficult to identify tar-
get-binding motifs. Only 1% of all peptides isolated against FXIIa contained FXIIa-binding 
motifs (some of the motifs were known from previous work). Most of the 99% remaining 
sequences are most likely peptides that were isolated through non-specific interactions. 
Our software could nevertheless identify two consensus sequences. We also investigated 
the possibility of reliably identifying specific-binding sequences by performing in parallel 
independent selections. We reasoned that this approach could allow the identification of 
specific target-binding ligands from noisy datasets and for the identification of parasitic 
sequences. By comparing the output of two selections performed in parallel against FXIIa 
(one selection round), we indeed could differentiate specific target-binding clusters from 
background clusters. Inter-dataset comparison may also be applied to identify peptides 
that bind to the streptavidin magnetic beads rather than to the protein target. 
Our work confirmed that peptide ligands can be efficiently identified in a single round of 
phage selection if isolated clones are analyzed by high-throughput sequencing. In con-
trast to previous work that identified peptides ligands based on their abundance, we 
show that extensive comparison of sequences can identify additional attractive ligand 
candidates. Phage selection of peptide ligands in a single instead of multiple rounds has 
also the advantage that propagation-related bias is reduced to a minimum75,159,160. This 
could be particularly important when genetically engineered phage systems containing 
unnatural amino acids are used161. Finally, a single round of phage panning may also 
facilitate the application of phage display by scientists that have no prior experience with 
this technique. Readily prepared libraries could simply be pipetted to a target and cap-
tured phage sequenced. Phage amplification and purification would not be necessary, 
and equipment for bacteria culture and phage handling would not be required. 
In summary, we have developed a strategy and software to compare large numbers of 
phage-selected peptides that were sequenced by high-throughput methods. With this 
strategy, we were able to identify rare target-binding peptide motifs, as well as to define 
more precisely consensus sequences and sub-groups of consensus sequences. This in-
formation is valuable to choose peptide leads for drug development and it facilitates 
identification of epitopes. 
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3.4 Experimental procedures 
3.4.1 Phage selection 
Libraries A, B, 3×3 and 4×4 were previously described62,154. In these libraries, pep-
tides are displayed on around five copies of the phage coat protein pIII. Libraries A and B 
contain peptides of the format ACXmCXnCG (C = cysteine, X = any amino acid). In library 
A, the combinations of ‘m’ and ‘n’ are 3/4, 4/3, 4/4, 3/5 and 5/3; in library B they are 
3/6, 6/3, 4/5 and 5/4. Library 3×3 contains peptides of the format XCX3CX3CX. Library 
4×4 contains peptides of the format XCX4CX4CX. Random positions are coded by NNK 
codons. Phage production, reaction of cysteines with chemical linker to generate bicyclic 
peptides on phage, and phage panning against the different targets were performed as 
described before58,62,154. The vector for S. aureus sortase A expression pHTT14162 was 
kindly provided by Prof. O. Schneewind (University of Chicago, IL, US). Sortase A was 
expressed in E. coli (amino acid 26-206, polyhistidine tag at N-terminus) and purified by 
nickel affinity chromatography followed by size exclusion chromatography. Human 
urokinase-type plasminogen activator N322Q was expressed in mammalian cells, acti-
vated and purified as described before61. Human coagulation factor XIIa (β-form) and 
human plasma kallikrein were purchased from Molecular Innovations (Novi, MI, USA). 
The proteins were biotinylated and immobilized on streptavidin magnetic beads 
(Dynabeads M-280, Life Technologies, Carlsbad, CA, USA). For streptavidin selections, the 
commercial streptavidin magnetic beads were readily used.  
3.4.2 Sample preparation for high throughput sequencing 
Phage vector was extracted from TG1 E. coli bacteria that were stored as glycerol 
stocks after infection with phage isolated after one round of selection. The DNA was iso-
lated with a commercial plasmid purification kit (NucleoSpin Plasmid; Macherey-Nagel, 
Düren, Germany). 100 ng phage vector DNA was amplified by PCR using primers contain-
ing adapter sequences and barcodes (primer sequences are provided in APPENDIX II-
Table S2). The PCR reaction in a volume of 50 μL contained final concentrations of 
250 μM dNTP, 500 nM primer, 1 unit Taq polymerase, and standard buffer (75 mM Tris-
HCl, 20 mM (NH4)2SO4, 2mM MgCl2, 0.01% Tween 20). 25 PCR cycles (30 sec. 95 °C, 
30 sec. 55 °C, 30 sec. 72 °C) were performed but resulted in formation of DNA 
heteroduplexes and only about 30% of all sequences could be read. Reduction of the 
number of PCR cycles to 13 solved this problem. PCR products were purified from a 2.5% 
agarose gel (UltraPure agarose, Invitrogen, Carlsbad, CA, US) using a commercial agarose 
gel purification kit (NucleoSpin Gel and PCR Clean-up; Macherey-Nagel). The concentra-
tion of DNA was determined using a High Sensitivity DNA Assay Kit (Agilent, Santa Clara, 
CA, US), following the manufacturer's protocol. Ion Torrent sequencing was performed 
by the Lausanne Center of Genomic Technologies (University of Lausanne, Switzerland) 
or the Centre for Research in Agricultural Genomics (Barcelona, Spain) on a Ion Personal 
Genome Machine (PGMTM) Sequencer. The procedure involved ligating the DNA frag-
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ments onto Ion Sphere Particles (ISPs), amplifying them by emulsion PCR, enriching the 
templated ISPs, loading onto an Ion Torrent 316TM chip, and sequencing. 
3.4.3 Analysis 
MatLab scripts were developed for the analysis of high-throughput sequencing data 
(all descriptions can be found in the APPENDIX II). A first script, Step1.m, sorts the reads 
according to the specified barcodes and distributes them to separate files. Reads with 
mutations, insertions or deletions in barcodes were discarded unless specified. A second 
script, Step2.m, removes low quality reads, translates the sequences, sorts them by abun-
dance, and optionally corrects sequencing errors. Reads having more than three bases 
with quality score lower than Q18 were not considered, unless specified otherwise. Se-
quences differing in one or two bases from an abundant sequence were corrected as the 
small differences likely origin from sequencing errors. MatLab scripts LoopLengths.m, 
Clustering.m, FindSeq.m and CommonSeq.m were used for the comparison and analysis of 
peptide sequences. Script LoopLengths.m separates the sequences into different files 
according to the number of cysteine residues and the number of amino acids between 
them. Script Clustering.m compares a chosen number of sequences, groups them into 
families that share high sequence similarity, and optionally generates sequence logos for 
each group. Script FindSeq.m searches the dataset for all peptide sequences containing a 
specified motif. Script CommonSeq.m compares up to three different datasets and dis-
tributes common and exclusive sequences in different files.  
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Chapter 4  
 
Development of selective peptide macrocycle 
inhibitors of S. aureus sortase A 
 
4.1 Introduction 
The development of antibiotic resistance among life-threatening human pathogens 
has prompted the exploration of new alternative targets beyond those exploited by con-
ventional antibiotics. A group of proteins that are considered as interesting novel targets 
are sortases. They are membrane-bound transpeptidases that catalyze the transfer and 
covalent immobilization of surface proteins to the cell wall in gram-positive bacteria. In 
S. aureus, one of the most relevant pathogens due to the existence of strains resistant to 
virtually all antibiotics in the clinic, two sortases have been described: sortase A (SrtA) 
and sortase B (SrtB)100,101, which recognize two different motifs and therefore anchor 
different surface proteins. A number of important virulence factors such as protein A, 
clumping factors and fibronectin-binding proteins are anchored to the cell wall by SrtA. 
They enable adhesion and infection of host cells and tissues, evasion from the immune 
system and biofilm formation163-165. SrtA knockouts show reduced adhesion to matrix 
proteins and reduced pathogenicity in animal models for S. aureus infections102-104,166, as 
well as for infections caused by other microorganisms167,168. Consequently, great interest 
has arisen in the development of SrtA inhibitors for therapy164,169. 
A range of small molecules have been reported to inhibit SrtA in cleaving fluorescence-
based peptide substrates, including natural products, such as berberine chloride 
(IC50 = 23.3 μM)123 and curcumin (IC50 = 37.5 μM)114, and small molecules from chemical 
libraries and rational design, such as the diarylacrylonitrile-derived compound DMMA 
(IC50 = 9.1 μM)124 and phenyl-vinyl sulfone (IC50 = 700 μM)125. Most of the compounds 
were found to inhibit adhesion of S. aureus to matrix proteins, and this activity was at-
tributed to SrtA inhibition114,124,125. The therapeutic potential of one of the compounds, 
DMMA, has been evaluated in mice. S. aureus infections in mice treated with DMMA 
showed reduced virulence leading to higher survival rates124. Besides small molecules, a 
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peptide-based ligand of SrtA isolated from a lantipeptide library by mRNA display also 
showed good affinity (1.3 μM), but did not inhibit SrtA170. 
In this study, we aimed at developing potent and selective SrtA inhibitors based on pep-
tide macrocycles for further evaluation of the target and for a potential use as leads in 
antibiotic drug development. We envisioned developing inhibitors based on bicyclic pep-
tides that contain two macrocyclic rings for interaction with the target. Bicyclic peptide 
ligands with nanomolar or even picomolar affinity have recently been developed in our 
laboratory to a range of protein targets using a phage display-based approach43,44,58,62. In 
this work, we identified a series of SrtA bicyclic peptide inhibitors in the low micromolar 
range and applied them to evaluate the SrtA target of S. aureus. 
4.2 Results and discussion 
4.2.1 Phage selection of bicyclic peptide SrtA ligands 
Three combinatorial peptide libraries of the form Ala-Cys-(Xaa)m-Cys-(Xaa)n-Cys-Gly 
(m, n = number of random amino acids) were displayed on phage and cyclized by react-
ing the cysteines with tris-(bromomethyl)benzene (TBMB) as previously described153,154. 
Library A contained bicyclic peptides with 7-8 random residues (m×n = 3×4, 4×3, 3×5, 
5×3, 4×4), library B contained peptides with 9 random residues (4×5, 5×4, 3×6, 6×3), and 
library 6×6 contained bicyclic peptides with 12 random residues (6×6). After two rounds 
of selection, we analyzed the selected peptides both by Sanger sequencing of 30-35 
clones (Figure 23A) and by high-throughput sequencing (HTS) (Figure 23B). In all cases, 
the most abundant clones identified by HTS (representing more than 4% of the popula-
tion) were also identified by clone-picking. The 20 most abundant clones from each li-
brary are shown in Figure1B and additional clones in the APPENDIX III. Nearly all pep-
tides isolated from libraries A and B contained the amino acid motif “LPP” (98% and 99% 
of the peptides, respectively). The motif was present at the C-terminal position of rings 
containing five amino acids (…CXXLPPC…), and appeared more often in the first one of 
the two rings. Peptides isolated from library 6×6 converged to two consensus motifs: 
around one third of the peptides (37%) contained a fourth cysteine and the consensus 
sequence “ACXXK/RXVCCL/VXXD/EXXCG” and half of the peptides (50%) contained the 
“LPP” motif in either of the two rings (Figure 23). Previous studies in our laboratory 
showed that peptides having four cysteine residues are likely isolated in the form of bi-
cyclic peptides with two disulfide bridges63. Peptides with unmodified cysteines can oxi-
dize during phage preparation or affinity selection. Although the fraction of unmodified 
peptide is typically low171, peptides with two disulfide bridges can be enriched if they 
bind particularly well to the target protein. Analysis of all the sequences obtained by HTS 
did not lead to the identification of other motifs.  
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Figure 23. Phage selections against SrtA. Three bicyclic peptide libraries were panned 
against S. aureus SrtA. Selected peptides were identified after two rounds of selection, 
and their inhibitory activities were evaluated. Kis (averages of at least 3 independent 
measurements and standard deviations) for SrtA are indicated, N.I.: no inhibition was ob-
served at the highest concentration tested (300 μM). (A) Sanger sequencing of 30-35 
clones. Peptides found multiple times are indicated. (B) High-throughput sequencing us-
ing Ion Torrent PGM. The 20 most abundant sequences for each library are indicated, 
with their frequency (% of the population). Peptides found by clone-picking are indicated 
with a hash symbol (#). 
4.2.2 Bicyclic peptide inhibitors of SrtA 
We synthesized 16 bicyclic peptides and tested the inhibition of SrtA with a fluores-
cence-quenched substrate Dabcyl-LPETG-Edans. All LPP-containing peptides that were 
tested blocked SrtA with Ki values in the micromolar range (Figure 23). The “LPP” motif 
is similar to the sorting sequence LPXTG recognized by SrtA in its natural substrates and 
might bind in a similar manner as the substrate172. Conversely, no inhibitory activity was 
observed for peptides containing two disulfide bridges that were isolated from the 6×6 
library. The best inhibitors, with potencies in the single-digit micromolar range, con-
tained the extended motif “PQ/LLPP” in either the first or the second ring (Figure 23). 
Analysis of the HTS data showed that proline was indeed the most frequent amino acid in 
the first position of the 5 amino acid loop (Figure 24A). At the second position, leucine, 
valine and glutamine were the most frequent amino acids. In the SrtA inhibitors with the 
“PQ/LLPP” motif in the first ring, the second ring did not converge to a specific sequence 
(Figure 24A). In contrast, in the group of peptides with the “PQ/LLPP” motif in the second 
ring, some amino acids in the first ring appeared to be preferred. In order to evaluate 
whether the non-conserved loop was contributing to the binding, we performed an ala-
nine scan with two peptides SRT1 (ACPQLPPCRVSCG, Ki = 4.3 μM) and SRT2 
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(ACTQRCPQLPPCG, Ki = 2.4 μM) (Figure 24C). Mutation of amino acids in the second ring 
of SRT1 did not affect the Ki, suggesting that the second ring was not interacting with the 
target. Mutation of amino acids in the first ring of SRT2 reduced the inhibitory activity 
substantially. Mutation of Gln4 and Arg5 to Ala reduced the activity 7 and 22-fold, re-
spectively (Figure 24C). The preference for an arginine in position 5 was also visible 
from the HTS results analysis. The additional sequence requirements in amino acids po-
sitions 4 and 5 might have been the reason why fewer peptides were selected with the 
LPP motif in the C-terminal loop. We further characterized the binding affinity of these 
two prototypic peptides, SRT1 and SRT2, by fluorescence polarization. The peptides la-
beled at the N-terminal amino groups with fluorescein-NHS bound SrtA with Kd values of 
8.8 μM and 1.5 μM, respectively (Figure 24D). These binding affinities were in line with 
the inhibitory constants Ki of the two peptides. 
 
Figure 24. (A) Sequence logos of peptides containing the CxxLPPC motif in the first or in 
the second loop of bicyclic peptides. (B) Bicyclic peptide SRT4 (ACHSRCPQLPPCG, modi-
fied with TBMB) and monocyclic peptide SRTmono (ACPQLPPCG, modified with BBMB). 
(C) Alanine scanning of the non-conserved ring in the bicyclic peptides SRT1 and SRT2. 
The non-conserved C-terminal loop of SRT1 was not able to establish interactions with 
the target, whereas the non-conserved N-terminal loop in SRT2 did. Searching the HTS 
data for more peptides with the conserved PQ/LLPP sequence in the second ring led to 
the identification of SRT3 and SRT4 with around 2-fold better activities. The conserved 
ring alone (SRTmono) had a Ki of 4.9 μM. (D) Binding affinity of SRT1 and SRT2 meas-
ured by fluorescence polarization. Affinities correlated well with inhibitory activities 
(SRT1 Kd = 1.5 μM, SRT2 Kd = 8.8 μM). 
To test more peptides containing the “PQ/LLPP” motif in the second ring, we searched the 
vast sequence data from the HTS for such peptides. The next most abundant peptides we 
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found were SRT3 and SRT4 and inhibited SrtA with Ki values of 1.8 and 1.1 μM. A peptide 
with a single ring ("SRTmono") was prepared by cyclizing ACPQLPPCG with 1,3-
bis(bromomethyl)benzene (BBMB, Figure 24B). The peptide inhibited SrtA with a Ki of 
4.9 μM. The best bicyclic peptide was thus around 4-fold better than the monocyclic pep-
tide. 
4.2.3 Inhibition of cell adhesion by bicyclic peptides 
We evaluated the capacity of the bicyclic peptides to block adhesion of S. aureus strain 
Newman to fibrinogen. In S. aureus, fibrinogen adhesion is mainly driven by ClfA, a SrtA-
anchored surface protein. The cells were grown until mid-exponential phase 
(OD600 = 0.5) with or without the bicyclic peptide SRT4 at concentrations up to 500 μM. 
Cells were added to wells of 96-well microtitre plates coated with fibrinogen (5×107 cells 
per well), and adhered cells were detected with crystal violet173. Unfortunately, we ob-
served no decrease in the binding capacity of the bacteria grown in the presence of inhib-
itor (Figure 25A). The positive control applied in this experiment, a SrtA knockout of the 
S. aureus Newman strain (SKM12) showed reduced binding of 30%. Adhesion tests were 
repeated using different bicyclic peptides and a different strain and ligand protein (Cow-
an and fibronectin), further confirming the absence of effect (APPENDIX III-Figure S9). 
We speculated that small reductions of adhesion proteins on the surface of S. aureus may 
not be detected in the cell binding assay due to multivalent binding. In order to detect 
small changes, we measured surface levels of protein A by ELISA. Protein A is also an-
chored to the peptidoglycan wall by SrtA. 2×107 cells of the Newman strain were coated 
by adhesion to wells of microtiter plates and protein A detected with an antibody. SRT4-
treated cultures showed similar levels of protein A on the surface (Figure 25B).  
 
Figure 25. (A) Adhesion of S. aureus strains Newman to fibrinogen. The isogenic SrtA 
knockout strain SKM12 was used as a control. Cells were grown until OD600 = 0.5 in the 
presence or absence of 500 μM SRT4. (B) Protein A levels on the cell surface of S. aureus 
Newman (OD600 = 0.5) grown in the presence or absence of SRT4. SKM12 was used as a 
control. 
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To evaluate whether the lack of effect was due to degradation of the bicyclic peptides, we 
performed activity assays with supernatants from S. aureus Newman cultures after over-
night incubation with bicyclic peptides. They inhibited cleavage of the fluorogenic sub-
strate by SrtA with the expected activity. Additionally, the inhibitory activity of the bicy-
clic peptides was not impaired by any component in the bacterial supernatant, as the 
presence of 40% supernatant in the activity assay did not affect the obtained IC50s 
(APPENDIX III-Figure S10).  
4.2.4 Evaluation of reported SrtA inhibitors 
It was surprising for us to find that the bicyclic peptides did not inhibit S. aureus ad-
hesion while several of the small molecule inhibitors are reported inhibitors of cell adhe-
sion. We chose to compare directly the activity of some commercially available inhibitors 
with the bicyclic peptides in our experimental setup. 
The natural products morin and curcumin were reported to inhibit cleavage of a 
fluorogenic peptide substrate by SrtA both with an IC50 of 37.5 μM114,121. The same mole-
cules were also reported to inhibit SrtB from S. aureus and SrtA from S. mutans with IC50s 
in the same range121,174, and to reduce biofilm formation in S. mutans175,176. We found 
that fluorescence of morin interfered with the fluorogenic substrate used to measure 
SrtA activity (Dabcyl-LPETG-edans). The cleaved SrtA substrate has fluorescence excita-
tion and emission maxima of 335 and 495 nm (corresponding to the edans fluorophore). 
Morin has fluorescence excitation and emission maxima of 390 and 510 nm. Therefore in 
the measurements, the fluorescence was the result of the cleaved substrate and the in-
hibitor added to the mix. However, the fluorescence of morin decreased over time, caus-
ing the apparent slope to decrease. It is not clear how the authors accounted for this ef-
fect, which might have previously been interpreted as inhibition activity. After correction 
for this interference effect, no inhibition of SrtA was observed at the expected concentra-
tions. In the case of curcumin, no interference was observed, but the inhibition activity 
was lower than reported (APPENDIX III-Figure S11). 
We next considered the SrtA inhibitor DMMA (IC50 = 9.1 μM) and phenyl-vinyl sulfone 
(IC50 = 736 μM) as positive controls (Figure 11 in pg. 21). The activity of these com-
pounds on cell adhesion had been tested with the Newman strain adhering to 
fibronectin-coated surfaces124,125. Adhesion of this strain to fibronectin is limited since it 
carries a truncated version of the two fibronectin-binding proteins (FnBPs) that is lack-
ing the SrtA-recognition motif177. Inhibition of SrtA would therefore not have an effect on 
the binding of this strain to fibronectin. The observed reduced cell adhesion with the 
small molecules was thus most likely resulting from unspecific effects on other targets or 
on growth. 
We anyway tested one of the compounds that was commercially available, phenyl-vinyl 
sulfone (PVS). PVS inhibited SrtA with a similar IC50 in our assay (900 μM, APPENDIX III-
Figure S12). However, the inhibitor did not inhibit the binding capabilities of S. aureus 
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Newman to fibrinogen (Figure 26B). We found that PVS greatly slowed growth of the 
Newman strain at values close to the IC50 (Figure 26A). In the study that reported inhibi-
tion of cell adhesion for PVS, cell cultures with and without the inhibitor were grown in 
parallel and the binding of cells from these cultures was directly assessed without nor-
malizing the cell number. It is likely that the PVS treatment led to a smaller number of 
cells and that this was the reason that fewer cells bound to the fibronectin coated wells. 
We concluded that the observed effect in decreased adherence to fibronectin by PVS was 
not SrtA-mediated but due to the reduced number of cells compared to the control upon 
addition of PVS. 
The study with the reported SrtA inhibitors suggested that inhibition of S. aureus cell 
adhesion via blocking SrtA activity by small molecules is not yet established. While the 
observations were disillusioning, they enforced our efforts to further test if SrtA on 
S. aureus cells is inhibited by the bicyclic peptides. 
 
Figure 26. (A) Effect of SrtA inhibitors on growth. S. aureus Newman was grown in the 
presence or absence of PVS (left) or SRT2 (right). Although PVS has a MIC = 6 mM, it 
drastically slows growth at lower values. In comparison, bicyclic peptide inhibitors did 
not affect growth at the highest concentration tested (1 mM). (B) Adhesion of S. aureus 
Newman to fibrinogen upon treatment with PVS. 1 mM PVS (1% DMSO final concentra-
tion) was added to the culture at OD600 = 0.5. Aliquots were taken immediately after addi-
tion (t = 0), after 45 minutes and after 2 h. 
4.2.5 Inhibition of SrtA on cells by bicyclic peptides 
The activity of SrtA on S. aureus cells can be measured with fluorescently labeled pep-
tides containing the LPETG sequence. Such substrates, when added to the culture, can be 
incorporated to the cell wall of S. aureus by SrtA178,179. We synthesized a fluorescein-
labeled LPETG substrate and analyzed its incorporation to the cell wall in the presence of 
SRT4. SRT4 was able to prevent the incorporation of such externally added substrate, 
albeit with a higher IC50 than in the in vitro assays (Figure 27). This demonstrates that 
SRT4 was able to inhibit native SrtA on the membrane of S. aureus. However, it was not 
sufficient to prevent anchoring of the natural substrates of the enzyme. Much higher po-
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tencies seem to be needed to efficiently block SrtA on the surface of S. aureus. A limiting 
factor to efficiently prevent SrtA-mediated anchoring of surface proteins could be the co-
localization of native substrates and SrtA on the bacterial membrane and at specific loca-
tions (e.g. at the septum cross wall180), which implies that native substrates may have 
higher effective concentrations. A second limiting factor could be the diffusion rate of 
SrtA inhibitors through the cell wall, and in particular through the septum cross wall, to 
efficiently reach such locations. 
 
Figure 27. Inhibition of SrtA-mediated incorporation of external fluorescent substrates. 
S. aureus Newman was grown in the presence of 0.3 mM Fluo-GSLPETGGS and different 
concentrations of SRT4 for 24 hours. The SrtA knockout strain SKM12 was used as a con-
trol. Averages and standard deviations of at least three independent experiments are 
shown. 
4.3 Conclusion 
Since its initial discovery, SrtA has been proposed as a potential antivirulence target 
and while many sortase inhibitors have been described, no antisortase drugs have 
reached the clinic yet. Previous studies with SrtA inhibitors suggested that effective 
blocking of SrtA on the cells could be achieved with potencies in the micromolar range. 
However, certain studies have been performed using unsuitable enzymatic and adhesion 
assays. Moreover, the specificity of SrtA inhibitors was generally assessed by MIC values, 
which do not guarantee the absence of effect on growth (as in the case of PVS). In our 
study, we have developed selective bicyclic peptide inhibitors of SrtA with potent in vitro 
activities. They were also able to inhibit SrtA-mediated anchoring of external synthetic 
substrates to the cell wall, although with much lower potency, and they could not com-
pete with the natural substrates of SrtA. More potent inhibitors are needed to effectively 
reach and block SrtA on S. aureus cells than previously thought. Bicyclic peptide inhibi-
tors can reach nanomolar activities towards their targets, and affinity maturation of the 
Chapter 4. Development of selective macrocycle inhibitors of S. aureus sortase A 
59 
peptides reported in this work could lead to promising candidates for the development 
of antisortase therapeutics. 
4.4 Experimental procedures 
4.4.1 Phage selection 
Libraries A, B and 6×6 were previously described43,154. In these libraries, peptides are 
displayed on five copies of the phage coat protein pIII. Libraries A and B contain peptides 
of the format ACXmCXnCG (C = cysteine, X = any amino acid). In library A, the 
combinations of ‘m’ and ‘n’ are 3×4, 4×3, 4×4, 3×5 and 5×3; in library B they are 3×6, 6×3, 
4×5 and 5×4. Library 6×6 contains peptides of the format ACX6CX6CG. Phage production, 
reaction of cysteines with chemical linker to generate bicyclic peptides on phage, and 
phage panning against the different targets were performed as described before58,62,154. 
SrtA was produced as previously described120 (APPENDIX III). SrtA was biotinylated and 
immobilized on streptavidin magnetic beads (Dynabeads M-280, Life Technologies, 
Carlsbad, CA, USA) for the first round, and on neutravidin magnetic beads for the second 
round. High throughput sequencing was performed using Ion Torrent PGMTM, and is 
described in APPENDIX III. 
4.4.2 Peptide synthesis 
Peptides were synthesized in house by standard solid-phase peptide synthesis using 
Fmoc-protected amino acids (scale 0.03 mmol). As solid support, Rink amide AM resin 
was used to obtain peptides with a free N-terminus and an amidated C-terminus. 
Peptides were cleaved from the resin under reducing conditions (90% TFA, 2.5% H2O, 
2,5% thioanisol, 2,5% phenol, 2.5% 1.2-ethanedithiol) and partially purified by 
precipitation. In the case of bicyclic peptides, crude peptide at 0.5 mM was reacted with 
1 mM TBMB in 80% aqueous buffer (20 mM NH4HCO3, 5 mM EDTA, pH 8.0) and 20% 
acetonitrile for 1 h at 30 °C. The product was purified by RP-HPLC on a C18 column, and 
H2O/0.1% TFA and 95% ACN/5% H2O/0.1% TFA were used as solvents. Pure bicyclic 
peptides were lyophilized and dissolved in water. The purity was assessed by RP-HPLC 
and was >95% for all peptides. The identity was confirmed by ESI or MALDI-TOF 
spectrometry. 
Fluorescein-labelled peptides SRT1 and SRT2 were labeled by incubating 1 mM peptide 
with 3 mM 5(6)-carboxyfluorescein N-hydroxysuccinimide ester (Sigma-Aldrich, St. 
Louis, USA) in 40 μL PBS for 3 hrs at RT. 0.96 mL H2O containing 0.1% TFA (v/v) was 
added to the reaction mixture and the peptide purified by HPLC on an analytical C18 
column (Vydac C18, 218TP column, 4.6×250 mm) using a solvent system of 99.9% 
H2O/0.1% TFA and 99.9% ACN/0.1% TFA. The fluorescein-modified peptide was 
lyophilized and the mass confirmed by ESI-MS. 
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For the substrate Fluo-GSLPETGGS, 5(6)-carboxyfluorescein (Sigma–Aldrich, St. Louis, 
USA) was coupled to the N-terminus of the peptide GSLPETGGS during solid-phase 
peptide synthesis. 2 equiv (0.06 mmol) of 5(6)-carboxyfluorescein, HOBt, and DCC, each 
in 0.25 ml DMF were added to the resin and incubated for 30 min at 400 rpm. The resin 
was washed four times with DMF and the fluorescence-labeled peptides cleaved as 
described above. 
4.4.3 In vitro SrtA activity assays 
Inhibitory activity of bicyclic peptides was determined by incubation of 2.5 μM SrtA 
with various peptide concentrations and quantification of the residual activity with 
20 μM of fluorogenic substrate Dabcyl-LPETG-Edans (Anaspec, Fremont, USA) and 
200 μM of triglycine (Sigma-Aldrich, St. Louis, USA). Residual enzymatic activities were 
measured in reaction buffer (50 mM Tris-Cl, pH 7.4, 150 mM NaCl, 5 mM CaCl2) 
containing 0.1% w/v BSA in a volume of 75 μL. Fluorescence intensity was measured 
with a multiwell plate reader (Infinite® 200 PRO, TECAN, Maennedorf, Switzerland) 
(excitation at 350 nm, emission at 480 nm). The reactions were performed at 37 °C. The 
inhibitory constant Ki was calculated using equations described in the APPENDIX III, and 
was not influenced by the presence of triglycine (data not shown). Average and standard 
deviations of at least three measurements are reported. Phenyl vinyl sulfone, curcumin 
and morin hydrate (Sigma-Aldrich, St. Louis, USA) were used as received without further 
purification. Activity assays with these inhibitors were performed as described above 
including 1.5% DMSO in the reaction buffer (which did not affect the activity of the en-
zyme). In the case of curcumin, reaction buffer without BSA was used. 
4.4.4 Fluorescence polarization 
SrtA was serially diluted in reaction buffer. Fluorescein-labeled peptide at a 
concentration of 200 nM was also prepared in reaction buffer. 30 μL of each SrtA and 
fluorescein-peptide solutions were transferred into a well of a black 96-well half area 
microplate (Greiner Bio-One international AG, Monroe, USA) and incubated at room 
temperature for at least 15 min. The fluorescence polarization of each solution was 
measured in a multiwell plate reader (Infinite® 200 PRO, TECAN, Maennedorf, 
Switzerland) using a 485 nm excitation filter and a 535 nm emission filter. The 
dissociation constants (Kd) were determined by non-linear regression analyses of 
fluorescence polarization (Fp) versus total concentration of SrtA using the equation 
described in APPENDIX III. 
4.4.5 S. aureus growth 
S. aureus SrtA knockout strain SKM12 was kindly provided by Prof. Olaf Schneewind 
(University of Chicago, IL, USA). For all assays, S. aureus was grown in TSB medium at 
37 °C, SKM12 was grown in TSB medium supplemented with 50 μg/mL erythromycin. 
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For adhesion and protein A ELISA tests, cultures were grown until mid-exponential 
phase (OD600 = 0.5) in the presence or absence of inhibitor, cells were pelleted and 
washed 3 times with cold PBS, and an aliquot was taken for cell count determination. 
Washed pellets were stored at -20 °C until use. 
4.4.6 S. aureus adherence 
Adhesion tests were performed as described previously173. 96-well plates (Nunc-
Immuno MaxiSorp, Sigma-Aldrich) were coated with 1 μg/well fibrinogen or 1 μg/well 
fibronectin in PBS overnight at 4 °C. They were washed 3 times with PBS and subse-
quently blocked with PBS + 2% BSA for one hour at RT.  S. aureus pellets from cultures in 
the presence or absence of the inhibitor at OD 0.5 were re-suspended in PBS to a final 
concentration of 6.25×108 cells/mL,  80 μL were added to each well (5×107 cells/well), 
and incubated at 37 °C without shaking for 90 minutes. After washing with PBS, the plate 
was dried for 45 minutes at 50 °C. 80 μL crystal violet was added to each well and incu-
bated for 45 minutes at RT. After incubation with crystal violet, the plate was extensively 
washed with PBS and 80 μL citrate buffer (20 mM, pH 4.3) was added to each well. Ab-
sorbance at 570 nm was measured after 45 minutes. 
4.4.7 S. aureus protein A ELISA assays 
S. aureus pellets from cultures in the presence or absence of the inhibitor at 
OD600 = 0.5 were re-suspended in PBS to a final concentration of 2.5×108 cells/mL. 96-
well plates (Nunc-Immuno MaxiSorp, Sigma-Aldrich) were coated with 2×107 cells/well 
for 90 minutes at RT. They were washed 3 times with PBS and subsequently blocked 
with PBS + 1% BSA for one hour at RT.  After washing with PBS, anti-protein A HRP-
conjugated antibody (ab7245, Abcam, Cambridge, UK) was added (1:30,000 in PBS-BSA) 
and the plate was incubated at RT for 30 minutes. The plate was extensively washed with 
PBS and 80 μL TMB substrate (Ultra TMB-ELISA, Thermo Scientific, Waltham, USA) was 
added to each well. After 10 minutes the reaction was quenched with 2 M H2SO4 and ab-
sorbance at 470 nm was measured. Data from different plates were normalized to the 
signal of the Newman control (untreated). 
4.4.8 Incorporation of synthetic substrates on S. aureus 
S. aureus Newman or SKM12 were grown in the presence of 0.3 mM Fluo-GSLPETGGS 
and different concentrations of SRT4. After 24 h, cells were pelleted and washed with 
cold PBS. Non-covalently bound molecules to the cell wall were removed by treatment 
with 5% SDS at 60 °C for 5 minutes. Cells were pelleted and washed again twice with cold 
PBS. Fluorescence of the cells was measured in a multiwell plate reader (Infinite® 200 





Chapter 5  
 
Conclusion and outlook 
The strategy for the generation and screening of libraries of bicyclic peptides by 
phage display was recently developed and is well established in our laboratory. The goals 
of my PhD were three-fold. Firstly, I wanted to explore ring size diversity in bicyclic pep-
tide ligands in order to find potent inhibitors to a wider range of targets. Secondly, I 
aimed to apply high throughput sequencing to the outcome of the selections, in order to 
gain a deeper insight into sequence diversity. Thirdly, I tried to combine these improve-
ments to identify new antibacterial molecules. In this last chapter, I summarize the find-
ings and discuss the outlook of this work. 
5.1 Ring size diversity in bicyclic peptides 
Selections with an initial proof-of-concept library, consisting of bicyclic peptides hav-
ing a fixed ring size of six amino acids (format 6×6), had yielded potent and selective 
binders to different targets. However, this ring size combination might not be optimal to 
identify the most potent binders to all targets. To systematically explore different ring 
size combinations, I generated libraries of bicyclic peptides containing all possible com-
binations of loops of 3, 4, 5, or 6 amino acids. The resulting structures are smaller than 
the 6×6 peptides and therefore more constrained molecules. 
As a first trial, I performed selections against the protease uPA, for which the nanomolar 
inhibitor UK18 had been previously identified from the 6×6 library used initially in our 
laboratory. I hoped to find a more suitable ring size combination that would lead to the 
discovery of even more potent inhibitors. Interestingly, micromolar inhibitors from all 
combinations of loop lengths could be isolated, suggesting that a variety of peptide for-
mats can be accommodated in the active site of uPA. Each ring size combination had a 
preference for one or several different amino acid motifs, and certain motifs were exclu-
sively found in peptides with a defined ring size combination. Among the inhibitors iso-
lated, the most potent ones corresponded to the 6×6 format and contained a RGR motif 
also present in the previously found UK18. In the case of uPA, more potent binders could 
not be isolated. However, the identification of diverse leads containing different motifs 
represents a great asset. Of these, certain motifs can inherently present disadvantages 
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(e.g. if they are cleaved by proteases in plasma). Moreover, some binding orientations 
may allow affinity maturation of non-conserved regions, helping to achieve higher poten-
cies. 
In contrast, when panning these variable ring size libraries against SrtA, there was a clear 
bias towards specific loop lengths, namely loops of 5 amino acids, and only one binding 
motif could be identified. It is noteworthy that no other consensus motif could be identi-
fied in spite of deep sequencing analysis of peptides selected after one or two rounds of 
phage selection. This highlights that the importance of ring size diversity varies from 
target to target, as some might have pockets able to accommodate peptides of many dif-
ferent formats, such as uPA, and some might only allow peptides of a certain format, such 
as SrtA. 
These bicyclic peptide libraries with different ring sizes can be used for selections 
against any future target, and are currently being applied in our laboratory and others in 
different research projects. When combined with the newly available cyclization rea-
gents developed in our laboratory, a huge repertoire of peptide macrocycles can be ob-
tained, increasing the chances to find potent peptide leads for drug development. 
5.2 HTS of bicyclic peptide selections 
In a second part of my work, I applied high throughput sequencing (HTS) for the 
analysis of phage-selected peptides. In our laboratory, typically one or several 96-well 
plates of selected clones were sequenced per selection experiment, a costly and labor-
intensive procedure. Sequencing the outputs by HTS would allow the coverage of all the 
diversity of the selected peptides. This can help to identify specific target-binding motifs 
and provides useful information about conserved residues for affinity maturation or for 
rational peptide design. 
We decided to use the Ion Torrent PGMTM platform because it provides an adequate 
throughput and read length for our needs (5×106 sequences of 200 bp length on the 
Ion 316TM Chips used). Given the absence of broadly applicable software, I needed to 
develop tailor-made bioinformatic tools for data analysis and interpretation. These tools 
provide a complete processing pipeline for HTS data, from the initial sequencing file to 
the identification of conserved motifs in the dataset. They include: (i) a quality filter to 
remove non-reliable reads, (ii) a step to correct homopolymer sequencing errors, a rela-
tively frequent (around 1%) error in Ion Torrent platforms, (iii) classification of the pep-
tides according to the number of cysteine residues and ring sizes, and (iv) clustering of 
the sequences into similarity groups, allowing the identification of conserved motifs. 
These tools can be applied to peptide selections derived from different libraries and se-
quenced on different platforms. One limitation is the number of different peptide se-
quences that can be analyzed for similarity. At present, 200 sequences can be compared 
within minutes on a standard laptop computer, but the processing time increases 
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quadratically, putting an upper limit to the number of different sequences that can be 
compared. 
In spite of these limitations, the developed procedures for Ion Torrent sequencing and 
data analysis represent broadly applicable tools, which are currently used by our group 
and others. In addition to the gain in time, it provides much more information than 
standard clone-picking and Sanger sequencing. The developed analysis software is also 
well documented and can be used on standard computers. 
5.3 Bicyclic peptide inhibitors of sortase A 
Concerning the development of bicyclic peptide inhibitors of the antivirulence target 
sortase A, many questions remain open. I developed bicyclic peptide inhibitors of 
sortase A from Staphylococcus aureus with potent in vitro activities. However, bicyclic 
peptide inhibitors against SrtA were around 100-fold less potent against the natively 
expressed SrtA on cell surface than against the recombinantly expressed SrtA in enzy-
matic in vitro assays. It would be interesting to evaluate whether this is also the case for 
other reported small molecule inhibitors. This highlights the importance of having repre-
sentative in vitro assays of physiological scenarios for the development of successful drug 
leads. Limited diffusion through the cell wall, restricted accessibility to the active site 
and/or co-localization of the target with their natural substrates might be responsible for 
this effect, although further studies are needed to elucidate mechanistic details. This will 
provide essential information for the future design of new antisortase drugs. 
Additionally, this work underlines the need of specific ligands. Previously reported small 
molecule inhibitors of SrtA were reported to have activities in the micromolar range and 
seemed to be sufficient to effectively block SrtA-mediated anchoring of virulence factors 
on the surface of the microorganism. However, the effects of some of them were most 
likely due to off-target effects. Potent and specific inhibitors are not only useful for the 
development of therapeutics, but also to gain a better understanding about biological 
processes and how to target them. In this sense, bicyclic peptide inhibitors might consti-
tute valuable research tools. In order to efficiently block SrtA on S. aureus cells, more 
potent inhibitors are needed than previously thought. Bicyclic peptides with nanomolar 
or even picomolar activities have been developed in our laboratory against certain tar-
gets. It is likely that the inhibitors developed in this work can be improved by affinity 
maturation and rational design, and may constitute promising leads for the future devel-
opment of antisortase therapeutics. 
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Supplementary experimental procedures 
Vector 21tet(5) cloning 
The vector 21tet(5) is based on the phage vector fdg3p0ss21 and contains a 2.5 kb stuff-
er fragment instead of the gene region coding for D1 and D2 domains of phage p3. The 
vector was obtained by ligating two SfiI-digested PCR products amplified with the primer 
pairs g3pNba/pelbsfifo and tetsfiba/tetsfifo from the vectors fdg3p0ss21 (around 7 kb) 
and fd-tet-DOG1181(around 2.5 kb). The ligated DNA was transformed into TG1 cells. 
Production and biotinylation of human uPA  
The catalytic domain of human uPA (a N145Q mutant deficient in the glycosylation site) 
was expressed as pro-enzyme (pro-uPA) in mammalian cells and purified as previously 
described44. After the purification, pro-uPA showed an apparent molecular mass of about 
32 kDa in SDS-PAGE. The protein was subsequently activated by plasmin cleavage: 
12.3 mg pro-uPA were incubated with 49.4 μg plasmin (HPLM, from human plasma, 
85 kDa, Molecular Innovations, Novi, MI, USA) in 50 mM HEPES, 150 mM NaCl, pH 8 for 6 
hours at room-temperature. The activated protein (uPA) was purified by size exclusion 
chromatography using a HiLoad 16/60 Superdex 75 prep-grade column (GE Healthcare, 
Glattbrugg, Switzerland). The protein was eluted as a monomer giving a single band in 
SDS-PAGE, confirming the complete cleavage, with a molecular mass of about 28 kDa 
under reducing conditions (see Figure S1). 
For biotinylation, uPA (10 μM) was incubated with EZ-link Sulfo-NHS-LC-biotin (200 μM; 
Pierce) in 50 μl PBS (pH 8) for 1 h at 25 °C. Excess of biotinylation reagent was removed 
by gel filtration with a Sephacryl S100 column (GE Healthcare) using 50 mM NaAc buffer, 
200 mM NaCl, pH 5.5. The ability of the biotinylated uPA to bind to either streptavidin or 
neutravidin was verified by incubating the protein with magnetic streptavidin and 
neutravidin beads respectively and analyzing the bound and unbound protein fraction by 
SDS-PAGE. 
Chemical synthesis of peptides 
Fmoc-protected amino acids and Fmoc-rink amide AM resin (0.26 mmol/g resin) were 
purchased from Iris Biotech GmbH (Marktredwitz, Germany). O-Benzotriazole-N,N,N',N'-
tetramethyl-uronium-hexafluoro-phosphate (HBTU, ChemPep, Wellington, FL, USA), N,N-
Diisopropylethylamine (DIPEA, Merck Schuchardt OHG, Hohenbrunn, Germany), 
trifluoroacetic acid (TFA, Sigma-Aldrich Chemie GmbH, Steinheim, Germany), 1,2-
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ethanedithiol (EDT, Fluka Chemie GmbH, Buchs, Switzerland), thioanisole (Fluka), 
piperidine (Fluka), phenol (Acros Organics, Geel, Belgium) and  1,3,5-
tris(bromomethyl)benzene (TBMB) were used as received without further purification. 
Peptides were synthesized on an Advanced ChemTech 348Ω peptide synthesizer 
(Aapptec, Louisville, USA) by standard Fmoc (9-fluorenylmethyloxycarbonyl) solid-phase 
chemistry on a Rink Amide AM resin (0.03 mmol scale). Coupling steps were carried out 
twice, for each time amino acid (4 eq., 0.2 M solution in DMF), HBTU (4 eq, 0.45 M solu-
tion in DMF), OxymaPure (4 eq, 0.45 M solution in DMF) and DIPEA (6 eq, 0.5 M solution 
in DMF) were used. Fmoc groups were removed using a 20% (v/v) solution of piperidine 
in DMF (2.5 ml × 2). The final peptides were deprotected (side-chain protected groups) 
and cleaved from the resin using a TFA/thioanisole/H2O/phenol/EDT mixture 
(90/2.5/2.5/2.5/2.5 v/v, 4 ml) for 3 hours at room temperature. The resin was removed 
by filtration under vacuum and the peptides were precipitated with cold diethyl ether 
(40 ml). The precipitated peptides were resuspended and washed twice with diethyl 
ether (20 ml each time). Finally, the peptides were dissolved in H2O: CH3CN (1:1) and 
lyophilized. 
Mass spectrometric analysis of synthetic peptides 
The molecular masses of synthetic peptides before and after chemical modification were 
determined with an Axima-CFR plus MALDI-TOF mass spectrometer (Axima-CFR plus, 
Kratos Shimadzu Biotech, Manchester, UK). HPLC-purified peptides (0.1-10 μM in 0.1% 
v/v TFA/10-30% v/v CH3CN in water) were mixed 1:1 with a saturated solution of 
matrixα-cyano-4-hydroxycinnamic acid (α-CHCA) in 50% v/v CH3CN, 49.9% v/v H2O, 
0.1% v/v TFA and loaded onto a MALDI carrier plate for mass determination.  
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Supplementary table 





















Table S1. DNA sequences of the primers (5' to 3') used for 21tet(5) vector generation and 
library cloning. SfiI restriction sites are underlined. Diversity was introduced by using the 
degenerate codon NNK in the synthetic primers. N represents any of the 4 nucleotides 
and K thymidine (T) and guanosine (G).   
  




Figure S1. Expression and purification of the catalytic domain of human uPA. (A) Amino 
acid sequence of the protein expressed in mammalian cells. The Ig κ-chain leader se-
quence is highlighted in green, 8 random amino acids inserted due to the cloning strategy 
are shown in grey and the C-terminal fragment of chain A as well as the catalytic domain 
of human uPA (chain B) are shown in black wherein a mutated residue (N145Q) is high-
lighted in red. Signal peptide peptidase and plasmin proteolysis cleavage sites are indi-
cated by black broken lines. (B) SDS-PAGE analysis of the protein secreted by mammalian 
cells before (Pro-uPA, approximately 31 kDa) and after activation with human plasmin 
(uPA, approximately 28 kDa) under reducing conditions. The protein was stained with 
Coomassie blue dye. M: molecular weight marker. (C) Active uPA-N145Q (uPA), analyzed 
by size exclusion chromatography, showed a high degree of purity. 
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Name Peptide sequence m/z expected  (TBMB modified) 
m/z found 
 (TBMB modified) 
UK327 ACTARTCPATQVLCG 1607.7 1608.0 
UK339 ACNWKFSLCETQRNQCG 2100.9 2101.6 
UK340 ACNSRFALCSPSSQMCG 1874.8 1875.3 
UK343 ACTEFQTDCRGRSSICG 1946.8 1948.3 
UK344 ACNHAATDCRGRGGPCG 1758.7 1759.0 
UK346 ACKQSVCTARTLCG 1553.7 1554.5 
UK348 ACKHSDCTARFPCG 1608.7 1608.9 
UK368 ACRGGCKFTMCG 1346.6 1346.8 
UK377 ACLQGERGCENRRPSCG 1948.9 1948.9 
 
Figure S2. Sequence, mass values predicted and experimentally determined by MALDI-
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Figure S3. Inhibition of human uPA by the nine TBMB modified peptides tested. The re-
sidual activity of the protease was measured with a fluorogenic substrate and plotted 
against the concentration of bicyclic peptide (logarithmic scale). 
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Barcodes were designed so they could be identified even if one or two of the six bases 
were wrongly sequenced. We included in the MatLab script an option to allow one mis-
match in the barcode (one insertion, mutation or deletion). Application of this procedure 
did not increase much the number of sequences that could be used because most of the 
rescued sequences were filtered out in the subsequent quality filter due to bad quality 
values in the peptide region (Figure S4). For all the analysis in this work, we therefore 
used only sequences in which the barcode showed a perfect match. 
Validation of the mathematical model to estimate the number of different se-
quences 
For a homogeneous population of sequences (where all clones are equally represented in 
the pool), the number of different sequences found (y) in function of the number of se-
quences sampled (x) will increase linearly at the beginning, decreasing the rate as it ap-
proaches saturation (Figure S5). This system could be approximated by equation S1 
(ܽ − ݕ) =  k ௗ௬ௗ௫  (S1) 
where a is the total number of different sequences in the pool, and the rate of finding 
new sequences (dy/dx) is proportional to the number of new sequences remaining in the 
sample, with a proportionality constant k. Solving the differential equation, the number 
of different sequences corresponds to equation S2: 
ݕ = ܽ൫1 − ݁ି௫/௞൯ (S2) 
Taylor approximation near 0, where the function behaves almost linearly (x << a), allows 
the determination of the initial slope of the curve as shown in equation S3: 
ݕ = ௔௞ ݔ, ݂݋ݎ ݔ ≪ ܽ (S3) 
In the case of a homogeneous dataset, the initial slope should be close to one, and there-
fore ܽ = ݇. Indeed, simulation of an ideal homogeneously distributed dataset gave the 
expected curve and fitted parameters corresponded to the ones simulated (Figure S5). 
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In the case of non-homogeneous datasets, where a few sequences might represent a sig-
nificant fraction of the population, we anticipated that the system would behave similar-
ly, but with a lower initial slope. We validated this approach by fitting a series of simulat-
ed datasets representing populations with different abundance distributions (Figure S6). 
The parameter ܽ/݇ takes values between 0 and 1, and could be used to quantify the ho-
mogeneity of the sample: 
(less homogeneous) 0 < ܽ/݇ ≤ 1 (homogeneous) 
In the experimental datasets, at larger number of reads, the number of different se-
quences increased linearly and did not converge to a maximal value. The linear increase 
was due to sequencing errors, which were directly proportional to the number of reads. 
To give account for this effect, a linear component was added to equation S2: 
ݕ = ܽ൫1 − ݁ି௫/௞൯ + ܾݔ (S4) 
where b is a global error rate for the population. Equation S4 was used to fit the data in 
this study. We additionally simulated the same sets presented in Figure S6, adding differ-
ent percentages of random mutations, and using equation S4 to fit the data, obtaining a 
good estimation of the parameters (Figure S7). 
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Supplementary Tables 
Primer name Sequence 
Primers for PCR amplification of Library A and Library B 
IT_Fw1 5' CCATCTCATCCCTGCGTGTCTCCGACTCAGGCATAGTTTCTATGCGGCCCAGC 3' 
IT_Fw2 5' CCATCTCATCCCTGCGTGTCTCCGACTCAGCGTATCTTTCTATGCGGCCCAGC 3' 
IT_Fw3 5' CCATCTCATCCCTGCGTGTCTCCGACTCAGATCGCATTTCTATGCGGCCCAGC 3' 
IT_Fw4 5' CCATCTCATCCCTGCGTGTCTCCGACTCAGACGATATTTCTATGCGGCCCAGC 3' 
IT_Fw5 5' CCATCTCATCCCTGCGTGTCTCCGACTCAGAGACTCTTTCTATGCGGCCCAGC 3' 
IT_Fw6 5' CCATCTCATCCCTGCGTGTCTCCGACTCAGGATACATTTCTATGCGGCCCAGC 3' 
IT_Fw7 5' CCATCTCATCCCTGCGTGTCTCCGACTCAGCATCTCTTTCTATGCGGCCCAGC 3' 
IT_Fw8 5' CCATCTCATCCCTGCGTGTCTCCGACTCAGGTTCAGTTTCTATGCGGCCCAGC 3' 
IT_Fw9 5' CCATCTCATCCCTGCGTGTCTCCGACTCAGTACCAGTTTCTATGCGGCCCAGC 3' 
IT_Fw10 5' CCATCTCATCCCTGCGTGTCTCCGACTCAGATGGAGTTTCTATGCGGCCCAGC 3' 
IT_Rev1 5' CCTCTCTATGGGCAGTCGGTGATGTTTCAGCGCCAGAACC 3' 
Primers for PCR amplification of Library 3×3 and Library 4×4 
IT_Fw11 5' CCATCTCATCCCTGCGTGTCTCCGACTCAGAGTTACCGCAATTCCTTTAGTTGTTC 3' 
IT_Fw12 5' CCATCTCATCCCTGCGTGTCTCCGACTCAGGGTGAACGCAATTCCTTTAGTTGTTC 3' 
IT_Rev2 5' CCTCTCTATGGGCAGTCGGTGATTTTCAACAGTTTCAGCGGAGTG 3' 
Table S2. Primers for PCR amplification and subsequent Ion Torrent sequencing. For-
ward primers contain adaptor sequence, barcode (underlined) and template-specific se-
quence. Reverse primers contain adaptor sequence and template-specific sequence. 
 


















SrtA – Library A 2817 0.743 3.3% 2814 0.712 1.8% 
SrtA – Library B 1442 0.212 2.8% 1422 0.222 1.4% 
uPA – Library B 3129 0.319 5.1% 2980 0.321 1.6% 
FXII – 4×4 7884 0.671 5.1% 7839 0.719 1.1% 
PK – 3×3, 4×4 1376 0.670 4.5% 1333 0.704 0.6% 
SA – 3×3, 4×4 343 0.641 2.8% 311 0.725 0.2% 
Table S3. Correction of errors in sequences of phage-selected peptides. Diversity, homo-
geneity and error rate were estimated before and after correcting sequencing errors for 
different datasets (datasets were obtained after one round of phage selection and the 
correction was applied to all sequences). The estimated error rate (parameter b) is con-
siderably reduced, while the estimated number of different sequences and homogeneity 
remain almost unchanged. 




Figure S4. Number of sequences found for each barcode. Bars labeled with ‘perfect’ show 
the number of sequences having a perfect match of the barcode. Bars labeled with 
‘indelmut’ show the sum of sequences with a perfect match and those having one inser-
tion, deletion or mutation in the barcode. The white area within the bars shows sequenc-
es that passed the quality filter after analyzing the peptide region (quality parameters: 
maximum 3 bases < Q18). 
 
Figure S5. Simulation of an ideal dataset of homogeneously distributed sequences. The 
dataset was chosen to contain 4000 different sequences. The number of different se-
quences is indicated in dependence of the number of reads sampled (black squares). 
Equation 2 was used to fit the data (grey line). Calculated parameters (total number of 
different sequences = 4000, a/k = 0.995) corresponded with the ones simulated. 
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Figure S6. Simulation of datasets presenting different abundance distributions of peptide 
sequences. (A) Representation of the homogeneous population and different simulated 
heterogeneous populations (case 1 to case 4). All contained a total of 4000 different se-
quences but they were present in different relative abundances. Top 200 most abundant 
sequences are separated as blocks shown in different colors. (B) Saturation plots of these 
heterogeneous populations and subsequent fitting of equation S2. (C) Calculated parame-
ters from the fitting. For case 4, 106 reads were sampled to reach saturation. 
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Figure S7. Simulation of populations containing 4000 different sequences and presenting 
different abundance distributions and different sequencing error rates. (A) Saturation 
plots of simulated populations and fitting of equation S4. (B) Calculated parameters from 
the fitting. Good estimates for the total number of different sequences a, the error rate b 
and the homogeneity of the population a/k were obtained. 
 
Figure S8. Libraries analyzed before (naive library) and after one round of amplification 
(infection of bacteria without affinity selection; amplified library). A sub-population of 
the library is being preferentially amplified, but the most abundant clone represents less 
than 0.02% of the population.  
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Similartiy clusters (Figure 20) 
Computational comparison of peptide sequences for the identification of target-binding 
motifs. Sequence data was analyzed before with the MatLab scripts Step1.m and Step2.m 
(using standard quality parameters). Sequencing errors of the 500 most abundant se-
quences were corrected by script fixingerrors.m. Groups are shown as found by the soft-
ware (stringency = 0.5 except for uPA and FXII where stringency = 0.4). The same data is 
shown in Figure 20 after manual editing. 
 
SrtA – Library A 
 Group1 
MAACSILPPCTIQCGGSG           76       ATGGCAGCATGCTCTATTCTTCCTCCGTGCACGATTTAGTGTGGCGGTTCTGGCG 
MAACSILPPCTTHCGGSG           70       ATGGCAGCATGCTCCATTTTGCCGCCTTGCACGACGCATTGTGGCGGTTCTGGCG 
MAACSVLPPCSFSCGGSG           148      ATGGCAGCATGCTCTGTTCTTCCTCCCTGCTCCTTCTCGTGTGGCGGTTCTGGCG 
MAACSVLPPCSVPCGGSG           57       ATGGCAGCATGCAGTGTCCTGCCTCCGTGCTCTGTCCCCTGTGGCGGTTCTGGCG 
MAACSILPPCNSPCGGSG           41       ATGGCAGCATGCTCGATTCTGCCGCCGTGCAATAGTCCTTGTGGCGGTTCTGGCG 
MAACGILPPCAMSCGGSG           59       ATGGCAGCATGCGGGATTCTTCCTCCGTGCGCTATGTCTTGTGGCGGTTCTGGCG 
MAACSILPPCSQNCGGSG           109      ATGGCAGCATGCTCTATCCTTCCTCCTTGCTCTTAGAATTGTGGCGGTTCTGGCG 
MAACALLPPCNQNCGGSG           55       ATGGCAGCATGCGCTCTGCTGCCGCCCTGCAATTAGAACTGTGGCGGTTCTGGCG 
MAACTMLPPCSSNCGGSG           51       ATGGCAGCATGCACTATGTTGCCTCCTTGCTCGTCTAACTGTGGCGGTTCTGGCG 
MAACPVLPPCISNCGGSG           67       ATGGCAGCATGCCCCGTTCTCCCCCCCTGCATTAGTAATTGTGGCGGTTCTGGCG 
MAACTILPPCVSNCGGSG           36       ATGGCAGCATGCACCATCTTGCCGCCTTGCGTGTCCAACTGTGGCGGTTCTGGCG 
MAACSILPPCFQTCGGSG           68       ATGGCAGCATGCAGCATCTTGCCCCCCTGCTTCTAGACCTGTGGCGGTTCTGGCG 
MAACPSLPPCPWNCGGSG           91       ATGGCAGCATGCCCGAGTCTTCCCCCGTGCCCCTGGAATTGTGGCGGTTCTGGCG 
MAACPVLPPCPINCGGSG           74       ATGGCAGCATGCCCCGTCCTGCCTCCCTGCCCTATTAACTGTGGCGGTTCTGGCG 
 
 Group2 
MAACSRSCPVLPPCGGSG           65       ATGGCAGCATGCTCTCGTTCCTGCCCTGTGCTTCCCCCCTGTGGCGGTTCTGGCG 
MAACSHQCPVLPPCGGSG           35       ATGGCAGCATGCTCGCACCAGTGCCCTGTGCTCCCTCCTTGTGGCGGTTCTGGCG 
MAACTNNCPLLPPCGGSG           86       ATGGCAGCATGCACTAACAATTGCCCCCTTTTGCCTCCTTGTGGCGGTTCTGGCG 
MAACQTGCPILPPCGGSG           98       ATGGCAGCATGCTAGACGGGTTGCCCGATTCTGCCTCCCTGTGGCGGTTCTGGCG 
MAACYTSCPVLPPCGGSG           37       ATGGCAGCATGCTACACTTCTTGCCCTGTTCTGCCTCCCTGTGGCGGTTCTGGCG 
MAACGHGCPYLPPCGGSG           69       ATGGCAGCATGCGGTCACGGCTGCCCTTACCTGCCTCCTTGTGGCGGTTCTGGCG 
MAACSQGCPSLPPCGGSG           43       ATGGCAGCATGCAGTTAGGGGTGCCCGTCGCTGCCTCCGTGTGGCGGTTCTGGCG 
MAACVSSCPSLPPCGGSG           52       ATGGCAGCATGCGTGTCCAGTTGCCCGAGTCTTCCCCCCTGTGGCGGTTCTGGCG 
MAACVSNCPYLPPCGGSG           38       ATGGCAGCATGCGTTTCTAATTGCCCCTACTTGCCGCCGTGTGGCGGTTCTGGCG 
MAACISLCPQLPPCGGSG           37       ATGGCAGCATGCATTTCTCTTTGCCCTCAGCTCCCTCCTTGTGGCGGTTCTGGCG 
MAACVLACPYLPPCGGSG           38       ATGGCAGCATGCGTCCTGGCCTGCCCCTATCTTCCCCCCTGTGGCGGTTCTGGCG 
MAACSGLCTVLPPCGGSG           97       ATGGCAGCATGCAGTGGTTTGTGCACTGTCCTCCCTCCTTGTGGCGGTTCTGGCG 
MAACRGTCPVLPPCGGSG           75       ATGGCAGCATGCAGGGGCACCTGCCCCGTTCTGCCTCCTTGTGGCGGTTCTGGCG 
MAACSGYCPYLPPCGGSG           89       ATGGCAGCATGCAGCGGTTATTGCCCCTACCTCCCGCCTTGTGGCGGTTCTGGCG 
MAACNGFCPSLPPCGGSG           86       ATGGCAGCATGCAATGGTTTTTGCCCGAGTCTCCCTCCTTGTGGCGGTTCTGGCG 
MAACNTLCPYLPPCGGSG           146      ATGGCAGCATGCAATACTCTTTGCCCTTATCTGCCCCCTTGTGGCGGTTCTGGCG 
MAACSWRCPSLPPCGGSG           194      ATGGCAGCATGCTCGTGGCGGTGCCCGTCTCTCCCTCCGTGTGGCGGTTCTGGCG 
MAACSVRCDTLPPCGGSG           41       ATGGCAGCATGCAGTGTGCGGTGCGATACTCTTCCTCCCTGTGGCGGTTCTGGCG 
MAACASRCHQLPPCGGSG           36       ATGGCAGCATGCGCCTCCAGGTGCCACCAGCTGCCTCCGTGTGGCGGTTCTGGCG 
 
 Group3 
MAACVLPPCFYHDCGGSG           40       ATGGCAGCATGCGTTCTCCCTCCGTGCTTTTATCATGATTGTGGCGGTTCTGGCG 
MAACVLPPCFTYDCGGSG           36       ATGGCAGCATGCGTGCTCCCGCCGTGCTTTACTTATGATTGTGGCGGTTCTGGCG 
MAACVLPPCSSLDCGGSG           63       ATGGCAGCATGCGTCCTGCCTCCCTGCTCCTCCTTGGACTGTGGCGGTTCTGGCG 
MAACILPPCSSVDCGGSG           37       ATGGCAGCATGCATTTTGCCCCCCTGCTCGAGTGTTGATTGTGGCGGTTCTGGCG 
MAACLLPPCTPLDCGGSG           89       ATGGCAGCATGCCTCCTTCCGCCCTGCACTCCCCTCGATTGTGGCGGTTCTGGCG 
MAACLLPPCSYMECGGSG           37       ATGGCAGCATGCCTTCTGCCTCCTTGCAGCTATATGGAGTGTGGCGGTTCTGGCG 
MAACLLPPCSYIDCGGSG           107      ATGGCAGCATGCCTCCTCCCTCCTTGCTCTTACATTGACTGTGGCGGTTCTGGCG 
MAACLLPPCSYIDCGGSG           81       ATGGCAGCATGCCTTCTTCCCCCTTGCTCCTACATCGATTGTGGCGGTTCTGGCG 
MAACLLPPCNFLDCGGSG           52       ATGGCAGCATGCCTCCTTCCGCCTTGCAATTTTCTGGATTGTGGCGGTTCTGGCG 
MAACILPPCQFKDCGGSG           44       ATGGCAGCATGCATTCTGCCTCCCTGCTAGTTCAAGGATTGTGGCGGTTCTGGCG 
MAACVLPPCTFADCGGSG           35       ATGGCAGCATGCGTTCTTCCCCCTTGCACCTTTGCGGACTGTGGCGGTTCTGGCG 
MAACILPPCSYTQCGGSG           78       ATGGCAGCATGCATCTTGCCTCCCTGCTCTTACACGTAGTGTGGCGGTTCTGGCG 
MAACHLPPCSLHLCGGSG           125      ATGGCAGCATGCCATCTTCCCCCTTGCTCCTTGCACTTGTGTGGCGGTTCTGGCG 
MAACHLPPCDATLCGGSG           60       ATGGCAGCATGCCACCTGCCGCCTTGCGATGCTACGCTTTGTGGCGGTTCTGGCG 
 
 Group4 
MAACPTLPPCEAPCGGSG           72       ATGGCAGCATGCCCCACTCTGCCCCCTTGCGAGGCCCCGTGTGGCGGTTCTGGCG 
MAACATLPPCQAPCGGSG           56       ATGGCAGCATGCGCGACTCTCCCTCCTTGCTAGGCTCCTTGTGGCGGTTCTGGCG 
MAACAYLPPCEANCGGSG           56       ATGGCAGCATGCGCGTATTTGCCCCCTTGCGAGGCTAATTGTGGCGGTTCTGGCG 
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MAACLQLPPCSSPCGGSG           92       ATGGCAGCATGCTTGTAGCTTCCTCCCTGCTCGTCCCCGTGTGGCGGTTCTGGCG 
MAACRQLPPCSDPCGGSG           59       ATGGCAGCATGCCGTTAGTTGCCTCCCTGCAGCGATCCCTGTGGCGGTTCTGGCG 
MAACAELPPCNNPCGGSG           41       ATGGCAGCATGCGCGGAGCTGCCTCCTTGCAACAATCCTTGTGGCGGTTCTGGCG 
 
 Group5 
MAACFFPCGVLPPCGGSG           74       ATGGCAGCATGCTTCTTTCCGTGCGGTGTGCTTCCCCCTTGTGGCGGTTCTGGCG 
MAACLYPCGVLPPCGGSG           50       ATGGCAGCATGCCTGTACCCGTGCGGTGTGCTGCCCCCCTGTGGCGGTTCTGGCG 
MAACDFTCGILPPCGGSG           67       ATGGCAGCATGCGATTTTACTTGCGGTATTCTGCCTCCGTGTGGCGGTTCTGGCG 
 
 Group6 
MAACNIQSCLPPCGGSG           75       ATGGCAGCATGCAACATTTAGTCTTGCCTTCCTCCTTGTGGCGGTTCTGGCG 
MAACTIESCLPPCGGSG           53       ATGGCAGCATGCACGATTGAGTCTTGCCTTCCTCCTTGTGGCGGTTCTGGCG 
MAACSLVSCLPPCGGSG           55       ATGGCAGCATGCAGTCTCGTTAGTTGCTTGCCTCCCTGTGGCGGTTCTGGCG 
MAACSIITCLPPCGGSG           45       ATGGCAGCATGCTCCATCATCACGTGCTTGCCTCCTTGTGGCGGTTCTGGCG 
MAACSYELCLPPCGGSG           37       ATGGCAGCATGCAGTTATGAGTTGTGCCTCCCTCCTTGTGGCGGTTCTGGCG 
MAACPFVPCLPPCGGSG           39       ATGGCAGCATGCCCTTTCGTCCCTTGCCTTCCTCCTTGTGGCGGTTCTGGCG 
 
 Group7 
MAACPILPPCHAHCGGSG           135      ATGGCAGCATGCCCCATTCTTCCCCCTTGCCATGCTCATTGTGGCGGTTCTGGCG 
MAACPILPPCHIMCGGSG           38       ATGGCAGCATGCCCTATTTTGCCTCCGTGCCACATCATGTGTGGCGGTTCTGGCG 
MAACPALPPCHSDCGGSG           45       ATGGCAGCATGCCCTGCGCTGCCCCCGTGCCATTCCGATTGTGGCGGTTCTGGCG 
MAACPSLPPCNQHCGGSG           48       ATGGCAGCATGCCCCTCTCTCCCTCCCTGCAATTAGCATTGTGGCGGTTCTGGCG 
MAACPYLPPCNGHCGGSG           43       ATGGCAGCATGCCCGTATCTGCCTCCTTGCAATGGTCATTGTGGCGGTTCTGGCG 
MAACPLLPPCSLDCGGSG           317      ATGGCAGCATGCCCCCTGCTGCCGCCTTGCAGTCTGGATTGTGGCGGTTCTGGCG 
MAACPFLPPCSLKCGGSG           43       ATGGCAGCATGCCCGTTTCTTCCTCCGTGCTCTTTGAAGTGTGGCGGTTCTGGCG 
MAACPLLPPCGIGCGGSG           79       ATGGCAGCATGCCCTCTGCTGCCTCCGTGCGGTATTGGCTGTGGCGGTTCTGGCG 
MAACPLLPPCADDCGGSG           701      ATGGCAGCATGCCCCTTGCTCCCTCCCTGCGCTGATGATTGTGGCGGTTCTGGCG 
MAACPYLPPCGTICGGSG           71       ATGGCAGCATGCCCCTATCTGCCTCCTTGCGGCACGATCTGTGGCGGTTCTGGCG 
MAACPLLPPCSGICGGSG           42       ATGGCAGCATGCCCCCTCCTGCCTCCCTGCTCTGGTATCTGTGGCGGTTCTGGCG 
MAACPSLPPCINSCGGSG           67       ATGGCAGCATGCCCCTCCCTGCCTCCCTGCATTAACTCGTGTGGCGGTTCTGGCG 
MAACPVLPPCLASCGGSG           62       ATGGCAGCATGCCCTGTGCTCCCGCCCTGCCTGGCTTCTTGTGGCGGTTCTGGCG 
MAACPRLPPCSSSCGGSG           36       ATGGCAGCATGCCCGCGTTTGCCTCCTTGCTCGAGTTCTTGTGGCGGTTCTGGCG 
MAACPQLPPCRVSCGGSG           114      ATGGCAGCATGCCCTTAGCTCCCTCCCTGCCGCGTGTCTTGTGGCGGTTCTGGCG 
MAACPALPPCQLSCGGSG           63       ATGGCAGCATGCCCTGCGTTGCCCCCGTGCTAGTTGTCTTGTGGCGGTTCTGGCG 
MAACPSLPPCVLGCGGSG           50       ATGGCAGCATGCCCTTCTCTCCCTCCCTGCGTTCTTGGGTGTGGCGGTTCTGGCG 
MAACPSLPPCFHRCGGSG           69       ATGGCAGCATGCCCCAGTCTTCCCCCCTGCTTTCACCGCTGTGGCGGTTCTGGCG 
MAACPSLPPCTHRCGGSG           41       ATGGCAGCATGCCCGTCTCTTCCCCCCTGCACTCATAGGTGTGGCGGTTCTGGCG 
MAACPTLPPCSYRCGGSG           40       ATGGCAGCATGCCCCACTTTGCCTCCTTGCTCTTACAGGTGTGGCGGTTCTGGCG 
 
 Group8 
MAACSNRCTLLPPCGGSG           104      ATGGCAGCATGCTCTAATCGGTGCACCTTGTTGCCGCCTTGTGGCGGTTCTGGCG 
MAACSKRCNILPPCGGSG           49       ATGGCAGCATGCAGCAAGCGTTGCAATATTTTGCCCCCTTGTGGCGGTTCTGGCG 
MAACTRRCLILPPCGGSG           42       ATGGCAGCATGCACTCGTCGCTGCCTTATTCTCCCTCCGTGTGGCGGTTCTGGCG 
MAACNTKCSILPPCGGSG           103      ATGGCAGCATGCAACACTAAGTGCTCTATTCTCCCCCCCTGTGGCGGTTCTGGCG 
MAACVSTCQILPPCGGSG           85       ATGGCAGCATGCGTTAGTACGTGCTAGATCCTCCCCCCTTGTGGCGGTTCTGGCG 
MAACVMRCQVLPPCGGSG           65       ATGGCAGCATGCGTTATGCGTTGCTAGGTCCTGCCTCCCTGTGGCGGTTCTGGCG 
MAACVDRCFILPPCGGSG           38       ATGGCAGCATGCGTTGATCGCTGCTTTATTCTTCCCCCGTGTGGCGGTTCTGGCG 
 
 Group9 
MAACSRHCLTLPPCGGSG           364      ATGGCAGCATGCAGTCGTCATTGCCTGACTCTTCCTCCGTGTGGCGGTTCTGGCG 
MAACSKHCTTLPPCGGSG           37       ATGGCAGCATGCAGTAAGCATTGCACCACGCTCCCTCCTTGTGGCGGTTCTGGCG 
MAACSRKCVELPPCGGSG           35       ATGGCAGCATGCTCCAGGAAGTGCGTGGAGTTGCCTCCGTGTGGCGGTTCTGGCG 
 
 Group10 
MAACKRTHCLPPCCGGSG           743      ATGGCAGCATGCAAGCGTACCCATTGCCTCCCCCCCTGTTGTGGCGGTTCTGGCG 
MAACPRARCLPPCCGGSG           35       ATGGCAGCATGCCCTCGGGCTCGGTGCCTTCCTCCCTGCTGTGGCGGTTCTGGCG 
MAACKSVCLPPCCGGSG            52       ATGGCAGCATGCAAGTCTGTCTGCCTTCCTCCGTGCTGTGGCGGTTCTGGCG 
MAACRSITCLPPCCGGSG           43       ATGGCAGCATGCCGGTCGATTACCTGCCTTCCTCCGTGCTGTGGCGGTTCTGGCG 
MAACRVACLPPCCGGSG            46       ATGGCAGCATGCCGTGTCGCCTGCCTTCCTCCTTGCTGTGGCGGTTCTGGCG 
MAACRVMRCLPPCCGGSG           45       ATGGCAGCATGCCGTGTCATGCGGTGCCTTCCTCCGTGTTGTGGCGGTTCTGGCG 
 
 Group11 
MAACYQLPPCDHSCGGSG           140      ATGGCAGCATGCTACTAGTTGCCTCCCTGCGATCACAGTTGTGGCGGTTCTGGCG 
MAACYLPPCDHSCGGSG            48       ATGGCAGCATGCTACCTGCCCCCGTGCGACCATTCCTGTGGCGGTTCTGGCG 
MAACRELPPCGHSCGGSG           81       ATGGCAGCATGCCGTGAGTTGCCGCCTTGCGGTCATTCGTGTGGCGGTTCTGGCG 
 
 Group12 
MAACHSRCPTLPPCGGSG           91       ATGGCAGCATGCCACTCTCGCTGCCCCACTTTGCCCCCTTGTGGCGGTTCTGGCG 
MAACHSRCPQLPPCGGSG           40       ATGGCAGCATGCCATAGTAGGTGCCCCTAGCTTCCCCCGTGTGGCGGTTCTGGCG 
MAACDSRCPRLPPCGGSG           36       ATGGCAGCATGCGATAGTCGGTGCCCTCGGCTCCCCCCTTGTGGCGGTTCTGGCG 
MAACTSRCPQLPPCGGSG           42       ATGGCAGCATGCACCTCGCGGTGCCCTCAGCTCCCTCCGTGTGGCGGTTCTGGCG 
MAACTQRCPQLPPCGGSG           40       ATGGCAGCATGCACCTAGAGGTGCCCTCAGCTCCCCCCCTGTGGCGGTTCTGGCG 
 
 Group13 
MAACILPPCPSSCGGSG            68       ATGGCAGCATGCATTCTCCCCCCGTGCCCTTCTTCGTGTGGCGGTTCTGGCG 
MAACILPPCPFSCGGSG            51       ATGGCAGCATGCATCTTGCCGCCTTGCCCCTTTTCCTGTGGCGGTTCTGGCG 
MAACILPPCPYHCGGSG            102      ATGGCAGCATGCATCCTGCCCCCTTGCCCGTACCATTGTGGCGGTTCTGGCG 
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 Group14 
MAACLLYSCEDQCGGSG            36       ATGGCAGCATGCCTCCTCTACAGTTGCGAGGACTAGTGTGGCGGTTCTGGCG 
MAACMGYCSCWAQCGGSG           39       ATGGCAGCATGCATGGGTTATTGCTCGTGCTGGGCTTAGTGTGGCGGTTCTGGCG 
MAACTILPPCPSYCGGSG           41       ATGGCAGCATGCACTATTTTGCCCCCTTGCCCCTCTTATTGTGGCGGTTCTGGCG 
MAACHILPPCDSICGGSG           39       ATGGCAGCATGCCACATTTTGCCCCCTTGCGACTCTATTTGTGGCGGTTCTGGCG 
MAACRILPPCADHCGGSG           45       ATGGCAGCATGCCGGATCCTCCCGCCTTGCGCTGATCATTGTGGCGGTTCTGGCG 
MAACQLLPPCPFNCGGSG           78       ATGGCAGCATGCTAGCTCCTTCCGCCTTGCCCTTTTAATTGTGGCGGTTCTGGCG 
MAACWVLPPCGSWCGGSG           55       ATGGCAGCATGCTGGGTGCTTCCTCCTTGCGGCTCTTGGTGTGGCGGTTCTGGCG 
MAACPQLPPCKYICGGSG           36       ATGGCAGCATGCCCTTAGCTTCCCCCTTGCAAGTACATTTGTGGCGGTTCTGGCG 
MAACGQLPPCSVVCGGSG           36       ATGGCAGCATGCGGGTAGCTCCCTCCCTGCTCCGTTGTCTGTGGCGGTTCTGGCG 
MAACRQLPPCSFECGGSG           302      ATGGCAGCATGCAGGTAGCTTCCTCCTTGCTCTTTCGAGTGTGGCGGTTCTGGCG 
MAACLQLPPCAWTCGGSG           64       ATGGCAGCATGCTTGCAGCTGCCCCCTTGCGCTTGGACGTGTGGCGGTTCTGGCG 
MAACLQLPPCNVSCGGSG           96       ATGGCAGCATGCCTGTAGCTTCCTCCTTGCAACGTGTCCTGTGGCGGTTCTGGCG 
MAACILPPCGLFYCGGSG           35       ATGGCAGCATGCATTCTCCCGCCCTGCGGTCTGTTTTATTGTGGCGGTTCTGGCG 
MAACILPPCELNHCGGSG           39       ATGGCAGCATGCATTCTTCCTCCCTGCGAGCTTAATCATTGTGGCGGTTCTGGCG 
MAACYLPPCSKSRCGGSG           57       ATGGCAGCATGCTACCTCCCTCCTTGCAGCAAGTCTCGGTGTGGCGGTTCTGGCG 
MAACMLPPCFYDICGGSG           35       ATGGCAGCATGCATGCTCCCTCCTTGCTTCTATGATATTTGTGGCGGTTCTGGCG 
 
 Group15 
MAACLPPCPLLPCGGSG            54       ATGGCAGCATGCCTGCCTCCTTGCCCGTTGTTGCCGTGTGGCGGTTCTGGCG 
MAACGPPCILPPCGGSG            72       ATGGCAGCATGCGGTCCCCCCTGCATTTTGCCTCCCTGTGGCGGTTCTGGCG 
MAACFAPCNILPPCGGSG           43       ATGGCAGCATGCTTCGCTCCTTGCAACATCCTTCCCCCCTGTGGCGGTTCTGGCG 
MAACFAPCPFLPPCGGSG           37       ATGGCAGCATGCTTCGCTCCTTGCCCGTTCTTGCCTCCTTGTGGCGGTTCTGGCG 
MAACRNQCLILPPCGGSG           39       ATGGCAGCATGCCGCAACCAGTGCTTGATTCTTCCTCCCTGTGGCGGTTCTGGCG 
MAACGGHCVILPPCGGSG           77       ATGGCAGCATGCGGTGGTCACTGCGTTATTCTCCCCCCGTGTGGCGGTTCTGGCG 
MAACYGECQVLPPCGGSG           41       ATGGCAGCATGCTACGGCGAGTGCTAGGTGTTGCCTCCTTGTGGCGGTTCTGGCG 
MAACYGQCTQLPPCGGSG           95       ATGGCAGCATGCTACGGTCAGTGCACTTAGCTGCCTCCTTGTGGCGGTTCTGGCG 
MAACHGKCAFLPPCGGSG           36       ATGGCAGCATGCCACGGTAAGTGCGCGTTTTTGCCCCCCTGTGGCGGTTCTGGCG 
MAACHSGCYVLPPCGGSG           36       ATGGCAGCATGCCACTCGGGGTGCTACGTTCTGCCTCCGTGTGGCGGTTCTGGCG 
MAACGQVCLPPYCGGSG            81       ATGGCAGCATGCGGGTAGGTTTGCTTGCCTCCGTATTGTGGCGGTTCTGGCG 
MAACYYTCLPPYCGGSG            49       ATGGCAGCATGCTACTATACGTGCTTGCCCCCGTATTGTGGCGGTTCTGGCG 
MAACYALCLPPYQCGGSG           56       ATGGCAGCATGCTATGCGTTGTGCCTTCCCCCTTATCAGTGTGGCGGTTCTGGCG 
 
 Group16 
MAACSLICSIGSCGGSG            41       ATGGCAGCATGCTCCTTGATTTGCAGCATTGGTTCTTGTGGCGGTTCTGGCG 
MAACSSICAIGLCGGSG            41       ATGGCAGCATGCAGTAGTATTTGCGCTATTGGGTTGTGTGGCGGTTCTGGCG 
MAACNYQCTLAYCGGSG            45       ATGGCAGCATGCAACTACCAGTGCACTCTTGCGTATTGTGGCGGTTCTGGCG 
MAACTTTCSFVYCGGSG            46       ATGGCAGCATGCACTACTACTTGCTCGTTTGTGTACTGTGGCGGTTCTGGCG 
MAACMYDCGYTYCGGSG            37       ATGGCAGCATGCATGTATGACTGCGGCTATACCTACTGTGGCGGTTCTGGCG 
MAACSYLCPQSFCGGSG            40       ATGGCAGCATGCTCTTATCTTTGCCCCTAGTCCTTTTGTGGCGGTTCTGGCG 
MAACRAHCSVSLCGGSG            58       ATGGCAGCATGCCGTGCTCACTGCTCTGTCTCGCTCTGTGGCGGTTCTGGCG 
MAACVRACQLSLCGGSG            62       ATGGCAGCATGCGTTCGTGCTTGCTAGCTCAGTCTTTGTGGCGGTTCTGGCG 
MAACLRSNCSLVACGGSG           36       ATGGCAGCATGCCTCAGGAGTAATTGCTCGTTGGTTGCTTGTGGCGGTTCTGGCG 
 
 Group17 
MAACIQRSCVTHLCGGSG           37       ATGGCAGCATGCATTTAGCGTAGTTGCGTCACCCACCTTTGTGGCGGTTCTGGCG 
MAACVQRCLLDLECGGSG           37       ATGGCAGCATGCGTTTAGCGTTGCCTGTTGGACCTTGAGTGTGGCGGTTCTGGCG 
MAACTTNCVNQMCGGSG            37       ATGGCAGCATGCACCACTAATTGCGTGAACTAGATGTGTGGCGGTTCTGGCG 
MAACPSRCMNVICGGSG            40       ATGGCAGCATGCCCTTCGAGGTGCATGAACGTGATCTGTGGCGGTTCTGGCG 
 
 Group18 
MAACNRTCHPQFPCGGSG           44       ATGGCAGCATGCAACCGGACGTGCCATCCCCAGTTCCCTTGTGGCGGTTCTGGCG 
MAACEVGCHPQFACGGSG           44       ATGGCAGCATGCGAGGTGGGTTGCCATCCTTAGTTTGCTTGTGGCGGTTCTGGCG 
MAACGIDCHPQGGCGGSG           93       ATGGCAGCATGCGGCATTGATTGCCATCCTTAGGGTGGGTGTGGCGGTTCTGGCG 
 
 Group MIXED 
MAACQRVCSRWQCGGSG            38       ATGGCAGCATGCTAGAGGGTTTGCAGTAGGTGGCAGTGTGGCGGTTCTGGCG 
MAACSPICWRYKCGGSG            45       ATGGCAGCATGCTCTCCTATCTGCTGGCGGTACAAGTGTGGCGGTTCTGGCG 
MAACHVNACYALSCGGSG           36       ATGGCAGCATGCCACGTTAACGCTTGCTATGCGTTGTCCTGTGGCGGTTCTGGCG 
MAACHYTPCHQDSCGGSG           46       ATGGCAGCATGCCATTACACTCCTTGCCATTAGGATTCTTGTGGCGGTTCTGGCG 
MAACNKGCNYPVCGGSG            35       ATGGCAGCATGCAACAAGGGTTGCAATTATCCTGTGTGTGGCGGTTCTGGCG 
MAACLGGCYPVPCGGSG            41       ATGGCAGCATGCCTGGGCGGGTGCTATCCGGTTCCTTGTGGCGGTTCTGGCG 
MAACHPQNCPLVFCGGSG           37       ATGGCAGCATGCCACCCTTAGAATTGCCCCCTCGTGTTTTGTGGCGGTTCTGGCG 
MAACKGQTCPQVVCGGSG           51       ATGGCAGCATGCAAGGGGTAGACGTGCCCTTAGGTTGTGTGTGGCGGTTCTGGCG 
MAACCNKRVCLDCCGGSG           39       ATGGCAGCATGCTGTAACAAGCGGGTGTGCCTTGACTGTTGTGGCGGTTCTGGCG 
MAACAKRVCTSCCGGSG            43       ATGGCAGCATGCGCTAAGCGGGTGTGCACTTCCTGTTGTGGCGGTTCTGGCG 
MAACSGYCRTGVSWGGSG           41       ATGGCAGCATGCTCGGGTTATTGCAGGACGGGGGTTTCTTGGGGCGGTTCTGGCG 
MAARMKSSCLPPCCGGSG           106      ATGGCAGCACGCATGAAGAGTAGTTGCCTCCCTCCGTGCTGTGGCGGTTCTGGCG 
MAACKVGCLYSWCGGSG            47       ATGGCAGCATGCAAGGTTGGCTGCTTGTATAGTTGGTGTGGCGGTTCTGGCG 
MAACQQSCLYKACGGSG            35       ATGGCAGCATGCTAGCAGTCGTGCTTGTACAAGGCGTGTGGCGGTTCTGGCG 
MAACYRACSFKLVCGGSG           65       ATGGCAGCATGCTATCGTGCGTGCAGTTTTAAGTTGGTGTGTGGCGGTTCTGGCG 
MAACQVFCSFDMFCGGSG           41       ATGGCAGCATGCTAGGTTTTCTGCTCGTTCGATATGTTTTGTGGCGGTTCTGGCG 
MAACERVCHVDSACGGSG           39       ATGGCAGCATGCGAGCGTGTGTGCCATGTGGATTCTGCGTGTGGCGGTTCTGGCG 
MAACQSICAVPGFCGGSG           35       ATGGCAGCATGCTAGTCGATCTGCGCTGTCCCTGGCTTTTGTGGCGGTTCTGGCG 
MAACFGSCFNLLYCGGSG           41       ATGGCAGCATGCTTCGGTAGTTGCTTTAATCTCCTGTATTGTGGCGGTTCTGGCG 
MAACLHSCSDECLCGGSG           45       ATGGCAGCATGCTTGCACAGCTGCAGCGATGAGTGTCTTTGTGGCGGTTCTGGCG 
MAACQHRCCDVHFCGGSG           36       ATGGCAGCATGCTAGCATCGTTGTTGCGATGTGCATTTTTGTGGCGGTTCTGGCG 
MAACCSLSCDLQTCGGSG           41       ATGGCAGCATGCTGCAGTCTTTCCTGCGACCTCTAGACTTGTGGCGGTTCTGGCG 
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MAACDALMCTHSSCGGSG           36       ATGGCAGCATGCGATGCTTTGATGTGCACCCATAGCTCTTGTGGCGGTTCTGGCG 
MAACSSSICNHICGGSG            37       ATGGCAGCATGCTCCAGTAGTATTTGCAATCACATTTGTGGCGGTTCTGGCG 
MAACFGSSCCVICGGSG            72       ATGGCAGCATGCTTTGGGTCTAGCTGCTGTGTTATCTGTGGCGGTTCTGGCG 
MAACNSSVCSCIICGGSG           46       ATGGCAGCATGCAATTCTAGTGTTTGCTCGTGTATCATTTGTGGCGGTTCTGGCG 
MAACPVVCQWFTCGGSG            64       ATGGCAGCATGCCCTGTCGTTTGCTAGTGGTTCACCTGTGGCGGTTCTGGCG 
MAACRFTCVKVPCGGSG            42       ATGGCAGCATGCAGGTTTACCTGCGTGAAGGTTCCCTGTGGCGGTTCTGGCG 
MAACDYYTCWQFPCGGSG           36       ATGGCAGCATGCGACTATTATACGTGCTGGTAGTTCCCTTGTGGCGGTTCTGGCG 
MAACCYACFQPCGCGGSG           41       ATGGCAGCATGCTGTTACGCCTGCTTTTAGCCTTGTGGTTGTGGCGGTTCTGGCG 
MAACQELVLPPCFCGGSG           74       ATGGCAGCATGCTAGGAGTTGGTGCTCCCGCCATGTTTTTGTGGCGGTTCTGGCG 
MAACLTYCLPTGCGGSG            44       ATGGCAGCATGCCTCACCTACTGCCTTCCGACTGGGTGTGGCGGTTCTGGCG 
MAACMNICLPPTNCGGSG           43       ATGGCAGCATGCATGAATATTTGCTTGCCTCCGACCAATTGTGGCGGTTCTGGCG 
MAACSQFCLPPFSCGGSG           46       ATGGCAGCATGCAGTCAGTTTTGCTTGCCTCCGTTCTCTTGTGGCGGTTCTGGCG 
MAACSICCMSEIQCGGSG           62       ATGGCAGCATGCAGCATCTGTTGCATGTCTGAGATTTAGTGTGGCGGTTCTGGCG 
MAACPAGCMTTCSCGGSG           47       ATGGCAGCATGCCCTGCGGGTTGCATGACTACCTGTTCGTGTGGCGGTTCTGGCG 
MAACQGTCLLCGDCGGSG           42       ATGGCAGCATGCCAGGGTACTTGCCTGTTGTGTGGTGACTGTGGCGGTTCTGGCG 
MAACLRYCTQLPPCGGSG           40       ATGGCAGCATGCTTGCGTTATTGCACCTAGCTTCCCCCCTGTGGCGGTTCTGGCG 
MAACPSYCTQGLPCGGSG           42       ATGGCAGCATGCCCTTCTTATTGCACTTAGGGCCTTCCCTGTGGCGGTTCTGGCG 
MAACIVQWCRVPCGGSG            45       ATGGCAGCATGCATTGTTTAGTGGTGCCGTGTTCCGTGTGGCGGTTCTGGCG 
MAACLPPCYHHFLCGGSG           37       ATGGCAGCATGCCTTCCCCCGTGCTATCATCACTTTCTCTGTGGCGGTTCTGGCG 
MAACLPPYSWTDCGGSG            36       ATGGCAGCATGCCTGCCCCCTTACAGCTGGACCGACTGTGGCGGTTCTGGCG 
MAACSRYNMCPFMCGGSG           35       ATGGCAGCATGCTCCCGGTATAATATGTGCCCGTTCATGTGTGGCGGTTCTGGCG 
MAACNLYPLCSPYCGGSG           35       ATGGCAGCATGCAATCTGTATCCTCTCTGCAGCCCCTACTGTGGCGGTTCTGGCG 
MAACGWFYCSWTCGGSG            78       ATGGCAGCATGCGGTTGGTTCTATTGCTCTTGGACGTGTGGCGGTTCTGGCG 
 
SrtA – Library B 
 Group1 
MAACAILPPCGQLSCGGSG           290      ATGGCAGCATGCGCTATTCTGCCGCCGTGCGGGCAGCTTAGTTGTGGCGGTTCTGGCG 
MAACAYLPPCGSMLCGGSG           67       ATGGCAGCATGCGCTTATCTTCCTCCGTGCGGTTCTATGTTGTGTGGCGGTTCTGGCG 
MAACQLLPPCQFLQCGGSG           311      ATGGCAGCATGCCAGCTTCTGCCTCCTTGCTAGTTTTTGCAGTGTGGCGGTTCTGGCG 
MAACQYLPPCSFLVCGGSG           65       ATGGCAGCATGCCAGTATCTTCCTCCTTGCTCTTTTTTGGTTTGTGGCGGTTCTGGCG 
MAACSVLPPCSFVACGGSG           773      ATGGCAGCATGCTCGGTGTTGCCTCCTTGCTCTTTTGTTGCGTGTGGCGGTTCTGGCG 
MAACSLLPPCTFVACGGSG           233      ATGGCAGCATGCTCGTTGCTGCCGCCGTGCACTTTTGTGGCGTGTGGCGGTTCTGGCG 
MAACALLPPCSWVSCGGSG           229      ATGGCAGCATGCGCGTTGCTGCCGCCGTGCTCGTGGGTGTCTTGTGGCGGTTCTGGCG 
MAACAILPPCHFRSCGGSG           38       ATGGCAGCATGCGCGATTCTTCCGCCTTGCCATTTTCGGTCGTGTGGCGGTTCTGGCG 
MAACSRLPPCVILDCGGSG           237      ATGGCAGCATGCTCTAGGCTTCCTCCTTGCGTTATTCTTGATTGTGGCGGTTCTGGCG 
MAACTRLPPCVQLSCGGSG           35       ATGGCAGCATGCACTCGTTTGCCGCCTTGCGTTTAGCTTTCGTGTGGCGGTTCTGGCG 
MAACSQLPPCTYLSCGGSG           283      ATGGCAGCATGCTCTCAGCTTCCGCCTTGCACTTATCTTTCGTGTGGCGGTTCTGGCG 
MAACSVLPPCIQWSCGGSG           198      ATGGCAGCATGCTCTGTTCTGCCTCCGTGCATTCAGTGGAGTTGTGGCGGTTCTGGCG 
MAACELLPPCLLSECGGSG           166      ATGGCAGCATGCGAGCTTTTGCCGCCTTGCCTGCTGTCGGAGTGTGGCGGTTCTGGCG 
MAACALLPPCFIQECGGSG           69       ATGGCAGCATGCGCTCTGTTGCCGCCGTGCTTTATTTAGGAGTGTGGCGGTTCTGGCG 
MAACLTLPPCVLQQCGGSG           147      ATGGCAGCATGCTTGACGCTGCCGCCGTGCGTGCTGCAGTAGTGTGGCGGTTCTGGCG 
MAACTLLPPCVFQQCGGSG           33       ATGGCAGCATGCACGCTGTTGCCTCCGTGCGTTTTTCAGCAGTGTGGCGGTTCTGGCG 
MAACLVLPPCFLVDCGGSG           789      ATGGCAGCATGCCTTGTTCTTCCGCCTTGCTTTTTGGTGGATTGTGGCGGTTCTGGCG 
MAACLVLPPCMIMECGGSG           131      ATGGCAGCATGCCTTGTGCTTCCTCCGTGCATGATTATGGAGTGTGGCGGTTCTGGCG 
MAACQVLPPCGLQLCGGSG           2302     ATGGCAGCATGCCAGGTGTTGCCTCCGTGCGGTCTGTAGCTGTGTGGCGGTTCTGGCG 
MAACQLLPPCAIQWCGGSG           661      ATGGCAGCATGCCAGTTGCTTCCGCCGTGCGCGATTTAGTGGTGTGGCGGTTCTGGCG 
MAACQLLPPCVDKNCGGSG           65       ATGGCAGCATGCTAGCTTTTGCCTCCTTGCGTGGATAAGAATTGTGGCGGTTCTGGCG 
 
 Group2 
MAACLAKRCLTLPPCGGSG           227      ATGGCAGCATGCCTTGCTAAGCGTTGCCTGACTCTTCCTCCTTGTGGCGGTTCTGGCG 
MAACAGNRCLLLPPCGGSG           65       ATGGCAGCATGCGCGGGTAATCGGTGCTTGCTTCTTCCTCCTTGTGGCGGTTCTGGCG 
MAACRGRTCLVLPPCGGSG           78       ATGGCAGCATGCCGGGGGCGTACTTGCTTGGTGCTTCCTCCGTGTGGCGGTTCTGGCG 
MAACVAFTCPILPPCGGSG           439      ATGGCAGCATGCGTGGCGTTTACGTGCCCGATTCTGCCTCCGTGTGGCGGTTCTGGCG 
MAACIGSLCPVLPPCGGSG           86       ATGGCAGCATGCATTGGTAGTTTGTGCCCGGTTCTTCCTCCGTGTGGCGGTTCTGGCG 
MAACLLASCPILPPCGGSG           316      ATGGCAGCATGCTTGCTGGCTTCGTGCCCGATTCTTCCTCCGTGTGGCGGTTCTGGCG 
MAACRMSSCPILPPCGGSG           52       ATGGCAGCATGCCGTATGTCTTCGTGCCCTATTTTGCCTCCTTGTGGCGGTTCTGGCG 
MAACQSTFCPILPPCGGSG           492      ATGGCAGCATGCTAGTCTACGTTTTGCCCGATTCTGCCTCCTTGTGGCGGTTCTGGCG 
MAACEGLMCPLLPPCGGSG           33       ATGGCAGCATGCGAGGGTCTGATGTGCCCTCTTCTTCCTCCGTGTGGCGGTTCTGGCG 
MAACPNQTCPLLPPCGGSG           209      ATGGCAGCATGCCCTAATTAGACGTGCCCTTTGCTGCCTCCTTGTGGCGGTTCTGGCG 
MAACDAWRCPVLPPCGGSG           61       ATGGCAGCATGCGATGCTTGGAGGTGCCCTGTGTTGCCTCCGTGTGGCGGTTCTGGCG 
MAACVFSECSILPPCGGSG           134      ATGGCAGCATGCGTTTTTTCTGAGTGCTCTATTCTTCCTCCGTGTGGCGGTTCTGGCG 
MAACTLSFCSVLPPCGGSG           34       ATGGCAGCATGCACGCTGTCTTTTTGCAGTGTTCTTCCTCCTTGTGGCGGTTCTGGCG 
MAACVYQYCAILPPCGGSG           44       ATGGCAGCATGCGTGTATCAGTATTGCGCGATTTTGCCGCCTTGTGGCGGTTCTGGCG 
MAACQYLHCSVLPPCGGSG           138      ATGGCAGCATGCTAGTATTTGCATTGCTCTGTTCTGCCTCCGTGTGGCGGTTCTGGCG 
MAACHYTSCVILPPCGGSG           57       ATGGCAGCATGCCATTATACGAGTTGCGTTATTTTGCCGCCTTGTGGCGGTTCTGGCG 
MAACNESSCTILPPCGGSG           42       ATGGCAGCATGCAATGAGTCTTCGTGCACTATTCTGCCTCCTTGTGGCGGTTCTGGCG 
MAACQLGSCMVLPPCGGSG           61       ATGGCAGCATGCTAGCTTGGTTCTTGCATGGTGTTGCCTCCGTGTGGCGGTTCTGGCG 
 
 Group3 
MAACILPPCPTSEYCGGSG           82       ATGGCAGCATGCATTCTGCCTCCTTGCCCGACTTCGGAGTATTGTGGCGGTTCTGGCG 
MAACILPPCPTTIPCGGSG           49       ATGGCAGCATGCATTCTTCCGCCGTGCCCGACGACGATTCCGTGTGGCGGTTCTGGCG 
MAACYLPPCPSLPHCGGSG           66       ATGGCAGCATGCTATCTTCCTCCGTGCCCGTCTCTGCCTCATTGTGGCGGTTCTGGCG 
 
 Group4 
MAACPQKQCVWLPPCGGSG           63       ATGGCAGCATGCCCTCAGAAGCAGTGCGTTTGGCTTCCTCCTTGTGGCGGTTCTGGCG 
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MAACGAKYCSYLPPCGGSG           78       ATGGCAGCATGCGGGGCGAAGTATTGCTCGTATTTGCCTCCTTGTGGCGGTTCTGGCG 
MAACCARLCAYLPPCGGSG           59       ATGGCAGCATGCTGTGCGCGTCTGTGCGCTTATTTGCCGCCTTGTGGCGGTTCTGGCG 
 
 Group5 
MAACRQLPPCAEYVCGGSG           1231     ATGGCAGCATGCCGGTAGCTGCCTCCTTGCGCTGAGTATGTTTGTGGCGGTTCTGGCG 
MAACTLLPPCAEYVCGGSG           33       ATGGCAGCATGCACGCTGTTGCCTCCTTGCGCTGAGTATGTTTGTGGCGGTTCTGGCG 
MAACRVLPPCSEYNCGGSG           197      ATGGCAGCATGCAGGGTGTTGCCTCCGTGCTCTGAGTATAATTGTGGCGGTTCTGGCG 
MAACTRLPPCSEFFCGGSG           109      ATGGCAGCATGCACGCGGCTTCCGCCTTGCTCTGAGTTTTTTTGTGGCGGTTCTGGCG 
MAACRTLPPCSDLTCGGSG           146      ATGGCAGCATGCCGTACGCTGCCTCCTTGCTCTGATCTTACTTGTGGCGGTTCTGGCG 
MAACSLLPPCGSTTCGGSG           102      ATGGCAGCATGCTCTTTGTTGCCTCCTTGCGGTTCTACTACGTGTGGCGGTTCTGGCG 
MAACSLLPPCHSTNCGGSG           66       ATGGCAGCATGCAGTCTTCTTCCTCCGTGCCATTCGACGAATTGTGGCGGTTCTGGCG 
MAACTLLPPCSSLQCGGSG           325      ATGGCAGCATGCACTTTGTTGCCGCCGTGCTCTTCTCTTCAGTGTGGCGGTTCTGGCG 
MAACRLLPPCSSSICGGSG           40       ATGGCAGCATGCCGTCTGTTGCCTCCTTGCTCGTCGTCTATTTGTGGCGGTTCTGGCG 
MAACSSLPPCSTSECGGSG           53       ATGGCAGCATGCTCGAGTTTGCCTCCTTGCTCGACTTCTGAGTGTGGCGGTTCTGGCG 
MAACQILPPCHSPGCGGSG           410      ATGGCAGCATGCTAGATTCTGCCTCCTTGCCATTCGCCGGGGTGTGGCGGTTCTGGCG 
MAACSVLPPCKSQGCGGSG           61       ATGGCAGCATGCTCTGTGTTGCCGCCGTGCAAGAGTTAGGGGTGTGGCGGTTCTGGCG 
MAACSLLPPCTPVLCGGSG           130      ATGGCAGCATGCTCTCTGCTTCCGCCTTGCACTCCTGTTTTGTGTGGCGGTTCTGGCG 
MAACSLLPPCSPILCGGSG           64       ATGGCAGCATGCAGTTTGCTGCCTCCTTGCTCACCGATTCTTTGTGGCGGTTCTGGCG 
MAACLLLPPCAPTTCGGSG           282      ATGGCAGCATGCTTGTTGCTGCCGCCTTGCGCGCCGACTACTTGTGGCGGTTCTGGCG 
MAACSILPPCNPPQCGGSG           5860     ATGGCAGCATGCTCGATTCTTCCTCCGTGCAATCCTCCGTAGTGTGGCGGTTCTGGCG 
MAACTLLPPCTPDQCGGSG           3990     ATGGCAGCATGCACGCTGTTGCCTCCTTGCACGCCGGATTAGTGTGGCGGTTCTGGCG 
MAACPILPPCPPTQCGGSG           165      ATGGCAGCATGCCCTATTTTGCCTCCTTGCCCGCCGACTCAGTGTGGCGGTTCTGGCG 
MAACNLLPPCPPLSCGGSG           114      ATGGCAGCATGCAATCTGCTGCCTCCTTGCCCGCCTCTGTCTTGTGGCGGTTCTGGCG 
MAACLLLPPCPIMTCGGSG           340      ATGGCAGCATGCCTTCTGCTTCCGCCTTGCCCGATTATGACGTGTGGCGGTTCTGGCG 
MAACVVLPPCPLQTCGGSG           58       ATGGCAGCATGCGTGGTGTTGCCTCCGTGCCCGTTGCAGACTTGTGGCGGTTCTGGCG 
MAACLQLPPCPLYSCGGSG           71       ATGGCAGCATGCCTTTAGCTTCCGCCTTGCCCGTTGTATTCTTGTGGCGGTTCTGGCG 
MAACLTLPPCPSFTCGGSG           295      ATGGCAGCATGCTTGACTTTGCCGCCGTGCCCGTCTTTTACTTGTGGCGGTTCTGGCG 
MAACIVLPPCNSFTCGGSG           65       ATGGCAGCATGCATTGTGTTACCTCCTTGCAATTCTTTTACGTGTGGCGGTTCTGGCG 
MAACYLLPPCPSTSCGGSG           204      ATGGCAGCATGCTATTTGTTGCCGCCGTGCCCTTCGACGTCTTGTGGCGGTTCTGGCG 
MAACLLLPPCPSINCGGSG           170      ATGGCAGCATGCCTTCTGCTTCCTCCGTGCCCTTCGATTAATTGTGGCGGTTCTGGCG 
MAACKLLPPCPKVVCGGSG           43       ATGGCAGCATGCAAGCTTCTTCCTCCTTGCCCTAAGGTTGTGTGTGGCGGTTCTGGCG 
MAACMVLPPCPHQRCGGSG           222      ATGGCAGCATGCATGGTGTTGCCTCCGTGCCCTCATCAGCGGTGTGGCGGTTCTGGCG 
MAACYELPPCPQLFCGGSG           36       ATGGCAGCATGCTATGAGTTGCCGCCGTGCCCTCAGCTGTTTTGTGGCGGTTCTGGCG 
MAACLTLPPCQAVSCGGSG           419      ATGGCAGCATGCCTTACTCTTCCTCCTTGCTAGGCGGTTTCTTGTGGCGGTTCTGGCG 
MAACLLLPPCQRTSCGGSG           34       ATGGCAGCATGCCTTTTGTTGCCTCCGTGCTAGAGGACTTCTTGTGGCGGTTCTGGCG 
MAACIQLPPCQQSSCGGSG           279      ATGGCAGCATGCATTCAGCTTCCGCCTTGCTAGCAGTCTTCGTGTGGCGGTTCTGGCG 
MAACLELPPCQFASCGGSG           625      ATGGCAGCATGCTTGGAGTTGCCGCCGTGCCAGTTTGCTTCGTGTGGCGGTTCTGGCG 
MAACLTLPPCATTYCGGSG           190      ATGGCAGCATGCTTGACGTTGCCTCCGTGCGCTACGACTTATTGTGGCGGTTCTGGCG 
MAACLTLPPCLSTLCGGSG           99       ATGGCAGCATGCTTGACTCTGCCTCCTTGCCTGTCTACGCTTTGTGGCGGTTCTGGCG 
MAACYLLPPCAISVCGGSG           243      ATGGCAGCATGCTATCTTTTGCCGCCTTGCGCGATTTCGGTTTGTGGCGGTTCTGGCG 
MAACFLLPPCQVALCGGSG           66       ATGGCAGCATGCTTTCTTTTGCCTCCTTGCTAGGTTGCGCTTTGTGGCGGTTCTGGCG 
MAACMLLPPCQLNFCGGSG           87       ATGGCAGCATGCATGTTGCTGCCTCCGTGCCAGCTGAATTTTTGTGGCGGTTCTGGCG 
MAACLQLPPCQVIVCGGSG           285      ATGGCAGCATGCCTGCAGCTGCCTCCTTGCTAGGTTATTGTTTGTGGCGGTTCTGGCG 
MAACLQLPPCGVSLCGGSG           139      ATGGCAGCATGCCTGTAGCTGCCGCCTTGCGGTGTTAGTCTGTGTGGCGGTTCTGGCG 
MAACIMLPPCSVIRCGGSG           68       ATGGCAGCATGCATTATGCTTCCGCCTTGCTCGGTTATTCGTTGTGGCGGTTCTGGCG 
MAACLLLPPCSIQGCGGSG           38       ATGGCAGCATGCCTTTTGTTGCCGCCTTGCTCTATTTAGGGTTGTGGCGGTTCTGGCG 
 
 Group6 
MAACEILPPCLQFQCGGSG           607      ATGGCAGCATGCGAGATTTTGCCTCCTTGCCTTTAGTTTCAGTGTGGCGGTTCTGGCG 
MAACQELPPCLQIQCGGSG           53       ATGGCAGCATGCCAGGAGCTTCCGCCTTGCCTGCAGATTTAGTGTGGCGGTTCTGGCG 
MAACWLLPPCLQMQCGGSG           127      ATGGCAGCATGCTGGCTTCTGCCTCCGTGCCTGCAGATGTAGTGTGGCGGTTCTGGCG 
MAACWLLPPCLTILCGGSG           49       ATGGCAGCATGCTGGCTTCTTCCTCCGTGCTTGACGATTCTGTGTGGCGGTTCTGGCG 
MAACGLLPPCHQFHCGGSG           206      ATGGCAGCATGCGGGCTTTTGCCGCCTTGCCATTAGTTTCATTGTGGCGGTTCTGGCG 
MAACPSLPPCWQLQCGGSG           1131     ATGGCAGCATGCCCTAGTTTGCCTCCTTGCTGGCAGTTGTAGTGTGGCGGTTCTGGCG 
MAACSSLPPCYPFQCGGSG           35       ATGGCAGCATGCAGTTCGTTGCCTCCTTGCTATCCGTTTTAGTGTGGCGGTTCTGGCG 
 
 Group7 
MAACGYRTCYSLPPCGGSG           76       ATGGCAGCATGCGGGTATCGTACTTGCTATTCTCTGCCTCCTTGTGGCGGTTCTGGCG 
MAACGLQRCYLLPPCGGSG           73       ATGGCAGCATGCGGTTTGTAGAGGTGCTATCTTTTGCCTCCTTGTGGCGGTTCTGGCG 
MAACRFQFCHQLPPCGGSG           39       ATGGCAGCATGCAGGTTTCAGTTTTGCCATCAGTTGCCTCCGTGTGGCGGTTCTGGCG 
 
 Group8 
MAACPMLPPCDLSYCGGSG           1258     ATGGCAGCATGCCCTATGCTGCCTCCGTGCGATCTGAGTTATTGTGGCGGTTCTGGCG 
MAACPLLPPCHLSFCGGSG           537      ATGGCAGCATGCCCGTTGCTGCCTCCGTGCCATCTTTCTTTTTGTGGCGGTTCTGGCG 
MAACPLLPPCHLPQCGGSG           4327     ATGGCAGCATGCCCGTTGCTTCCGCCGTGCCATCTTCCTTAGTGTGGCGGTTCTGGCG 
MAACPGLPPCMFSQCGGSG           45       ATGGCAGCATGCCCTGGTTTGCCGCCTTGCATGTTTTCTTAGTGTGGCGGTTCTGGCG 
MAACPTLPPCQPGYCGGSG           329      ATGGCAGCATGCCCGACGTTGCCTCCTTGCCAGCCTGGTTATTGTGGCGGTTCTGGCG 
MAACPSLPPCLPTICGGSG           199      ATGGCAGCATGCCCGAGTTTGCCGCCGTGCTTGCCGACGATTTGTGGCGGTTCTGGCG 
MAACPSLPPCFNTYCGGSG           230      ATGGCAGCATGCCCGTCGCTTCCGCCTTGCTTTAATACTTATTGTGGCGGTTCTGGCG 
MAACPQLPPCIHSYCGGSG           38       ATGGCAGCATGCCCTCAGCTGCCTCCGTGCATTCATTCTTATTGTGGCGGTTCTGGCG 
MAACPLLPPCRNTVCGGSG           393      ATGGCAGCATGCCCTCTGTTGCCTCCTTGCCGGAATACGGTTTGTGGCGGTTCTGGCG 
MAACPTLPPCHNQLCGGSG           114      ATGGCAGCATGCCCGACGCTTCCTCCGTGCCATAATTAGTTGTGTGGCGGTTCTGGCG 
MAACPVLPPCFTRLCGGSG           35       ATGGCAGCATGCCCGGTTCTGCCTCCGTGCTTTACTCGTTTGTGTGGCGGTTCTGGCG 
MAACPVLPPCRTIWCGGSG           467      ATGGCAGCATGCCCGGTGCTGCCTCCGTGCCGTACTATTTGGTGTGGCGGTTCTGGCG 
MAACPVLPPCTRVHCGGSG           303      ATGGCAGCATGCCCTGTTCTGCCTCCTTGCACGCGGGTTCATTGTGGCGGTTCTGGCG 
 
 Group9 
MAACFWLDCTILPPCGGSG           85       ATGGCAGCATGCTTTTGGCTGGATTGCACGATTCTTCCGCCGTGTGGCGGTTCTGGCG 
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MAACTWLQCTILPPCGGSG           64       ATGGCAGCATGCACGTGGTTGTAGTGCACGATTCTGCCTCCTTGTGGCGGTTCTGGCG 
MAACVWNNCSLLPPCGGSG           723      ATGGCAGCATGCGTGTGGAATAATTGCTCTCTTCTGCCTCCTTGTGGCGGTTCTGGCG 
 
 Group10 
MAACLLLPPCQHQMCGGSG           75       ATGGCAGCATGCCTTCTGCTGCCGCCTTGCCAGCATTAGATGTGTGGCGGTTCTGGCG 
MAACTLLPPCLNQLCGGSG           37       ATGGCAGCATGCACGTTGCTGCCTCCGTGCCTGAATTAGCTGTGTGGCGGTTCTGGCG 
MAACTVLPPCEQALCGGSG           38       ATGGCAGCATGCACTGTGTTGCCTCCTTGCGAGCAGGCTCTTTGTGGCGGTTCTGGCG 
MAACYVLPPCSNVVCGGSG           188      ATGGCAGCATGCTATGTTCTTCCTCCGTGCTCTAATGTGGTGTGTGGCGGTTCTGGCG 
MAACYILPPCSREMCGGSG           60       ATGGCAGCATGCTATATTTTGCCTCCGTGCTCTCGTGAGATGTGTGGCGGTTCTGGCG 
MAACLILPPCSDLLCGGSG           352      ATGGCAGCATGCCTTATTCTGCCGCCTTGCTCGGATCTTCTTTGTGGCGGTTCTGGCG 
MAACVILPPCSRLLCGGSG           105      ATGGCAGCATGCGTTATTCTTCCGCCTTGCTCGCGGTTGTTGTGTGGCGGTTCTGGCG 
 
 Group11 
MAACPELPPCQLMLCGGSG           2326     ATGGCAGCATGCCCGGAGCTTCCGCCGTGCTAGTTGATGCTGTGTGGCGGTTCTGGCG 
MAACPELPPCLLLFCGGSG           35       ATGGCAGCATGCCCTGAGTTGCCTCCGTGCTTGTTGTTGTTTTGTGGCGGTTCTGGCG 
MAACPELPPCTVLKCGGSG           554      ATGGCAGCATGCCCTGAGCTGCCGCCTTGCACGGTTCTTAAATGTGGCGGTTCTGGCG 
 
 Group12 
MAACAQLPPCDYSGCGGSG           505      ATGGCAGCATGCGCGTAGCTTCCTCCGTGCGATTATTCTGGGTGTGGCGGTTCTGGCG 
MAACDILPPCVYTKCGGSG           130      ATGGCAGCATGCGATATTCTTCCTCCTTGCGTGTATACTAAGTGTGGCGGTTCTGGCG 
MAACTELPPCGWLKCGGSG           115      ATGGCAGCATGCACTGAGCTTCCTCCTTGCGGTTGGCTTAAGTGTGGCGGTTCTGGCG 
MAACRYLPPCPYKLCGGSG           616      ATGGCAGCATGCCGGTATCTTCCTCCTTGCCCTTATAAGCTGTGTGGCGGTTCTGGCG 
MAACPYLPPCSWDLCGGSG           576      ATGGCAGCATGCCCTTATCTTCCTCCGTGCTCGTGGGATCTGTGTGGCGGTTCTGGCG 
MAACQQLPPCMPRFCGGSG           54       ATGGCAGCATGCCAGTAGTTGCCTCCTTGCATGCCTCGGTTTTGTGGCGGTTCTGGCG 
MAACTQLPPCTPRRCGGSG           36       ATGGCAGCATGCACGTAGCTTCCTCCTTGCACTCCTAGGCGTTGTGGCGGTTCTGGCG 
MAACHYLPPCQPAICGGSG           88       ATGGCAGCATGCCATTATTTGCCGCCTTGCTAGCCGGCGATTTGTGGCGGTTCTGGCG 
MAACPMLPPCGIFPCGGSG           120      ATGGCAGCATGCCCGATGCTTCCGCCTTGCGGGATTTTTCCTTGTGGCGGTTCTGGCG 
MAACRVLPPCQVSPCGGSG           51       ATGGCAGCATGCCGTGTTCTTCCGCCTTGCTAGGTGTCTCCGTGTGGCGGTTCTGGCG 
MAACLSLPPCGRPACGGSG           36       ATGGCAGCATGCTTGTCGTTGCCTCCGTGCGGTAGGCCTGCGTGTGGCGGTTCTGGCG 
MAACHLLPPCGRQSCGGSG           250      ATGGCAGCATGCCATCTTTTGCCTCCGTGCGGTCGTTAGTCGTGTGGCGGTTCTGGCG 
MASCPMLPPCMKHSCGGSG           37       ATGGCATCATGCCCTATGCTTCCTCCTTGCATGAAGCATTCGTGTGGCGGTTCTGGCG 
 
 Group13 
MAACMQVWCHPQGGCGGSG           61       ATGGCAGCATGCATGCAGGTGTGGTGCCATCCTCAGGGTGGGTGTGGCGGTTCTGGCG 
MAACRWWVCHPQSGCGGSG           66       ATGGCAGCATGCCGGTGGTGGGTTTGCCATCCGTAGTCGGGTTGTGGCGGTTCTGGCG 
MAACRFAYCHPQGDCGGSG           153      ATGGCAGCATGCCGGTTTGCGTATTGCCATCCTTAGGGGGATTGTGGCGGTTCTGGCG 
MAACAYSSCHPQAPCGGSG           507      ATGGCAGCATGCGCTTATAGTTCTTGCCATCCTCAGGCTCCGTGTGGCGGTTCTGGCG 
MAACPVTECHPQVFCGGSG           133      ATGGCAGCATGCCCTGTGACTGAGTGCCATCCTTAGGTGTTTTGTGGCGGTTCTGGCG 
 
 Group14 
MAACLLPPCSWWYDCGGSG           74       ATGGCAGCATGCCTGCTTCCTCCTTGCTCGTGGTGGTATGATTGTGGCGGTTCTGGCG 
MAACVLPPCHWSLQCGGSG           133      ATGGCAGCATGCGTTCTTCCTCCTTGCCATTGGTCGCTGCAGTGTGGCGGTTCTGGCG 
MAACILPPCDFRFACGGSG           113      ATGGCAGCATGCATTCTTCCGCCTTGCGATTTTCGTTTTGCGTGTGGCGGTTCTGGCG 
MAACLLPPCGYRWGCGGSG           41       ATGGCAGCATGCTTGTTGCCGCCGTGCGGTTATCGTTGGGGTTGTGGCGGTTCTGGCG 
MAACELLPCIFRWMCGGSG           46       ATGGCAGCATGCGAGTTGTTGCCGTGCATTTTTCGTTGGATGTGTGGCGGTTCTGGCG 
 
 Group15 
MAACLAKCSQLSRHCGGSG           34       ATGGCAGCATGCCTTGCGAAGTGCTCGTAGCTGTCTCGTCATTGTGGCGGTTCTGGCG 
MAACLDRCNLLPPYCGGSG           36       ATGGCAGCATGCCTTGATCGGTGCAATTTGCTTCCTCCTTATTGTGGCGGTTCTGGCG 
MAACQLGCSLLRPMCGGSG           56       ATGGCAGCATGCTAGCTTGGGTGCTCGCTGTTGCGTCCGATGTGTGGCGGTTCTGGCG 
 
 Group16 
MAACPTKSCLLLPPCGGSG           156      ATGGCAGCATGCCCTACGAAGTCTTGCCTTTTGCTTCCTCCGTGTGGCGGTTCTGGCG 
MAACSSKFCLLLPPCGGSG           130      ATGGCAGCATGCTCTTCTAAGTTTTGCTTGTTGCTTCCTCCTTGTGGCGGTTCTGGCG 
MAACTSNSCQFTPPCGGSG           36       ATGGCAGCATGCACTTCTAATTCGTGCTAGTTTACTCCTCCTTGTGGCGGTTCTGGCG 
MAACASGTCTTLPPCGGSG           43       ATGGCAGCATGCGCGTCTGGTACGTGCACTACTCTTCCTCCGTGTGGCGGTTCTGGCG 
MAACQSPTCHTLPPCGGSG           34       ATGGCAGCATGCTAGTCGCCGACTTGCCATACTTTGCCTCCGTGTGGCGGTTCTGGCG 
MAACVPLRCTLLPPCGGSG           124      ATGGCAGCATGCGTTCCTCTTCGGTGCACTCTTCTGCCTCCGTGTGGCGGTTCTGGCG 
MAACVPYPCNLLPPCGGSG           55       ATGGCAGCATGCGTTCCTTATCCGTGCAATTTGTTGCCGCCTTGTGGCGGTTCTGGCG 
MAACLTIPCGLLPPCGGSG           39       ATGGCAGCATGCCTTACTATTCCTTGCGGTCTTCTTCCTCCGTGTGGCGGTTCTGGCG 
MAACPRRCCTFLPPCGGSG           87       ATGGCAGCATGCCCGAGGCGTTGTTGCACGTTTCTGCCTCCGTGTGGCGGTTCTGGCG 
MAACIQRTCLFLPPCGGSG           139      ATGGCAGCATGCATTCAGCGGACTTGCTTGTTTCTTCCGCCGTGTGGCGGTTCTGGCG 
MAACMNSQCIELPPCGGSG           34       ATGGCAGCATGCATGAATTCGTAGTGCATTGAGTTGCCTCCTTGTGGCGGTTCTGGCG 
MAACFTAKCLQLPPCGGSG           90       ATGGCAGCATGCTTTACGGCTAAGTGCCTTTAGCTTCCGCCTTGTGGCGGTTCTGGCG 
MAACNGHQCLSLPPCGGSG           56       ATGGCAGCATGCAATGGTCATCAGTGCTTGTCGTTGCCTCCGTGTGGCGGTTCTGGCG 
MAACRPKQCWQLPPCGGSG           1798     ATGGCAGCATGCCGTCCGAAGCAGTGCTGGCAGTTGCCTCCGTGTGGCGGTTCTGGCG 
MAACYREQCPHLPPCGGSG           43       ATGGCAGCATGCTATCGTGAGCAGTGCCCTCATCTTCCTCCTTGTGGCGGTTCTGGCG 
MAACLYPRCPSLPPCGGSG           465      ATGGCAGCATGCCTGTATCCGCGTTGCCCTTCTCTTCCTCCGTGTGGCGGTTCTGGCG 
MAACFKSCCHQLPPCGGSG           39       ATGGCAGCATGCTTTAAGAGTTGTTGCCATTAGCTTCCGCCTTGTGGCGGTTCTGGCG 
MAACFWDLCHLLPPCGGSG           92       ATGGCAGCATGCTTTTGGGATCTTTGCCATCTGCTTCCTCCGTGTGGCGGTTCTGGCG 
 
 Group17 
MAACLWLGGCHPQSCGGSG           49       ATGGCAGCATGCCTTTGGTTGGGGGGTTGCCATCCGTAGTCTTGTGGCGGTTCTGGCG 
MAACHWSAWCHPQNCGGSG           49       ATGGCAGCATGCCATTGGTCGGCGTGGTGCCATCCTCAGAATTGTGGCGGTTCTGGCG 
MAACSFIQDCHPQSCGGSG           1574      ATGGCAGCATGCTCTTTTATTTAGGATTGCCATCCTCAGTCGTGTGGCGGTTCTGGCG 
MAACTYFSDCHPQHCGGSG           356       ATGGCAGCATGCACGTATTTTTCGGATTGCCATCCTTAGCATTGTGGCGGTTCTGGCG 
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MAACFWLLPPCSHSCGGSG           33       ATGGCAGCATGCTTTTGGTTGTTGCCTCCTTGCTCTCATTCGTGTGGCGGTTCTGGCG 
MAACMFVLPPCQLECGGSG           33       ATGGCAGCATGCATGTTTGTTTTGCCTCCGTGCTAGCTGGAGTGTGGCGGTTCTGGCG 
MAACSVFRCSSESQCGGSG           34       ATGGCAGCATGCTCGGTGTTTAGGTGCTCTTCGGAGTCTTAGTGTGGCGGTTCTGGCG 
MAACSILPCPHPVQCGGSG           36       ATGGCAGCATGCTCTATTCTGCCTTGCCCTCATCCTGTTTAGTGTGGCGGTTCTGGCG 
MAACPHPQFCYFYNCGGSG           64       ATGGCAGCATGCCCTCATCCTTAGTTTTGCTATTTTTATAATTGTGGCGGTTCTGGCG 
MAACPFENVLCYPQCGGSG           39       ATGGCAGCATGCCCGTTTGAGAATGTGTTGTGCTATCCTCAGTGTGGCGGTTCTGGCG 
MAACHPQVCPSKSACGGSG           50       ATGGCAGCATGCCATCCTTAGGTGTGCCCGTCTAAGTCGGCGTGTGGCGGTTCTGGCG 
MAACPCSASCSVPHCGGSG           62       ATGGCAGCATGCCCGTGTAGTGCTAGTTGCTCTGTTCCTCATTGTGGCGGTTCTGGCG 
MAACVPKHCVHPQVCGGSG           35       ATGGCAGCATGCGTGCCTAAGCATTGCGTTCATCCTTAGGTTTGTGGCGGTTCTGGCG 
MAACLPPHSCWNQVCGGSG           1227     ATGGCAGCATGCCTGCCTCCGCATTCTTGCTGGAATCAGGTTTGTGGCGGTTCTGGCG 
MAACVSRCDNTLFPCGGSG           45       ATGGCAGCATGCGTTTCGCGTTGCGATAATACTCTGTTTCCTTGTGGCGGTTCTGGCG 
MAACLSGCQDVLPPCGGSG           81       ATGGCAGCATGCTTGTCGGGTTGCTAGGATGTTTTGCCTCCTTGTGGCGGTTCTGGCG 
MAACQGEPACIQYPCGGSG           37       ATGGCAGCATGCTAGGGTGAGCCTGCTTGCATTCAGTATCCGTGTGGCGGTTCTGGCG 
MAACSIAYQCLAQHCGGSG           49       ATGGCAGCATGCTCGATAGCTTATCAGTGCTTGGCGTAGCATTGTGGCGGTTCTGGCG 
MAACIYYCDCSLNLCGGSG           62       ATGGCAGCATGCATTTATTATTGTGATTGCTCGCTTAATTTGTGTGGCGGTTCTGGCG 
MAACTRYQICTASLCGGSG           35       ATGGCAGCATGCACGCGGTATTAGATTTGCACTGCTAGTTTGTGTGGCGGTTCTGGCG 
MAACYAVVHCPASSCGGSG           77       ATGGCAGCATGCTATGCGGTGGTTCATTGCCCGGCTAGTTCTTGTGGCGGTTCTGGCG 
MAACLKVFNCCLANCGGSG           35       ATGGCAGCATGCCTTAAGGTGTTTAATTGCTGTCTTGCTAATTGTGGCGGTTCTGGCG 
MAACSSPRCLYLTACGGSG           36       ATGGCAGCATGCTCGTCGCCTCGTTGCCTGTATCTTACGGCGTGTGGCGGTTCTGGCG 
MAACYLPPCDPFILCGGSG           95       ATGGCAGCATGCTATCTTCCTCCGTGCGATCCGTTTATTTTGTGTGGCGGTTCTGGCG 
MAACFKKICPPCWKCGGSG           38       ATGGCAGCATGCTTTAAGAAGATTTGCCCGCCTTGTTGGAAGTGTGGCGGTTCTGGCG 
MAACPQGSCQAHPNCGGSG           34       ATGGCAGCATGCCCGTAGGGGTCGTGCTAGGCTCATCCTAATTGTGGCGGTTCTGGCG 
MAACWRFSCGSQTICGGSG           42       ATGGCAGCATGCTGGAGGTTTTCGTGCGGTTCGTAGACGATTTGTGGCGGTTCTGGCG 
MAACVWFLCSSTPVCGGSG           40       ATGGCAGCATGCGTTTGGTTTTTGTGCTCTTCGACTCCGGTTTGTGGCGGTTCTGGCG 
MAACVYVVCWQPLNCGGSG           40       ATGGCAGCATGCGTTTATGTTGTTTGCTGGTAGCCTTTGAATTGTGGCGGTTCTGGCG 
MAACYITCHPQFFTCGGSG           115      ATGGCAGCATGCTATATTACTTGCCATCCGTAGTTTTTTACTTGTGGCGGTTCTGGCG 
MAACPTIPPHCYQACGGSG           50       ATGGCAGCATGCCCGACTATTCCTCCTCATTGCTATTAGGCGTGTGGCGGTTCTGGCG 
MAACLPPWGQCFYSCGGSG           47       ATGGCAGCATGCTTGCCGCCTTGGGGTTAGTGCTTTTATAGTTGTGGCGGTTCTGGCG 
MAACLYRVSECNTLCGGSG           47       ATGGCAGCATGCCTGTATCGTGTTTCGGAGTGCAATACGTTGTGTGGCGGTTCTGGCG 
 
uPA – Library B 
 Group1 
MAACAHSWCTARIHCGGSG           127       ATGGCAGCATGCGCTCATTCGTGGTGCACTGCTCGTATTCATTGTGGCGGTTCTGGCG 
MAACAHQLCTARAYCGGSG           87        ATGGCAGCATGCGCTCATCAGCTGTGCACTGCGCGTGCTTATTGTGGCGGTTCTGGCG 
MAACLHPMCTARSSCGGSG           146       ATGGCAGCATGCTTGCATCCTATGTGCACTGCGCGTTCGTCGTGTGGCGGTTCTGGCG 
MAACLQPGCTARVSCGGSG           115       ATGGCAGCATGCCTTCAGCCTGGGTGCACGGCGCGTGTGTCTTGTGGCGGTTCTGGCG 
MAACLRPLCSARMHCGGSG           87        ATGGCAGCATGCCTGCGTCCGTTGTGCTCGGCGCGTATGCATTGTGGCGGTTCTGGCG 
MAACMGQLCTARSGCGGSG           428       ATGGCAGCATGCATGGGTTAGCTGTGCACGGCGAGGTCTGGTTGTGGCGGTTCTGGCG 
MAACMQHRCSARTGCGGSG           166       ATGGCAGCATGCATGTAGCATAGGTGCTCGGCGCGGACTGGTTGTGGCGGTTCTGGCG 
MAACSSDNCTARVTCGGSG           109       ATGGCAGCATGCTCGTCTGATAATTGCACGGCTAGGGTTACTTGTGGCGGTTCTGGCG 
MAACPAVNCTARTTCGGSG           104       ATGGCAGCATGCCCTGCTGTGAATTGCACTGCGCGTACGACGTGTGGCGGTTCTGGCG 
MAACSASQCSARIGCGGSG           1493      ATGGCAGCATGCTCTGCTTCGTAGTGCTCTGCTAGGATTGGTTGTGGCGGTTCTGGCG 
MAACSATQCTARLSCGGSG           145       ATGGCAGCATGCTCTGCGACTCAGTGCACTGCGCGTTTGTCGTGTGGCGGTTCTGGCG 
MAACKETQCTARITCGGSG           268       ATGGCAGCATGCAAGGAGACGTAGTGCACGGCGCGGATTACTTGTGGCGGTTCTGGCG 
MAACFNTQCTARLSCGGSG           99        ATGGCAGCATGCTTTAATACGTAGTGCACTGCGCGTCTTTCTTGTGGCGGTTCTGGCG 
MAACRTAVCTARLLCGGSG           215       ATGGCAGCATGCCGTACTGCTGTGTGCACTGCTCGTTTGTTGTGTGGCGGTTCTGGCG 
MAACRSAVCTARVRCGGSG           191       ATGGCAGCATGCCGGTCTGCTGTGTGCACTGCGCGGGTGCGTTGTGGCGGTTCTGGCG 
MAACAASVCTARLFCGGSG           751       ATGGCAGCATGCGCGGCTTCGGTGTGCACTGCTAGGTTGTTTTGTGGCGGTTCTGGCG 
MAACSAAYCTARLQCGGSG           162       ATGGCAGCATGCAGTGCGGCTTATTGCACGGCTAGGCTGTAGTGTGGCGGTTCTGGCG 
MAACRQSTCSARTYCGGSG           493       ATGGCAGCATGCCGGTAGTCTACTTGCTCTGCTAGGACGTATTGTGGCGGTTCTGGCG 
MAACKQSVCTARTLCGGSG           262       ATGGCAGCATGCAAGTAGAGTGTGTGCACGGCTAGGACGTTGTGTGGCGGTTCTGGCG 
MAACTQSACSARVVCGGSG           5410      ATGGCAGCATGCACGTAGTCTGCTTGCTCGGCGAGGGTTGTGTGTGGCGGTTCTGGCG 
MAACLESSCSARIVCGGSG           108       ATGGCAGCATGCCTTGAGAGTTCTTGCTCGGCTCGTATTGTTTGTGGCGGTTCTGGCG 
MAACNESVCSARKQCGGSG           148       ATGGCAGCATGCAATGAGTCGGTGTGCTCTGCGCGTAAGTAGTGTGGCGGTTCTGGCG 
MAACYGSACSARSSCGGSG           266       ATGGCAGCATGCTATGGGTCTGCGTGCAGTGCGCGTTCTTCTTGTGGCGGTTCTGGCG 
MAACFNSACTARSMCGGSG           238       ATGGCAGCATGCTTTAATTCGGCTTGCACTGCTCGGTCGATGTGTGGCGGTTCTGGCG 
MAACTYALCTARTFCGGSG           1905      ATGGCAGCATGCACTTATGCTCTGTGCACTGCGCGTACGTTTTGTGGCGGTTCTGGCG 
MAACNFSLCSARFFCGGSG           96        ATGGCAGCATGCAATTTTTCTCTTTGCTCGGCGCGTTTTTTTTGTGGCGGTTCTGGCG 
MAACSVSFCSARSFCGGSG           103       ATGGCAGCATGCAGTGTGTCTTTTTGCTCTGCGCGGTCTTTTTGTGGCGGTTCTGGCG 
MAACSLASCSARMLCGGSG           413       ATGGCAGCATGCTCTCTGGCGAGTTGCTCGGCGCGTATGTTGTGTGGCGGTTCTGGCG 
MAACTLGNCTARAICGGSG           195       ATGGCAGCATGCACTCTTGGTAATTGCACGGCGAGGGCTATTTGTGGCGGTTCTGGCG 
MAACPLSACSGRTLCGGSG           1026      ATGGCAGCATGCCCGCTTTCTGCGTGCTCGGGGAGGACGTTGTGTGGCGGTTCTGGCG 
MAACPVRSCTARQACGGSG           298       ATGGCAGCATGCCCTGTGCGTAGTTGCACGGCTCGTTAGGCGTGTGGCGGTTCTGGCG 
MAACPETSCTARQVCGGSG           120       ATGGCAGCATGCCCTGAGACGTCTTGCACTGCGCGTTAGGTTTGTGGCGGTTCTGGCG 
MAACPQASCSARRYCGGSG           165       ATGGCAGCATGCCCTCAGGCGTCTTGCTCTGCGCGTCGGTATTGTGGCGGTTCTGGCG 
MAACLPSLCSARSRCGGSG           179       ATGGCAGCATGCCTGCCGAGTCTTTGCTCGGCGAGGTCTCGTTGTGGCGGTTCTGGCG 
MAACVPTQCSARSSCGGSG           117       ATGGCAGCATGCGTTCCGACGCAGTGCTCGGCGCGTTCGAGTTGTGGCGGTTCTGGCG 
MAACSPSQCTARAGCGGSG           799       ATGGCAGCATGCTCTCCTTCGTAGTGCACTGCTCGTGCGGGGTGTGGCGGTTCTGGCG 
MAACSPSMCTARVACGGSG           173       ATGGCAGCATGCAGTCCTTCGATGTGCACTGCGCGTGTTGCGTGTGGCGGTTCTGGCG 
MAACSPSMCSGRRSCGGSG           449       ATGGCAGCATGCTCGCCGTCGATGTGCAGTGGGCGTAGGTCTTGTGGCGGTTCTGGCG 
MAACSPSTCSGRSLCGGSG           107       ATGGCAGCATGCTCGCCGTCGACGTGCTCTGGGCGTTCTTTGTGTGGCGGTTCTGGCG 
MAACRPALCSGRTACGGSG           99        ATGGCAGCATGCCGTCCTGCGCTTTGCAGTGGTCGGACTGCTTGTGGCGGTTCTGGCG 
MAACAPSECSARFLCGGSG           192       ATGGCAGCATGCGCGCCGTCAGAGTGCTCTGCTCGGTTTTTGTGTGGCGGTTCTGGCG 
MAACAPFTCSARFTCGGSG           111       ATGGCAGCATGCGCTCCTTTTACGTGCTCTGCGCGTTTTACGTGTGGCGGTTCTGGCG 
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MAACVPHSCTARTFCGGSG           330       ATGGCAGCATGCGTGCCTCATTCGTGCACTGCTCGTACTTTTTGTGGCGGTTCTGGCG 
MAACLPTSCTARLWCGGSG           261       ATGGCAGCATGCCTGCCTACGTCTTGCACTGCGCGTTTGTGGTGTGGCGGTTCTGGCG 
MAACMPSACTRRDFCGGSG           339       ATGGCAGCATGCATGCCTTCTGCGTGCACGCGGCGTGATTTTTGTGGCGGTTCTGGCG 
MAACQPSRCSARDHCGGSG           248       ATGGCAGCATGCCAGCCGAGTAGGTGCAGTGCTCGGGATCATTGTGGCGGTTCTGGCG 
MAACWTPTCSARSHCGGSG           890       ATGGCAGCATGCTGGACGCCTACGTGCTCTGCTCGTTCGCATTGTGGCGGTTCTGGCG 
MAACWMASCSARSDCGGSG           221       ATGGCAGCATGCTGGATGGCTTCGTGCTCTGCGCGTTCTGATTGTGGCGGTTCTGGCG 
MAACGVVTCTARQHCGGSG           683       ATGGCAGCATGCGGTGTTGTGACGTGCACGGCTCGTTAGCATTGTGGCGGTTCTGGCG 
MAACGIANCTARAQCGGSG           162       ATGGCAGCATGCGGGATTGCTAATTGCACGGCGCGTGCTTAGTGTGGCGGTTCTGGCG 
 
 Group2 
MAACAQATSCQTARCGGSG           805       ATGGCAGCATGCGCGTAGGCGACTTCGTGCTAGACTGCGCGTTGTGGCGGTTCTGGCG 
MAACSVVTSCLTARCGGSG           147       ATGGCAGCATGCTCTGTTGTGACTTCTTGCTTGACGGCTCGGTGTGGCGGTTCTGGCG 
MAACITYSSCSTARCGGSG           236       ATGGCAGCATGCATTACGTATTCGTCGTGCTCGACTGCTCGGTGTGGCGGTTCTGGCG 
MAACSSYDACISARCGGSG           437       ATGGCAGCATGCTCGTCTTATGATGCTTGCATTTCTGCGAGGTGTGGCGGTTCTGGCG 
MAACLSLRSCLSARCGGSG           159       ATGGCAGCATGCCTTTCTTTGCGGTCGTGCCTGTCTGCTAGGTGTGGCGGTTCTGGCG 
MAACRPMRSCFSARCGGSG           111       ATGGCAGCATGCAGGCCTATGCGGTCGTGCTTTTCTGCGAGGTGTGGCGGTTCTGGCG 
MAACFEQESCLSARCGGSG           165       ATGGCAGCATGCTTTGAGCAGGAGTCTTGCCTTTCTGCTCGGTGTGGCGGTTCTGGCG 
MAACRLDLSCLSARCGGSG           408       ATGGCAGCATGCCGTTTGGATTTGAGTTGCTTGTCGGCGCGTTGTGGCGGTTCTGGCG 
MAACQVNLACTSARCGGSG           339       ATGGCAGCATGCTAGGTGAATCTTGCGTGCACTTCGGCTAGGTGTGGCGGTTCTGGCG 
MAACSYTLSCLSGRCGGSG           181       ATGGCAGCATGCTCGTATACTTTGAGTTGCTTGTCTGGTCGGTGTGGCGGTTCTGGCG 
MAACMLSCLTGRCGGSG             135       ATGGCAGCATGCATGCTGTCGTGCTTGACGGGGCGGTGTGGCGGTTCTGGCG 
MAACILSLPCVSARCGGSG           168       ATGGCAGCATGCATTTTGTCGTTGCCTTGCGTTAGTGCGCGTTGTGGCGGTTCTGGCG 
MAACLLMAPCQTARCGGSG           103       ATGGCAGCATGCTTGCTTATGGCGCCGTGCTAGACTGCGAGGTGTGGCGGTTCTGGCG 
MAACLWRMPCLTARCGGSG           238       ATGGCAGCATGCCTGTGGAGGATGCCTTGCCTGACTGCTCGTTGTGGCGGTTCTGGCG 
MAACALRVPCFTGRCGGSG           380       ATGGCAGCATGCGCTCTGAGGGTTCCTTGCTTTACTGGGCGGTGTGGCGGTTCTGGCG 
MAACVTVYPCTTARCGGSG           417       ATGGCAGCATGCGTTACTGTGTATCCGTGCACGACGGCGAGGTGTGGCGGTTCTGGCG 
MAACRALYPCGTARCGGSG           193       ATGGCAGCATGCCGTGCGTTGTATCCTTGCGGGACGGCTCGTTGTGGCGGTTCTGGCG 
MAACTARQPCSTARCGGSG           185       ATGGCAGCATGCACTGCTAGGCAGCCGTGCTCGACGGCGCGTTGTGGCGGTTCTGGCG 
 
 Group3 
MAACATARCMQAYLCGGSG           347       ATGGCAGCATGCGCGACTGCTAGGTGCATGTAGGCTTATTTGTGTGGCGGTTCTGGCG 
MAACLTARCQSSFLCGGSG           109       ATGGCAGCATGCCTGACTGCTAGGTGCTAGTCTTCGTTTTTGTGTGGCGGTTCTGGCG 
MAACPTARCPQSVLCGGSG           118       ATGGCAGCATGCCCTACTGCTCGTTGCCCTTAGTCTGTTTTGTGTGGCGGTTCTGGCG 
MAACSTARCLLSYQCGGSG           264       ATGGCAGCATGCTCGACGGCTCGGTGCCTGTTGTCTTATCAGTGTGGCGGTTCTGGCG 
MAACSTARCPLSYACGGSG           94        ATGGCAGCATGCTCTACGGCGCGTTGCCCGTTGTCTTATGCGTGTGGCGGTTCTGGCG 
MAACSSTARCELSYCGGSG           116       ATGGCAGCATGCTCGTCTACTGCGCGTTGCGAGCTTTCGTATTGTGGCGGTTCTGGCG 
MAACATARCSLPSLCGGSG           200       ATGGCAGCATGCGCGACTGCTCGTTGCTCTCTGCCGTCTCTTTGTGGCGGTTCTGGCG 
MAACETARCSFYSLCGGSG           124       ATGGCAGCATGCGAGACTGCTAGGTGCTCGTTTTATTCGCTGTGTGGCGGTTCTGGCG 
MAACSTARCSDRSMCGGSG           404       ATGGCAGCATGCTCGACTGCGCGTTGCTCGGATCGTTCGATGTGTGGCGGTTCTGGCG 
MAACPTARCRVPQLCGGSG           95        ATGGCAGCATGCCCGACGGCTCGGTGCCGGGTTCCTTAGTTGTGTGGCGGTTCTGGCG 
MAACNTARCFPSSWCGGSG           200       ATGGCAGCATGCAATACTGCGCGTTGCTTTCCGTCGAGTTGGTGTGGCGGTTCTGGCG 
MAACSTARCTPTEFCGGSG           122       ATGGCAGCATGCTCGACTGCGAGGTGCACTCCTACGGAGTTTTGTGGCGGTTCTGGCG 
MAACPTARCIPWTSCGGSG           188       ATGGCAGCATGCCCTACGGCTAGGTGCATTCCTTGGACTTCTTGTGGCGGTTCTGGCG 
MAACATARCLWTMTCGGSG           138       ATGGCAGCATGCGCGACGGCGCGTTGCCTGTGGACTATGACTTGTGGCGGTTCTGGCG 
 
 Group4 
MAACSYSCLSARTSCGGSG           667       ATGGCAGCATGCTCGTATTCGTGCTTGTCTGCTAGGACTAGTTGTGGCGGTTCTGGCG 
MAACTLACLSARGSCGGSG           297       ATGGCAGCATGCACTTTGGCGTGCCTGAGTGCTAGGGGTTCGTGTGGCGGTTCTGGCG 
MAACQFSCISARSFCGGSG           399       ATGGCAGCATGCTAGTTTTCGTGCATTTCGGCGCGGTCTTTTTGTGGCGGTTCTGGCG 
MAACVYACFTARSQCGGSG           289       ATGGCAGCATGCGTGTATGCGTGCTTTACTGCTCGGTCTTAGTGTGGCGGTTCTGGCG 
MAACNLSCYTGRSLCGGSG           182       ATGGCAGCATGCAATCTATCGTGCTATACTGGGCGTTCTCTTTGTGGCGGTTCTGGCG 
MAACLVGCTTARTFCGGSG           163       ATGGCAGCATGCCTGGTGGGGTGCACTACTGCTCGGACGTTTTGTGGCGGTTCTGGCG 
 
 Group5 
MAACPVLPQCSARSCGGSG           541       ATGGCAGCATGCCCTGTGCTTCCTTAGTGCTCGGCGAGGTCTTGTGGCGGTTCTGGCG 
MAACPSSPRCTARSCGGSG           249       ATGGCAGCATGCCCTTCTTCGCCGCGTTGCACTGCTAGGAGTTGTGGCGGTTCTGGCG 
MAACIVNPICTARTCGGSG           138       ATGGCAGCATGCATTGTGAATCCTATTTGCACTGCGCGTACGTGTGGCGGTTCTGGCG 
MAACMLSGSCTARSCGGSG           1381      ATGGCAGCATGCATGTTGTCTGGTTCTTGCACGGCTAGGTCGTGTGGCGGTTCTGGCG 
MAACTLKNNCTARYCGGSG           130       ATGGCAGCATGCACGCTGAAGAATAATTGCACTGCTCGTTATTGTGGCGGTTCTGGCG 
MAACLPQSQCTARYCGGSG           219       ATGGCAGCATGCCTTCCGCAGTCTCAGTGCACTGCTCGGTATTGTGGCGGTTCTGGCG 
MAACGPQPDCTARYCGGSG           157       ATGGCAGCATGCGGGCCGTAGCCTGATTGCACTGCTCGTTATTGTGGCGGTTCTGGCG 
 
 Group6 
MAACLQFCSSQSARCGGSG           117       ATGGCAGCATGCCTGTAGTTTTGCTCGTCTCAGTCGGCTCGTTGTGGCGGTTCTGGCG 
MAACLWYCAAESARCGGSG           106       ATGGCAGCATGCCTTTGGTATTGCGCGGCTGAGTCTGCGCGTTGTGGCGGTTCTGGCG 
MAACFQTCTLQTARCGGSG           365       ATGGCAGCATGCTTTCAGACGTGCACGCTTTAGACTGCTCGTTGTGGCGGTTCTGGCG 
MAACRSVCAVATARCGGSG           109       ATGGCAGCATGCCGTTCGGTGTGCGCTGTGGCGACGGCGAGGTGTGGCGGTTCTGGCG 
MAACGLLCSSLSARCGGSG           340       ATGGCAGCATGCGGGTTGCTTTGCTCTTCTTTGTCGGCGCGTTGTGGCGGTTCTGGCG 
 
 Group7 
MAACAPDQCTKFTMCGGSG           2493      ATGGCAGCATGCGCTCCGGATCAGTGCACTAAGTTTACTATGTGTGGCGGTTCTGGCG 
MAACAQTSCSKYSLCGGSG           112       ATGGCAGCATGCGCGTAGACGTCTTGCTCGAAGTATTCGCTGTGTGGCGGTTCTGGCG 
MAACPAQNCTKYTLCGGSG           447       ATGGCAGCATGCCCTGCTCAGAATTGCACTAAGTATACTTTGTGTGGCGGTTCTGGCG 
MAACPTRLCTKFTLCGGSG           93        ATGGCAGCATGCCCGACGCGGTTGTGCACGAAGTTTACGTTGTGTGGCGGTTCTGGCG 
MAACPPVMCQRFALCGGSG           442       ATGGCAGCATGCCCTCCTGTTATGTGCCAGCGGTTTGCGTTGTGTGGCGGTTCTGGCG 
MAACSPVYCEKFTLCGGSG           170       ATGGCAGCATGCTCGCCGGTGTATTGCGAGAAGTTTACTTTGTGTGGCGGTTCTGGCG 
 
 Group8 
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MAACFRYQCTARSHCGGSG           1081      ATGGCAGCATGCTTTCGTTATCAGTGCACGGCGCGTTCTCATTGTGGCGGTTCTGGCG 
MAACFTYLCSARHHCGGSG           90        ATGGCAGCATGCTTTACTTATCTTTGCTCGGCTCGGCATCATTGTGGCGGTTCTGGCG 
MAACKDYVCSARLHCGGSG           105       ATGGCAGCATGCAAGGATTATGTGTGCTCGGCTCGTTTGCATTGTGGCGGTTCTGGCG 
MAACFDFLCSARTCGGSG            128       ATGGCAGCATGCTTTGATTTCCTGTGCTCGGCTAGGACTTGTGGCGGTTCTGGCG 
 
 Group9 
MAACKHSDCTARFPCGGSG           1315      ATGGCAGCATGCAAGCATAGTGATTGCACTGCTCGGTTTCCTTGTGGCGGTTCTGGCG 
MAACTSSDCTRRYPCGGSG           121       ATGGCAGCATGCACGAGTTCGGATTGCACGCGGCGTTATCCTTGTGGCGGTTCTGGCG 
MAACVLSDCSARLPCGGSG           87        ATGGCAGCATGCGTGCTGTCGGATTGCTCTGCGAGGTTGCCTTGTGGCGGTTCTGGCG 
MAACPLQLCTARYPCGGSG           761       ATGGCAGCATGCCCTTTGTAGTTGTGCACGGCTCGGTATCCTTGTGGCGGTTCTGGCG 
MAACSLSLCSARYPCGGSG           166       ATGGCAGCATGCTCTCTGAGTCTTTGCTCTGCGCGTTATCCGTGTGGCGGTTCTGGCG 
 
 Group10 
MAACLKRCSGTARCGGSG            256       ATGGCAGCATGCCTGAAGCGTTGCTCTGGTACTGCTCGTTGTGGCGGTTCTGGCG 
MAACAYRSCQGTARCGGSG           918       ATGGCAGCATGCGCTTATCGGTCGTGCTAGGGGACGGCTAGGTGTGGCGGTTCTGGCG 
MAACYWSSCTGTARCGGSG           189       ATGGCAGCATGCTATTGGTCGTCTTGCACTGGGACGGCGAGGTGTGGCGGTTCTGGCG 
MAACMWQVCASTARCGGSG           97        ATGGCAGCATGCATGTGGCAGGTGTGCGCTTCGACGGCGCGGTGTGGCGGTTCTGGCG 
MAACYAICSSTARSCGGSG           326       ATGGCAGCATGCTATGCTATTTGCAGTTCGACGGCTCGGTCTTGTGGCGGTTCTGGCG 
MAACYMHFCHTTARCGGSG           101       ATGGCAGCATGCTATATGCATTTTTGCCATACGACGGCTCGTTGTGGCGGTTCTGGCG 
MAACNPYLCNPTARCGGSG           93        ATGGCAGCATGCAATCCGTATCTGTGCAATCCGACTGCTAGGTGTGGCGGTTCTGGCG 
MAACSPLRCTLTARCGGSG           156       ATGGCAGCATGCAGTCCTCTTCGTTGCACTTTGACGGCGCGGTGTGGCGGTTCTGGCG 
MAACTARLCQQSARCGGSG           95        ATGGCAGCATGCACGGCGAGGCTTTGCTAGCAGTCGGCTCGTTGTGGCGGTTCTGGCG 
 
 Group11 
MAACSLSTARCPMQCGGSG           348       ATGGCAGCATGCTCTTTGAGTACGGCGCGGTGCCCTATGCAGTGTGGCGGTTCTGGCG 
MAACLSTARCPMQPCGGSG           164       ATGGCAGCATGCCTGTCGACGGCGCGTTGCCCGATGTAGCCGTGTGGCGGTTCTGGCG 
MAACSSSARHCPLVCGGSG           150       ATGGCAGCATGCTCTTCGAGTGCTCGTCATTGCCCTCTTGTGTGTGGCGGTTCTGGCG 
MAACVVTARCPAFHCGGSG           181       ATGGCAGCATGCGTGGTTACGGCTAGGTGCCCGGCGTTTCATTGTGGCGGTTCTGGCG 
MAACNSSARCPSFTCGGSG           135       ATGGCAGCATGCAATTCTTCTGCGCGGTGCCCTTCGTTTACGTGTGGCGGTTCTGGCG 
MAACVTARCPSYPFCGGSG           104       ATGGCAGCATGCGTGACGGCTCGTTGCCCGAGTTATCCGTTTTGTGGCGGTTCTGGCG 
 
 Group12 
MAACNVPLCTARLSCGGSG           778       ATGGCAGCATGCAATGTTCCGTTGTGCACTGCTCGTTTGTCGTGTGGCGGTTCTGGCG 
MAACLAGWCSARQACGGSG           120       ATGGCAGCATGCTTGGCTGGTTGGTGCAGTGCGAGGTAGGCGTGTGGCGGTTCTGGCG 
MAACLTGLCTARGYCGGSG           728       ATGGCAGCATGCTTGACGGGTCTGTGCACTGCTCGTGGTTATTGTGGCGGTTCTGGCG 
MAACVTSGCTARWWCGGSG           88        ATGGCAGCATGCGTTACTAGTGGGTGCACGGCGCGGTGGTGGTGTGGCGGTTCTGGCG 
MAACKSSLCSARQWCGGSG           251       ATGGCAGCATGCAAGTCTTCTCTGTGCAGTGCTCGGCAGTGGTGTGGCGGTTCTGGCG 
MAACSYAHCSARWTCGGSG           334       ATGGCAGCATGCTCTTATGCTCATTGCAGTGCTAGGTGGACGTGTGGCGGTTCTGGCG 
MAACLESHCSARWSCGGSG           264       ATGGCAGCATGCTTGGAGTCGCATTGCTCGGCGCGTTGGTCGTGTGGCGGTTCTGGCG 
MAACRHLSCTARTNCGGSG           269       ATGGCAGCATGCAGGCATCTGTCTTGCACGGCTCGTACTAATTGTGGCGGTTCTGGCG 
 
 Group13 
MAACDNRAGCSTARCGGSG           195       ATGGCAGCATGCGATAATAGGGCTGGTTGCAGTACTGCTCGGTGTGGCGGTTCTGGCG 
MAACMNRPSCNSARCGGSG           355       ATGGCAGCATGCATGAATAGGCCTAGTTGCAATTCTGCGCGTTGTGGCGGTTCTGGCG 
MAACVPKLACESARCGGSG           255       ATGGCAGCATGCGTTCCTAAGTTGGCTTGCGAGTCTGCGCGTTGTGGCGGTTCTGGCG 
MAACSLMPFCYSARCGGSG           164       ATGGCAGCATGCAGTTTGATGCCTTTTTGCTATTCTGCGCGTTGTGGCGGTTCTGGCG 
MAACKQQPMCATARCGGSG           460       ATGGCAGCATGCAAGCAGTAGCCGATGTGCGCGACGGCTAGGTGTGGCGGTTCTGGCG 
MAACPPPPSCFTARCGGSG           392       ATGGCAGCATGCCCTCCTCCGCCGTCGTGCTTTACGGCTAGGTGTGGCGGTTCTGGCG 
MAACPVKPSCHSGRCGGSG           1056      ATGGCAGCATGCCCTGTTAAGCCGTCTTGCCATTCTGGGAGGTGTGGCGGTTCTGGCG 
MAACFHLQHCATARCGGSG           98        ATGGCAGCATGCTTTCATCTTTAGCATTGCGCTACGGCTCGTTGTGGCGGTTCTGGCG 
 
 Group14 
MAACNALFSGCAYMCGGSG           263       ATGGCAGCATGCAATGCTCTTTTTTCGGGTTGCGCTTATATGTGTGGCGGTTCTGGCG 
MAACTPYYSLCTHPCGGSG           254       ATGGCAGCATGCACGCCTTATTATTCGCTGTGCACGCATCCGTGTGGCGGTTCTGGCG 
MAACKPLFSLCRAPCGGSG           130       ATGGCAGCATGCAAGCCGCTGTTTTCGTTGTGCCGTGCGCCGTGTGGCGGTTCTGGCG 
 
 Group15 
MAACSLNSCFSARSCGGSG           336       ATGGCAGCATGCTCGTTGAATTCTTGCTTTTCGGCTCGTTCTTGTGGCGGTTCTGGCG 
MAACQYPSCMTARSCGGSG           108       ATGGCAGCATGCCAGTATCCGTCTTGCATGACTGCTAGGTCTTGTGGCGGTTCTGGCG 
MAACLYSSCPTARYCGGSG           162       ATGGCAGCATGCCTGTATTCGTCGTGCCCGACTGCGCGTTATTGTGGCGGTTCTGGCG 
MAACLQISCSTARMCGGSG           87        ATGGCAGCATGCCTTTAGATTAGTTGCTCTACGGCTCGGATGTGTGGCGGTTCTGGCG 
MAACRQACATARANCGGSG           556       ATGGCAGCATGCAGGCAGGCTTGCGCGACTGCGCGGGCTAATTGTGGCGGTTCTGGCG 
MAACTQPCLTARATCGGSG           274       ATGGCAGCATGCACGTAGCCTTGCCTGACTGCTCGGGCTACTTGTGGCGGTTCTGGCG 
MAACRRDPCATARNCGGSG           544       ATGGCAGCATGCCGTCGGGATCCGTGCGCGACTGCGAGGAATTGTGGCGGTTCTGGCG 
 
 Group16 
MAACSTARCWTHSPCGGSG           111       ATGGCAGCATGCTCGACTGCGCGTTGCTGGACGCATTCTCCTTGTGGCGGTTCTGGCG 
MAACPTARCTQLPPCGGSG           143       ATGGCAGCATGCCCTACGGCGCGGTGCACGTAGTTGCCTCCTTGTGGCGGTTCTGGCG 
MAACLTARCQFATACGGSG           165       ATGGCAGCATGCTTGACTGCTAGGTGCTAGTTTGCTACTGCTTGTGGCGGTTCTGGCG 
MAACSTARCRYLANCGGSG           223       ATGGCAGCATGCTCTACTGCGCGGTGCCGTTATCTGGCGAATTGTGGCGGTTCTGGCG 
MAACLTARCFDTPNCGGSG           751       ATGGCAGCATGCTTGACTGCGAGGTGCTTTGATACTCCGAATTGTGGCGGTTCTGGCG 
MAACGTARCHALFSCGGSG           396       ATGGCAGCATGCGGGACTGCGAGGTGCCATGCTCTTTTTTCTTGTGGCGGTTCTGGCG 
MAACGTGRCSTYFSCGGSG           263       ATGGCAGCATGCGGGACTGGGCGGTGCTCTACGTATTTTTCTTGTGGCGGTTCTGGCG 
MAACETARCLALWACGGSG           126       ATGGCAGCATGCGAGACGGCTCGGTGCCTGGCTTTGTGGGCTTGTGGCGGTTCTGGCG 
 
 Group17 
MAACHKLMNCRFSLCGGSG           781       ATGGCAGCATGCCATAAGTTGATGAATTGCCGTTTTTCGCTTTGTGGCGGTTCTGGCG 
MAACSYMGNCKFSLCGGSG           193       ATGGCAGCATGCTCGTATATGGGTAATTGCAAGTTTTCGTTGTGTGGCGGTTCTGGCG 
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MAACIFYKSCKYSLCGGSG           588       ATGGCAGCATGCATTTTTTATAAGTCTTGCAAGTATTCGTTGTGTGGCGGTTCTGGCG 
 
 Group MIXED 
MAACAPPWYLTYSICGGSG           147       ATGGCAGCATGCGCGCCGCCTTGGTACTTGACGTATTCGATTTGTGGCGGTTCTGGCG 
MAACCQWWDCSRGLCGGSG           529       ATGGCAGCATGCTGTCAGTGGTGGGATTGCTCTCGTGGTTTGTGTGGCGGTTCTGGCG 
MAACMDSCLSRRSHCGGSG           111       ATGGCAGCATGCATGGATTCTTGCTTGTCTCGTCGTTCGCATTGTGGCGGTTCTGGCG 
MAACATSCTARMQYCGGSG           309       ATGGCAGCATGCGCTACTTCGTGCACTGCTAGGATGTAGTATTGTGGCGGTTCTGGCG 
MAACTARYHCCSFGCGGSG           140       ATGGCAGCATGCACGGCGCGGTATCATTGCTGTAGTTTTGGTTGTGGCGGTTCTGGCG 
MAACTARAHCPSQMCGGSG           101       ATGGCAGCATGCACGGCGCGTGCTCATTGCCCGTCTTAGATGTGTGGCGGTTCTGGCG 
MAACGDCLSCSTARCGGSG           156       ATGGCAGCATGCGGGGATTGTCTGTCTTGCTCGACGGCGCGGTGTGGCGGTTCTGGCG 
MAACGSFFPCFSARCGGSG           95        ATGGCAGCATGCGGGAGTTTTTTTCCTTGCTTTAGTGCTCGGTGTGGCGGTTCTGGCG 
MAACPVSCWNETARCGGSG           118       ATGGCAGCATGCCCTGTGTCTTGCTGGAATGAGACGGCGAGGTGTGGCGGTTCTGGCG 
MAACPVSCEVTARTCGGSG           109       ATGGCAGCATGCCCGGTGTCTTGCGAGGTTACGGCTCGTACGTGTGGCGGTTCTGGCG 
MAACPQVTARCSTMCGGSG           179       ATGGCAGCATGCCCGTAGGTGACTGCGAGGTGCTCTACGATGTGTGGCGGTTCTGGCG 
MAACPSARTRCESICGGSG           149       ATGGCAGCATGCCCTTCTGCGCGGACGCGTTGCGAGTCGATTTGTGGCGGTTCTGGCG 
MAACTSWFDCTARFCGGSG           117       ATGGCAGCATGCACTTCTTGGTTTGATTGCACGGCTCGTTTTTGTGGCGGTTCTGGCG 
MAACSWYTCTARLACGGSG           99        ATGGCAGCATGCTCGTGGTATACTTGCACTGCGCGGTTGGCTTGTGGCGGTTCTGGCG 
MAACESMSALCTARCGGSG           97        ATGGCAGCATGCGAGTCTATGTCGGCGTTGTGCACTGCGAGGTGTGGCGGTTCTGGCG 
MAACSKIASDCTARCGGSG           128       ATGGCAGCATGCTCGAAGATTGCTTCGGATTGCACGGCTCGGTGTGGCGGTTCTGGCG 
MAACPFPPCYMPYPCGGSG           105       ATGGCAGCATGCCCTTTTCCTCCGTGCTATATGCCGTATCCTTGTGGCGGTTCTGGCG 
MAACFAWDCARYLYCGGSG           93        ATGGCAGCATGCTTTGCGTGGGATTGCGCGCGTTATTTGTATTGTGGCGGTTCTGGCG 
MAACNAYYKLCVVQCGGSG           138       ATGGCAGCATGCAATGCGTATTATAAGCTTTGCGTTGTGTAGTGTGGCGGTTCTGGCG 
MAACLLSTARCWSSCGGSG           148       ATGGCAGCATGCCTGCTGTCGACTGCGAGGTGCTGGTCTTCGTGTGGCGGTTCTGGCG 
MAACTTARSGCWFQCGGSG           104       ATGGCAGCATGCACGACTGCGCGGTCTGGTTGCTGGTTTCAGTGTGGCGGTTCTGGCG 
MAACCKRHCPSSLTCGGSG           126       ATGGCAGCATGCTGTAAGCGGCATTGCCCGTCGTCGCTTACTTGTGGCGGTTCTGGCG 
MAACSLRSCPFTQFCGGSG           378       ATGGCAGCATGCTCGCTGCGTTCGTGCCCGTTTACGTAGTTTTGTGGCGGTTCTGGCG 
MAACEFRCCNPYYSCGGSG           565       ATGGCAGCATGCGAGTTTCGGTGTTGCAATCCTTATTATTCGTGTGGCGGTTCTGGCG 
MAACSGRCTHPTGRCGGSG           210       ATGGCAGCATGCTCGGGGAGGTGCACGCATCCTACGGGTAGGTGTGGCGGTTCTGGCG 
MAACQQLCTARSTCCGGSG           666       ATGGCAGCATGCTAGCAGCTTTGCACTGCTCGTTCGACGTGTTGTGGCGGTTCTGGCG 
MAACQQQQTCTARTCGGSG           455       ATGGCAGCATGCTAGCAGCAGCAGACTTGCACGGCTCGTACTTGTGGCGGTTCTGGCG 
MAACRMMECTARGWCGGSG           278       ATGGCAGCATGCCGTATGATGGAGTGCACGGCTAGGGGGTGGTGTGGCGGTTCTGGCG 
MAACVISTCSARHDCGGSG           129       ATGGCAGCATGCGTTATTAGTACGTGCAGTGCGCGGCATGATTGTGGCGGTTCTGGCG 
MAACVARPSFCSARCGGSG           139       ATGGCAGCATGCGTTGCGCGGCCGTCTTTTTGCTCGGCGCGGTGTGGCGGTTCTGGCG 
MAACLPVSFCSARSCGGSG           91        ATGGCAGCATGCCTTCCGGTTTCGTTTTGCTCTGCTCGTTCGTGTGGCGGTTCTGGCG 
MAACLPSSHCLTARCGGSG           98        ATGGCAGCATGCCTTCCTTCTTCTCATTGCCTGACTGCTAGGTGTGGCGGTTCTGGCG 
MAACKYSLCFYSSSCGGSG           139       ATGGCAGCATGCAAGTATTCTTTGTGCTTTTATAGTAGTTCGTGTGGCGGTTCTGGCG 
 
FXIIa – Library 4×4 
 Group1 
MAVCDQWACGQEWCVSHS           381      ATGGCAGTGTGTGATCAGTGGGCGTGCGGTTAGGAGTGGTGTGTGTCTCACTCCG 
MAFCSLQKCGQDWCPSHS           90       ATGGCATTTTGTAGTCTGCAGAAGTGCGGTTAGGATTGGTGTCCGTCTCACTCCG 
MAWCVQGKCIHAVCASHS           99       ATGGCATGGTGTGTTTAGGGGAAGTGCATTCATGCTGTTTGTGCTTCTCACTCCG 
MAWCDLGRCIEGGCLSHS           85       ATGGCATGGTGTGATCTGGGTCGTTGCATTGAGGGTGGTTGTTTGTCTCACTCCG 
MAWCANYQCISETCMSHS           86       ATGGCATGGTGTGCTAATTATTAGTGCATTTCGGAGACTTGTATGTCTCACTCCG 
MAWCAHLRCRHVGCPSHS           102      ATGGCATGGTGTGCGCATCTGAGGTGCCGGCATGTTGGGTGTCCTTCTCACTCCG 
MAWCQGQVCMQCRCFSHS           91       ATGGCATGGTGTTAGGGTCAGGTGTGCATGCAGTGTCGGTGTTTTTCTCACTCCG 
MAWCSLSVCQHCTCWSHS           80       ATGGCATGGTGTAGTCTGAGTGTGTGCTAGCATTGTACTTGTTGGTCTCACTCCG 
MAWCARDGCRSCACRSHS           94       ATGGCATGGTGTGCTCGTGATGGTTGCCGGAGTTGTGCTTGTCGTTCTCACTCCG 
 
 Group2 
MAGCMSLACLQDMCWSHS           85       ATGGCAGGGTGTATGTCGCTGGCGTGCCTGTAGGATATGTGTTGGTCTCACTCCG 
MASCGCALCSAQACVSHS           123      ATGGCAAGTTGTGGTTGTGCGTTGTGCTCTGCGTAGGCGTGTGTTTCTCACTCCG 
MAQCNCGVCSPQDCLSHS           77       ATGGCACAGTGTAATTGTGGTGTGTGCTCTCCGTAGGATTGTCTGTCTCACTCCG 
MACCGCMLCSHLRCQSHS           248      ATGGCATGTTGTGGTTGTATGTTGTGCTCGCATCTGCGGTGTTAGTCTCACTCCG 
MALCGCRWCTSWGCPSHS           98       ATGGCATTGTGTGGGTGTAGGTGGTGCACGTCGTGGGGTTGTCCTTCTCACTCCG 
MAACCGCRCTSPTCPSHS           94       ATGGCAGCTTGTTGTGGTTGTAGGTGCACGAGTCCGACTTGTCCGTCTCACTCCG 
 
 Group3 
MASCTRSWCVTSRCDSHS           280      ATGGCAAGTTGTACTCGTAGTTGGTGCGTTACTTCTAGGTGTGATTCTCACTCCG 
MARCVPDWCISKRCRSHS           123      ATGGCAAGGTGTGTTCCTGATTGGTGCATTTCTAAGCGGTGTAGGTCTCACTCCG 
MAGCPTAWCLVELCLSHS           175      ATGGCAGGTTGTCCGACGGCTTGGTGCCTTGTGGAGTTGTGTCTGTCTCACTCCG 
MANCVSGWCLVRQCFSHS           79       ATGGCAAATTGTGTTTCTGGTTGGTGCCTTGTGCGTCAGTGTTTTTCTCACTCCG 
MAQCGLSLCSWNACASHS           79       ATGGCATAGTGTGGTCTGTCGTTGTGCTCTTGGAATGCGTGTGCGTCTCACTCCG 
MAQCVVSACSWTKCISHS           78       ATGGCATAGTGTGTGGTGAGTGCGTGCTCTTGGACTAAGTGTATTTCTCACTCCG 
MASCYVATCSWWQCGSHS           94       ATGGCATCTTGTTATGTTGCTACTTGCTCTTGGTGGTAGTGTGGGTCTCACTCCG 
MASCLLGSCKWQLCQSHS           127      ATGGCATCTTGTCTGCTGGGTAGTTGCAAGTGGTAGCTGTGTCAGTCTCACTCCG 
MARCTGRSCEWHACGSHS           369      ATGGCAAGGTGTACGGGGCGGTCGTGCGAGTGGCATGCTTGTGGTTCTCACTCCG 
 
 Group4 
MAVCEGTQCSLQCCSSHS           252       ATGGCAGTGTGTGAGGGTACGCAGTGCAGTTTGTAGTGTTGTTCGTCTCACTCCG 
MACCEGTSCYVTECQSHS           123       ATGGCATGTTGTGAGGGGACTTCGTGCTATGTGACGGAGTGTTAGTCTCACTCCG 
MALCSPVDCAVQLCQSHS           244       ATGGCACTGTGTTCTCCGGTTGATTGCGCGGTGTAGTTGTGTCAGTCTCACTCCG 
MAVCQSVDCALRWCQSHS           82        ATGGCAGTGTGTCAGAGTGTTGATTGCGCGCTGCGTTGGTGTTAGTCTCACTCCG 
MAPCQSVRCSVQLCRSHS           100       ATGGCACCTTGTTAGAGTGTTCGTTGCAGTGTTTAGCTGTGTCGTTCTCACTCCG 
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MAACESLTCALIVCQSHS           434       ATGGCAGCTTGTGAGTCTCTGACTTGCGCTTTGATTGTTTGTTAGTCTCACTCCG 
MAECVSLRCALPLCQSHS           79        ATGGCAGAGTGTGTTTCTCTGCGTTGCGCTCTTCCTCTTTGTTAGTCTCACTCCG 
MAGCGAVACCLRSCQSHS           300       ATGGCAGGGTGTGGGGCTGTGGCTTGCTGTCTGCGTTCTTGTTAGTCTCACTCCG 
MAQCRSIVCCLSDCKSHS           96        ATGGCATAGTGTAGGTCTATTGTGTGCTGTCTTTCGGATTGTAAGTCTCACTCCG 
MATCVELQCKTLQCQSHS           81        ATGGCAACTTGTGTTGAGTTGTAGTGCAAGACTTTGTAGTGTTAGTCTCACTCCG 
MAQCIGLSCESRECQSHS           79        ATGGCACAGTGTATTGGGTTGTCGTGCGAGAGTCGTGAGTGTTAGTCTCACTCCG 
MAVCVGYGCSRIQCQSHS           115       ATGGCAGTTTGTGTGGGTTATGGGTGCAGTCGTATTCAGTGTTAGTCTCACTCCG 
MAACVGMDCHWWRCQSHS           110       ATGGCAGCTTGTGTTGGGATGGATTGCCATTGGTGGCGTTGTTAGTCTCACTCCG 
MAKCQDVTCSLVRCTSHS           91        ATGGCAAAGTGTTAGGATGTGACGTGCTCGTTGGTTCGTTGTACGTCTCACTCCG 
MAQCSLVVCQLFRCPSHS           88        ATGGCATAGTGTTCTCTGGTTGTGTGCCAGCTGTTTAGGTGTCCTTCTCACTCCG 
MAGCSSTTCQSRACGSHS           232       ATGGCAGGGTGTAGTAGTACTACGTGCCAGTCTCGTGCGTGTGGTTCTCACTCCG 
MAACDLVDCQQRACGSHS           80        ATGGCAGCGTGTGATTTGGTGGATTGCTAGCAGCGTGCTTGTGGGTCTCACTCCG 
MAECLIASCQYRACTSHS           96        ATGGCAGAGTGTCTGATTGCTTCGTGCTAGTATCGTGCGTGTACTTCTCACTCCG 
MAECRLQRCHYVACSSHS           81        ATGGCAGAGTGTAGGTTGTAGCGTTGCCATTATGTTGCTTGTTCGTCTCACTCCG 
MASCISRKCLAMQCHSHS           300       ATGGCATCGTGTATTAGTCGGAAGTGCTTGGCTATGTAGTGTCATTCTCACTCCG 
MASCAAERCYVQHCMSHS           82        ATGGCATCTTGTGCTGCGGAGAGGTGCTATGTGTAGCATTGTATGTCTCACTCCG 
MAYCVWDKCLLQLCGSHS           156       ATGGCATATTGTGTGTGGGATAAGTGCTTGTTGTAGTTGTGTGGGTCTCACTCCG 
MAGCVSDKCIIQYCNSHS           76        ATGGCAGGGTGTGTTAGTGATAAGTGCATTATTTAGTATTGTAATTCTCACTCCG 
MASCVVGKCLVQYCASHS           146       ATGGCATCTTGTGTTGTTGGGAAGTGCTTGGTTTAGTATTGTGCGTCTCACTCCG 
MAACVMGKCLMQTCVSHS           103       ATGGCAGCTTGTGTGATGGGGAAGTGCTTGATGTAGACTTGTGTTTCTCACTCCG 
MAPCVEGKCLKQSCSSHS           83        ATGGCACCGTGTGTGGAGGGTAAGTGCTTGAAGTAGTCGTGTAGTTCTCACTCCG 
MAGCVLGKCLQDFCQSHS           87        ATGGCAGGTTGTGTTTTGGGGAAGTGCCTGTAGGATTTTTGTCAGTCTCACTCCG 
MARCSSQVCRTTVCLSHS           189       ATGGCACGGTGTAGTAGTCAGGTGTGCAGGACGACTGTGTGTTTGTCTCACTCCG 
MAQCARTVCRGSECLSHS           124       ATGGCACAGTGTGCGCGTACGGTTTGCCGTGGTTCGGAGTGTCTGTCTCACTCCG 
 
 Group5 
MAWCKVRECQRLGCVSHS           271       ATGGCATGGTGTAAGGTGCGGGAGTGCCAGAGGTTGGGTTGTGTTTCTCACTCCG 
MAVCIGRSCQNLGCVSHS           104       ATGGCAGTTTGTATTGGGCGGTCTTGCTAGAATCTGGGGTGTGTTTCTCACTCCG 
MALCQAHLCNPVSCRSHS           228       ATGGCACTTTGTTAGGCTCATTTGTGCAATCCGGTTTCTTGTCGGTCTCACTCCG 
MALCVGCHCGPVSCQSHS           77        ATGGCATTGTGTGTGGGTTGTCATTGCGGTCCTGTTTCGTGTTAGTCTCACTCCG 
MAHCSGSLCSQLSCVSHS           172       ATGGCACATTGTTCTGGGTCTTTGTGCTCGTAGCTTTCTTGTGTGTCTCACTCCG 
MATCQIALCGQVLCVSHS           105       ATGGCAACGTGTTAGATTGCGCTGTGCGGTTAGGTTTTGTGTGTGTCTCACTCCG 
MASCHQGLCESPHCQSHS           77        ATGGCAAGTTGTCATCAGGGGCTGTGCGAGTCTCCTCATTGTTAGTCTCACTCCG 
MAVCLRQTCSSANCGSHS           425       ATGGCAGTGTGTCTGCGGTAGACGTGCAGTTCTGCGAATTGTGGTTCTCACTCCG 
MAGCLPQACTVANCASHS           83        ATGGCAGGTTGTCTTCCTTAGGCGTGCACTGTGGCGAATTGTGCTTCTCACTCCG 
MALCLHFICDQQLCASHS           142       ATGGCACTTTGTCTTCATTTTATTTGCGATCAGTAGCTGTGTGCGTCTCACTCCG 
MAVCVLFVCNESLCSSHS           93        ATGGCAGTTTGTGTTCTGTTTGTGTGCAATGAGTCGCTGTGTTCTTCTCACTCCG 
MAACVQMLCGVSLCASHS           93        ATGGCAGCTTGTGTTTAGATGCTTTGCGGGGTTTCGTTGTGTGCTTCTCACTCCG 
MAICGQFLCFYSQCASHS           131       ATGGCAATTTGTGGGTAGTTTCTTTGCTTTTATTCGTAGTGTGCTTCTCACTCCG 
 
 Group6 
MAWCWGWGCFSSMCSSHS           96        ATGGCATGGTGTTGGGGGTGGGGGTGCTTTTCGAGTATGTGTAGTTCTCACTCCG 
MADCWQPFCVYSHCTSHS           271       ATGGCAGATTGTTGGTAGCCGTTTTGCGTTTATTCGCATTGTACTTCTCACTCCG 
MAICWAPYCTNLACTSHS           178       ATGGCAATTTGTTGGGCTCCGTATTGCACGAATTTGGCGTGTACGTCTCACTCCG 
MAVCWLPQCISHLSHS             84        ATGGCAGTGTGTTGGTTGCCTTAGTGCATTTCTCATTTGTCTCACTCCG 
 
 Group7 
MAICDGVVCSFGKCGSHS           83        ATGGCAATTTGTGATGGGGTGGTGTGCTCTTTTGGGAAGTGTGGGTCTCACTCCG 
MAFCQQVLCALGACSSHS           80        ATGGCATTTTGTCAGTAGGTGCTGTGCGCGCTGGGTGCGTGTTCTTCTCACTCCG 
MAQCWQMPCSLGSCPSHS           344       ATGGCATAGTGTTGGCAGATGCCGTGCTCGTTGGGGTCGTGTCCTTCTCACTCCG 
MAVCGCVGCQVGDCLSHS           150       ATGGCAGTGTGTGGTTGTGTTGGGTGCTAGGTTGGTGATTGTTTGTCTCACTCCG 
MAVCHAIWCMVGHCLSHS           81        ATGGCAGTTTGTCATGCGATTTGGTGCATGGTGGGTCATTGTTTGTCTCACTCCG 
MASCGWIGCLMGICYSHS           102       ATGGCAAGTTGTGGGTGGATTGGTTGCTTGATGGGGATTTGTTATTCTCACTCCG 
MAMCGFSSCVDGICQSHS           102       ATGGCAATGTGTGGTTTTTCTTCGTGCGTTGATGGTATTTGTTAGTCTCACTCCG 
MAMCGLPGCQLDRCYSHS           86        ATGGCAATGTGTGGGTTGCCGGGTTGCTAGTTGGATCGTTGTTATTCTCACTCCG 
MAMCDDRGCGLGMCQSHS           138       ATGGCAATGTGTGATGATCGTGGTTGCGGTCTGGGGATGTGTTAGTCTCACTCCG 
MACCGRGSCGLGQCQSHS           95        ATGGCATGTTGTGGGAGGGGGTCTTGCGGTCTGGGTCAGTGTTAGTCTCACTCCG 
MAECRGPRCSGGLCGSHS           168       ATGGCAGAGTGTAGGGGGCCGAGGTGCTCGGGGGGTCTTTGTGGGTCTCACTCCG 
MANCRGPGCQQGYCGSHS           81        ATGGCAAATTGTCGTGGTCCTGGTTGCCAGTAGGGGTATTGTGGGTCTCACTCCG 
MATCERPGCRVGPCSSHS           87        ATGGCAACTTGTGAGCGTCCGGGTTGCAGGGTTGGTCCGTGTTCGTCTCACTCCG 
 
 Group8 
MARCLSPGCSQSLCCSHS           99       ATGGCACGGTGTCTTAGTCCGGGTTGCAGTCAGTCTTTGTGTTGTTCTCACTCCG 
MARCAIRGCVKSLCCSHS           76       ATGGCAAGGTGTGCTATTCGGGGTTGCGTTAAGTCTTTGTGTTGTTCTCACTCCG 
MAECLMPGCSSRLCQSHS           94       ATGGCAGAGTGTCTGATGCCTGGTTGCAGTTCGCGGCTTTGTTAGTCTCACTCCG 
MAECLSRTCTQALCISHS           120      ATGGCAGAGTGTCTTAGTCGTACGTGCACTTAGGCTCTTTGTATTTCTCACTCCG 
MAACLSDTCRQGLCSSHS           87       ATGGCAGCGTGTTTGTCGGATACGTGCCGTTAGGGGTTGTGTTCGTCTCACTCCG 
 
 Group9 
MAECGGIPCTQSTCVSHS           100       ATGGCAGAGTGTGGTGGGATTCCGTGCACTTAGTCTACTTGTGTTTCTCACTCCG 
MAGCAGLPCSQPSCWSHS           79        ATGGCAGGTTGTGCGGGGCTTCCTTGCTCTTAGCCGTCGTGTTGGTCTCACTCCG 
MAGCALAPCTQRYCASHS           87        ATGGCAGGGTGTGCGTTGGCGCCGTGCACGTAGCGTTATTGTGCTTCTCACTCCG 
 
 Group10 
MATCYSSWCFGWWCQSHS           84        ATGGCAACGTGTTATTCGTCGTGGTGCTTTGGGTGGTGGTGTTAGTCTCACTCCG 
MAQCWADTCLRWVCLSHS           98        ATGGCATAGTGTTGGGCGGATACGTGCTTGCGTTGGGTGTGTCTTTCTCACTCCG 
MAHCWVSACRHWRCQSHS           795       ATGGCACATTGTTGGGTGAGTGCTTGCCGGCATTGGCGGTGTTAGTCTCACTCCG 
MAQCRPRLCVVWNCQSHS           133       ATGGCACAGTGTCGGCCTCGGTTGTGCGTGGTTTGGAATTGTTAGTCTCACTCCG 
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MAQCDTRLCPYWSCDSHS           77       ATGGCATAGTGTGATACGCGTTTGTGCCCTTATTGGAGTTGTGATTCTCACTCCG 
 
 Group11 
MALCSRSGCAYGCWSHS            108       ATGGCACTTTGTTCTCGTTCGGGTTGCGCGTATGGGTGTTGGTCTCACTCCG 
MAMCCSSKCLLPNCWSHS           97        ATGGCAATGTGTTGTTCGTCTAAGTGCCTGTTGCCTAATTGTTGGTCTCACTCCG 
MAGCQSFGCAGRTCWSHS           104       ATGGCAGGGTGTTAGAGTTTTGGGTGCGCTGGGCGTACTTGTTGGTCTCACTCCG 
MAVCRFATCAGPQCWSHS           206       ATGGCAGTGTGTCGGTTTGCGACTTGTGCTGGGCCGTAGTGTTGGTCTCACTCCG 
MAQCMVAGCALFECRSHS           124       ATGGCATAGTGTATGGTGGCTGGTTGCGCTTTGTTTGAGTGTCGGTCTCACTCCG 
 
 Group12 
MALCLMQPCASFACMSHS           94        ATGGCACTTTGTCTTATGTAGCCGTGCGCTTCGTTTGCGTGTATGTCTCACTCCG 
MALCVSQHCDRFGCLSHS           105       ATGGCATTGTGTGTGTCTTAGCATTGCGATCGTTTTGGGTGTCTGTCTCACTCCG 
MALCRSSVCSEGGCRSHS           87        ATGGCACTGTGTAGGAGTTCGGTGTGCTCTGAGGGTGGTTGTAGGTCTCACTCCG 
MAVCPTFICTAMGCRSHS           279       ATGGCAGTTTGTCCTACTTTTATTTGCACGGCTATGGGGTGTAGGTCTCACTCCG 
 
 Group13 
MAQCGGRSCQGSSCPSHS           90       ATGGCACAGTGTGGTGGTAGGAGTTGCCAGGGGTCGTCGTGTCCGTCTCACTCCG 
MAYCCGRDCQSETCQSHS           141      ATGGCATATTGTTGTGGTAGGGATTGCTAGTCTGAGACTTGTCAGTCTCACTCCG 
MAACWCRQCQLHVCLSHS           96       ATGGCAGCTTGTTGGTGTCGGCAGTGCTAGCTTCATGTGTGTTTGTCTCACTCCG 
MATCDLRSCQSDVCLSHS           84       ATGGCAACGTGTGATCTTCGGTCGTGCTAGTCTGATGTGTGTTTGTCTCACTCCG 
MAGCVWRRCGLEACSSHS           136      ATGGCAGGTTGTGTGTGGCGGCGTTGCGGTTTGGAGGCTTGTTCGTCTCACTCCG 
MAVCVMHKCQLNACSSHS           169      ATGGCAGTGTGTGTGATGCATAAGTGCTAGCTGAATGCGTGTTCTTCTCACTCCG 
 
 Group14 
MATCVRLYCMGLTCVSHS           81       ATGGCAACTTGTGTTCGTCTGTATTGCATGGGTCTTACGTGTGTGTCTCACTCCG 
MAKCLRGSCGGLSCYSHS           81       ATGGCAAAGTGTTTGCGTGGTTCGTGCGGTGGGCTTTCTTGTTATTCTCACTCCG 
MAVCNQRWCGGLSCRSHS           141      ATGGCAGTTTGTAATCAGCGTTGGTGCGGGGGGCTTAGTTGTCGGTCTCACTCCG 
MAWCWYIGCAGIGCASHS           322      ATGGCATGGTGTTGGTATATTGGTTGCGCTGGTATTGGGTGTGCGTCTCACTCCG 
MARCTLLGCNGVSCASHS           199      ATGGCACGGTGTACGCTTCTGGGGTGCAATGGTGTTTCGTGTGCTTCTCACTCCG 
MASCDQIYCVPFSCASHS           86       ATGGCATCGTGTGATTAGATTTATTGCGTTCCGTTTTCTTGTGCGTCTCACTCCG 
MACCDQMACEAICCVSHS           161      ATGGCATGTTGTGATTAGATGGCTTGCGAGGCTATTTGTTGTGTTTCTCACTCCG 
 
 Group15 
MAGCHSWQCTVIMCKSHS           90       ATGGCAGGTTGTCATTCTTGGTAGTGCACGGTTATTATGTGTAAGTCTCACTCCG 
MAACQLWPCDVDNCVSHS           96       ATGGCAGCTTGTTAGTTGTGGCCTTGCGATGTGGATAATTGTGTGTCTCACTCCG 
MALCRAWDCANCACTSHS           146      ATGGCACTGTGTAGGGCTTGGGATTGCGCTAATTGTGCTTGTACTTCTCACTCCG 
MARCSKWSCQHMGCVSHS           167      ATGGCACGGTGTAGTAAGTGGTCGTGCCAGCATATGGGTTGTGTCTCTCACTCCG 
 
 Group16 
MAGCRAVTCAKQRCCSHS           103       ATGGCAGGGTGTCGTGCTGTGACTTGCGCTAAGTAGAGGTGTTGTTCTCACTCCG 
MAGCQEQGCEQLRCCSHS           192       ATGGCAGGTTGTTAGGAGCAGGGGTGCGAGCAGTTGCGTTGTTGTTCTCACTCCG 
MAGCGRNICVKNLCCSHS           114       ATGGCAGGGTGTGGGCGGAATATTTGCGTTAAGAATCTTTGTTGTTCTCACTCCG 
MASCGSQNCWLRVCCSHS           126       ATGGCATCTTGTGGGTCGTAGAATTGCTGGCTGCGGGTGTGTTGTTCTCACTCCG 
MASCQYQHCWFHVCCSHS           121       ATGGCATCGTGTCAGTATTAGCATTGCTGGTTTCATGTTTGTTGTTCTCACTCCG 
 
 Group17 
MALCSWGTCMQDLCVSHS           80       ATGGCACTTTGTAGTTGGGGTACTTGCATGTAGGATCTTTGTGTTTCTCACTCCG 
MAVCLWGGCKQTSCSSHS           88       ATGGCAGTGTGTTTGTGGGGTGGGTGCAAGTAGACGAGTTGTTCTTCTCACTCCG 
MAGCAWQICKEQTCASHS           101      ATGGCAGGTTGTGCGTGGCAGATTTGCAAGGAGTAGACTTGTGCGTCTCACTCCG 
MAVCEWQLCVSDPCFSHS           101      ATGGCAGTTTGTGAGTGGTAGCTTTGCGTTTCGGATCCGTGTTTTTCTCACTCCG 
MAICSWTWCAREGCDSHS           162      ATGGCAATTTGTTCGTGGACGTGGTGCGCTCGTGAGGGGTGTGATTCTCACTCCG 
 
 Group18 
MAVCATYPCPSLVCTSHS           89       ATGGCAGTTTGTGCTACGTATCCGTGCCCGTCTTTGGTGTGTACTTCTCACTCCG 
MAGCGDYACPGLQCMSHS           160      ATGGCAGGTTGTGGGGATTATGCGTGCCCTGGGCTGTAGTGTATGTCTCACTCCG 
MAGCWARPCPLALCQSHS           178      ATGGCAGGGTGTTGGGCTAGGCCGTGCCCTCTTGCGTTGTGTTAGTCTCACTCCG 
MAACDARPCPQTYCLSHS           307      ATGGCAGCGTGTGATGCTCGTCCGTGCCCTTAGACTTATTGTTTGTCTCACTCCG 
 
 Group19 
MANCQLAVCQGSYCCSHS           78       ATGGCAAATTGTTAGCTTGCTGTTTGCCAGGGGTCTTATTGTTGTTCTCACTCCG 
MALCTRSVCQVSYCISHS           170      ATGGCATTGTGTACGAGGTCGGTTTGCTAGGTGTCTTATTGTATTTCTCACTCCG 
MAACQMNYCRSDYCKSHS           111      ATGGCAGCTTGTTAGATGAATTATTGCAGGTCGGATTATTGTAAGTCTCACTCCG 
 
 Group MIXED 
MAKCSDADCCGLRCGSHS           140       ATGGCAAAGTGTTCGGATGCGGATTGCTGTGGTTTGCGGTGTGGGTCTCACTCCG 
MAKCSDQPCELMACKSHS           319       ATGGCAAAGTGTTCTGATTAGCCGTGCGAGTTGATGGCTTGTAAGTCTCACTCCG 
MASCTLAECDCPACQSHS           89        ATGGCAAGTTGTACGCTTGCGGAGTGCGATTGTCCTGCTTGTTAGTCTCACTCCG 
MAVCALISCVCYSCPSHS           92        ATGGCAGTGTGTGCGCTTATTTCTTGCGTGTGTTATTCTTGTCCTTCTCACTCCG 
MANCVLGTCGRRPCVSHS           101       ATGGCAAATTGTGTGTTGGGTACTTGCGGTCGGCGGCCTTGTGTGTCTCACTCCG 
MASCAVAHCGLSPCDSHS           186       ATGGCATCGTGTGCGGTTGCTCATTGCGGTTTGAGTCCGTGTGATTCTCACTCCG 
MARCTKSLCCQSHS               81        ATGGCACGGTGTACTAAGTCGCTTTGCTGTCAGTCTCACTCCG 
MAGCSKNLCCVRNSHS             79        ATGGCAGGTTGTTCGAAGAATTTGTGCTGTGTTCGTAATTCTCACTCCG 
MACCRVGGCITLRCDSHS           90        ATGGCATGTTGTCGTGTTGGGGGGTGCATTACGCTGAGGTGTGATTCTCACTCCG 
MAACQVAGCLWEHCDSHS           99        ATGGCAGCGTGTCAGGTGGCTGGTTGCTTGTGGGAGCATTGTGATTCTCACTCCG 
MATCMRLGCCRDNCWSHS           121       ATGGCAACTTGTATGCGTCTGGGGTGCTGTCGGGATAATTGTTGGTCTCACTCCG 
MARCLEQGCCSDECHSHS           153       ATGGCACGGTGTTTGGAGTAGGGGTGCTGTAGTGATGAGTGTCATTCTCACTCCG 
MAICLLVCCKRIGCYSHS           107       ATGGCAATTTGTTTGCTTGTTTGTTGCAAGCGGATTGGTTGTTATTCTCACTCCG 
MAVCVLLVCQFVCCYSHS           87        ATGGCAGTGTGTGTGTTGTTGGTGTGCCAGTTTGTGTGTTGTTATTCTCACTCCG 
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MASCYYGNCMQQPCYSHS           184       ATGGCATCTTGTTATTATGGGAATTGCATGCAGTAGCCGTGTTATTCTCACTCCG 
MALCYRLTCQQLPCYSHS           80        ATGGCACTGTGTTATCGGCTTACGTGCTAGCAGCTGCCTTGTTATTCTCACTCCG 
MARCALCLCGQGESLSHS           193       ATGGCACGTTGTGCGCTGTGTCTGTGCGGTTAGGGTGAGTCTTTGTCTCACTCCG 
MAVCGPLQCIGWDCRSHS           112       ATGGCAGTGTGTGGGCCTTTGTAGTGCATTGGTTGGGATTGTCGGTCTCACTCCG 
MAQCVPFKCVPGACDSHS           104       ATGGCATAGTGTGTTCCGTTTAAGTGCGTGCCGGGGGCGTGTGATTCTCACTCCG 
MAQCFSRLCLRELCRSHS           84        ATGGCACAGTGTTTTTCGCGTTTGTGCCTTCGTGAGCTGTGTAGGTCTCACTCCG 
MATCVSNRCCDWRCLSHS           80        ATGGCAACTTGTGTTTCGAATAGGTGCTGTGATTGGCGGTGTCTTTCTCACTCCG 
MARCCALRCWLLSCPSHS           218       ATGGCACGGTGTTGTGCGCTTAGGTGCTGGTTGTTGTCTTGTCCTTCTCACTCCG 
MARCCVIQCDHGACMSHS           93        ATGGCAAGGTGTTGTGTGATTTAGTGCGATCATGGGGCTTGTATGTCTCACTCCG 
MAACGSRGCWQAGCYSHS           118       ATGGCAGCGTGTGGTAGTCGTGGGTGCTGGTAGGCTGGTTGTTATTCTCACTCCG 
MASCGGDRCPWDGCWSHS           107       ATGGCATCTTGTGGTGGTGATCGTTGCCCTTGGGATGGTTGTTGGTCTCACTCCG 
MAKCWDRACWGQFCTSHS           113       ATGGCAAAGTGTTGGGATCGTGCGTGCTGGGGGTAGTTTTGTACGTCTCACTCCG 
MAYCQPAWCWCRNCSSHS           249       ATGGCATATTGTTAGCCTGCGTGGTGCTGGTGTCGTAATTGTTCGTCTCACTCCG 
MAYCDVTVCWRGSCQSHS           78        ATGGCATATTGTGATGTTACGGTTTGCTGGCGGGGGAGTTGTTAGTCTCACTCCG 
MANCSYGACWIGSCQSHS           126       ATGGCAAATTGTTCGTATGGGGCGTGCTGGATTGGGTCGTGTTAGTCTCACTCCG 
MAMCVGQACWVRACRSHS           83        ATGGCAATGTGTGTTGGTCAGGCGTGCTGGGTGAGGGCTTGTCGGTCTCACTCCG 
MAGCPGQVCWPVSCSSHS           167       ATGGCAGGGTGTCCGGGTTAGGTGTGCTGGCCTGTTTCTTGTAGTTCTCACTCCG 
MASCMLAPCSLVICWSHS           91        ATGGCATCGTGTATGTTGGCTCCGTGCAGTTTGGTGATTTGTTGGTCTCACTCCG 
MARCPLSHCAEQLCWSHS           86        ATGGCACGGTGTCCGTTGTCGCATTGCGCTGAGTAGTTGTGTTGGTCTCACTCCG 
MAPCHDAQCARDQCDSHS           91        ATGGCACCGTGTCATGATGCTTAGTGCGCTCGGGATCAGTGTGATTCTCACTCCG 
MALCQEGNCFAPTCASHS           251       ATGGCACTTTGTTAGGAGGGGAATTGCTTTGCTCCGACTTGTGCGTCTCACTCCG 
MALCFDDVCMAGPCLSHS           83        ATGGCATTGTGTTTTGATGATGTTTGCATGGCGGGTCCGTGTTTGTCTCACTCCG 
MAACRTSQCCPQGCASHS           297       ATGGCAGCGTGTCGGACGAGTCAGTGCTGTCCGTAGGGTTGTGCGTCTCACTCCG 
MAVCRQSLCDSVLCQSHS           99        ATGGCAGTTTGTCGTCAGAGTCTTTGCGATAGTGTGTTGTGTCAGTCTCACTCCG 
MALCPRQRCGTVHCASHS           180       ATGGCACTGTGTCCTCGGTAGAGGTGCGGTACGGTTCATTGTGCGTCTCACTCCG 
MAHCSLQQCGLWFCGSHS           110       ATGGCACATTGTAGTTTGCAGTAGTGCGGGTTGTGGTTTTGTGGTTCTCACTCCG 
MADCAQHCCGVATCRSHS           198       ATGGCAGATTGTGCGTAGCATTGTTGCGGTGTTGCGACTTGTCGGTCTCACTCCG 
MARCGFNACKPTQCLSHS           104       ATGGCACGGTGTGGGTTTAATGCGTGCAAGCCGACTTAGTGTCTGTCTCACTCCG 
MALCGGGWCQLQACGSHS           101       ATGGCACTTTGTGGTGGGGGGTGGTGCTAGCTGCAGGCTTGTGGCTCTCACTCCG 
MAFCHGRNCAVLSCSSHS           80        ATGGCATTTTGTCATGGTAGGAATTGCGCTGTGCTGTCGTGTTCTTCTCACTCCG 
 
PK – Libraries 3×3, 4×4 
 Group1 
MALCFDQCRVSCASHS           180       ATGGCACTTTGTTTTGATCAGTGCCGTGTTTCGTGTGCTTCTCACTCCG 
MAMCFDSCRVNCTSHS           138       ATGGCAATGTGTTTTGATTCTTGCAGGGTTAATTGTACGTCTCACTCCG 
MAVCYPRCRVSCSSHS           273       ATGGCAGTGTGTTATCCGCGGTGCCGGGTTTCTTGTTCTTCTCACTCCG 
MATCFHFCRVSCGSHS           230       ATGGCAACTTGTTTTCATTTTTGCCGGGTTTCGTGTGGGTCTCACTCCG 
MATCFHHCRVNCSSHS           95        ATGGCAACGTGTTTTCATCATTGCCGGGTGAATTGTTCTTCTCACTCCG 
MATCFHRCRVTCISHS           93        ATGGCAACTTGTTTTCATCGGTGCCGTGTGACGTGTATTTCTCACTCCG 
MARCFALCRVTCESHS           183       ATGGCACGGTGTTTTGCGTTGTGCAGGGTGACTTGTGAGTCTCACTCCG 
MAKCFRLCRVTCHSHS           98        ATGGCAAAGTGTTTTCGTCTTTGCCGTGTGACGTGTCATTCTCACTCCG 
MADCYQLCRVSCESHS           501       ATGGCAGATTGTTATTAGCTGTGCCGGGTTTCGTGTGAGTCTCACTCCG 
MAVCYALCRVSCDSHS           149       ATGGCAGTTTGTTATGCGCTTTGCAGGGTGAGTTGTGATTCTCACTCCG 
MATCFTMCRVSCDSHS           117       ATGGCAACTTGTTTTACGATGTGCCGTGTGAGTTGTGATTCTCACTCCG 
MAICFLLCRVSCPSHS           257       ATGGCAATTTGTTTTCTTCTTTGCCGTGTGAGTTGTCCGTCTCACTCCG 
MATCFLVCRVGCASHS           238       ATGGCAACTTGTTTTCTGGTGTGCAGGGTTGGTTGTGCTTCTCACTCCG 
MAGCFEVCRVSCSSHS           140       ATGGCAGGGTGTTTTGAGGTTTGCCGTGTTTCGTGTTCTTCTCACTCCG 
MASCFRECRVACPSHS           100       ATGGCAAGTTGTTTTCGGGAGTGCCGGGTTGCGTGTCCGTCTCACTCCG 
MAVCFQECRVDCPSHS           100       ATGGCAGTGTGTTTTCAGGAGTGCCGGGTTGATTGTCCTTCTCACTCCG 
MAQCFSRCRVGCPSHS           159       ATGGCACAGTGTTTTTCGAGGTGCCGTGTGGGTTGTCCTTCTCACTCCG 
MAQCFERCRVNCDSHS           127       ATGGCATAGTGTTTTGAGAGGTGCCGTGTTAATTGTGATTCTCACTCCG 
MAECFIRCRVNCDSHS           101       ATGGCAGAGTGTTTTATTCGGTGCAGGGTTAATTGTGATTCTCACTCCG 
MATCLVVCRVNCDSHS           120       ATGGCAACTTGTCTGGTGGTTTGCCGTGTTAATTGTGATTCTCACTCCG 
MADCFHQCRVGCDSHS           138       ATGGCAGATTGTTTTCATCAGTGCCGGGTTGGGTGTGATTCTCACTCCG 
MASCFWKCRVGCDSHS           106       ATGGCATCTTGTTTTTGGAAGTGCAGGGTGGGGTGTGATTCTCACTCCG 
 
 Group2 
MAWCFPGCRVLCVSHS           164       ATGGCATGGTGTTTTCCGGGTTGCAGGGTGTTGTGTGTTTCTCACTCCG 
MAWCWERCRVLCVSHS           113       ATGGCATGGTGTTGGGAGCGGTGCCGGGTTCTGTGTGTGTCTCACTCCG 
MAWCFMQCKVVCYSHS           97        ATGGCATGGTGTTTTATGTAGTGCAAGGTGGTTTGTTATTCTCACTCCG 
MAWCFDVCRVGCLSHS           161       ATGGCATGGTGTTTTGATGTGTGCAGGGTGGGGTGTCTGTCTCACTCCG 
MAWCFTKCRTGCTSHS           124       ATGGCATGGTGTTTTACTAAGTGCCGTACTGGTTGTACTTCTCACTCCG 
 
 Group3 
MAGCWQHCRVLCWSHS           166       ATGGCAGGTTGTTGGTAGCATTGCCGGGTTCTTTGTTGGTCTCACTCCG 
MASCWSYCRVYCWSHS           135       ATGGCATCGTGTTGGTCGTATTGCCGTGTGTATTGTTGGTCTCACTCCG 
MARCWETCRVSCWSHS           227       ATGGCACGGTGTTGGGAGACTTGCCGGGTTTCGTGTTGGTCTCACTCCG 
MASCWERCRVRCWSHS           164       ATGGCAAGTTGTTGGGAGCGTTGCAGGGTGAGGTGTTGGTCTCACTCCG 
MARCWQLCRVGCNSHS           157       ATGGCACGGTGTTGGCAGCTTTGCCGGGTTGGGTGTAATTCTCACTCCG 
MAQCWQLCRVSCSSHS           108       ATGGCACAGTGTTGGTAGCTGTGCCGGGTGTCTTGTAGTTCTCACTCCG 
MARCWLLCRVSCESHS           143       ATGGCACGGTGTTGGTTGTTGTGCCGGGTTAGTTGTGAGTCTCACTCCG 
MALCWELCRVRCQSHS           157       ATGGCATTGTGTTGGGAGTTGTGCCGGGTGCGGTGTCAGTCTCACTCCG 
MANCWRLCRVDCLSHS           105       ATGGCAAATTGTTGGCGTCTGTGCCGGGTTGATTGTCTGTCTCACTCCG 
MAGCWTLCRVRCHSHS           134       ATGGCAGGGTGTTGGACGTTGTGCCGTGTTAGGTGTCATTCTCACTCCG 
MAGCWTLCRASCYSHS           113       ATGGCAGGTTGTTGGACTCTGTGCCGTGCTAGTTGTTATTCTCACTCCG 
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MAGCWTECRVNCLSHS           120       ATGGCAGGTTGTTGGACGGAGTGCCGTGTGAATTGTTTGTCTCACTCCG 
MAACWSVCRVGCMSHS           134       ATGGCAGCGTGTTGGTCGGTTTGCCGTGTTGGTTGTATGTCTCACTCCG 
MAGCWSLCRVGCSSHS           133       ATGGCAGGGTGTTGGTCTTTGTGCAGGGTGGGGTGTTCTTCTCACTCCG 
MAACWVRCRVGCISHS           109       ATGGCAGCGTGTTGGGTGCGTTGCCGGGTGGGGTGTATTTCTCACTCCG 
MAACWLLCRAGCYSHS           118       ATGGCAGCTTGTTGGTTGCTGTGCAGGGCGGGGTGTTATTCTCACTCCG 
MAACYRLCRVGCYSHS           94        ATGGCAGCGTGTTATCGGTTGTGCCGGGTGGGTTGTTATTCTCACTCCG 
MAVCFGLCRVGCLSHS           112       ATGGCAGTGTGTTTTGGTCTTTGCCGTGTGGGGTGTTTGTCTCACTCCG 
MAKCWGLCRVGCLSHS           103       ATGGCAAAGTGTTGGGGGCTTTGCAGGGTTGGTTGTTTGTCTCACTCCG 
MAVCWGVCRVACLSHS           207       ATGGCAGTGTGTTGGGGTGTGTGCCGTGTGGCTTGTCTTTCTCACTCCG 
MAQCWRDCRVLCMSHS           91        ATGGCATAGTGTTGGAGGGATTGCCGTGTGTTGTGTATGTCTCACTCCG 
MAQCWWSCRVNCTSHS           146       ATGGCATAGTGTTGGTGGAGTTGCAGGGTGAATTGTACCTCTCACTCCG 
MAQCWYSCRVQCYSHS           116       ATGGCATAGTGTTGGTATTCTTGCCGGGTGCAGTGTTATTCTCACTCCG 
 
 Group4 
MAACFQMCRVNCLSHS           186       ATGGCAGCGTGTTTTCAGATGTGCCGGGTTAATTGTCTTTCTCACTCCG 
MASCFQTCRVYCLSHS           156       ATGGCATCTTGTTTTTAGACTTGCAGGGTTTATTGTTTGTCTCACTCCG 
MASCFNSCRVVCISHS           179       ATGGCAAGTTGTTTTAATAGTTGCCGGGTGGTTTGTATTTCTCACTCCG 
MAACFDSCRVVCLSHS           97        ATGGCAGCGTGTTTTGATAGTTGCAGGGTTGTGTGTCTGTCTCACTCCG 
MAACFTQCRVMCPSHS           201       ATGGCAGCTTGTTTTACTTAGTGCCGTGTTATGTGTCCTTCTCACTCCG 
MAECFTQCRVMCLSHS           144       ATGGCAGAGTGTTTTACGTAGTGCCGTGTGATGTGTCTGTCTCACTCCG 
MADCFQGCRVFCSSHS           124       ATGGCAGATTGTTTTTAGGGTTGCCGTGTTTTTTGTTCGTCTCACTCCG 
MAYCFQGCRVLCYSHS           107       ATGGCATATTGTTTTCAGGGGTGCCGTGTGTTGTGTTATTCTCACTCCG 
MARCFSSCRVLCNSHS           118       ATGGCAAGGTGTTTTAGTAGTTGCCGTGTTCTGTGTAATTCTCACTCCG 
MARCFSGCRVLCFSHS           91        ATGGCACGTTGTTTTTCGGGGTGCAGGGTGCTTTGTTTTTCTCACTCCG 
MAQCFTGCRVSCGSHS           184       ATGGCATAGTGTTTTACTGGTTGCCGTGTTTCGTGTGGGTCTCACTCCG 
MAQCFIGCRVNCGSHS           178       ATGGCATAGTGTTTTATTGGGTGCAGGGTTAATTGTGGGTCTCACTCCG 
MAPCFRGCRVNCSSHS           142       ATGGCACCGTGTTTTAGGGGGTGCAGGGTTAATTGTTCGTCTCACTCCG 
MASCFTGCRVACPSHS           137       ATGGCATCGTGTTTTACGGGTTGCCGTGTGGCTTGTCCGTCTCACTCCG 
MASCFSGCRVACRSHS           134       ATGGCATCGTGTTTTAGTGGGTGCCGTGTGGCTTGTCGGTCTCACTCCG 
MAKCFQGCRVHCVSHS           155       ATGGCAAAGTGTTTTCAGGGGTGCCGGGTGCATTGTGTGTCTCACTCCG 
MAKCWQGCRVNCMSHS           145       ATGGCAAAGTGTTGGTAGGGGTGCAGGGTTAATTGTATGTCTCACTCCG 
MAECLHGCRVACLSHS           196       ATGGCAGAGTGTTTGCATGGTTGCCGGGTGGCGTGTCTGTCTCACTCCG 
MAQCFQLCRTACVSHS           137       ATGGCACAGTGTTTTTAGCTTTGCAGGACGGCTTGTGTGTCTCACTCCG 
MAQCFRSCRVACVSHS           134       ATGGCACAGTGTTTTCGGTCTTGCAGGGTGGCGTGTGTGTCTCACTCCG 
 
 Group5 
MAKCFQACRTLCFSHS           178       ATGGCAAAGTGTTTTTAGGCTTGCAGGACGCTTTGTTTTTCTCACTCCG 
MAKCFMSCRGLCFSHS           99        ATGGCAAAGTGTTTTATGTCGTGCCGTGGGCTGTGTTTTTCTCACTCCG 
MAFCFQNCKALCFSHS           202       ATGGCATTTTGTTTTCAGAATTGCAAGGCTCTTTGTTTTTCTCACTCCG 
MALCFANCRALCFSHS           127       ATGGCACTTTGTTTTGCTAATTGCCGGGCGTTGTGTTTTTCTCACTCCG 
MATCFQTCRALCWSHS           115       ATGGCAACTTGTTTTCAGACTTGCAGGGCTCTGTGTTGGTCTCACTCCG 
MATCFQVCRALCVSHS           105       ATGGCAACTTGTTTTCAGGTGTGCCGTGCGCTGTGTGTTTCTCACTCCG 
MAPCFQPCRSICMSHS           92        ATGGCACCGTGTTTTTAGCCTTGCAGGAGTATTTGTATGTCTCACTCCG 
MAECFRLCRTLCSSHS           166       ATGGCAGAGTGTTTTCGTCTGTGCCGTACTCTTTGTTCTTCTCACTCCG 
MAHCFRPCRALCPSHS           102       ATGGCACATTGTTTTCGTCCGTGCCGGGCGTTGTGTCCGTCTCACTCCG 
 
 Group6 
MAGCFTPCRTMCWSHS           317       ATGGCAGGGTGTTTTACTCCGTGCAGGACTATGTGTTGGTCTCACTCCG 
MAKCFPKCRVMCWSHS           187       ATGGCAAAGTGTTTTCCGAAGTGCCGTGTGATGTGTTGGTCTCACTCCG 
MARCFVSCRGVCWSHS           92        ATGGCACGGTGTTTTGTGAGTTGCAGGGGTGTTTGTTGGTCTCACTCCG 
MAECFLVCRVACWSHS           108       ATGGCAGAGTGTTTTTTGGTGTGCAGGGTTGCGTGTTGGTCTCACTCCG 
MASCLWVCRVACWSHS           91        ATGGCAAGTTGTCTGTGGGTGTGCAGGGTGGCGTGTTGGTCTCACTCCG 
MAQCFWFCRTGCWSHS           169       ATGGCATAGTGTTTTTGGTTTTGCAGGACTGGGTGTTGGTCTCACTCCG 
MARCFSLCRVQCWSHS           120       ATGGCAAGGTGTTTTTCGTTGTGCCGGGTTCAGTGTTGGTCTCACTCCG 
MAHCYSVCRVNCWSHS           117       ATGGCACATTGTTATAGTGTTTGCCGTGTGAATTGTTGGTCTCACTCCG 
 
 Group7 
MARCYMPCRVNCVSHS           118       ATGGCACGTTGTTATATGCCTTGCCGTGTTAATTGTGTTTCTCACTCCG 
MALCFVPCRVDCVSHS           109       ATGGCATTGTGTTTTGTGCCGTGCCGGGTGGATTGTGTTTCTCACTCCG 
MAQCFSPCRVECLSHS           101       ATGGCATAGTGTTTTTCTCCGTGCCGTGTTGAGTGTCTTTCTCACTCCG 
 
 Group8 
MANCFQTCRVSCYSHS           350       ATGGCAAATTGTTTTCAGACGTGCCGTGTGTCTTGTTATTCTCACTCCG 
MAKCFQACRASCYSHS           137       ATGGCAAAGTGTTTTTAGGCTTGCCGTGCTTCGTGTTATTCTCACTCCG 
MASCFDRCRVGCYSHS           241       ATGGCATCTTGTTTTGATCGGTGCCGTGTTGGTTGTTATTCTCACTCCG 
MAECFDRCRVSCYSHS           95        ATGGCAGAGTGTTTTGATAGGTGCAGGGTGAGTTGTTATTCTCACTCCG 
MATCFRSCKVACYSHS           219       ATGGCAACTTGTTTTCGTAGTTGCAAGGTTGCTTGTTATTCTCACTCCG 
MADCFSSCKVACYSHS           195       ATGGCAGATTGTTTTAGTTCTTGCAAGGTGGCGTGTTATTCTCACTCCG 
MAVCFDSCRAACYSHS           248       ATGGCAGTTTGTTTTGATTCGTGCAGGGCTGCGTGTTATTCTCACTCCG 
 
 Group9 
MALCFVACRVHCLSHS           175       ATGGCACTGTGTTTTGTTGCTTGCCGGGTGCATTGTCTGTCTCACTCCG 
MALCFVGCRVMCISHS           142       ATGGCATTGTGTTTTGTGGGTTGCCGTGTGATGTGTATTTCTCACTCCG 
MALCYTACRVLCASHS           153       ATGGCATTGTGTTATACGGCGTGCCGTGTTTTGTGTGCGTCTCACTCCG 
 
 Group10 
MAFCWSPCRVSCGSHS           232       ATGGCATTTTGTTGGTCTCCTTGCCGGGTGTCTTGTGGTTCTCACTCCG 
MAFCWSQCRVSCMSHS           198       ATGGCATTTTGTTGGTCGTAGTGCCGGGTTTCGTGTATGTCTCACTCCG 
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MATCWTSCRVSCGSHS           97       ATGGCAACGTGTTGGACTAGTTGCAGGGTTTCTTGTGGGTCTCACTCCG 
 
 Group11 
MAKCYRQCMQNCRSHS           285       ATGGCAAAGTGTTATCGGCAGTGCATGCAGAATTGTCGGTCTCACTCCG 
MAECYRSCHAMCRSHS           99       ATGGCAGAGTGTTATCGGAGTTGCCATGCTATGTGTAGGTCTCACTCCG 
MAGCYQQCPMYCRSHS           130       ATGGCAGGGTGTTATTAGCAGTGCCCGATGTATTGTAGGTCTCACTCCG 
MANCFVNCRVACHSHS           123       ATGGCAAATTGTTTTGTTAATTGCAGGGTTGCGTGTCATTCTCACTCCG 
MADCFVRCRVACASHS           105       ATGGCAGATTGTTTTGTGCGTTGCCGGGTTGCGTGTGCGTCTCACTCCG 
MANCFLMCRAACISHS           134       ATGGCAAATTGTTTTCTGATGTGCCGGGCTGCTTGTATTTCTCACTCCG 
MASCFVRCRTICYSHS           164       ATGGCAAGTTGTTTTGTTAGGTGCAGGACGATTTGTTATTCTCACTCCG 
MASCFVQCRTQCYSHS           108       ATGGCATCTTGTTTTGTTCAGTGCCGGACGTAGTGTTATTCTCACTCCG 
MARCFIYCRTLCMSHS           415       ATGGCAAGGTGTTTTATTTATTGCCGGACGTTGTGTATGTCTCACTCCG 
MAFCYVRCRVNCMSHS           206       ATGGCATTTTGTTATGTTCGTTGCCGTGTTAATTGTATGTCTCACTCCG 
MAGCYTRCRVDCFSHS           249       ATGGCAGGTTGTTATACTCGGTGCCGGGTTGATTGTTTTTCTCACTCCG 
MANCFMPCRVHCRSHS           113       ATGGCAAATTGTTTTATGCCTTGCAGGGTGCATTGTAGGTCTCACTCCG 
MARCFGHCRVACESHS           123       ATGGCAAGGTGTTTTGGGCATTGCCGGGTGGCTTGTGAGTCTCACTCCG 
MARCFPLCRANCYSHS           136       ATGGCACGGTGTTTTCCTTTGTGCCGTGCTAATTGTTATTCTCACTCCG 
MAHCLRLCRVACYSHS           227       ATGGCACATTGTTTGCGTCTGTGCAGGGTGGCGTGTTATTCTCACTCCG 
MAVCFPLCRVPCISHS           278       ATGGCAGTGTGTTTTCCGTTGTGCAGGGTGCCGTGTATTTCTCACTCCG 
MAVCYELCRVMCMSHS           107       ATGGCAGTTTGTTATGAGTTGTGCAGGGTTATGTGTATGTCTCACTCCG 
MANCWYVCRALCVSHS           221       ATGGCAAATTGTTGGTATGTGTGCCGGGCGTTGTGTGTGTCTCACTCCG 
MAVCWVSCRALCVSHS           192       ATGGCAGTGTGTTGGGTTTCGTGCCGGGCGCTGTGTGTGTCTCACTCCG 
MAQCWIACRVVCLSHS           292       ATGGCACAGTGTTGGATTGCGTGCCGGGTTGTTTGTCTTTCTCACTCCG 
MASCWFLCRGACYSHS           147       ATGGCAAGTTGTTGGTTTCTGTGCCGTGGGGCGTGTTATTCTCACTCCG 
MAFCWFTCRGMCYSHS           97        ATGGCATTTTGTTGGTTTACTTGCCGGGGTATGTGTTATTCTCACTCCG 
MAACWDRCRVACQSHS           211       ATGGCAGCTTGTTGGGATCGGTGCCGTGTTGCGTGTCAGTCTCACTCCG 
MAVCWRPCRVACWSHS           95        ATGGCAGTTTGTTGGCGGCCTTGCAGGGTGGCTTGTTGGTCTCACTCCG 
MAMCHTGCGVMCLSHS           169       ATGGCAATGTGTCATACGGGTTGCGGTGTTATGTGTCTTTCTCACTCCG 
MAWCHTSCQVACSSHS           290       ATGGCATGGTGTCATACGAGTTGCCAGGTGGCTTGTTCTTCTCACTCCG 
MAGCYSFCCILCISHS           94        ATGGCAGGTTGTTATTCTTTTTGCTGTATTCTTTGTATTTCTCACTCCG 
MAVCFTGCCLLCPSHS           212       ATGGCAGTTTGTTTTACTGGGTGCTGTCTTTTGTGTCCGTCTCACTCCG 
 
 Group12 
MALCWERRCVMQSCTSHS          92        ATGGCACTGTGTTGGGAGCGTAGGTGCGTGATGTAGTCTTGTACGTCTCACTCCG 
MASCYEKRCVIRTCRSHS          129       ATGGCAAGTTGTTATGAGAAGCGGTGCGTTATTCGTACGTGTCGTTCTCACTCCG 
MAMCEQRACTFRECWSHS          417       ATGGCAATGTGTGAGTAGAGGGCGTGCACTTTTCGTGAGTGTTGGTCTCACTCCG 
MATCERRACVMRECASHS          165       ATGGCAACTTGTGAGAGGCGTGCGTGCGTTATGCGTGAGTGTGCGTCTCACTCCG 
MATCEKRCCPRCSSHS            114       ATGGCAACGTGTGAGAAGCGGTGCTGTCCGCGTTGTTCGTCTCACTCCG 
MAICTKRCFNSCTSHS            151       ATGGCAATTTGTACTAAGCGGTGCTTTAATTCGTGTACGTCTCACTCCG 
 
 Group13 
MAKCKTRSCTSLICSSHS           113       ATGGCAAAGTGTAAGACTCGTTCGTGCACTTCTTTGATTTGTTCGTCTCACTCCG 
MARCVTGRCSMMVCASHS           139       ATGGCAAGGTGTGTGACTGGGCGGTGCTCTATGATGGTTTGTGCTTCTCACTCCG 
MARCASGLCIGFICLSHS           127       ATGGCACGTTGTGCGAGTGGTCTGTGCATTGGGTTTATTTGTCTGTCTCACTCCG 
 
 Group14 
MAQCSMLCAGDCASHS           92        ATGGCACAGTGTTCGATGTTGTGCGCGGGTGATTGTGCTTCTCACTCCG 
MASCTLFCQASCVSHS           200       ATGGCAAGTTGTACGTTGTTTTGCCAGGCGAGTTGTGTGTCTCACTCCG 
MASCGIICEGYCFSHS           146       ATGGCATCTTGTGGTATTATTTGCGAGGGTTATTGTTTTTCTCACTCCG 
MAACLLVCSGCCGSHS           104       ATGGCAGCTTGTCTGCTTGTGTGCTCGGGTTGTTGTGGTTCTCACTCCG 
MARCNLRCSDGCLSHS           114       ATGGCACGTTGTAATTTGCGGTGCTCGGATGGGTGTCTTTCTCACTCCG 
 
 Group15 
MAGCGRLCSEMCGSHS           123       ATGGCAGGGTGTGGGCGGTTGTGCTCGGAGATGTGTGGTTCTCACTCCG 
MAGCGRACALGCLSHS           183       ATGGCAGGTTGTGGGAGGGCGTGCGCTCTGGGTTGTTTGTCTCACTCCG 
MAMCGRNACSPLSCESHS         114       ATGGCAATGTGTGGTCGGAATGCTTGCTCGCCGCTGTCTTGTGAGTCTCACTCCG 
 
 Group MIXED 
MAICVSRSCLELWCLSHS         129       ATGGCAATTTGTGTGAGTCGTTCGTGCTTGGAGCTGTGGTGTTTGTCTCACTCCG 
MAVCSCRCAAWCLSHS           283       ATGGCAGTTTGTTCGTGTAGGTGCGCTGCGTGGTGTCTTTCTCACTCCG 
MAWCATDLCDACVCQSHS         309       ATGGCATGGTGTGCGACGGATCTGTGCGATGCTTGTGTGTGTTAGTCTCACTCCG 
MAACGEIYCRVSHS             214       ATGGCAGCTTGTGGGGAGATTTATTGCCGTGTTTCTCACTCCG 
MAYCLHCRVSHS               217       ATGGCATATTGTTTACATTGCCGTGTTTCTCACTCCG 
MALCLGQRCESVVCLSHS         198       ATGGCACTTTGTTTGGGTCAGCGTTGCGAGTCTGTGGTGTGTCTTTCTCACTCCG 
MARCLGHRCGAWICSSHS         287       ATGGCACGTTGTTTGGGTCATCGGTGCGGGGCGTGGATTTGTTCGTCTCACTCCG 
MAACGVSCATRCGSHS           146       ATGGCAGCTTGTGGGGTTAGTTGCGCGACTAGGTGTGGTTCTCACTCCG 
MAECHVRCGRHCGSHS           225       ATGGCAGAGTGTCATGTGCGGTGCGGTCGGCATTGTGGTTCTCACTCCG 
MALCSSQMCSTRPCRSHS         110       ATGGCACTTTGTTCGAGTTAGATGTGCTCTACTCGTCCGTGTAGGTCTCACTCCG 
MAMCNARICRLSPCSSHS         114       ATGGCAATGTGTAATGCGCGGATTTGCCGGTTGTCTCCGTGTAGTTCTCACTCCG 
MAGCEGAWCALARCWSHS         95        ATGGCAGGTTGTGAGGGTGCGTGGTGCGCGCTTGCTCGGTGTTGGTCTCACTCCG 
MAACWIGWCSLARCISHS         104       ATGGCAGCTTGTTGGATTGGTTGGTGCTCTCTGGCTAGGTGTATTTCTCACTCCG 
MATCFMGCSNSCLSHS           125       ATGGCAACTTGTTTTATGGGGTGCTCTAATTCGTGTCTTTCTCACTCCG 
MALCVFSCARSCLSHS           170       ATGGCACTGTGTGTTTTTTCTTGCGCTCGGTCTTGTTTGTCTCACTCCG 
MAKCEIPCAVSCLSHS           114       ATGGCAAAGTGTGAGATTCCTTGCGCGGTTTCGTGTTTGTCTCACTCCG 
MAQCENPCPTSCCSHS           159       ATGGCATAGTGTGAGAATCCGTGCCCTACGAGTTGTTGTTCTCACTCCG 
MAYTSHS                    128       ATGGCATATACGTCTCACTCCG 
MAFCSVWVREAYLCASHS         99        ATGGCATTTTGTTCGGTTTGGGTGCGTGAGGCGTATTTGTGTGCTTCTCACTCCG 
MAGCLCFRCDGHVCDSHS         149       ATGGCAGGGTGTTTGTGTTTTAGGTGCGATGGTCATGTGTGTGATTCTCACTCCG 
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MAVCYRVWCLDWLCRSHS           125       ATGGCAGTTTGTTATCGGGTTTGGTGCTTGGATTGGCTTTGTCGTTCTCACTCCG 
MAYCVWANCFGWMCLSHS           149       ATGGCATATTGTGTTTGGGCGAATTGCTTTGGTTGGATGTGTTTGTCTCACTCCG 
MALCLWRCIWACPSHS             92        ATGGCACTTTGTCTGTGGCGGTGCATTTGGGCGTGTCCTTCTCACTCCG 
MALCAIAQCGQHYCGSHS           117       ATGGCACTTTGTGCGATTGCGCAGTGCGGGTAGCATTATTGTGGTTCTCACTCCG 
MAWCVSSCFQGCISHS             133       ATGGCATGGTGTGTTTCGAGTTGCTTTTAGGGTTGTATTTCTCACTCCG 
MASCIQSCGYHCVSHS             141       ATGGCATCGTGTATTTAGTCGTGCGGTTATCATTGTGTGTCTCACTCCG 
MAYCLDKCGSRCESHS             100       ATGGCATATTGTCTTGATAAGTGCGGGTCGAGGTGTGAGTCTCACTCCG 
MAPCRFRCGPVCWSHS             185       ATGGCACCTTGTCGTTTTCGGTGCGGTCCGGTGTGTTGGTCTCACTCCG 
MARCVVCCDMTCWSHS             199       ATGGCAAGGTGTGTGGTTTGTTGCGATATGACGTGTTGGTCTCACTCCG 
MALCKVCCRPLCMSHS             93        ATGGCACTTTGTAAGGTGTGTTGCCGGCCGTTGTGTATGTCTCACTCCG 
MAGCNDLCHSGCCSHS             120       ATGGCAGGTTGTAATGATTTGTGCCATTCGGGTTGTTGTTCTCACTCCG 
MASCVDYCVGTCCSHS             105       ATGGCATCTTGTGTGGATTATTGCGTTGGTACGTGTTGTTCTCACTCCG 
MACCKLLCSQVCRSHS             96        ATGGCATGTTGTAAGCTTCTTTGCTCTCAGGTGTGTAGGTCTCACTCCG 
MAGCQTKCNSPCKSHS             129       ATGGCAGGGTGTTAGACTAAGTGCAATAGTCCTTGTAAGTCTCACTCCG 
MAVCSLHGCWRIGCMSHS           282       ATGGCAGTTTGTTCTCTGCATGGTTGCTGGCGTATTGGTTGTATGTCTCACTCCG 
MAPCCSQDCRVDYCASHS           127       ATGGCACCTTGTTGTTCGTAGGATTGCAGGGTGGATTATTGTGCGTCTCACTCCG 
MAGCGFHDCQTRRCPSHS           103       ATGGCAGGGTGTGGTTTTCATGATTGCTAGACGCGTCGGTGTCCGTCTCACTCCG 
MATCSWGKCQVTDCGSHS           295       ATGGCAACTTGTAGTTGGGGTAAGTGCTAGGTGACGGATTGTGGGTCTCACTCCG 
MARCGCQGCSVADCSSHS           149       ATGGCAAGGTGTGGGTGTCAGGGGTGCAGTGTTGCTGATTGTAGTTCTCACTCCG 
MAACRSWSCTCGLCYSHS           255       ATGGCAGCTTGTCGGTCGTGGTCGTGCACTTGTGGGTTGTGTTATTCTCACTCCG 
MAKCRQPVCLPSFCASHS           185       ATGGCAAAGTGTAGGTAGCCTGTTTGCCTGCCGAGTTTTTGTGCTTCTCACTCCG 
MALCVSGVCHHEACPSHS           132       ATGGCACTTTGTGTTAGTGGTGTGTGCCATCATGAGGCGTGTCCTTCTCACTCCG 
MADCWDSVCYRVLCWSHS           704       ATGGCAGATTGTTGGGATAGTGTGTGCTATAGGGTGTTGTGTTGGTCTCACTCCG 
MALCIGSVCQEADCWSHS           92        ATGGCATTGTGTATTGGTTCGGTGTGCTAGGAGGCTGATTGTTGGTCTCACTCCG 
MATCHQLLCMAMSCVSHS           117       ATGGCAACTTGTCATTAGCTGTTGTGCATGGCGATGTCTTGTGTTTCTCACTCCG 
MAQCGGILCGALPCFSHS           127       ATGGCATAGTGTGGTGGTATTCTTTGCGGGGCGCTTCCTTGTTTTTCTCACTCCG 
MALCLSVMCTALECFSHS           114       ATGGCATTGTGTCTTAGTGTGATGTGCACTGCTTTGGAGTGTTTTTCTCACTCCG 
MATCMSRLCSGGMCKSHS           201       ATGGCAACGTGTATGTCTCGTTTGTGCTCTGGTGGTATGTGTAAGTCTCACTCCG 
MAMCDLSLCIGSLCASHS           244       ATGGCAATGTGTGATTTGAGTCTGTGCATTGGTTCTCTTTGTGCGTCTCACTCCG 
MAVCTLDLCTGDGCGSHS           99        ATGGCAGTGTGTACGTTGGATTTGTGCACTGGTGATGGGTGTGGTTCTCACTCCG 
MARCSDCMCASCRCQSHS           91        ATGGCACGTTGTTCGGATTGTATGTGCGCTTCGTGTCGTTGTTAGTCTCACTCCG 
MAECDGGPCVQQVCKSHS           146       ATGGCAGAGTGTGATGGTGGGCCGTGCGTTCAGTAGGTTTGTAAGTCTCACTCCG 
 
SA – Libraries 3×3, 4×4 
 Group1 
MAQCQTRCTAVCASHS           702       ATGGCACAGTGTTAGACGAGGTGCACGGCTGTGTGTGCGTCTCACTCCG 
MATCQTLCSRTCISHS           102       ATGGCAACTTGTTAGACTCTGTGCTCGCGTACTTGTATTTCTCACTCCG 
MAGCQQRCGLVCCSHS           243       ATGGCAGGGTGTCAGCAGAGGTGCGGGCTGGTTTGTTGTTCTCACTCCG 
MASCHTECQYICWSHS           198       ATGGCAAGTTGTCATACTGAGTGCTAGTATATTTGTTGGTCTCACTCCG 
MASCQRACAWHCVSHS           471       ATGGCATCTTGTTAGAGGGCGTGCGCTTGGCATTGTGTGTCTCACTCCG 
MATCQVTCVDHCLSHS           167       ATGGCAACTTGTTAGGTTACGTGCGTTGATCATTGTCTGTCTCACTCCG 
MASCRDVCCSHCLSHS           795       ATGGCATCGTGTAGGGATGTGTGCTGTAGTCATTGTCTGTCTCACTCCG 
MASCRPLCLSRCLSHS           184       ATGGCAAGTTGTAGGCCGTTGTGCCTTAGTCGTTGTCTGTCTCACTCCG 
MARCSMTCQQCCESHS           273       ATGGCACGGTGTTCTATGACGTGCCAGCAGTGTTGTGAGTCTCACTCCG 
MARCSFECSQSCLSHS           202       ATGGCACGTTGTTCTTTTGAGTGCAGTTAGAGTTGTTTGTCTCACTCCG 
MARCAVRCGVPCLSHS           140       ATGGCAAGGTGTGCTGTGCGTTGCGGGGTTCCGTGTTTGTCTCACTCCG 
MAQCEIFCRVKCISHS           199       ATGGCATAGTGTGAGATTTTTTGCAGGGTGAAGTGTATTTCTCACTCCG 
MAQCRQECRPQCMSHS           129       ATGGCACAGTGTCGGTAGGAGTGCCGGCCGCAGTGTATGTCTCACTCCG 
MARCSQVCRATCASHS           358       ATGGCACGTTGTTCTTAGGTGTGCAGGGCTACGTGTGCGTCTCACTCCG 
MARCGEFCRVLCSSHS           111       ATGGCAAGGTGTGGGGAGTTTTGCCGTGTGCTTTGTTCTTCTCACTCCG 
MAQCNRVCDVRCGSHS           123       ATGGCATAGTGTAATCGTGTGTGCGATGTTAGGTGTGGGTCTCACTCCG 
MAQCGMACGLRCGSHS           121       ATGGCACAGTGTGGTATGGCGTGCGGGTTGAGGTGTGGTTCTCACTCCG 
MAECVTDCQMRCGSHS           182       ATGGCAGAGTGTGTGACTGATTGCTAGATGCGGTGTGGTTCTCACTCCG 
MARCVPSCSRHCSSHS           240       ATGGCACGGTGTGTGCCTAGTTGCAGTCGGCATTGTTCTTCTCACTCCG 
MAQCAPMCSVRCSSHS           152       ATGGCACAGTGTGCTCCGATGTGCTCTGTTCGGTGTAGTTCTCACTCCG 
MAECMSPCLRGCASHS           185       ATGGCAGAGTGTATGTCTCCTTGCTTGCGTGGTTGTGCTTCTCACTCCG 
MAACVSYCVDGCWSHS           101       ATGGCAGCGTGTGTTAGTTATTGCGTGGATGGGTGTTGGTCTCACTCCG 
MAYCSGACSSGCFSHS           143       ATGGCATATTGTTCTGGGGCGTGCAGTTCTGGTTGTTTTTCTCACTCCG 
MARCASSCTTGCLSHS           114       ATGGCACGGTGTGCGTCGAGTTGCACTACGGGGTGTCTGTCTCACTCCG 
MAHCKMLCTGGCYSHS           111       ATGGCACATTGTAAGATGTTGTGCACGGGTGGTTGTTATTCTCACTCCG 
MAMCLMVCSVRCRSHS           216       ATGGCAATGTGTCTGATGGTTTGCAGTGTGAGGTGTCGGTCTCACTCCG 
MAGCLQTCQASCRSHS           166       ATGGCAGGGTGTTTGTAGACTTGCCAGGCTTCTTGTCGTTCTCACTCCG 
MAGCCLDCTLACRSHS           239       ATGGCAGGTTGTTGTCTGGATTGCACTTTGGCTTGTCGGTCTCACTCCG 
MAGCVADCGLGCESHS           104       ATGGCAGGGTGTGTTGCGGATTGCGGGCTGGGGTGTGAGTCTCACTCCG 
MAPCMRNCYQACRSHS           213       ATGGCACCTTGTATGAGGAATTGCTATTAGGCGTGTAGGTCTCACTCCG 
MAVCGGVCGHACRSHS           195       ATGGCAGTGTGTGGGGGGGTGTGCGGTCATGCGTGTCGGTCTCACTCCG 
MARCEIGCGHACRSHS           110       ATGGCACGGTGTGAGATTGGGTGCGGTCATGCTTGTCGTTCTCACTCCG 
MASCHQSCGTRCMSHS           270       ATGGCATCTTGTCATCAGTCGTGCGGGACGCGGTGTATGTCTCACTCCG 
MASCGESCGRSCKSHS           142       ATGGCATCGTGTGGGGAGTCGTGCGGTCGTTCTTGTAAGTCTCACTCCG 
MAGCTQSCPCRCDSHS           447       ATGGCAGGGTGTACGTAGAGTTGCCCGTGTAGGTGTGATTCTCACTCCG 
MAGCDSLCPERCQSHS           210       ATGGCAGGTTGTGATTCGTTGTGCCCGGAGCGGTGTTAGTCTCACTCCG 
MAGCNLLCAYSCPSHS           110       ATGGCAGGTTGTAATCTTCTGTGCGCTTATTCTTGTCCTTCTCACTCCG 
 
 Group2 
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MASCVVSGCHPQVCPSHS           124       ATGGCAAGTTGTGTGGTTTCGGGGTGCCATCCGTAGGTGTGTCCGTCTCACTCCG 
MAQCWKTGCHPQQCPSHS           116       ATGGCACAGTGTTGGAAGACTGGTTGCCATCCGTAGCAGTGTCCGTCTCACTCCG 
MAPCQFQLCHPQVCPSHS           354       ATGGCACCGTGTCAGTTTTAGTTGTGCCATCCTCAGGTGTGTCCGTCTCACTCCG 
MASCDPAHCHPQVCYSHS           555       ATGGCATCTTGTGATCCGGCGCATTGCCATCCTTAGGTGTGTTATTCTCACTCCG 
MAWCSLSACHPQGCFSHS           180       ATGGCATGGTGTAGTCTGTCGGCGTGCCATCCTTAGGGGTGTTTTTCTCACTCCG 
MAVCVMNGCHPQGCVSHS           161       ATGGCAGTTTGTGTGATGAATGGGTGCCATCCTTAGGGGTGTGTGTCTCACTCCG 
MAYCHAYACHPQNCRSHS           483       ATGGCATATTGTCATGCTTATGCGTGCCATCCGTAGAATTGTCGTTCTCACTCCG 
MAKCLSFACHPQNCTSHS           260       ATGGCAAAGTGTCTGTCTTTTGCTTGCCATCCTCAGAATTGTACTTCTCACTCCG 
MAFCGWLGCHPQGCSSHS           490       ATGGCATTTTGTGGGTGGCTGGGGTGCCATCCGTAGGGTTGTTCGTCTCACTCCG 
MAVCGELSCHPQFCGSHS           112       ATGGCAGTTTGTGGTGAGTTGAGTTGCCATCCTTAGTTTTGTGGGTCTCACTCCG 
MATCSCSPCLSSRCPSHS           233       ATGGCAACGTGTTCTTGTTCTCCGTGCCTGTCGTCTCGTTGTCCTTCTCACTCCG 
MAICGTLPCASRRCPSHS           186       ATGGCAATTTGTGGTACGCTGCCGTGCGCGTCTCGTCGTTGTCCGTCTCACTCCG 
MASCQLLSCGYSECSSHS           200       ATGGCATCTTGTTAGCTGCTTTCTTGCGGGTATTCGGAGTGTTCGTCTCACTCCG 
MASCQVLGCWNSTCSSHS           104       ATGGCATCGTGTTAGGTTTTGGGGTGCTGGAATTCGACTTGTAGTTCTCACTCCG 
 
 Group3 
MAVCGVHLCSSGPCKSHS           373       ATGGCAGTTTGTGGGGTGCATTTGTGCTCTAGTGGTCCTTGTAAGTCTCACTCCG 
MAICSLVVCRSGLCSSHS           140       ATGGCAATTTGTTCGCTTGTGGTGTGCCGGTCTGGGTTGTGTAGTTCTCACTCCG 
MAYCRAGMCGQGPCSSHS           358       ATGGCATATTGTCGGGCGGGTATGTGCGGGTAGGGTCCGTGTTCGTCTCACTCCG 
MACCQGGICGKGTCLSHS           206       ATGGCATGTTGTTAGGGTGGTATTTGCGGGAAGGGGACGTGTTTGTCTCACTCCG 
MAQCVASICLYSNCSSHS           144       ATGGCACAGTGTGTTGCGTCTATTTGCTTGTATTCGAATTGTTCTTCTCACTCCG 
MAYCAASICLQDICGSHS           138       ATGGCATATTGTGCTGCTTCTATTTGCTTGTAGGATATTTGTGGGTCTCACTCCG 
MAECISSVCTRGVCLSHS           1791       ATGGCAGAGTGTATTTCTAGTGTGTGCACTAGGGGTGTTTGTTTGTCTCACTCCG 
MASCFKDLCTRGLCNSHS           265       ATGGCATCGTGTTTTAAGGATCTGTGCACTAGGGGGCTGTGTAATTCTCACTCCG 
MAVCMRVCVGNCGSHS             221       ATGGCAGTTTGTATGAGGGTTTGCGTGGGGAATTGTGGGTCTCACTCCG 
MALCFRVCSGSCVSHS             148       ATGGCATTGTGTTTTCGTGTGTGCTCGGGTTCGTGTGTGTCTCACTCCG 
MACCELVCGGSCDSHS             114       ATGGCATGTTGTGAGTTGGTTTGCGGGGGTTCTTGTGATTCTCACTCCG 
 
 Group4 
MARCRFTGCDIQVCLSHS           235       ATGGCACGGTGTAGGTTTACTGGTTGCGATATTTAGGTTTGTTTGTCTCACTCCG 
MANCARLGCQVRLCLSHS           217       ATGGCAAATTGTGCTCGGTTGGGGTGCTAGGTGCGGTTGTGTTTGTCTCACTCCG 
MASCACTGCFVPVCMSHS           185       ATGGCATCGTGTGCGTGTACTGGTTGCTTTGTGCCGGTGTGTATGTCTCACTCCG 
MAGCRSSLCPWGMCFSHS           149       ATGGCAGGGTGTAGGTCTTCTTTGTGCCCTTGGGGTATGTGTTTTTCTCACTCCG 
 
 Group5 
MAVCVMRCGSTCGSHS           318       ATGGCAGTTTGTGTTATGCGGTGCGGGTCTACGTGTGGGTCTCACTCCG 
MAICYVNCGRDCASHS           247       ATGGCAATTTGTTATGTGAATTGCGGTCGTGATTGTGCTTCTCACTCCG 
MAICRLSCCHECGSHS           163       ATGGCAATTTGTCGTCTGTCTTGCTGTCATGAGTGTGGGTCTCACTCCG 
MAVCLPKCESFCASHS           272       ATGGCAGTGTGTCTGCCTAAGTGCGAGAGTTTTTGTGCGTCTCACTCCG 
MAICFEKCPNWCGSHS           193       ATGGCAATTTGTTTTGAGAAGTGCCCGAATTGGTGTGGTTCTCACTCCG 
MALCRIPCESTCISHS           220       ATGGCACTTTGTAGGATTCCGTGCGAGAGTACTTGTATTTCTCACTCCG 
MAGCRPPCDDTCGSHS           176       ATGGCAGGGTGTCGTCCTCCGTGCGATGATACGTGTGGTTCTCACTCCG 
MAVCMGPCPGCCVSHS           562       ATGGCAGTGTGTATGGGTCCGTGCCCTGGGTGTTGTGTGTCTCACTCCG 
MAQCTGKCGGCCSSHS           154       ATGGCATAGTGTACTGGGAAGTGCGGTGGGTGTTGTTCGTCTCACTCCG 
MAHCSGVCPRCCPSHS           156       ATGGCACATTGTTCGGGGGTGTGCCCTAGGTGTTGTCCTTCTCACTCCG 
MAVCLGDCPVDCASHS           255       ATGGCAGTGTGTCTTGGTGATTGCCCTGTGGATTGTGCGTCTCACTCCG 
MATCLGSCGMSCTSHS           100       ATGGCAACTTGTCTTGGTTCTTGCGGGATGTCTTGTACTTCTCACTCCG 
 
 Group6 
MAHCILGCVPMCGSHS           607       ATGGCACATTGTATTTTGGGTTGCGTTCCGATGTGTGGGTCTCACTCCG 
MAKCRLGCAPECGSHS           212       ATGGCAAAGTGTCGGCTGGGTTGCGCGCCTGAGTGTGGTTCTCACTCCG 
MASCYGGCAGLCGSHS           355       ATGGCATCTTGTTATGGGGGGTGCGCTGGGCTTTGTGGGTCTCACTCCG 
MAYCTLGCDTDCSSHS           718       ATGGCATATTGTACTTTGGGTTGCGATACGGATTGTTCTTCTCACTCCG 
MAYCAYSCNSACTSHS           144       ATGGCATATTGTGCTTATTCGTGCAATTCGGCGTGTACGTCTCACTCCG 
MADCAYGCDGECDSHS           332       ATGGCAGATTGTGCTTATGGGTGCGATGGGGAGTGTGATTCTCACTCCG 
MATCRQGCVGACSSHS           718       ATGGCAACGTGTCGGTAGGGTTGCGTGGGTGCTTGTAGTTCTCACTCCG 
MAGCRQGCSASCTSHS           161       ATGGCAGGTTGTAGGTAGGGGTGCAGTGCTTCTTGTACGTCTCACTCCG 
MANCRQVGCGFARCSSHS         315       ATGGCAAATTGTCGGCAGGTGGGGTGCGGGTTTGCTCGTTGTAGTTCTCACTCCG 
MANCRHGGCRGDHCTSHS         130       ATGGCAAATTGTAGGCATGGTGGTTGCCGGGGGGATCATTGTACGTCTCACTCCG 
 
 Group7 
MAVCGYDCSQMCSSHS           244       ATGGCAGTGTGTGGGTATGATTGCTCTTAGATGTGTTCTTCTCACTCCG 
MAICGGACWQQCASHS           159       ATGGCAATTTGTGGGGGTGCTTGCTGGTAGCAGTGTGCCTCTCACTCCG 
MAACGALCDPDCGSHS           274       ATGGCAGCTTGTGGTGCGTTGTGCGATCCGGATTGTGGGTCTCACTCCG 
MAICGRLCTPLCRSHS           104       ATGGCAATTTGTGGTAGGCTTTGCACTCCTTTGTGTCGGTCTCACTCCG 
 
 Group8 
MASCVTVCLWTCGSHS           257       ATGGCATCTTGTGTTACTGTGTGCCTTTGGACTTGTGGGTCTCACTCCG 
MACCNERCVWKCGSHS           241       ATGGCATGTTGTAATGAGCGGTGCGTGTGGAAGTGTGGGTCTCACTCCG 
MAWCPGQCAWKCGSHS           104       ATGGCATGGTGTCCGGGGCAGTGCGCTTGGAAGTGTGGGTCTCACTCCG 
 
 Group9 
MAGCGRYCDGWCNSHS           325       ATGGCAGGGTGTGGGCGTTATTGCGATGGTTGGTGTAATTCTCACTCCG 
MAVCGEHCDLWCYSHS           121       ATGGCAGTGTGTGGTGAGCATTGCGATTTGTGGTGTTATTCTCACTCCG 
MALCAKSCSKWCRSHS           142       ATGGCACTGTGTGCTAAGAGTTGCTCGAAGTGGTGTAGGTCTCACTCCG 
 
 Group10 
MAVCRSRCVMYCQSHS           428       ATGGCAGTGTGTCGGTCTCGGTGCGTGATGTATTGTTAGTCTCACTCCG 
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MAVCATQCMTMCQSHS           266       ATGGCAGTTTGTGCTACTTAGTGCATGACGATGTGTTAGTCTCACTCCG 
MAVCVQSCFIKCQSHS           212       ATGGCAGTTTGTGTGTAGAGTTGCTTTATTAAGTGTCAGTCTCACTCCG 
 
 Group11 
MAECMDCCSEECLSHS           106       ATGGCAGAGTGTATGGATTGTTGCTCTGAGGAGTGTTTGTCTCACTCCG 
MASCFDCCGWLCNSHS           305       ATGGCATCGTGTTTTGATTGTTGCGGGTGGCTGTGTAATTCTCACTCCG 
MASCELCCDVHCYSHS           178       ATGGCATCTTGTGAGTTGTGTTGCGATGTTCATTGTTATTCTCACTCCG 
MAFCQVCCHPLCYSHS           407       ATGGCATTTTGTTAGGTTTGTTGCCATCCGTTGTGTTATTCTCACTCCG 
MALCAVKCHWYCRSHS           202       ATGGCATTGTGTGCGGTTAAGTGCCATTGGTATTGTAGGTCTCACTCCG 
MAICAMVCGWFCASHS           111       ATGGCAATTTGTGCTATGGTGTGCGGTTGGTTTTGTGCTTCTCACTCCG 
MAKCAVWCQLYCPSHS           460       ATGGCAAAGTGTGCGGTGTGGTGCTAGTTGTATTGTCCTTCTCACTCCG 
MAVCSWECRVFCASHS           204       ATGGCAGTGTGTAGTTGGGAGTGCAGGGTGTTTTGTGCGTCTCACTCCG 
MAGCSAWECRVLCLSHS          167       ATGGCAGGGTGTAGTGCGTGGGAGTGCAGGGTTCTGTGTTTGTCTCACTCCG 
MAGCSWECMAWCWSHS           382       ATGGCAGGTTGTTCGTGGGAGTGCATGGCTTGGTGTTGGTCTCACTCCG 
MAGCKWVCDSLCVSHS           112       ATGGCAGGGTGTAAGTGGGTGTGCGATTCTTTGTGTGTTTCTCACTCCG 
MAGCALVCTRFCLSHS           132       ATGGCAGGTTGTGCGCTGGTGTGCACGCGTTTTTGTCTGTCTCACTCCG 
MASCPGMCRGSCTSHS           102       ATGGCAAGTTGTCCGGGGATGTGCCGTGGGAGTTGTACTTCTCACTCCG 
MASCSGFCLMPCNSHS           354       ATGGCAAGTTGTTCGGGGTTTTGCCTTATGCCGTGTAATTCTCACTCCG 
MAACSKRCLHPCLSHS           325       ATGGCAGCGTGTTCTAAGCGGTGCCTTCATCCTTGTCTTTCTCACTCCG 
MAACSKLRCVMHVCESHS         217       ATGGCAGCGTGTAGTAAGTTGAGGTGCGTTATGCATGTTTGTGAGTCTCACTCCG 
 
 Group12 
MAGCQELWCQVAHCWSHS           390       ATGGCAGGGTGTTAGGAGCTTTGGTGCCAGGTGGCTCATTGTTGGTCTCACTCCG 
MATCLWAVCLMSVCLSHS           113       ATGGCAACTTGTCTGTGGGCGGTGTGCTTGATGTCGGTTTGTCTTTCTCACTCCG 
MADCQWRCCLSRGCLSHS           201       ATGGCAGATTGTCAGTGGCGTTGTTGCTTGTCGAGGGGTTGTCTGTCTCACTCCG 
MAWCAWFSCATTDCGSHS           161       ATGGCATGGTGTGCGTGGTTTTCGTGCGCGACGACGGATTGTGGGTCTCACTCCG 
MAWCQWWYCQTHECLSHS           125       ATGGCATGGTGTCAGTGGTGGTATTGCTAGACTCATGAGTGTTTGTCTCACTCCG 
 
 Group13 
MARCWGEGCRGLLCHSHS           119       ATGGCAAGGTGTTGGGGTGAGGGTTGCAGGGGTTTGTTGTGTCATTCTCACTCCG 
MADCWDFACSGVVCPSHS           166       ATGGCAGATTGTTGGGATTTTGCTTGCTCTGGTGTTGTGTGTCCTTCTCACTCCG 
MAGCTGFGCSGQICSSHS           326       ATGGCAGGTTGTACGGGGTTTGGGTGCTCGGGTTAGATTTGTTCGTCTCACTCCG 
MAQCTAVGCHGGVCGSHS           568       ATGGCATAGTGTACGGCGGTGGGGTGCCATGGTGGTGTGTGTGGTTCTCACTCCG 
MASCLAYTCRARVCPSHS           164       ATGGCAAGTTGTTTGGCTTATACGTGCAGGGCGCGTGTTTGTCCTTCTCACTCCG 
MAPCLLQWCRLRVCKSHS           170       ATGGCACCTTGTTTGCTGTAGTGGTGCCGTTTGCGTGTGTGTAAGTCTCACTCCG 
 
 Group14 
MARCQTKSCLKWVCSSHS           123       ATGGCACGTTGTTAGACTAAGAGTTGCCTTAAGTGGGTTTGTAGTTCTCACTCCG 
MAGCQTRLCLGWECTSHS           192       ATGGCAGGGTGTTAGACTCGTTTGTGCCTGGGTTGGGAGTGTACTTCTCACTCCG 
MASCHPQVCLLWECGSHS           112       ATGGCATCGTGTCATCCTTAGGTGTGCCTTTTGTGGGAGTGTGGTTCTCACTCCG 
MACCQTRVCLVEFCGSHS           191       ATGGCATGTTGTTAGACTCGGGTGTGCCTTGTGGAGTTTTGTGGGTCTCACTCCG 
MANCSTVTCMELSCTSHS           102       ATGGCAAATTGTAGTACTGTTACGTGCATGGAGCTTTCTTGTACTTCTCACTCCG 
MANCQTMHCLRGDCSSHS           456       ATGGCAAATTGTTAGACTATGCATTGCTTGCGTGGTGATTGTAGTTCTCACTCCG 
MAGCPGKICWSGVCGSHS           302       ATGGCAGGGTGTCCTGGTAAGATTTGCTGGTCGGGTGTTTGTGGGTCTCACTCCG 
MAGCPEAACCLQVCGSHS           754       ATGGCAGGGTGTCCGGAGGCGGCTTGCTGTCTGTAGGTTTGTGGGTCTCACTCCG 
MALCYSALCSGVGCGSHS           100       ATGGCACTTTGTTATTCTGCTCTGTGCTCGGGTGTGGGGTGTGGGTCTCACTCCG 
MALCCHAVCDDGVCGSHS           191       ATGGCACTGTGTTGTCATGCGGTTTGCGATGATGGTGTTTGTGGGTCTCACTCCG 
 
 Group15 
MALCQGVDCVFFICFSHS           265       ATGGCATTGTGTTAGGGTGTTGATTGCGTTTTTTTTATTTGTTTTTCTCACTCCG 
MAQCAGTACMFWTCESHS           490       ATGGCATAGTGTGCTGGGACGGCGTGCATGTTTTGGACTTGTGAGTCTCACTCCG 
MAECVGGMCHMIACCSHS           412       ATGGCAGAGTGTGTGGGGGGTATGTGCCATATGATTGCTTGTTGTTCTCACTCCG 
MAVCEGCFCQMLICCSHS           274       ATGGCAGTGTGTGAGGGTTGTTTTTGCTAGATGTTGATTTGTTGTTCTCACTCCG 
 
 Group16 
MAGCCFPTCSWLVCLSHS           474       ATGGCAGGTTGTTGTTTTCCTACTTGCTCGTGGCTGGTGTGTCTTTCTCACTCCG 
MAQCCLSQCDWLVCLSHS           167       ATGGCATAGTGTTGTCTGAGTCAGTGCGATTGGTTGGTTTGTCTTTCTCACTCCG 
MASCKAGACVQKWCVSHS           223       ATGGCAAGTTGTAAGGCTGGTGCGTGCGTTTAGAAGTGGTGTGTTTCTCACTCCG 
MARCVMGLCEQVLCISHS           100       ATGGCACGTTGTGTTATGGGGTTGTGCGAGTAGGTGTTGTGTATTTCTCACTCCG 
MATCRDSSCEQLICQSHS           454       ATGGCAACGTGTCGTGATAGTAGTTGCGAGCAGCTTATTTGTTAGTCTCACTCCG 
MAWCKAGLCHGNFCLSHS           134       ATGGCATGGTGTAAGGCGGGGTTGTGCCATGGTAATTTTTGTTTGTCTCACTCCG 
MAWCYQGKCVGLLCASHS           220       ATGGCATGGTGTTATTAGGGTAAGTGCGTTGGTCTGCTTTGTGCGTCTCACTCCG 
 
 Group17 
MAVCHPQFCSGVLCYSHS           113       ATGGCAGTGTGTCATCCGTAGTTTTGCTCGGGGGTTTTGTGTTATTCTCACTCCG 
MAPCHPQVCRRELCVSHS           132       ATGGCACCGTGTCATCCTCAGGTGTGCAGGAGGGAGCTTTGTGTTTCTCACTCCG 
MAECHPQNCPSSWCLSHS           101       ATGGCAGAGTGTCATCCTTAGAATTGCCCTAGTTCTTGGTGTTTGTCTCACTCCG 
MAFCHPQNCSGSDCISHS           198       ATGGCATTTTGTCATCCGCAGAATTGCAGTGGTTCTGATTGTATTTCTCACTCCG 
MAGCHPQNCVLASCMSHS           124       ATGGCAGGGTGTCATCCGTAGAATTGCGTTCTTGCGAGTTGTATGTCTCACTCCG 
MASCCPQKCTESMCRSHS           207       ATGGCAAGTTGTTGTCCTTAGAAGTGCACGGAGAGTATGTGTCGGTCTCACTCCG 
 
 Group MIXED 
MATCPVPLCRVMPCRSHS           259       ATGGCAACTTGTCCTGTGCCTTTGTGCCGGGTGATGCCGTGTAGGTCTCACTCCG 
MALCPSTQCRTVPCVSHS           206       ATGGCATTGTGTCCGAGTACGTAGTGCCGGACTGTTCCGTGTGTTTCTCACTCCG 
MARCFSWECWVFGCSSHS           195       ATGGCACGTTGTTTTAGTTGGGAGTGCTGGGTGTTTGGGTGTAGTTCTCACTCCG 
MAVCLSWECWVFGCQSHS           147       ATGGCAGTTTGTTTGAGTTGGGAGTGCTGGGTTTTTGGGTGTTAGTCTCACTCCG 
MAWCVLIDWFCSHS               303       ATGGCATGGTGTGTACTAATTGACTGGTTTTGTTCTCACTCCG 
MADCGHPQFRVYVCPSHS           242       ATGGCAGATTGTGGGCATCCTTAGTTCCGGGTTTATGTTTGTCCGTCTCACTCCG 
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MAACTDNCFEWCFSHS             251       ATGGCAGCGTGTACGGATAATTGCTTTGAGTGGTGTTTTTCTCACTCCG 
MAACTPDNCMEPHCTSHS           255       ATGGCAGCGTGTACGCCTGATAATTGCATGGAGCCGCATTGTACCTCTCACTCCG 
MAVCPRWCMDPCKSHS             132       ATGGCAGTTTGTCCGCGGTGGTGCATGGATCCGTGTAAGTCTCACTCCG 
MAECCQGCIILCDSHS             311       ATGGCAGAGTGTTGTTAGGGGTGCATTATTTTGTGTGATTCTCACTCCG 
MADCGSVCPHMCFSHS             103       ATGGCAGATTGTGGGTCGGTTTGCCCGCATATGTGTTTTTCTCACTCCG 
MAGCGWGWCFTWPCISHS           199       ATGGCAGGTTGTGGGTGGGGTTGGTGCTTTACTTGGCCTTGTATTTCTCACTCCG 
MAGCGAWGCSVYISMSHS           133       ATGGCAGGGTGTGGTGCGTGGGGTTGCAGTGTTTATATTTCTATGTCTCACTCCG 
MAWCWGLWCSYGWCDSHS           218       ATGGCATGGTGTTGGGGGCTTTGGTGCAGTTATGGGTGGTGTGATTCTCACTCCG 
MAACQQIWCNFNSCMSHS           160       ATGGCAGCTTGTCAGTAGATTTGGTGCAATTTTAATTCTTGTATGTCTCACTCCG 
MAVCSPASCWFKCCQSHS           101       ATGGCAGTGTGTTCGCCGGCGTCTTGCTGGTTTAAGTGTTGTTAGTCTCACTCCG 
MAGCHQGVCSPSLCESHS           369       ATGGCAGGGTGTCATTAGGGTGTGTGCAGTCCTTCTTTGTGTGAGTCTCACTCCG 
MAGCMRGVCPVGDCGSHS           161       ATGGCAGGGTGTATGCGGGGGGTGTGCCCTGTGGGTGATTGTGGTTCTCACTCCG 
MARCPCSVCYDMHCGSHS           227       ATGGCACGGTGTCCGTGTAGTGTGTGCTATGATATGCATTGTGGTTCTCACTCCG 
MANCNGRPCALGGCGSHS           104       ATGGCAAATTGTAATGGGCGGCCGTGCGCGTTGGGTGGGTGTGGGTCTCACTCCG 
MAECRQEPCAQWGCYSHS           103       ATGGCAGAGTGTAGGTAGGAGCCGTGCGCTCAGTGGGGTTGTTATTCTCACTCCG 
MAYCRILDCGMSKCRSHS           128       ATGGCATATTGTCGTATTCTGGATTGCGGGATGAGTAAGTGTCGGTCTCACTCCG 
MARCRMEVCPYGRCQSHS           316       ATGGCAAGGTGTCGTATGGAGGTTTGCCCGTATGGTAGGTGTCAGTCTCACTCCG 
MAWCGRQACVVGECKSHS           176       ATGGCATGGTGTGGGCGGTAGGCGTGCGTTGTGGGGGAGTGTAAGTCTCACTCCG 
MAYCHLQACQDGCCLSHS           103       ATGGCATATTGTCATTTGCAGGCGTGCTAGGATGGTTGTTGTTTGTCTCACTCCG 
MASCGSVPCGVMHCVSHS           590       ATGGCATCGTGTGGGTCTGTTCCTTGCGGGGTTATGCATTGTGTGTCTCACTCCG 
MAWCVQMGCGDLHCVSHS           369       ATGGCATGGTGTGTTTAGATGGGGTGCGGTGATTTGCATTGTGTTTCTCACTCCG 
MAVCANRFCSVAACDSHS           196       ATGGCAGTTTGTGCGAATCGGTTTTGCAGTGTTGCGGCTTGTGATTCTCACTCCG 
MAFCDGVFCFRAPCFSHS           127       ATGGCATTTTGTGATGGGGTTTTTTGCTTTAGGGCTCCGTGTTTTTCTCACTCCG 
MALCGENGCPLSVCVSHS           107       ATGGCATTGTGTGGTGAGAATGGGTGCCCGTTGAGTGTGTGTGTGTCTCACTCCG 
MALCLENCCNMFECRSHS           154       ATGGCATTGTGTCTTGAGAATTGTTGCAATATGTTTGAGTGTCGGTCTCACTCCG 
MAHCYRKHCDMTDCPSHS           200       ATGGCACATTGTTATCGGAAGCATTGCGATATGACTGATTGTCCGTCTCACTCCG 
MAKCASLGCVLSSCPSHS           239       ATGGCAAAGTGTGCGTCGCTGGGTTGCGTTTTGTCTAGTTGTCCTTCTCACTCCG 
MAHCAYLRCTLLLCQSHS           798       ATGGCACATTGTGCGTATTTGCGGTGCACGTTGTTGTTGTGTTAGTCTCACTCCG 
MARCLERLCGCRVCFSHS           244       ATGGCACGGTGTCTGGAGCGGCTGTGCGGGTGTCGTGTGTGTTTTTCTCACTCCG 
MACCVGEPCSPVVCPSHS           488       ATGGCATGTTGTGTGGGTGAGCCGTGCTCGCCGGTTGTTTGTCCTTCTCACTCCG 
MAVCFTGTCPWWFCFSHS           294       ATGGCAGTGTGTTTTACGGGTACGTGCCCGTGGTGGTTTTGTTTTTCTCACTCCG 
MASCGSGECQVWFCPSHS           284       ATGGCATCGTGTGGGTCGGGGGAGTGCTAGGTTTGGTTTTGTCCGTCTCACTCCG 
MAECDLSDCWIVNCFSHS           106       ATGGCAGAGTGTGATCTTAGTGATTGCTGGATTGTGAATTGTTTTTCTCACTCCG 
MAECWQLECYWLMCGSHS           647       ATGGCAGAGTGTTGGTAGTTGGAGTGCTATTGGTTGATGTGTGGGTCTCACTCCG 
MAMCWFSSCWLGICLSHS           137       ATGGCAATGTGTTGGTTTAGTAGTTGCTGGTTGGGTATTTGTTTGTCTCACTCCG 
MAKCWRGDCALSVCASHS           1064      ATGGCAAAGTGTTGGCGTGGGGATTGCGCTCTGTCTGTGTGTGCGTCTCACTCCG 
MAHCWRKTCTGDMCLSHS           138       ATGGCACATTGTTGGCGTAAGACGTGCACGGGGGATATGTGTTTGTCTCACTCCG 
MACRGCGSHS                   223       ATGGCATGTCGTGGGTGTGGTTCTCACTCCG 
MALYIPSILSHS                 184       ATGGCTTTGTATATTCCTTCTATTTTGTCTCACTCCG 
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MatLab Scripts description 
Step1.m 
• It reads the initial filename.fastq file and generates files containing reads accord-
ing to their barcode (named BC1.txt, BC2.txt... BCNOT.txt), and saves them in a 
separate folder within the input folder (named "filename_BC"). BCNOT.txt con-
tains reads whose barcode did not correspond to any of the identified barcodes. 
If no input is indicated, a dialog box opens to choose the file and the barcodes 
used are the 12 described in this publication. 
• Input: (optional) 
o Step1('inname','filename.fastq','indir','path') indicates the file name and 
path to the folder where it is located. If not specified, a dialog box to 
choose the file will open. 
o Step1(...,'indelmut','on') allows one insertion, deletion or mutation in the 
barcodes. If not specified, it is off. 
o Step1(...,'bc',{'AAAAAA',' TTTTTT','GGGGGG';'...'}) indicates the barcodes 
used. They must be separated by comma, in single braket and within {}. If 
not specified, it uses the ones described in Table S2. 
• Output: 
o Command window: 
? chip-specific code 
? time taken to read different fractions of filename.fastq 
o A new folder called "filename_BC" with a series of files named BC1.txt, 
BC2.txt... BCn.txt, containing the reads corresponding to the first, se-
cond,... nth barcode respectively. Reads whose barcode did not corre-
spond to any of the identified barcodes are stored in BCNOT.txt. 
o BC_stats.txt file, containing information about how many reads where 
found per barcode. 
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Step2.m 
• It removes low quality reads from the datasets, groups identical DNA sequences 
and sorts them by abundance. It then translates them (amber codon is translated 
to glutamine). If no input is specified, a dialog box opens that allows choosing the 
file (a BCn.txt output of Step1). The constant DNA sequences flanking the random 
region must be indicated (if not indicated, start and end of the random region are 
the ones suitable for bicyclic peptide libraries used in this publication). Default 
quality parameters are 3 base calls below Q18. Optionally, a minimum, interme-
diate and maximum length of the peptide can be indicated. The additional cor-
recting error step is recommended for low-diversity datasets in which a few 
clones predominate in the library, but it may take 10-20 minutes. It will merge 
together sequencing having one or two different positions in the DNA sequence. 
• input (optional): 
o Step2('inname','filename.txt','indir','path') indicates the file name and 
path to the folder where it is located. If not specified, a dialog box to 
choose the file will open. Step2 can read the output file from Step1 
(BC1.txt, BC2.txt...). 
o Step2(...,'badmax',n) where n is the maximum number of bases below the 
quality threshold allowed. If not specified, badmax = 3 
o Step2(...,'q',Q) where Q indicates the quality threshold (18 for Q18, 20 for 
Q20, etc...). If not specified, Q = 18. 
o Step2(...,'uplimit',m,'downlimit',o,'midlimit',p) specifies the maximum 
(m) and minimum (o) peptide length (in residues). Additionally, an in-
ternal limit can be indicated (p). 
o Step2(...,'start','NNKNNK','end','NNKNNK') specifies constant regions at 
the start and end of the DNA region of interest. If not specified, it uses the 
ones described in this publication. The first nucleotide of 'start' must be 
the first nucleotide of the codon for the translation to be in frame. 
o Step2(...,'fixerr',n) allows to correct sequencing errors: it merges togeth-
er sequencing with only 1 or 2 differences in the DNA sequence. It cor-
rects only the top "n" abundant sequences. 
• output: 
o Translation_filename folder containing the file Translat-
ed_filename_GOOD.txt and Translated_stats.txt (indicating the number of 
different sequences, maximum abundance and total number of reads). 
o Optionally: additional files folder within the previous folder containing 
the translation files of the bad quality reads, too long reads and too short 
reads. 
o Optionally: QF_filename folder with QF_filename_GOOD.txt and 
QF_filename_BAD.txt containing good and bad quality reads respectively. 
QF_filename_NOLIM.txt contains reads where either the start or the end 
of the region of interest could not be found. QF_filename_toolong.txt and 
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QF_filename_tooshort.txt contain the reads whose peptides where short-
er or longer than the limits indicated. If an intermediate limit was indi-
cated, two files: a QF_filename_longGOOD.txt and a 
QF_filename_shortGOOD.txt, are created. IDEM with BAD. 
o If 'fixerr' option is on, within the Translation_filename folder, a file called 
"fixerrTranslated_filename.txt" appears, as well as an additional folder 
"correction data". In this folder there are files with all the correction 
events (potential conflict ones are in a separate file for an easier evalua-
tion, i.e. if the abundances differ in less than 4-fold). ErrorRates.txt con-
tains the error rate (1st column), the starting occurrence (2nd column) 
and the final occurrence after correcting (3rd column) of the peptides. 
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LoopLengths.m (for monocyclic and bicyclic peptide libraries) 
• Separates sequences in different files according to the peptide format (i.e. num-
ber of cysteines and the number of residues between them). If no input is speci-
fied, a dialog box opens that allows choosing the file (having the format: peptide 
seq - abundance - nucleotide seq). Optionally, one can indicate a minimum abun-
dance for a sequence to be considered, and a constant C-terminal peptide se-
quence to remove frame-shifted sequences. 
• Input (optional): 
o LoopLengths('inname','filename.txt','indir','path') indicates the file name 
and path to the folder where it is located. If not specified, a dialog box to 
choose the file will open. LoopLengths needs a file with data on the for-
mat: peptide seq - abundance - nucleotide seq. 
o  LoopLengths(...,'cutoff',n), where n specifies the minimum abundance to 
be considered. If not specified, no cutoff is applied and all sequences are 
considered. 
o LoopLengths(...,'cter','XXX'), where XXX is the amino acid sequence found 
at the C-terminus of the peptide. Allows to remove frame-shifted clones. 
• Output: 
o A new folder called "LoopLengths_filename" with 4 subfolders: 
• 2cys: containing files with the sequences corresponding to 2 
cysteines, subdivided by loop lenght. Example of the notation: 
3_twocys = C XXX C 
5_twocys = C XXXXX  
• 3cys: containing files with the sequences corresponding to 3 
cysteines, subdivided by loop lenght. Example of the notation: 
3_threecys = 0x3 = CC XXX C 
300_threecys = 3x0 = C XXX CC                       
304_threecys = 3x4 = C XXX C XXXX C 
305_threecys = 3x5 = C XXX C XXXXX C 
• 4cys: containing files with the sequences corresponding to 4 
cysteines, subdivided by loop lenght. Example of the notation: 
4_fourcys = 0x0x4 = CCC XXXX C 
400_fourcys = 0x4x0 = CC XXXX CC 
403_fourcys = 0x4x3 = CC XXXX C XXX C 
40000_fourcys = 4x0x0 = C XXXX CCC 
40302_fourcys = 4x3x2 = C XXXX C XXX C XX C$ 
• other: containing files with the sequences corresponding to 0, 1 or 
more than 4 cysteines; and "stats" file with the information about 
the number of total and different sequences assigned to each catego-
ry. 
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Clustering.m 
• Compares a chosen number of sequences (if not specified, compares top 200) 
and groups them into families that share high sequence similarity. Within a clus-
ter, more similar sequences appear together. A figure logo for each group is gen-
erated and saved as a .jpg file within the input folder. Optionally, the number of 
different sequences OR the minimum abundance can be indicated. If no input is 
indicated, a dialog box will open that allows choosing the file. It must be a file of 
the format: format peptide seq. – abundance - nucleotide seq. Additionally, two 
optional parameters allow fine-tuning of the clustering: "min_clustersize" and 
"stringency". 
• Input (optional): 
o Clustering('inname','filename.txt','indir','path') indicates the file name 
and path to the folder where it is located. If not specified, a dialog box to 
choose the file will open. Clustering can read the output files from Step2, 
LoopLengths and FindSeq. Requisites: data is on the format peptide seq – 
abundance - nucleotide seq. 
o Clustering(...,'number_dif',n) indicates how many different sequences 
will be clustered. If not specified, n = 200, i.e. top 200 most abundant se-
quences will be clustered. 
o Clustering(...,'min_clustersize',m) indicates the minimum number of se-
quences within a cluster to be considered. If a cluster has less than m se-
quences, it will be transferred to the "mixed" cluster. 
o Clustering(...'cter','XXXX') indicates a constant C-terminal region of the 
peptide. Peptides without this constant region will be not considered. 
o Clustering(...,'min_abun',n) indicates the minimum abundance for clones 
to be considered. 
o Clustering(...,'stringency',s) allows to fine-tune the clustering of the script 
to different datasets. In general, higher values of stringency will lead to 
more similar peptides within each cluster and more sequences in the 
mixed cluster. Lower values of stringency allow more differences within 
each cluster and as a result fewer sequences go to the mixed cluster. 
o Clustering(...,'logos','off') disables the generation of sequence logos (.jpg 
files) within the input folder. 
o Clustering(...'gappen',n) changes the value of gap opening and gap exten-
sion penalties. Default value is 8. 
• Output: 
o Clusters_filename.txt file within the same folder as the input file. 
o A series of .jpg files corresponding to the sequence logos of each group 
within the same folder as the input file. 
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FindSeq.m 
• Searches the dataset for all peptide sequences containing a specified motif. The 
motif must be specified in the input, and can be a string of characters or a regular 
expression. It distributed the peptides in two different files, according to whether 
they contain the specified motif or not. 
• Input: 
o FindSeq('seq','XXX'), will look for XXX motif. For example, 
FindSeq('seq','HPQ') will look for all sequences in the dataset containing 
HPQ. Regular expressions can be used instead, for example, 
FindSeq('seq','H.Q') will look for all sequences conatining HXQ, X being 
any amino acid. FindSeq('seq','H.?Q') will look for all sequences contain-
ing HQ or HXQ, X being any amino acid. For more informaiton about reg-
ular expressions, see MatLab help. 
• Input (optional): 
o FindSeq('inname','filename.txt','indir','path') indicates the file name and 
path to the folder where it is located. If not specified, a dialog box to 
choose the file will open. Requisites: data is on the format peptide seq – 
abundance - nucleotide seq. 
o FindSeq(...'cter','XXXX') indicates a constant C-terminal region of the 
peptide. Peptides without this constant region will be not considered. 
o FindSeq(...,'cutoff',n) indicates the minimum abundance for clones to be 
considered. 
• Output: 
o A new folder named "Seq" within the input folder, containing three files: 
Seq_XXX_match.txt (XXX is the specified regular expression where espe-
cial characters have been substituted by "_"), containing all sequences 
that match the expression. Seq_XXX_nomatch.txt, containing the se-
quences that do not match it. And Seq_XXX_stats.txt, containing how 
many total and different sequences were assigned to each file. 
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CommonSeq.m 
• Compares up to three different datasets and distributes common and exclusive 
sequences in different files.  
• Input (optional): 
o CommonSeq('inname1','filename1.txt','inname2','filename2.txt','inname
3','filename3.txt','indir1,'path1','indir2','path2','indir3','path3') specifies 
three files and three paths corresponding to them. If not specified, dialog 
boxes will open for each. 
o CommonSeq(...,'cutoff',n), where n is the minimum abundance to be con-
sidered 
o CommonSeq(...,'top',m), alternative to the previous one, it indicates the 
top m abundant sequences of each file will be considered 
o CommonSeq(...,'cter','XXX'), specifies constant C-terminal residues (al-
lows the removal of frame-shifted clones that do not have them) 
• Output 
o A new folder named "comparison" within the folder containing the FIRST 
FILE. The following files are generated: 
? Comparison_seq1.txt, Comparison_seq2.txt, Comparison_seq3.txt 
= contain sequences that appeared only in the first, second and 
third file respectively 
? Comparison_seq12.txt, Comparison_seq13.txt, Compari-
son_seq23.txt = contain sequences that appeared in two of the 
files 
? Comparison_seq123.txt = contains sequences that appeared in 
the three files 
? Comparison_stats.txt = contains the number of total/different 
sequences considered in each case and the number of different 
sequences assigned to each file 
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Supplementary experimental procedures 
SrtA production 
The vector pHTT14 for recombinant expression of (His)6-SrtA26-206 in E. coli was kindly 
provided by Prof. Olaf Schneewind (University of Chicago, IL, US). SrtA was produced as 
previously described. Briefly, pHTT14 was transformed in E. coli Xl1-blue, and was 
grown in LB (100 μg/ml ampicillin) until OD600 = 0.5. SrtA expression was induced by 
addition of 1 mM IPTG, and protein production was allowed for 4 h at 25 °C. Cells were 
harvested by centrifugation and resuspended in cold lysis buffer (30 mM NaH2PO4, 
300 mM NaCl, 0.1% Triton X-100, 50 μg/ml DNAse, 100 μg/ml lysozyme, pH 7.4), and 
sonicated. Lysates were cleared by centrifugation and (His)6-SrtA26-206 was purified by 
Nickel-column chromatography followed by size exclusion chromatography (Figure S13). 
Ion Torrent sequencing 
Phage vector was isolated from TG1 E. coli after infection with a commercial plasmid 
purification kit (NucleoSpin Plasmid; Macherey-Nagel, Düren, Germany), and samples 
were prepared as previously described (Chapter 3), 100 ng phage vector DNA was 
amplified by PCR using primers containing adapter sequences and barcodes. The 
concentration of DNA was determined using a High Sensitivity DNA Assay Kit (Agilent, 
Santa Clara, CA, US), following the manufacturer's protocol. Ion Torrent sequencing was 
performed by the Lausanne Center of Genomic Technologies (University of Lausanne, 
Switzerland) on an Ion Personal Genome Machine (PGMTM) Sequencer, using an Ion 
Torrent 316TM chip. 
Determination of inhibitory constants (Ki) 
For IC50s higher than 10 μM, the inhibitory constant Ki was calculated according to the 
equation of Cheng and Prusoff140 Ki = IC50/(1 + [S]0/Km), wherein IC50 is the functional 
strength of the inhibitor, [S]0 is the total substrate concentration, and Km is the 
Michaelis–Menten constant. The reported Km values for LPETG substrates of SrtA are 
between 5 and 7 mM, and therefore Ki ≈ IC50. For IC50s lower than 10 μM, a second series 
was performed using 1 μM enzyme and 50 μM substrate, and Kis were calculated 
accordingly. For IC50s lower than 3 μM in this second series, data was fitted to the 
Morrison equation: 
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௜ܸ
଴ܸൗ = 1 −
ܧ଴ + ܫ଴ + ܭ௜ − ඥ(ܧ଴ + ܫ଴ + ܭ௜)ଶ − 4ܧ଴ܫ଴
2ܧ଴  
, where Vi and V0 are the reaction velocities in the presence and absence of inhibitor, 
respectively. E0 and I0 represent the total enzyme and inhibitor concentration, 
respectively. Ki is the inhibition constant in the presence of fluorogenic substrate. Fitting 
curves were generated using OriginPro 8G software (OriginLab Corporation). 
Determination of dissociation constants (Kd) 
The dissociation constants (Kd) were determined by non-linear regression analyses of 
fluorescence polarization (Fp) versus total concentration of SrtA (PT) using the following 
equation: 
ܨ௣ = ܨ௣ ௠௜௡ + (ܨ௣ ௠௔௫ − ܨ௣ ௠௜௡)
ܮ் + ்ܲ + ܭ஽ − ඥ(ܮ் + ்ܲ + ܭ஽)ଶ − 4ܮ் ்ܲ
2ܮ்  
Fp min and Fp max are the fluorescence polarization for the free peptide and the fully bound 
peptide respectively, and LT is the total concentration of fluorescent ligand (200 nM). 
Fitting curves were generated using OriginPro 8G software (OriginLab Corporation). 




Figure S9. Adhesion tests using different bicyclic peptides (SRT2: ACTQRCPQLPPCG. 
SRT5: ACPLLPPCADDCG). Cultures of S. aureus strains Cowan and Newman were grown 
until mid-exponential phase (OD600 = 0.5) in the presence or absence of inhibitor. Adhe-
sion test was performed immobilizing 1 μg of ligand protein per well (fibronectin or fi-
brinogen) and 5×107 cells/well. Average and standard deviations of two independent 
cultures are shown. 
 
Figure S10. SRT2 is not degraded by proteases during S. aureus growth. Overnight super-
natants of S. aureus Newman cultures containing 100 or 500 μM SRT2 were used for an 
activity assay in vitro. Inhibitory activity corresponded well to the theoretically expected 
if all peptide was intact (plotted x values in the graph). The presence of 40% supernatant 
in the in vitro activity assay did not affect SRT2 inhibitory activity (dashed line, 
Ki = 3.1 +/- 0.6 μM). 




Figure S11. (A) Change of morin's fluorescence (ex. 350nm, em. 480nm) over time. (B) 
and (C) SrtA activity assays in the prescence of morin (B) or curcumin (C) using 2.5 μM 
SrtA and 20 μM Dab-LPETG-edans substrate, fluorescence (ex. 350nm, em. 480nm) was 
monitored for 1 h at 37 °C. (D) The IC50 of curcumin in our assays could not be precisely 
determined due to insolubility of the compound. At the maximum concentration tested 
(50 μM), 20% inhibition was observed. 
 
Figure S12. Inhibition of SrtA by phenyl-vinyl-sulfone (PVS). PVS was incubated at differ-
ent concentrations with 2.5 μM SrtA for 1 h (1.5% DMSO final concentration) prior to the 
addition of Dabcyl-LPETG-Edans substrate. Cleavage was monitored for 1 h at 37 °C 
(IC50 = 0.9 mM). For comparison, a parallel assay was performed with SRT2. 
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Figure S13. Purification of His6-SrtA∆N. Top: size exclusion chromatography after nickel-
column purification. Bottom: SrtA runs in the SDS-PAGE gel between 25 and 35 kDa. The 
mass of the purified fractions after size exclusion chromatography was verified by MS, 
and corresponded to the expected size. 
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Sequencing results (most abundant 100 clones) 
Peptide sequence, abundance and nucleotide sequence are indicated. 
Library A 
MAACRQLPPCSFECGGSG       5059      ATGGCAGCATGCAGGTAGCTTCCTCCTTGCTCTTTCGAGTGTGGCGGTTCTGGCG 
MAACQLLPPCPFNCGGSG       1514      ATGGCAGCATGCTAGCTCCTTCCGCCTTGCCCTTTTAATTGTGGCGGTTCTGGCG 
MAACPQLPPCRVSCGGSG       1343      ATGGCAGCATGCCCTTAGCTCCCTCCCTGCCGCGTGTCTTGTGGCGGTTCTGGCG 
MAACPLLPPCADDCGGSG       853      ATGGCAGCATGCCCCTTGCTCCCTCCCTGCGCTGATGATTGTGGCGGTTCTGGCG 
MAACAILPPCDQNCGGSG       684      ATGGCAGCATGCGCCATTCTCCCCCCGTGCGACTAGAATTGTGGCGGTTCTGGCG 
MAACLQLPPCNVSCGGSG       627      ATGGCAGCATGCCTGTAGCTTCCTCCTTGCAACGTGTCCTGTGGCGGTTCTGGCG 
MAACPLLPPCSLDCGGSG       601      ATGGCAGCATGCCCCCTGCTGCCGCCTTGCAGTCTGGATTGTGGCGGTTCTGGCG 
MAACPYLPPCQLACGGSG       598      ATGGCAGCATGCCCCTACCTTCCTCCCTGCTAGCTGGCGTGTGGCGGTTCTGGCG 
MAACLQLPPCSSPCGGSG       548      ATGGCAGCATGCTTGTAGCTTCCTCCCTGCTCGTCCCCGTGTGGCGGTTCTGGCG 
MAACPQLPPCGTFCGGSG       461      ATGGCAGCATGCCCTTAGCTGCCCCCTTGCGGTACTTTTTGTGGCGGTTCTGGCG 
MAACPALPPCQLSCGGSG       447      ATGGCAGCATGCCCTGCGTTGCCCCCGTGCTAGTTGTCTTGTGGCGGTTCTGGCG 
MAACPQLPPCLYPCGGSG       400      ATGGCAGCATGCCCCTAGCTCCCCCCGTGCCTGTATCCTTGTGGCGGTTCTGGCG 
MAACQQGCTVLPPCGGSG       383      ATGGCAGCATGCTAGCAGGGCTGCACTGTGCTTCCGCCCTGTGGCGGTTCTGGCG 
MAACPSLPPCPWNCGGSG       347      ATGGCAGCATGCCCGAGTCTTCCCCCGTGCCCCTGGAATTGTGGCGGTTCTGGCG 
MAACSQLPPCARGCGGSG       338      ATGGCAGCATGCAGCTAGTTGCCTCCTTGCGCTCGGGGTTGTGGCGGTTCTGGCG 
MAACLQLPPCNHHCGGSG       296      ATGGCAGCATGCCTCTAGCTGCCTCCTTGCAACCATCACTGTGGCGGTTCTGGCG 
MAACILPPCSYTQCGGSG       292      ATGGCAGCATGCATCTTGCCTCCCTGCTCTTACACGTAGTGTGGCGGTTCTGGCG 
MAACAILPPCQPRCGGSG       289      ATGGCAGCATGCGCCATTCTCCCTCCGTGCTAGCCTCGGTGTGGCGGTTCTGGCG 
MAACPLLPPCGIGCGGSG       289      ATGGCAGCATGCCCTCTGCTGCCTCCGTGCGGTATTGGCTGTGGCGGTTCTGGCG 
MAACYLLPPCQLGCGGSG       278      ATGGCAGCATGCTATCTGCTTCCCCCTTGCTAGTTGGGCTGTGGCGGTTCTGGCG 
MAACRGTCPVLPPCGGSG       269      ATGGCAGCATGCAGGGGCACCTGCCCCGTTCTGCCTCCTTGTGGCGGTTCTGGCG 
MAVRCPLPPYQCCGGSG        262      ATGGCAGTGCGCTGCCCCTTGCCGCCGTATTAGTGTTGTGGCGGTTCTGGCG 
MAACPYLPPCGESCGGSG       250      ATGGCAGCATGCCCGTACCTTCCCCCGTGCGGGGAGAGTTGTGGCGGTTCTGGCG 
MAACSILPPCSQNCGGSG       246      ATGGCAGCATGCTCTATCCTTCCTCCTTGCTCTTAGAATTGTGGCGGTTCTGGCG 
MAACQTGCPILPPCGGSG       246      ATGGCAGCATGCTAGACGGGTTGCCCGATTCTGCCTCCCTGTGGCGGTTCTGGCG 
MAACQILPPCFQPCGGSG       242      ATGGCAGCATGCTAGATTTTGCCGCCGTGCTTTCAGCCCTGTGGCGGTTCTGGCG 
MAACPSLPPCNQHCGGSG       242      ATGGCAGCATGCCCCTCTCTCCCTCCCTGCAATTAGCATTGTGGCGGTTCTGGCG 
MAACPYLPPCPLDCGGSG       210      ATGGCAGCATGCCCTTATCTCCCTCCTTGCCCTTTGGATTGTGGCGGTTCTGGCG 
MAACQVLPPCGFICGGSG       202      ATGGCAGCATGCTAGGTGCTTCCTCCGTGCGGTTTCATCTGTGGCGGTTCTGGCG 
MAACSLLPPCQLSCGGSG       202      ATGGCAGCATGCAGTCTGTTGCCCCCTTGCTAGTTGTCGTGTGGCGGTTCTGGCG 
MAACSILPPCFQTCGGSG       190      ATGGCAGCATGCAGCATCTTGCCCCCCTGCTTCTAGACCTGTGGCGGTTCTGGCG 
MAARMKSSCLPPCCGGSG       185      ATGGCAGCACGCATGAAGAGTAGTTGCCTCCCTCCGTGCTGTGGCGGTTCTGGCG 
MAACAQLPPCSLPCGGSG       183      ATGGCAGCATGCGCTTAGTTGCCGCCGTGCTCTCTTCCGTGTGGCGGTTCTGGCG 
MAACYQLPPCDHSCGGSG       177      ATGGCAGCATGCTACTAGTTGCCTCCCTGCGATCACAGTTGTGGCGGTTCTGGCG 
MAACPQLPPCVLACGGSG       171      ATGGCAGCATGCCCTTAGCTTCCGCCGTGCGTGCTCGCGTGTGGCGGTTCTGGCG 
MAACKRTHCLPPCCGGSG       169      ATGGCAGCATGCAAGCGTACCCATTGCCTCCCCCCCTGTTGTGGCGGTTCTGGCG 
MAACRQLPPCSDPCGGSG       164      ATGGCAGCATGCCGTTAGTTGCCTCCCTGCAGCGATCCCTGTGGCGGTTCTGGCG 
MAACRGHCPILPPCGGSG       162      ATGGCAGCATGCCGTGGCCATTGCCCTATCCTCCCTCCTTGTGGCGGTTCTGGCG 
MAACYLPPCQLQLCGGSG       157      ATGGCAGCATGCTATCTTCCCCCTTGCCAGCTGTAGTTGTGTGGCGGTTCTGGCG 
MAACSILPPCTTHCGGSG       154      ATGGCAGCATGCTCCATTTTGCCGCCTTGCACGACGCATTGTGGCGGTTCTGGCG 
MAACSRHCLTLPPCGGSG       149      ATGGCAGCATGCAGTCGTCATTGCCTGACTCTTCCTCCGTGTGGCGGTTCTGGCG 
MAACPVLPPCSRPCGGSG       149      ATGGCAGCATGCCCCGTGTTGCCCCCTTGCAGTCGTCCTTGTGGCGGTTCTGGCG 
MAACLQLPPCDFQCGGSG       147      ATGGCAGCATGCCTCTAGCTTCCTCCCTGCGATTTTCAGTGTGGCGGTTCTGGCG 
MAACPYLPPCGTICGGSG       147      ATGGCAGCATGCCCCTATCTGCCTCCTTGCGGCACGATCTGTGGCGGTTCTGGCG 
MAACALLPPCNQNCGGSG       145      ATGGCAGCATGCGCTCTGCTGCCGCCCTGCAATTAGAACTGTGGCGGTTCTGGCG 
MAACHSRCPQLPPCGGSG       138      ATGGCAGCATGCCATAGTAGGTGCCCCTAGCTTCCCCCGTGTGGCGGTTCTGGCG 
MAACLPPCPLLPCGGSG        133      ATGGCAGCATGCCTGCCTCCTTGCCCGTTGTTGCCGTGTGGCGGTTCTGGCG 
MAACKLLPPCQFECGGSG       130      ATGGCAGCATGCAAGCTTTTGCCTCCGTGCTAGTTCGAGTGTGGCGGTTCTGGCG 
MAACYGQCTQLPPCGGSG       129      ATGGCAGCATGCTACGGTCAGTGCACTTAGCTGCCTCCTTGTGGCGGTTCTGGCG 
MAACPYLPPCSYTCGGSG       129      ATGGCAGCATGCCCTTACCTTCCGCCGTGCTCCTACACTTGTGGCGGTTCTGGCG 
MAACPFLPPCSSACGGSG       126      ATGGCAGCATGCCCTTTCTTGCCCCCCTGCTCGAGTGCTTGTGGCGGTTCTGGCG 
MAACGQLPPCDAMCGGSG       126      ATGGCAGCATGCGGCTAGCTGCCCCCCTGCGATGCTATGTGTGGCGGTTCTGGCG 
MAACQTYASCVLRCGGSG       125      ATGGCAGCATGCTAGACTTATGCCTCGTGCGTGCTCCGGTGTGGCGGTTCTGGCG 
MAACGYLPPCPLSCGGSG       122      ATGGCAGCATGCGGTTATCTCCCTCCCTGCCCTCTCTCCTGTGGCGGTTCTGGCG 
MAACSVLPPCSFSCGGSG       122      ATGGCAGCATGCTCTGTTCTTCCTCCCTGCTCCTTCTCGTGTGGCGGTTCTGGCG 
MAACILPPCPSSCGGSG        122      ATGGCAGCATGCATTCTCCCCCCGTGCCCTTCTTCGTGTGGCGGTTCTGGCG 
MAACPVLPPCPINCGGSG       122      ATGGCAGCATGCCCCGTCCTGCCTCCCTGCCCTATTAACTGTGGCGGTTCTGGCG 
MAACSRSCPVLPPCGGSG       121      ATGGCAGCATGCTCTCGTTCCTGCCCTGTGCTTCCCCCCTGTGGCGGTTCTGGCG 
MAACYGECQVLPPCGGSG       116      ATGGCAGCATGCTACGGCGAGTGCTAGGTGTTGCCTCCTTGTGGCGGTTCTGGCG 
MAACPSQCTILPPCGGSG       112      ATGGCAGCATGCCCCTCCTAGTGCACCATTCTTCCGCCCTGTGGCGGTTCTGGCG 
MAACGVLPPCQRECGGSG       107      ATGGCAGCATGCGGCGTTCTTCCTCCCTGCTAGAGGGAGTGTGGCGGTTCTGGCG 
MAACTSRCPQLPPCGGSG       105      ATGGCAGCATGCACCTCGCGGTGCCCTCAGCTCCCTCCGTGTGGCGGTTCTGGCG 
MAACQLLPPCSYSCGGSG       104      ATGGCAGCATGCTAGCTGTTGCCCCCGTGCTCTTATTCCTGTGGCGGTTCTGGCG 
MAACNTKCSILPPCGGSG       101      ATGGCAGCATGCAACACTAAGTGCTCTATTCTCCCCCCCTGTGGCGGTTCTGGCG 
MAACTVLPPCNYKCGGSG       98      ATGGCAGCATGCACCGTCTTGCCCCCGTGCAATTATAAGTGTGGCGGTTCTGGCG 
MAACFDRCLQLPPCGGSG       97      ATGGCAGCATGCTTCGATCGCTGCCTTTAGTTGCCCCCTTGTGGCGGTTCTGGCG 
MAACHSRCPTLPPCGGSG       97      ATGGCAGCATGCCACTCTCGCTGCCCCACTTTGCCCCCTTGTGGCGGTTCTGGCG 
MAACLQLPPCAWTCGGSG       93      ATGGCAGCATGCTTGCAGCTGCCCCCTTGCGCTTGGACGTGTGGCGGTTCTGGCG 
MAACPVLPPCISNCGGSG       91      ATGGCAGCATGCCCCGTTCTCCCCCCCTGCATTAGTAATTGTGGCGGTTCTGGCG 
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MAACSILPPCTIQCGGSG       89      ATGGCAGCATGCTCTATTCTTCCTCCGTGCACGATTTAGTGTGGCGGTTCTGGCG 
MAACPYLPPCDFLCGGSG       87      ATGGCAGCATGCCCGTATCTCCCCCCCTGCGACTTCCTCTGTGGCGGTTCTGGCG 
MAACSGYCPYLPPCGGSG       86      ATGGCAGCATGCAGCGGTTATTGCCCCTACCTCCCGCCTTGTGGCGGTTCTGGCG 
MAACPVLPPCRSDCGGSG       86      ATGGCAGCATGCCCCGTGTTGCCGCCTTGCCGCTCGGATTGTGGCGGTTCTGGCG 
MAACPSLPPCRESCGGSG       84      ATGGCAGCATGCCCGAGCCTTCCCCCTTGCCGTGAGAGCTGTGGCGGTTCTGGCG 
MAACSNRCTLLPPCGGSG       83      ATGGCAGCATGCTCTAATCGGTGCACCTTGTTGCCGCCTTGTGGCGGTTCTGGCG 
MAACSILPPCNSPCGGSG       83      ATGGCAGCATGCTCGATTCTGCCGCCGTGCAATAGTCCTTGTGGCGGTTCTGGCG 
MAACLQLPPCSLSCGGSG       82      ATGGCAGCATGCTTGTAGCTCCCTCCGTGCAGTCTCAGCTGTGGCGGTTCTGGCG 
MAACVSTCQILPPCGGSG       82      ATGGCAGCATGCGTTAGTACGTGCTAGATCCTCCCCCCTTGTGGCGGTTCTGGCG 
MAACNVLPPCSSHCGGSG       81      ATGGCAGCATGCAACGTCTTGCCGCCTTGCTCCTCTCATTGTGGCGGTTCTGGCG 
MAACNIQSCLPPCGGSG        78      ATGGCAGCATGCAACATTTAGTCTTGCCTTCCTCCTTGTGGCGGTTCTGGCG 
MAACSQGCPSLPPCGGSG       77      ATGGCAGCATGCAGTTAGGGGTGCCCGTCGCTGCCTCCGTGTGGCGGTTCTGGCG 
MAACPFLPPCSMSCGGSG       76      ATGGCAGCATGCCCTTTTCTGCCTCCGTGCTCTATGTCCTGTGGCGGTTCTGGCG 
MAACSILPPCRSGCGGSG       74      ATGGCAGCATGCTCCATTCTCCCTCCTTGCCGCAGCGGGTGTGGCGGTTCTGGCG 
MAACPHLPPCNTLCGGSG       74      ATGGCAGCATGCCCTCATCTTCCCCCTTGCAACACTTTGTGTGGCGGTTCTGGCG 
MAACAAYCPQLPPCGGSG       73      ATGGCAGCATGCGCTGCTTATTGCCCCTAGCTTCCTCCTTGTGGCGGTTCTGGCG 
MAACQSGCGILPPCGGSG       72      ATGGCAGCATGCTAGAGCGGTTGCGGCATCTTGCCTCCTTGTGGCGGTTCTGGCG 
MAACAVGCPILPPCGGSG       72      ATGGCAGCATGCGCCGTTGGGTGCCCCATTTTGCCTCCCTGTGGCGGTTCTGGCG 
MAACPYLPPCNMQCGGSG       71      ATGGCAGCATGCCCCTACCTCCCGCCTTGCAATATGTAGTGTGGCGGTTCTGGCG 
MAACSQKCFQLPPCGGSG       70      ATGGCAGCATGCTCTTAGAAGTGCTTTTAGCTTCCTCCTTGTGGCGGTTCTGGCG 
MAACILPPCPFSCGGSG        68      ATGGCAGCATGCATCTTGCCGCCTTGCCCCTTTTCCTGTGGCGGTTCTGGCG 
MAACLRNCPVLPPCGGSG       68      ATGGCAGCATGCTTGAGGAATTGCCCTGTTCTTCCTCCTTGTGGCGGTTCTGGCG 
MAACSVRCGILPPCGGSG       67      ATGGCAGCATGCAGTGTTCGCTGCGGTATTTTGCCTCCTTGTGGCGGTTCTGGCG 
MAACPLLPPCGANCGGSG       67      ATGGCAGCATGCCCTCTTCTGCCCCCTTGCGGTGCGAATTGTGGCGGTTCTGGCG 
MAACRNQCLILPPCGGSG       67      ATGGCAGCATGCCGCAACCAGTGCTTGATTCTTCCTCCCTGTGGCGGTTCTGGCG 
MAACAILPPCTLTCGGSG       65      ATGGCAGCATGCGCCATTCTCCCCCCTTGCACGCTTACTTGTGGCGGTTCTGGCG 
MAACILPPCQFKDCGGSG       64      ATGGCAGCATGCATTCTGCCTCCCTGCTAGTTCAAGGATTGTGGCGGTTCTGGCG 
MAACGQLPPCSVVCGGSG       64      ATGGCAGCATGCGGGTAGCTCCCTCCCTGCTCCGTTGTCTGTGGCGGTTCTGGCG 
MAACNTLCPYLPPCGGSG       63      ATGGCAGCATGCAATACTCTTTGCCCTTATCTGCCCCCTTGTGGCGGTTCTGGCG 
MAACVGRCEVLPPCGGSG       62      ATGGCAGCATGCGTCGGGCGTTGCGAGGTTTTGCCTCCTTGTGGCGGTTCTGGCG 
MAACPQLPPCHVYCGGSG       62      ATGGCAGCATGCCCTTAGCTCCCTCCGTGCCACGTTTACTGTGGCGGTTCTGGCG 
MAACALLPPCPNACGGSG       62      ATGGCAGCATGCGCGCTGTTGCCGCCTTGCCCTAATGCGTGTGGCGGTTCTGGCG 
MAACQVRCDILPPCGGSG       62      ATGGCAGCATGCTAGGTCCGGTGCGACATCCTCCCGCCTTGTGGCGGTTCTGGCG 
MAACQFPCLVLPPCGGSG       62      ATGGCAGCATGCTAGTTTCCCTGCCTCGTCCTCCCTCCGTGTGGCGGTTCTGGCG 
 
Library B 
MAACSILPPCNPPQCGGSG       4513      ATGGCAGCATGCTCGATTCTTCCTCCGTGCAATCCTCCGTAGTGTGGCGGTTCTGGCG 
MAACPLLPPCHLPQCGGSG       2041      ATGGCAGCATGCCCGTTGCTTCCGCCGTGCCATCTTCCTTAGTGTGGCGGTTCTGGCG 
MAACQVLPPCGLQLCGGSG       1877      ATGGCAGCATGCCAGGTGTTGCCTCCGTGCGGTCTGTAGCTGTGTGGCGGTTCTGGCG 
MAACRQLPPCAEYVCGGSG       1291      ATGGCAGCATGCCGGTAGCTGCCTCCTTGCGCTGAGTATGTTTGTGGCGGTTCTGGCG 
MAACPELPPCQLMLCGGSG       1048      ATGGCAGCATGCCCGGAGCTTCCGCCGTGCTAGTTGATGCTGTGTGGCGGTTCTGGCG 
MAACPMLPPCDLSYCGGSG       650      ATGGCAGCATGCCCTATGCTGCCTCCGTGCGATCTGAGTTATTGTGGCGGTTCTGGCG 
MAACGLLPPCHQFHCGGSG       600      ATGGCAGCATGCGGGCTTTTGCCGCCTTGCCATTAGTTTCATTGTGGCGGTTCTGGCG 
MAACTLLPPCTPDQCGGSG       580      ATGGCAGCATGCACGCTGTTGCCTCCTTGCACGCCGGATTAGTGTGGCGGTTCTGGCG 
MAACRPKQCWQLPPCGGSG       571      ATGGCAGCATGCCGTCCGAAGCAGTGCTGGCAGTTGCCTCCGTGTGGCGGTTCTGGCG 
MAACAQLPPCDYSGCGGSG       459      ATGGCAGCATGCGCGTAGCTTCCTCCGTGCGATTATTCTGGGTGTGGCGGTTCTGGCG 
MAACQILPPCHSPGCGGSG       413      ATGGCAGCATGCTAGATTCTGCCTCCTTGCCATTCGCCGGGGTGTGGCGGTTCTGGCG 
MAACPSLPPCWQLQCGGSG       244      ATGGCAGCATGCCCTAGTTTGCCTCCTTGCTGGCAGTTGTAGTGTGGCGGTTCTGGCG 
MAACEILPPCLQFQCGGSG       224      ATGGCAGCATGCGAGATTTTGCCTCCTTGCCTTTAGTTTCAGTGTGGCGGTTCTGGCG 
MAACVWNNCSLLPPCGGSG       201      ATGGCAGCATGCGTGTGGAATAATTGCTCTCTTCTGCCTCCTTGTGGCGGTTCTGGCG 
MAACPYLPPCSWDLCGGSG       192      ATGGCAGCATGCCCTTATCTTCCTCCGTGCTCGTGGGATCTGTGTGGCGGTTCTGGCG 
MAACLELPPCQFASCGGSG       183      ATGGCAGCATGCTTGGAGTTGCCGCCGTGCCAGTTTGCTTCGTGTGGCGGTTCTGGCG 
MAACPELPPCTVLKCGGSG       176      ATGGCAGCATGCCCTGAGCTGCCGCCTTGCACGGTTCTTAAATGTGGCGGTTCTGGCG 
MAACIQLPPCQQSSCGGSG       175      ATGGCAGCATGCATTCAGCTTCCGCCTTGCTAGCAGTCTTCGTGTGGCGGTTCTGGCG 
MAACQLLPPCQFLQCGGSG       169      ATGGCAGCATGCCAGCTTCTGCCTCCTTGCTAGTTTTTGCAGTGTGGCGGTTCTGGCG 
MAACLPPHSCWNQVCGGSG       161      ATGGCAGCATGCCTGCCTCCGCATTCTTGCTGGAATCAGGTTTGTGGCGGTTCTGGCG 
MAACSQLPPCTYLSCGGSG       150      ATGGCAGCATGCTCTCAGCTTCCGCCTTGCACTTATCTTTCGTGTGGCGGTTCTGGCG 
MAACRYLPPCPYKLCGGSG       149      ATGGCAGCATGCCGGTATCTTCCTCCTTGCCCTTATAAGCTGTGTGGCGGTTCTGGCG 
MAACLYPRCPSLPPCGGSG       143      ATGGCAGCATGCCTGTATCCGCGTTGCCCTTCTCTTCCTCCGTGTGGCGGTTCTGGCG 
MAACLQLPPCGVSLCGGSG       137      ATGGCAGCATGCCTGTAGCTGCCGCCTTGCGGTGTTAGTCTGTGTGGCGGTTCTGGCG 
MAACQLLPPCAIQWCGGSG       126      ATGGCAGCATGCCAGTTGCTTCCGCCGTGCGCGATTTAGTGGTGTGGCGGTTCTGGCG 
MAACAILPPCGQLSCGGSG       123      ATGGCAGCATGCGCTATTCTGCCGCCGTGCGGGCAGCTTAGTTGTGGCGGTTCTGGCG 
MAACLTLPPCQAVSCGGSG       122      ATGGCAGCATGCCTTACTCTTCCTCCTTGCTAGGCGGTTTCTTGTGGCGGTTCTGGCG 
MAACYLLPPCPSTSCGGSG       122      ATGGCAGCATGCTATTTGTTGCCGCCGTGCCCTTCGACGTCTTGTGGCGGTTCTGGCG 
MAACLTLPPCPSFTCGGSG       106      ATGGCAGCATGCTTGACTTTGCCGCCGTGCCCGTCTTTTACTTGTGGCGGTTCTGGCG 
MAACILPPCPTSEYCGGSG       104      ATGGCAGCATGCATTCTGCCTCCTTGCCCGACTTCGGAGTATTGTGGCGGTTCTGGCG 
MAACSVLPPCSFVACGGSG       100      ATGGCAGCATGCTCGGTGTTGCCTCCTTGCTCTTTTGTTGCGTGTGGCGGTTCTGGCG 
MAACHYLPPCQPAICGGSG       90      ATGGCAGCATGCCATTATTTGCCGCCTTGCTAGCCGGCGATTTGTGGCGGTTCTGGCG 
MAACSLLPPCHSTNCGGSG       73      ATGGCAGCATGCAGTCTTCTTCCTCCGTGCCATTCGACGAATTGTGGCGGTTCTGGCG 
MAACPLLPPCHLSFCGGSG       70      ATGGCAGCATGCCCGTTGCTGCCTCCGTGCCATCTTTCTTTTTGTGGCGGTTCTGGCG 
MAACQSTFCPILPPCGGSG       68      ATGGCAGCATGCTAGTCTACGTTTTGCCCGATTCTGCCTCCTTGTGGCGGTTCTGGCG 
MAACGYLPPCNYLHCGGSG       61      ATGGCAGCATGCGGTTATTTGCCTCCTTGCAATTATCTGCATTGTGGCGGTTCTGGCG 
MAACTLLPPCSSLQCGGSG       59      ATGGCAGCATGCACTTTGTTGCCGCCGTGCTCTTCTCTTCAGTGTGGCGGTTCTGGCG 
MAACPLLPPCRNTVCGGSG       57      ATGGCAGCATGCCCTCTGTTGCCTCCTTGCCGGAATACGGTTTGTGGCGGTTCTGGCG 
MAACPNQTCPLLPPCGGSG       53      ATGGCAGCATGCCCTAATTAGACGTGCCCTTTGCTGCCTCCTTGTGGCGGTTCTGGCG 
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MAACKVLPPCSAQRCGGSG       52      ATGGCAGCATGCAAGGTTCTGCCTCCGTGCTCGGCTTAGCGGTGTGGCGGTTCTGGCG 
MAACLLLPPCPIMTCGGSG       48      ATGGCAGCATGCCTTCTGCTTCCGCCTTGCCCGATTATGACGTGTGGCGGTTCTGGCG 
MAACLLASCPILPPCGGSG       47      ATGGCAGCATGCTTGCTGGCTTCGTGCCCGATTCTTCCTCCGTGTGGCGGTTCTGGCG 
MAACILPPCPTTIPCGGSG       43      ATGGCAGCATGCATTCTTCCGCCGTGCCCGACGACGATTCCGTGTGGCGGTTCTGGCG 
MAACRHLPPCTQLRCGGSG       42      ATGGCAGCATGCCGTCATCTGCCGCCGTGCACGTAGCTTCGGTGTGGCGGTTCTGGCG 
MAACAQLPPCPSQACGGSG       40      ATGGCAGCATGCGCGTAGTTGCCTCCGTGCCCTTCTTAGGCGTGTGGCGGTTCTGGCG 
MAACSALPPCQWAQCGGSG       40      ATGGCAGCATGCAGTGCTCTGCCGCCTTGCTAGTGGGCTCAGTGTGGCGGTTCTGGCG 
MAACHLLPPCGRQSCGGSG       37      ATGGCAGCATGCCATCTTTTGCCTCCGTGCGGTCGTTAGTCGTGTGGCGGTTCTGGCG 
MAACSRLPPCVILDCGGSG       36      ATGGCAGCATGCTCTAGGCTTCCTCCTTGCGTTATTCTTGATTGTGGCGGTTCTGGCG 
MAACQQLPPCMPRFCGGSG       36      ATGGCAGCATGCCAGTAGTTGCCTCCTTGCATGCCTCGGTTTTGTGGCGGTTCTGGCG 
MAACPVLPPCFTRLCGGSG       35      ATGGCAGCATGCCCGGTTCTGCCTCCGTGCTTTACTCGTTTGTGTGGCGGTTCTGGCG 
MAACSLLPPCTFVACGGSG       33      ATGGCAGCATGCTCGTTGCTGCCGCCGTGCACTTTTGTGGCGTGTGGCGGTTCTGGCG 
MAACAILPPCHFRSCGGSG       30      ATGGCAGCATGCGCGATTCTTCCGCCTTGCCATTTTCGGTCGTGTGGCGGTTCTGGCG 
MAACYLLPPCAISVCGGSG       29      ATGGCAGCATGCTATCTTTTGCCGCCTTGCGCGATTTCGGTTTGTGGCGGTTCTGGCG 
MAACALLPPCFIQECGGSG       29      ATGGCAGCATGCGCTCTGTTGCCGCCGTGCTTTATTTAGGAGTGTGGCGGTTCTGGCG 
MAACLLLPPCPSINCGGSG       29      ATGGCAGCATGCCTTCTGCTTCCTCCGTGCCCTTCGATTAATTGTGGCGGTTCTGGCG 
MAACLTLPPCVLQQCGGSG       28      ATGGCAGCATGCTTGACGCTGCCGCCGTGCGTGCTGCAGTAGTGTGGCGGTTCTGGCG 
MAACPQLPPCIHSYCGGSG       28      ATGGCAGCATGCCCTCAGCTGCCTCCGTGCATTCATTCTTATTGTGGCGGTTCTGGCG 
MAACKFLPPCGGSG            27      ATGGCAGCATGCAAGTTTCTTCCTCCTTGTGGCGGTTCTGGCG 
MAACPMLPPCGIFPCGGSG       27      ATGGCAGCATGCCCGATGCTTCCGCCTTGCGGGATTTTTCCTTGTGGCGGTTCTGGCG 
MAACRVLPPCSEYNCGGSG       26      ATGGCAGCATGCAGGGTGTTGCCTCCGTGCTCTGAGTATAATTGTGGCGGTTCTGGCG 
MAACPILPPCPPTQCGGSG       26      ATGGCAGCATGCCCTATTTTGCCTCCTTGCCCGCCGACTCAGTGTGGCGGTTCTGGCG 
MAACLLLPPCAPTTCGGSG       26      ATGGCAGCATGCTTGTTGCTGCCGCCTTGCGCGCCGACTACTTGTGGCGGTTCTGGCG 
MAACSLLPPCTPVLCGGSG       26      ATGGCAGCATGCTCTCTGCTTCCGCCTTGCACTCCTGTTTTGTGTGGCGGTTCTGGCG 
MAACVLPPCHWSLQCGGSG       26      ATGGCAGCATGCGTTCTTCCTCCTTGCCATTGGTCGCTGCAGTGTGGCGGTTCTGGCG 
MAACVVLPPCPLQTCGGSG       24      ATGGCAGCATGCGTGGTGTTGCCTCCGTGCCCGTTGCAGACTTGTGGCGGTTCTGGCG 
MAACNLLPPCPPLSCGGSG       22      ATGGCAGCATGCAATCTGCTGCCTCCTTGCCCGCCTCTGTCTTGTGGCGGTTCTGGCG 
MAACSTLPPCQLLHCGGSG       21      ATGGCAGCATGCAGTACGCTGCCGCCTTGCTAGTTGTTGCATTGTGGCGGTTCTGGCG 
MAACQLGSCMVLPPCGGSG       21      ATGGCAGCATGCTAGCTTGGTTCTTGCATGGTGTTGCCTCCGTGTGGCGGTTCTGGCG 
MAACARSTCPQLPPCGGSG       21      ATGGCAGCATGCGCGCGGTCTACGTGCCCGCAGCTGCCTCCTTGTGGCGGTTCTGGCG 
MAACQYLHCSVLPPCGGSG       20      ATGGCAGCATGCTAGTATTTGCATTGCTCTGTTCTGCCTCCGTGTGGCGGTTCTGGCG 
MAACFLLPPCQVALCGGSG       20      ATGGCAGCATGCTTTCTTTTGCCTCCTTGCTAGGTTGCGCTTTGTGGCGGTTCTGGCG 
MAACPTLPPCHNQLCGGSG       19      ATGGCAGCATGCCCGACGCTTCCTCCGTGCCATAATTAGTTGTGTGGCGGTTCTGGCG 
MAACMVLPPCPHQRCGGSG       19      ATGGCAGCATGCATGGTGTTGCCTCCGTGCCCTCATCAGCGGTGTGGCGGTTCTGGCG 
MAACDAWRCPVLPPCGGSG       19      ATGGCAGCATGCGATGCTTGGAGGTGCCCTGTGTTGCCTCCGTGTGGCGGTTCTGGCG 
MAACSLLPPCGSTTCGGSG       18      ATGGCAGCATGCTCTTTGTTGCCTCCTTGCGGTTCTACTACGTGTGGCGGTTCTGGCG 
MAACPVLPPCRTIWCGGSG       18      ATGGCAGCATGCCCGGTGCTGCCTCCGTGCCGTACTATTTGGTGTGGCGGTTCTGGCG 
MAACPPQPCPYLPPCGGSG       17      ATGGCAGCATGCCCGCCTTAGCCGTGCCCTTATCTGCCTCCTTGTGGCGGTTCTGGCG 
MAACPTLPPCQPGYCGGSG       16      ATGGCAGCATGCCCGACGTTGCCTCCTTGCCAGCCTGGTTATTGTGGCGGTTCTGGCG 
MAACLPPHNCPLSLCGGSG       16      ATGGCAGCATGCCTGCCGCCTCATAATTGCCCGCTTTCTCTTTGTGGCGGTTCTGGCG 
MAACFTAKCLQLPPCGGSG       16      ATGGCAGCATGCTTTACGGCTAAGTGCCTTTAGCTTCCGCCTTGTGGCGGTTCTGGCG 
MAACRFLSCSVLPPCGGSG       16      ATGGCAGCATGCAGGTTTTTGAGTTGCAGTGTTTTGCCTCCTTGTGGCGGTTCTGGCG 
MAACYHFTCPVLPPCGGSG       14      ATGGCAGCATGCTATCATTTTACTTGCCCTGTGCTTCCTCCTTGTGGCGGTTCTGGCG 
MAACSRVPCNQLPPCGGSG       13      ATGGCAGCATGCTCTCGGGTTCCTTGCAATTAGCTTCCTCCGTGTGGCGGTTCTGGCG 
MAACQELPPCLQIQCGGSG       12      ATGGCAGCATGCCAGGAGCTTCCGCCTTGCCTGCAGATTTAGTGTGGCGGTTCTGGCG 
MAACPTKSCLLLPPCGGSG       12      ATGGCAGCATGCCCTACGAAGTCTTGCCTTTTGCTTCCTCCGTGTGGCGGTTCTGGCG 
MAACPTARCTQLPPCGGSG       12      ATGGCAGCATGCCCTACGGCGCGGTGCACGTAGTTGCCTCCTTGTGGCGGTTCTGGCG 
MAACFYLPPCQDLFCGGSG       12      ATGGCAGCATGCTTTTATCTGCCTCCGTGCTAGGATTTGTTTTGTGGCGGTTCTGGCG 
MAACYLPPCPSLPHCGGSG       11      ATGGCAGCATGCTATCTTCCTCCGTGCCCGTCTCTGCCTCATTGTGGCGGTTCTGGCG 
MAACLRRPCDILPPCGGSG       11      ATGGCAGCATGCTTGCGTCGGCCGTGCGATATTCTTCCGCCTTGTGGCGGTTCTGGCG 
MAACSSLPPCYPFQCGGSG       11      ATGGCAGCATGCAGTTCGTTGCCTCCTTGCTATCCGTTTTAGTGTGGCGGTTCTGGCG 
MAACGAKYCSYLPPCGGSG       11      ATGGCAGCATGCGGGGCGAAGTATTGCTCGTATTTGCCTCCTTGTGGCGGTTCTGGCG 
MAACSSLPPCSTSECGGSG       11      ATGGCAGCATGCTCGAGTTTGCCTCCTTGCTCGACTTCTGAGTGTGGCGGTTCTGGCG 
MAACQYLPPCSFLVCGGSG       11      ATGGCAGCATGCCAGTATCTTCCTCCTTGCTCTTTTTTGGTTTGTGGCGGTTCTGGCG 
MAACVPLRCTLLPPCGGSG       10      ATGGCAGCATGCGTTCCTCTTCGGTGCACTCTTCTGCCTCCGTGTGGCGGTTCTGGCG 
MAACLLLPPCSIQGCGGSG       10      ATGGCAGCATGCCTTTTGTTGCCGCCTTGCTCTATTTAGGGTTGTGGCGGTTCTGGCG 
MAACIGSLCPVLPPCGGSG       9      ATGGCAGCATGCATTGGTAGTTTGTGCCCGGTTCTTCCTCCGTGTGGCGGTTCTGGCG 
MAACRTLPPCSDLTCGGSG       9      ATGGCAGCATGCCGTACGCTGCCTCCTTGCTCTGATCTTACTTGTGGCGGTTCTGGCG 
MAACSQLPPCSIIKCGGSG       9      ATGGCAGCATGCTCGTAGCTTCCGCCGTGCAGTATTATTAAGTGTGGCGGTTCTGGCG 
MAACLLLPPCQHQMCGGSG       8      ATGGCAGCATGCCTTCTGCTGCCGCCTTGCCAGCATTAGATGTGTGGCGGTTCTGGCG 
MAACALLPPCSWVSCGGSG       8      ATGGCAGCATGCGCGTTGCTGCCGCCGTGCTCGTGGGTGTCTTGTGGCGGTTCTGGCG 
MAACKTLPPCPLRLCGGSG       8      ATGGCAGCATGCAAGACTCTGCCTCCTTGCCCTCTGCGTCTTTGTGGCGGTTCTGGCG 
MAACYVLPPCSNVVCGGSG       8      ATGGCAGCATGCTATGTTCTTCCTCCGTGCTCTAATGTGGTGTGTGGCGGTTCTGGCG 
MAACKHLPPCSVAYCGGSG       8      ATGGCAGCATGCAAGCATTTGCCTCCTTGCTCTGTTGCTTATTGTGGCGGTTCTGGCG 
MAACLVLPPCFLVDCGGSG       8      ATGGCAGCATGCCTTGTTCTTCCGCCTTGCTTTTTGGTGGATTGTGGCGGTTCTGGCG 
Library 6x6 
MAACRAKQVCCLAADRTCGGSG       4773      ATGGCAGCGTGTCGTGCGAAGCAGGTGTGTTGCTTGGCGGCGGATCGTACGTGTGGCGGTTCTGGCG 
MAACWKRQVCCLSQDRLCGGSG       3992      ATGGCAGCGTGTTGGAAGAGGCAGGTGTGTTGCCTTTCGTAGGATAGGTTGTGTGGCGGTTCTGGCG 
MAACQGILPPCGRGGGGCGGSG       3402      ATGGCAGCGTGTTAGGGGATTTTGCCGCCTTGCGGGCGTGGTGGTGGTGGGTGTGGCGGTTCTGGCG 
MAACTCRKVCCLAQEMPCGGSG       2782      ATGGCAGCGTGTACGTGTCGGAAGGTGTGTTGCTTGGCGTAGGAGATGCCTTGTGGCGGTTCTGGCG 
MAACTHRKGCCVAQEVVCGGSG       1709      ATGGCAGCGTGTACTCATAGGAAGGGGTGTTGCGTGGCTTAGGAGGTTGTTTGTGGCGGTTCTGGCG 
MAACGPRKVCCLSQEVICGGSG       1529      ATGGCAGCGTGTGGGCCGAGGAAGGTTTGTTGCCTGAGTTAGGAGGTGATTTGTGGCGGTTCTGGCG 
MAACSWLQSECSIISSGCGGSG       1406      ATGGCAGCGTGTTCTTGGTTGTAGAGTGAGTGCAGTATTATTAGTAGTGGGTGTGGCGGTTCTGGCG 
MAACGQVLPPCEHSGASRGGSG       936      ATGGCAGCGTGTGGGTAGGTGCTTCCTCCTTGCGAGCATTCTGGGGCGTCGCGTGGCGGTTCTGGCG 
MAACMYQAALCSSILPPCGGSG       924      ATGGCAGCGTGTATGTATTAGGCGGCGTTGTGCTCTAGTATTCTTCCTCCGTGTGGCGGTTCTGGCG 
APPENDIX III: Supplementary Information for Chapter 4 
113 
MAACMQRQVCCLSYEKQCGGSG       821      ATGGCAGCGTGTATGTAGAGGCAGGTGTGTTGCCTGAGTTATGAGAAGCAGTGTGGCGGTTCTGGCG 
MAACWRKTVCCLAAERSCGGSG       768      ATGGCAGCGTGTTGGCGGAAGACTGTGTGTTGCCTGGCTGCTGAGAGGAGTTGTGGCGGTTCTGGCG 
MAACERRAVCCVSPELHCGGSG       658      ATGGCAGCGTGTGAGAGGCGGGCTGTTTGTTGCGTTTCTCCTGAGTTGCATTGTGGCGGTTCTGGCG 
MAACLQWRADCQHVLPPCGGSG       454      ATGGCAGCGTGTCTTCAGTGGAGGGCGGATTGCTAGCATGTGCTGCCTCCGTGTGGCGGTTCTGGCG 
MAACYGVLPPCQFTGGPCGGSG       442      ATGGCAGCGTGTTATGGTGTTCTGCCTCCGTGCTAGTTTACTGGTGGTCCTTGTGGCGGTTCTGGCG 
MAACIWAQGYCGEPARNCGGSG       421      ATGGCAGCGTGTATTTGGGCGTAGGGGTATTGCGGGGAGCCTGCTCGGAATTGTGGCGGTTCTGGCG 
MAACGVSQAFSLPPWHCGGSG        402      ATGGCAGCGTGTGGCGTCTCATAGGCCTTCTCGTTGCCTCCGTGGCATTGTGGCGGTTCTGGCG 
MAACQGGVVTCPHILPPCGGSG       400      ATGGCAGCGTGTTAGGGTGGGGTTGTGACGTGCCCTCATATTTTGCCGCCGTGTGGCGGTTCTGGCG 
MAACFTRSVCCLSKELLCGGSG       372      ATGGCAGCGTGTTTTACTCGTAGTGTGTGTTGCCTTTCTAAGGAGCTGCTGTGTGGCGGTTCTGGCG 
MAACLSRQVCCLQKDLPCGGSG       346      ATGGCAGCGTGTCTTAGTAGGCAGGTTTGTTGCTTGTAGAAGGATCTGCCTTGTGGCGGTTCTGGCG 
MAACGGILPPCTYQVPACGGSG       313      ATGGCAGCGTGTGGGGGGATTCTTCCTCCTTGCACGTATTAGGTGCCTGCGTGTGGCGGTTCTGGCG 
MAACQNYLKSCGLPPYDCGGSG       299      ATGGCAGCGTGTTAGAATTATTTGAAGAGTTGCGGGTTGCCTCCGTATGATTGTGGCGGTTCTGGCG 
MAACALLPPQCPAYVESCGGSG       298      ATGGCAGCGTGTGCTCTGTTGCCTCCGTAGTGCCCGGCGTATGTTGAGAGTTGTGGCGGTTCTGGCG 
MAACSGRYACCLSQELECGGSG       296      ATGGCAGCGTGTAGTGGGAGGTATGCGTGTTGCTTGTCGTAGGAGTTGGAGTGTGGCGGTTCTGGCG 
MAACSGEYGKCQVLPPCGGSG        249      ATGGCAGCGTGTTCGGGGGAGTATGGTAAGTGCTAGGTGCTGCCTCCGTGTGGCGGTTCTGGCG 
MAACHKQSNRCVGVLPPCGGSG       243      ATGGCAGCGTGTCATAAGTAGAGTAATCGGTGCGTGGGTGTTTTGCCGCCGTGTGGCGGTTCTGGCG 
MAACKLRQVCCVDAAGYCGGSG       226      ATGGCAGCGTGTAAGTTGAGGTAGGTTTGTTGCGTGGATGCTGCGGGGTATTGTGGCGGTTCTGGCG 
MAWCGGQLPPCGGSG              223      ATGGCTTGGTGCGGGGGTTAGTTGCCGCCTTGTGGCGGTTCTGGCG 
MAACLTVLPPYSSSCGGSG          194      ATGGCAGCGTGTCTGACGGTTTTGCCGCCTTATTCTAGTAGTTGTGGCGGTTCTGGCG 
MAACQDVTDGCTGILPPCGGSG       189      ATGGCAGCGTGTTAGGATGTGACTGATGGTTGCACTGGTATTCTTCCTCCGTGTGGCGGTTCTGGCG 
MAACQGILPPCNVGRTGCGGSG       184      ATGGCAGCGTGTTAGGGGATTCTGCCGCCGTGCAATGTGGGTCGTACTGGTTGTGGCGGTTCTGGCG 
MAACPYQLPPCDSSPLDCGGSG       183      ATGGCAGCGTGTCCGTATTAGCTTCCGCCTTGCGATTCTAGTCCTCTGGATTGTGGCGGTTCTGGCG 
MAACDLVLPPCWQGSQGWGGSG       174      ATGGCAGCGTGTGATCTGGTTCTGCCGCCTTGCTGGTAGGGGTCTTAGGGGTGGGGCGGTTCTGGCG 
MAACGGARKCCLDTSHSCGGSG       173      ATGGCAGCGTGTGGGGGTGCGAGGAAGTGTTGCTTGGATACGTCTCATTCTTGTGGCGGTTCTGGCG 
MASCQTLLPPCGGSG              171      ATGGCTTCGTGCTAGACGCTGCTTCCTCCTTGTGGCGGTTCTGGCG 
MAACGGPLKKCCGRLPPCGGSG       161      ATGGCAGCGTGTGGTGGGCCTTTGAAGAAGTGCTGTGGTAGGTTGCCTCCTTGTGGCGGTTCTGGCG 
MAACGGVLPPCQLEKVECGGSG       158      ATGGCAGCGTGTGGTGGGGTGTTGCCTCCGTGCTAGTTGGAGAAGGTTGAGTGTGGCGGTTCTGGCG 
MAACSWARVCCLQIDKECGGSG       155      ATGGCAGCGTGTTCTTGGGCGCGTGTGTGTTGCTTGTAGATTGATAAGGAGTGTGGCGGTTCTGGCG 
MAACLGVLPPCGMFNFQRGGSG       152      ATGGCAGCGTGTTTGGGTGTGTTGCCTCCGTGCGGTATGTTTAATTTTTAGCGTGGCGGTTCTGGCG 
MAACMKKGVCCLAPDVRCGGSG       141      ATGGCAGCGTGTATGAAGAAGGGGGTGTGTTGCCTTGCTCCGGATGTGAGGTGTGGCGGTTCTGGCG 
MAACTNALQRCGGTLPPCGGSG       136      ATGGCAGCGTGTACGAATGCTCTGTAGAGGTGCGGTGGTACGCTTCCGCCGTGTGGCGGTTCTGGCG 
MAACVKRVALCCGQLPPCGGSG       134      ATGGCAGCGTGTGTGAAGCGTGTTGCGTTGTGCTGTGGTTAGCTTCCTCCGTGTGGCGGTTCTGGCG 
MAACVGTERACFTQLPPCGGSG       130      ATGGCAGCGTGTGTGGGTACTGAGAGGGCGTGCTTTACTTAGTTGCCTCCTTGTGGCGGTTCTGGCG 
MAACRWDLQECSAYLPPCGGSG       130      ATGGCAGCGTGTCGGTGGGATTTGTAGGAGTGCAGTGCGTATCTTCCTCCGTGTGGCGGTTCTGGCG 
MAACDFQLQQCAFILPPCGGSG       125      ATGGCAGCGTGTGATTTTTAGTTGCAGCAGTGCGCGTTTATTCTTCCGCCTTGTGGCGGTTCTGGCG 
MAACGGQSLECRIYLPPCGGSG       121      ATGGCAGCGTGTGGTGGTTAGTCTTTGGAGTGCCGGATTTATCTTCCTCCTTGTGGCGGTTCTGGCG 
MAACSTTSLRCGGQLPPCGGSG       121      ATGGCAGCGTGTTCGACTACTTCTCTGAGGTGCGGTGGGTAGTTGCCTCCTTGTGGCGGTTCTGGCG 
MAACQLAKRCCGGALPPCGGSG       118      ATGGCAGCGTGTTAGCTTGCTAAGCGGTGTTGCGGGGGGGCTTTGCCTCCGTGTGGCGGTTCTGGCG 
MAACEWLDRACSQVLPPCGGSG       116      ATGGCAGCGTGTGAGTGGCTGGATCGTGCGTGCTCGTAGGTGCTGCCGCCTTGTGGCGGTTCTGGCG 
MAACWDQTRRCCKELPPCGGSG       115      ATGGCAGCGTGTTGGGATTAGACTCGTAGGTGCTGTAAGGAGTTGCCTCCGTGTGGCGGTTCTGGCG 
MAACSSRKVCCLASDVTCGGSG       113      ATGGCAGCGTGTAGTAGTAGGAAGGTGTGTTGCCTGGCTAGTGATGTTACTTGTGGCGGTTCTGGCG 
MAACPMVLPPCQHTLHECGGSG       111      ATGGCAGCGTGTCCTATGGTTCTGCCGCCTTGCTAGCATACTCTGCATGAGTGTGGCGGTTCTGGCG 
MAACRGILPPCAPQAYECGGSG       109      ATGGCAGCGTGTCGTGGGATTTTGCCTCCGTGCGCTCCTTAGGCGTATGAGTGTGGCGGTTCTGGCG 
MAACSSQLPPCDRVQELGGSG        108      ATGGCAGCGTGTTCGTCTCAGCTGCCGCCGTGCGATCGCGTGTAGGAATTGGGCGGTTCTGGCG 
MAACRYTQESCPHILPPCGGSG       107      ATGGCAGCGTGTCGTTATACGTAGGAGAGTTGCCCTCATATTTTGCCTCCGTGTGGCGGTTCTGGCG 
MAACWDKRVCCVAPWRPCGGSG       104      ATGGCAGCGTGTTGGGATAAGCGTGTGTGTTGCGTGGCGCCTTGGCGTCCTTGTGGCGGTTCTGGCG 
MAACQGTLPPCPAGIKPCGGSG       101      ATGGCAGCGTGTTAGGGGACGCTTCCGCCTTGCCCGGCGGGTATTAAGCCTTGTGGCGGTTCTGGCG 
MAACDTYQEECTHILPPCGGSG       98      ATGGCAGCGTGTGATACGTATTAGGAGGAGTGCACTCATATTTTGCCGCCTTGTGGCGGTTCTGGCG 
MAACPNLLPPCGGSQTACGGSG       97      ATGGCAGCGTGTCCTAATTTGCTTCCGCCTTGCGGGGGGTCTTAGACGGCTTGTGGCGGTTCTGGCG 
MAACSYLEQTCNQYLPPCGGSG       91      ATGGCAGCGTGTAGTTATCTTGAGCAGACGTGCAATTAGTATCTTCCTCCTTGTGGCGGTTCTGGCG 
MAACTSVLPPCSGNEQLCGGSG       90      ATGGCAGCGTGTACTTCGGTGCTTCCTCCGTGCTCTGGTAATGAGTAGCTTTGTGGCGGTTCTGGCG 
MAACSLLPPQCTFGSPSCGGSG       90      ATGGCAGCGTGTAGTCTGTTGCCTCCGTAGTGCACGTTTGGTTCGCCGTCTTGTGGCGGTTCTGGCG 
MAACTQHGRQCGHFLPPCGGSG       88      ATGGCAGCGTGTACGTAGCATGGGCGGCAGTGCGGGCATTTTCTGCCTCCGTGTGGCGGTTCTGGCG 
MAACLRVLGCCVSVERPCGGSG       88      ATGGCAGCGTGTTTGAGGGTTCTTGGGTGTTGCGTGAGTGTTGAGCGTCCGTGTGGCGGTTCTGGCG 
MAACVLFLPPCPQGSHLCGGSG       87      ATGGCAGCGTGTGTGCTTTTTCTTCCGCCGTGCCCTTAGGGGTCTCATCTGTGTGGCGGTTCTGGCG 
MAACGRYLPPCPQSPHNCGGSG       86      ATGGCAGCGTGTGGTAGGTATCTTCCGCCGTGCCCTCAGAGTCCTCATAATTGTGGCGGTTCTGGCG 
MAACGSARKCCLSVLPPCGGSG       86      ATGGCAGCGTGTGGGAGTGCGCGTAAGTGTTGCTTGTCTGTTCTGCCTCCTTGTGGCGGTTCTGGCG 
MAACLPLLPPCDGDCLQCGGSG       83      ATGGCAGCGTGTTTGCCGTTGCTGCCGCCTTGCGATGGTGATTGTCTTCAGTGTGGCGGTTCTGGCG 
MAACMTGQGRCGGVLPPCGGSG       82      ATGGCAGCGTGTATGACGGGTTAGGGGCGTTGCGGTGGGGTGTTGCCTCCTTGTGGCGGTTCTGGCG 
MAACHGRQVCCLAPARPCGGSG       81      ATGGCAGCGTGTCATGGTCGGCAGGTGTGTTGCCTTGCGCCTGCTCGGCCGTGTGGCGGTTCTGGCG 
MAACLLGPRECGQLPPLCGGSG       81      ATGGCAGCGTGTTTGCTGGGTCCGAGGGAGTGCGGTTAGTTGCCGCCTCTGTGTGGCGGTTCTGGCG 
MAACEGVLPPCPQLTQYCGGSG       81      ATGGCAGCGTGTGAGGGGGTGTTGCCTCCTTGCCCGTAGCTGACGCAGTATTGTGGCGGTTCTGGCG 
MAACTWINGVCDGILPPCGGSG       80      ATGGCAGCGTGTACTTGGATTAATGGTGTGTGCGATGGTATTCTGCCGCCTTGTGGCGGTTCTGGCG 
MAACPGLLPPCQLGRPGCGGSG       79      ATGGCAGCGTGTCCGGGTCTGTTGCCTCCGTGCTAGCTTGGTCGTCCGGGTTGTGGCGGTTCTGGCG 
MAACRQWLPPCPVGGTACGGSG       79      ATGGCAGCGTGTAGGCAGTGGCTGCCTCCTTGCCCTGTTGGGGGGACGGCTTGTGGCGGTTCTGGCG 
MAACGIAGLPCSQVLPPCGGSG       77      ATGGCAGCGTGTGGGATTGCTGGTCTTCCTTGCTCTTAGGTGCTTCCTCCTTGTGGCGGTTCTGGCG 
MAACTCYGKKCLNVLPPCGGSG       76      ATGGCAGCGTGTACTTGTTATGGTAAGAAGTGCCTTAATGTTCTGCCTCCTTGTGGCGGTTCTGGCG 
MAACGQILPPCNFQINGCGGSG       76      ATGGCAGCGTGTGGTTAGATTCTTCCTCCTTGCAATTTTTAGATTAATGGTTGTGGCGGTTCTGGCG 
MAACKHLLPPCDYMSQNCGGSG       73      ATGGCAGCGTGTAAGCATCTGCTTCCTCCGTGCGATTATATGAGTTAGAATTGTGGCGGTTCTGGCG 
MAACHSDVQPCPNILPPCGGSG       73      ATGGCAGCGTGTCATAGTGATGTTTAGCCGTGCCCGAATATTCTGCCTCCTTGTGGCGGTTCTGGCG 
MAACEYELQLCGNTLPPCGGSG       72      ATGGCAGCGTGTGAGTATGAGTTGTAGCTTTGCGGTAATACTCTTCCGCCGTGTGGCGGTTCTGGCG 
MAACVGRLPNCGLPPWQCGGSG       72      ATGGCAGCGTGTGTTGGTCGTCTGCCTAATTGCGGTCTTCCTCCTTGGTAGTGTGGCGGTTCTGGCG 
MAACVSRRVCCLDIAHQCGGSG       69      ATGGCAGCGTGTGTTTCGAGGCGGGTTTGTTGCCTGGATATTGCTCATCAGTGTGGCGGTTCTGGCG 
MAACQARFDRCGLPPWNCGGSG       69      ATGGCAGCGTGTTAGGCTAGGTTTGATCGTTGCGGTCTTCCGCCGTGGAATTGTGGCGGTTCTGGCG 
MAACTQYPQSCAGILPPCGGSG       68      ATGGCAGCGTGTACGTAGTATCCGCAGTCGTGCGCTGGGATTCTTCCGCCGTGTGGCGGTTCTGGCG 
MAACGIQRVCCLAPDVACGGSG       67      ATGGCAGCGTGTGGTATTTAGAGGGTGTGTTGCTTGGCTCCTGATGTTGCTTGTGGCGGTTCTGGCG 
MAACNSAVQKCCGQLPPCGGSG       67      ATGGCAGCGTGTAATTCTGCTGTGCAGAAGTGCTGTGGGTAGCTTCCGCCTTGTGGCGGTTCTGGCG 
MAACWHKQMCCVDIKAPCGGSG       67      ATGGCAGCGTGTTGGCATAAGTAGATGTGTTGCGTTGATATTAAGGCTCCGTGTGGCGGTTCTGGCG 
APPENDIX III: Supplementary Information for Chapter 4 
114 
MAACGGLLPPCGLSLQECGGSG       66      ATGGCAGCGTGTGGGGGGTTGCTGCCGCCGTGCGGTTTGAGTCTGTAGGAGTGTGGCGGTTCTGGCG 
MAACWWQAKRCGLILPPCGGSG       65      ATGGCAGCGTGTTGGTGGCAGGCGAAGCGGTGCGGGTTGATTCTTCCTCCTTGTGGCGGTTCTGGCG 
MAACFPKAVCCLASELLCGGSG       65      ATGGCAGCGTGTTTTCCGAAGGCTGTGTGTTGCTTGGCTTCTGAGTTGTTGTGTGGCGGTTCTGGCG 
MAACPLILPPCGLSGRNCGGSG       65      ATGGCAGCGTGTCCGCTTATTTTGCCTCCGTGCGGTCTGTCTGGGCGTAATTGTGGCGGTTCTGGCG 
MAACNVWEQHCQNILPPCGGSG       64      ATGGCAGCGTGTAATGTTTGGGAGCAGCATTGCTAGAATATTCTTCCTCCTTGTGGCGGTTCTGGCG 
MAACGGQLPPCGVVYSSCGGSG       63      ATGGCAGCGTGTGGTGGGTAGCTTCCGCCGTGCGGGGTGGTTTATTCTAGTTGTGGCGGTTCTGGCG 
MAACDSQVKKCANLLPPCGGSG       63      ATGGCAGCCTGTGATTCTTAGGTGAAGAAGTGCGCTAATCTGCTGCCTCCTTGTGGCGGTTCTGGCG 
MAACEYRVDPCGQLLPPCGGSG       63      ATGGCAGCGTGTGAGTATCGTGTGGATCCGTGCGGGTAGTTGTTGCCTCCGTGTGGCGGTTCTGGCG 
MAACGVVLPPCPQGMNWCGGSG       63      ATGGCAGCGTGTGGTGTGGTGCTGCCGCCTTGCCCTTAGGGTATGAATTGGTGTGGCGGTTCTGGCG 
MAACTGVLPPCSYKSERCGGSG       63      ATGGCAGCGTGTACTGGTGTGTTGCCGCCGTGCTCTTATAAGAGTGAGCGTTGTGGCGGTTCTGGCG 
MAACSGVLPPCSGRMQSCGGSG       63      ATGGCAGCGTGTAGTGGGGTGCTGCCTCCTTGCAGTGGGAGGATGTAGTCGTGTGGCGGTTCTGGCG 
MAACRGVLPPCNSAQVGCGGSG       63      ATGGCAGCGTGTAGGGGGGTGCTGCCTCCGTGCAATAGTGCGTAGGTGGGGTGTGGCGGTTCTGGCG 
MAACTRPQDACPHILPPCGGSG       62      ATGGCAGCGTGTACGCGGCCGTAGGATGCGTGCCCTCATATTCTGCCTCCGTGTGGCGGTTCTGGCG 
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